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In this book, several important points regarding Crohn’s disease are discussed. In the 
first section, we focus on etiopathogeny of Crohn’s disease and the recent advances in 
our overall understanding of the disease - specifically, the role of the gut epithelium, 
alterations of the epithelial crypts, and the roles of the different cytokines in the 
pathophysiology of Crohn’s disease. In the second section, a diagnosis of Crohn’s 
disease is discussed. Another particular area of  focus is in the diagnosis of intestinal 
tuberculosis, and the role of mycobacterium avium in Crohn’s disease. In the third and 
final section, the management of Crohn’s disease is discussed, with a focus on recent 
evidence-based medicine recommendations.
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Crohn’s disease (CD) is a lifelong disease arising from interaction between genetic and 
environmental factors. The precise aetiology of CD is unknown, and therefore, a causal 
treatment is not yet available. During the last few years, there have been many 
advances concerning etiopathogeny, diagnosis tools, and management of CD. 
Inflammatory bowel disease, and particularly CD, results from an inappropriate 
inflammatory response to intestinal microbes in a genetically susceptible host. The 
intestinal lamina propria contains a complex population of immune cells that balance 
the requirement for immune tolerance of luminal microbiota with the need to defend 
against pathogens and the excessive entry of luminal microbiota. The hallmark of 
active CD is a pronounced infiltration into the lamina propria of innate immune cells 
(neutrophils, macrophages, dendritic cells, and natural killer T cells), and adaptive 
immune cells (B cells and T cells). Increased numbers and activation of these cells in 
the intestinal mucosa elevate local levels of TNF alpha, interleukin 1 ß, interferon γ, 
and cytokines of the interleukin-23-Th17 pathway. CD is associated with a Th1 T cell 
mediated response, characterized by enhanced production of interferon γ and TNF α. 
IL-12 and possibly IL-23 govern the Th1 cell differentiation, but optimal induction and 
stabilization of polarized Th1 cells would require additional cytokines.  
Genetic factors are intimately involved in the pathogenesis of CD. To data, 
CARD15/NOD2 in the only confirmed CD susceptibility gene identified. There are a 
number of other likely candidates of genes and loci that have been described, although 
details remain less clear, and their roles less well characterized. Potential application of 
genetic testing in CD is a prediction of disease susceptibility, choice and response to 
therapy, and disease prevention with specific interventions. More recently, 
associations with CD have been established for ATG16L1 and immunity-related 
GTPase M Protein, two genes involved in autophagy.  
Clinical features of CD vary depending on the location, behaviour, and severity of 
disease, as well as extra-intestinal manifestations and medication. The diagnosis is 
confirmed by clinical evaluation, and a combination of endoscopic, histological, 
radiological, and/or biochemical investigations. Ileocolonoscopy with multiple biopsy 
specimens is well established as the first line procedure for the diagnosis of CD. In 
some cases, the diagnosis can be difficult, confounding by ileocoecal tuberculosis, 
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yersiniosis, and ulcerative colitis is a case of involvement of the colon. Histological, 
bacteriological, and some biochemical markers can help the clinicians to establish the 
right diagnosis and to prescribe the optimal treatment. 
The main goals of therapy in CD are to induce a clinical remission and then maintain 
that remission over time. Secondary management goals include mucosal healing, 
maintaining the quality of life of patients, restoring nutritional balance, preventing the 
complications of the disease, and timing surgical therapy to minimize the morbidity of 
the disease. Specific therapy of CD depends upon disease severity, location, and 
complications. In fact, current practice guidelines recommend using a sequential 
approach to treatment according to the severity of the clinical presentation and 
associated complications. Categories of severity are based on the type and acuity of 
symptoms, as well as response to medications, and include mild to moderate, 
moderate to severe, and severe to fulminant disease. Sulfasalazine and Mesalamine 
can still be considered first-line therapies for selected patients with mildly to 
moderately active CD. Studies have conclusively shown the benefit of corticosteroids 
in induction of remission in patients with CD. Patients unable to discontinue 
corticosteroids should be considered for alternative therapies such as azathioprine, 
methotrexate, or infliximab. Anti-TNF α antibodies and Natalizumab were both 
superior to a placebo in inducing remission and in preventing relapses in luminal CD 
patients.   
 
Dr Sami Karoui 
Department of Gastroenterology A 
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Alteration of the Crypt Epithelial-Stromal 
Interface by Proinflammatory Cytokines in 
Crohn's Disease 
Amira Seltana, Manon Lepage and Jean-François Beaulieu 
Université de Sherbrooke 
Canada 
1. Introduction 
The intestinal epithelium is a very dynamic tissue, being completely renewed over a 3-5 day 
period in the human. Epithelial cells in the intestine lie on a specialized layer of extracellular 
matrix material referred to as the basement membrane (BM). Intestinal epithelial cell 
interactions with BM molecules such as collagens, laminins, fibronectin and tenascin 
regulate crucial functions of the normal intestinal epithelial renewal process such as cell 
adhesion, migration, signalization and gene expression as well as anoikis. BM molecules can 
be secreted by epithelial cells but a number of them are exclusively synthesized and 
deposited by the subepithelial myofibroblasts. In this chapter, we will review alterations at 
the epithelial-stromal interface in Crohn's disease (CD) with a specific emphasis on 
epithelial cell and myofibroblast susceptibility to proinflammatory cytokines in the crypt 
region.  
2. Epithelial BM molecules in the normal human intestine 
The epithelial BM of the human intestine has been found to contain all the major 
components specific to most basement membranes as well as a number of non-exclusive BM 
components. There is good evidence that both types of BM components play an active role 
in intestinal epithelial cell biology through their interaction with specific cell membrane 
integrin and non-integrin receptors, which mediate cell adhesion, migration, cell cycle and 
gene expression. Current knowledge about epithelial BM composition in the normal human 
intestine is summarized below. More detailed information on BM molecules and their 
receptors in the intestine can be found elsewhere (Beaulieu 1997a, Beaulieu 2001, Lussier et 
al. 2000, Ménard et al. 2006, Teller&Beaulieu 2001). 
2.1 Exclusive and non-exclusive BM components   
As illustrated in Figure 1, exclusive BM components include the type IV collagens and 
laminins. These macromolecules are complex protein families composed of various sub-
units. Detailed analysis of various genetic forms of type IV collagens and laminins revealed 
the presence of at least two distinct types of type IV collagen heterotrimers based on the 
expression of the 1(IV)/2(IV) and 5(IV)/6(IV) chains (Beaulieu 1992, Beaulieu et al. 
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1994, Simoneau et al. 1998) and the 4 main laminins, LM-111, LM-211, LM-332 and LM-511 
(Beaulieu 1992, Beaulieu&Vachon 1994, Teller et al. 2007).  
A second interesting feature of the intestinal epithelial BM is the presence of a relatively 
large number of non-exclusive BM components, such as fibronectin, tenascin-C, osteopontin 
and type VI collagen that have been found to be integral epithelial BM components 
(Aufderheide&Ekblom 1988, Beaulieu et al. 1991, Beaulieu 1992, Groulx et al. 2011, Simon-




Fig. 1. The intestinal epithelial BM. The BM, which is located at the interface between the 
epithelial cells (e) and the subepithelial myofibroblasts (m), contains BM-specific 
macromolecules (e.g. type IV collagens and laminins) as well as non-exclusive BM 
components (e.g. tenascin-C and type VI collagen). Both types of components can originate 
from the epithelial cells and/or the subepithelial myofibroblasts (white arrows).  
The third interesting phenomenon relative to the epithelial BM in the intestine is the dual 
tissular origin of the BM components. Indeed, while the type IV collagen 5(IV) and 6(IV) 
chains as well as type VI collagen are expressed at least in part by epithelial cells, the major 
type IV collagen chains 1(IV) and 2(IV) are exclusively of stromal origin (Beaulieu et al. 
1994, Groulx et al. 2011, Simon-Assmann et al. 1990a, Simoneau et al. 1998, Vachon et al. 
1993), presumably synthesized by the subepithelial myofibroblasts (Fig. 1). Analysis of the 
tissular origin of the laminins also revealed dual epithelial/stromal origin for laminins LM-
111 and LM-332 (epithelial), LM211 (stromal) and LM511 (both) (Perreault et al. 1998, Teller 
et al. 2007). 
2.2 Spatial and temporal BM microenvironments   
Spatial and temporal patterns of expression for BM components in the intact intestinal 
epithelium have been very informative in evaluating the potential role of individual 
macromolecules in the regulation of cell functions, most notably cell growth and 
differentiation, under a normal environment. Indeed, during development, the process of 
endodermal differentiation into a functional epithelium coincides with the morphogenesis 
of the villi and the crypts in both the small and large intestines. In the mature intestine, the 
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epithelial renewing units consist of spatially well-separated proliferative and differentiated 
cell populations. Furthermore, the renewing units differ along the proximal-distal gradient, 
the crypt-to-villus axis of the small intestine being replaced by a gland-to-surface epithelial 
axis in the colon (Beaulieu 1997b, Ménard&Beaulieu 1994, Ménard et al. 2006) (Fig. 2). 
 
 
Fig. 2. Development and characteristics of the epithelium in the human small and large 
intestines. The human intestine develops relatively early during ontogeny. Villi develop 
between 9 and 11 weeks of gestation while crypts form around 16 weeks so that typical 
adult-like crypt-villus architecture is already established in the small intestine at mid-
gestation (18 to 20 weeks). Similar crypt-villus architecture is transitorily present in the 
developing colon up to mid-gestation. However, at birth, the villi have disappeared and the 
typical adult gland-to-surface epithelial architecture has been established (proximal-distal 
gradient). At maturity, the proliferative cell populations responsible for the renewing of the 
epithelium are located in the lower ⅔ of the small intestinal crypts and the lower ½ of the 
colonic glands. The functional cells of these renewing units are located on the villus and the 
surface epithelium of the small and large intestines, respectively (Adapted from 
(Teller&Beaulieu 2001).  
3. Alterations of epithelial BM composition in CD 
Alterations of epithelial BM composition have been reported in various intestinal 
pathologies (Belanger&Beaulieu 2000, Teller&Beaulieu 2001). Although none of these 
alterations has yet been demonstrated to be the primary defect in any intestinal disease, they 
are not exclusively secondary to the disruption of the epithelial-stromal interface. In 





1994, Simoneau et al. 1998) and the 4 main laminins, LM-111, LM-211, LM-332 and LM-511 
(Beaulieu 1992, Beaulieu&Vachon 1994, Teller et al. 2007).  
A second interesting feature of the intestinal epithelial BM is the presence of a relatively 
large number of non-exclusive BM components, such as fibronectin, tenascin-C, osteopontin 
and type VI collagen that have been found to be integral epithelial BM components 
(Aufderheide&Ekblom 1988, Beaulieu et al. 1991, Beaulieu 1992, Groulx et al. 2011, Simon-




Fig. 1. The intestinal epithelial BM. The BM, which is located at the interface between the 
epithelial cells (e) and the subepithelial myofibroblasts (m), contains BM-specific 
macromolecules (e.g. type IV collagens and laminins) as well as non-exclusive BM 
components (e.g. tenascin-C and type VI collagen). Both types of components can originate 
from the epithelial cells and/or the subepithelial myofibroblasts (white arrows).  
The third interesting phenomenon relative to the epithelial BM in the intestine is the dual 
tissular origin of the BM components. Indeed, while the type IV collagen 5(IV) and 6(IV) 
chains as well as type VI collagen are expressed at least in part by epithelial cells, the major 
type IV collagen chains 1(IV) and 2(IV) are exclusively of stromal origin (Beaulieu et al. 
1994, Groulx et al. 2011, Simon-Assmann et al. 1990a, Simoneau et al. 1998, Vachon et al. 
1993), presumably synthesized by the subepithelial myofibroblasts (Fig. 1). Analysis of the 
tissular origin of the laminins also revealed dual epithelial/stromal origin for laminins LM-
111 and LM-332 (epithelial), LM211 (stromal) and LM511 (both) (Perreault et al. 1998, Teller 
et al. 2007). 
2.2 Spatial and temporal BM microenvironments   
Spatial and temporal patterns of expression for BM components in the intact intestinal 
epithelium have been very informative in evaluating the potential role of individual 
macromolecules in the regulation of cell functions, most notably cell growth and 
differentiation, under a normal environment. Indeed, during development, the process of 
endodermal differentiation into a functional epithelium coincides with the morphogenesis 
of the villi and the crypts in both the small and large intestines. In the mature intestine, the 
Alteration of the Crypt Epithelial-Stromal Interface  
by Proinflammatory Cytokines in Crohn's Disease 
 
5 
epithelial renewing units consist of spatially well-separated proliferative and differentiated 
cell populations. Furthermore, the renewing units differ along the proximal-distal gradient, 
the crypt-to-villus axis of the small intestine being replaced by a gland-to-surface epithelial 
axis in the colon (Beaulieu 1997b, Ménard&Beaulieu 1994, Ménard et al. 2006) (Fig. 2). 
 
 
Fig. 2. Development and characteristics of the epithelium in the human small and large 
intestines. The human intestine develops relatively early during ontogeny. Villi develop 
between 9 and 11 weeks of gestation while crypts form around 16 weeks so that typical 
adult-like crypt-villus architecture is already established in the small intestine at mid-
gestation (18 to 20 weeks). Similar crypt-villus architecture is transitorily present in the 
developing colon up to mid-gestation. However, at birth, the villi have disappeared and the 
typical adult gland-to-surface epithelial architecture has been established (proximal-distal 
gradient). At maturity, the proliferative cell populations responsible for the renewing of the 
epithelium are located in the lower ⅔ of the small intestinal crypts and the lower ½ of the 
colonic glands. The functional cells of these renewing units are located on the villus and the 
surface epithelium of the small and large intestines, respectively (Adapted from 
(Teller&Beaulieu 2001).  
3. Alterations of epithelial BM composition in CD 
Alterations of epithelial BM composition have been reported in various intestinal 
pathologies (Belanger&Beaulieu 2000, Teller&Beaulieu 2001). Although none of these 
alterations has yet been demonstrated to be the primary defect in any intestinal disease, they 
are not exclusively secondary to the disruption of the epithelial-stromal interface. In 





invasion (Lohi 2001). Alteration in the distribution and/or expression of BM molecules were 
also observed in other intestinal pathologies such as tufting enteropathy (Goulet et al. 1995) 
and chronic inflammatory bowel conditions (Bouatrouss 1998). The alterations in the 
epithelial BM composition in the context of inflammatory bowel disease pathogenesis and as 
potential disease indicators will now be discussed. 
3.1 BM components in the crypts of inflamed specimens from CD patients    
Although clinically distinct, chronic inflammatory bowel diseases such as CD and ulcerative 
colitis share common histopathological features including mucosal inflammation, villous 
atrophy, crypt hypertrophy and epithelial cell injury (Chadwick 1991).  
In CD, an important redistribution of laminins was observed at the epithelial-stromal 
interface of inflamed specimens as compared to non-inflamed specimens from the same 
patients (Bouatrouss et al. 2000). First, the crypt specific laminin, LM-211, was found to be 
essentially absent from the mucosa. Second, two other laminins, LM-332 and LM-511, 
remained strongly expressed in the epithelial BM of the atrophied and inflamed villi. 
However, a significant upregulation of both LM-332 and LM-511 expression was observed 
in the lower crypts of inflamed CD specimens. Furthermore, a significant reduction in the 
levels of tenascin-C was also observed in the crypt region of inflamed CD specimens 
(Francoeur et al. 2009). Incidentally, the intestinal mucosa is among the few sites where 
tenascin-C remains expressed in adulthood (Belanger&Beaulieu 2000). Interestingly, in 
ulcerative colitis, most of the epithelial BM surrounding the glands has been found to be 
devoid of immunoreactive laminin (Schmehl et al. 2000) and tenascin-C (Francoeur et al. 
2009) in actively affected colonic tissues. Also, alterations in laminin and tenascin-C 
expression were not observed in celiac disease (Korhonen et al. 2000), an immune-mediated 
intestinal pathology that is also characterized by villus atrophy and crypt hyperplasia 
(Maki&Collin 1997), suggesting that the redistribution of laminins and tenascin-C in CD 
could be related to the chronic inflammatory condition. 
From these studies, it can be concluded that important alterations in epithelial BM molecule 
expression occur in the intestinal mucosa of patients with inflammatory bowel diseases. The 
fact that these alterations appear to be mainly confined to the crypts in these diseases, as 
summarized for CD in Fig. 3, suggests that compositional changes in the crypt epithelial BM 
may be of functional importance in the pathogenesis of these afflictions. 
3.2 Effects of proinflammatory cytokines on human intestinal epithelial crypt cells    
One of the landmarks of inflammatory bowel conditions such as CD is the chronic 
imbalance between immunoregulatory and proinflammatory cytokines (Bouma&Strober 
2003, Fiocchi 1997a, MacDonald&Monteleone 2006, Sartor 2006). Among the cytokines most 
frequently found to be elevated in the inflamed CD mucosa are interleukin-1 and 6 (IL-1 
and IL-6), tumor necrosis factor  (TNF) and interferon  (IFN). Because they represent 
the main component of the intestinal barrier, epithelial cells have been one of the 
nonimmune cell types most extensively studied in inflammatory bowel diseases. While 
morphological and functional alterations in epithelial integrity were described several years 
ago (Dvorak&Dickersin 1980, Hollander 1993), more recent work has provided evidence 
that these changes are primarily mediated by cytokines released from adjacent 
inflammatory cells as well as from the epithelial cells themselves (Abraham&Medzhitov 
2011, Dionne et al. 1999, Fiocchi 1997b, McKay&Baird 1999, Podolsky 2000).  
Alteration of the Crypt Epithelial-Stromal Interface  






Fig. 3. Alterations of epithelial BM composition in the human intestinal mucosa under 
normal vs inflammatory conditions. In the normal small intestine (left), laminins LM-322 
and LM-511 are found in the BM of the villus epithelial cells while laminin LM-211, is found 
in the BM of crypt epithelial cells. Tenascin-C (Tn-C) is found in the epithelial BM of both 
the crypts and villi. LM-332 and LM-511 of the epithelial BM are mainly produced by 
epithelial cells (E) while LM-211 and Tn-C are synthesized by the sub-epithelial 
myofibroblasts (SEMF). In inflamed CD specimens (inflammatory conditions), laminins LM-
332 and LM-511 remain expressed by epithelial cells of the atrophied villi while in the 
crypts, the other laminin, LM-211, as well as most of the Tn-C at the epithelial BM are lost 
and replaced by the neo-expression of laminins LM-332 and LM-511. Functionally, these 
events are associated with pro-inflammatory cytokines which a) stimulate LM-332 and LM-
511 production by crypt epithelial cells and b) induce apoptosis and de-differentiation of the 





invasion (Lohi 2001). Alteration in the distribution and/or expression of BM molecules were 
also observed in other intestinal pathologies such as tufting enteropathy (Goulet et al. 1995) 
and chronic inflammatory bowel conditions (Bouatrouss 1998). The alterations in the 
epithelial BM composition in the context of inflammatory bowel disease pathogenesis and as 
potential disease indicators will now be discussed. 
3.1 BM components in the crypts of inflamed specimens from CD patients    
Although clinically distinct, chronic inflammatory bowel diseases such as CD and ulcerative 
colitis share common histopathological features including mucosal inflammation, villous 
atrophy, crypt hypertrophy and epithelial cell injury (Chadwick 1991).  
In CD, an important redistribution of laminins was observed at the epithelial-stromal 
interface of inflamed specimens as compared to non-inflamed specimens from the same 
patients (Bouatrouss et al. 2000). First, the crypt specific laminin, LM-211, was found to be 
essentially absent from the mucosa. Second, two other laminins, LM-332 and LM-511, 
remained strongly expressed in the epithelial BM of the atrophied and inflamed villi. 
However, a significant upregulation of both LM-332 and LM-511 expression was observed 
in the lower crypts of inflamed CD specimens. Furthermore, a significant reduction in the 
levels of tenascin-C was also observed in the crypt region of inflamed CD specimens 
(Francoeur et al. 2009). Incidentally, the intestinal mucosa is among the few sites where 
tenascin-C remains expressed in adulthood (Belanger&Beaulieu 2000). Interestingly, in 
ulcerative colitis, most of the epithelial BM surrounding the glands has been found to be 
devoid of immunoreactive laminin (Schmehl et al. 2000) and tenascin-C (Francoeur et al. 
2009) in actively affected colonic tissues. Also, alterations in laminin and tenascin-C 
expression were not observed in celiac disease (Korhonen et al. 2000), an immune-mediated 
intestinal pathology that is also characterized by villus atrophy and crypt hyperplasia 
(Maki&Collin 1997), suggesting that the redistribution of laminins and tenascin-C in CD 
could be related to the chronic inflammatory condition. 
From these studies, it can be concluded that important alterations in epithelial BM molecule 
expression occur in the intestinal mucosa of patients with inflammatory bowel diseases. The 
fact that these alterations appear to be mainly confined to the crypts in these diseases, as 
summarized for CD in Fig. 3, suggests that compositional changes in the crypt epithelial BM 
may be of functional importance in the pathogenesis of these afflictions. 
3.2 Effects of proinflammatory cytokines on human intestinal epithelial crypt cells    
One of the landmarks of inflammatory bowel conditions such as CD is the chronic 
imbalance between immunoregulatory and proinflammatory cytokines (Bouma&Strober 
2003, Fiocchi 1997a, MacDonald&Monteleone 2006, Sartor 2006). Among the cytokines most 
frequently found to be elevated in the inflamed CD mucosa are interleukin-1 and 6 (IL-1 
and IL-6), tumor necrosis factor  (TNF) and interferon  (IFN). Because they represent 
the main component of the intestinal barrier, epithelial cells have been one of the 
nonimmune cell types most extensively studied in inflammatory bowel diseases. While 
morphological and functional alterations in epithelial integrity were described several years 
ago (Dvorak&Dickersin 1980, Hollander 1993), more recent work has provided evidence 
that these changes are primarily mediated by cytokines released from adjacent 
inflammatory cells as well as from the epithelial cells themselves (Abraham&Medzhitov 
2011, Dionne et al. 1999, Fiocchi 1997b, McKay&Baird 1999, Podolsky 2000).  
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Considering that changes in BM composition under inflammatory conditions are mainly 
observed in the lower part of the crypt (Fig. 3), our laboratory investigated the effect of 
proinflammatory cytokines on laminin expression in human intestinal epithelial cells using 
the well-characterized human intestinal epithelial crypt (HIEC) cell line as an experimental 
cell model representative of the human intestinal lower crypt (Benoit et al. 2010, Pageot et al. 
2000, Quaroni&Beaulieu 1997). Individually, all tested cytokines including IL-1, IL-6, TNF 
and IFN as well as transforming growth factor  (TGF) exerted relatively modest effects 
on laminin LM-332 and LM-511 production in HIEC cells. However in combination, a 
synergistic effect of TNF and IFN was observed on both laminin LM-332 and LM-511 
production at protein and transcript levels (Francoeur et al. 2004). TNF and IFN synergy 
has also been reported in various intestinal epithelial cell models for chemokine production 
(Warhurst et al. 1998), alteration in epithelial barrier properties (Wang et al. 2006), and 
acquisition of susceptibility to Fas-induced apoptosis (Begue et al. 2006, Ruemmele et al. 
1999). The TNF/IFN combination was also found to synergistically induce caspase-
dependent apoptosis in HIEC cells (Francoeur et al. 2004). Interestingly, caspase inhibitors 
completely prevented TNF/IFN-induced apoptosis but did not influence the induction of 
laminin expression indicating that the two events occurred independently.  
The contribution of TGF in the synergistic effects of TNF/IFN on laminin production 
was investigated in light of the fact that levels of TGF have been reported to be elevated in 
the mucosa of CD patients (Babyatsky et al. 1996) and that this multifunctional cytokine can 
exert a crucial function on intestinal epithelial wound healing (Podolsky 2000), in part 
through its ability to stimulate extracellular matrix molecule expression 
(Verrecchia&Mauviel 2002). Indeed, in rodent intestinal crypt cells, the promotion of 
epithelial healing by specific cytokines such as IL-1, IFN and TGF was found to act 
under a bioactive TGF dependent mechanism (Dignass&Podolsky 1993). However, TGF 
was found to be significantly less potent than the TNF/IFN combination in human 
intestinal crypt cells on laminin production suggesting a TGF-independent mechanism 
(Francoeur et al. 2004). 
In summary, the two proinflammatory cytokines TNF and IFN synergistically induce the 
expression of the specific BM molecules, laminin LM-332 and LM-511, in human intestinal 
crypt cells. The synergistic effect of the TNF/IFN combination on laminin production was 
found to be independent of the effect of these cytokines on cell apoptosis and appears to be 
controlled by an apparent TGF-independent mechanism.  
3.3 Effects of proinflammatory cytokines on human pericryptal subepithelial 
myofibroblasts   
Along with the epithelial cells, myofibroblasts are another important nonprofessional immune 
mucosal cell type for which evidence supports a participation in the pathogenesis of 
inflammatory bowel diseases (Fiocchi 1997b, Macdonald&Monteleone 2005). The 
myofibroblast  is an intermediate cell type between the smooth muscle cell and the fibroblast 
that is characterized by alpha smooth muscle actin (SMA) and vimentin expression (Gabbiani 
2003). While there is evidence that intramucosal myofibroblasts can be involved in CD 
(Vallance et al. 2005), it is the intestinal subepithelial myofibroblasts present immediately 
subjacent to the epithelial BM (Powell et al. 2005) in the form of a pericryptal sheath that have 
been the primary focus of attention in the pathogenesis of inflammatory bowel diseases. 
Because of their vicinity to the basal surface of epithelial cells, they are potential targets for 
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bacteria and their products deposited in the subepithelial compartment when the epithelial 
barrier is disrupted. In turn, when stimulated, myofibroblasts can release various cytokines 
and chemokines (Fiocchi 1997b, Powell et al. 1999, Powell et al. 2005) and extracellular matrix 
molecules (Riedl et al. 1992) suggesting that intestinal subepithelial myofibroblasts can 
participate in the innate immune response (Otte et al. 2003, Saada et al. 2006). Furthermore, the 
subepithelial myofibroblast represents a key component of epithelial-stromal interactions in 
the intestine (Ménard et al. 2006, Powell et al. 2005), which can regulate both basic and healing 
epithelial cell functions through the secretion of paracrine factors such as the Wnts, BMPs, and 
TGF, which target epithelial cells (Ménard et al. 2006, Powell et al. 2005), the release of 
proteinases (Kruidenier et al. 2006, McKaig et al. 2003) and the production of extracellular 
matrix molecules that contribute to the epithelial BM such as laminin LM-211 and tenascin-C 
(Beaulieu 1997a, Perreault et al. 1998, Riedl et al. 1992, Teller et al. 2007, Vachon et al. 1993). 
Analysis of subepithelial myofibroblast characteristics in inflamed small intestinal mucosa of 
CD patients revealed a number of alterations in the crypt region (Francoeur et al. 2009). First, a 
disappearance of SMA positive cells was observed in a large proportion of the crypts while in 
others, the SMA cellular staining was abnormally thick and co-stained by desmin suggesting 
a reorganization/redifferentiation into smooth muscle cells. Characterization of the pericryptal 
myofibroblastic sheath in the colonic mucosa from patients with various pathologic conditions 
including CD, ulcerative colitis, acute infectious colitis and noninfectious colitis confirmed the 
disappearance of SMA positive cells (also desmin negative) in the inflamed mucosa from 
inflammatory bowel diseases but not in other pathological conditions. Analysis of the 
expression of tenascin-C, which is exclusively produced by the myofibroblasts and muscle 
cells of the human intestine (Belanger&Beaulieu 2000) in the crypt epithelial BM revealed a 
close correlation between myofibroblast disappearance (loss of normal SMA staining) and 
loss of tenascin-C staining (Francoeur et al. 2009). The significant reduction of SMA positive 
cells in the pericryptal region concomitant with a disappearance of tenascin-C (Francoeur et al. 
2009) and laminin LM-211 (Bouatrouss et al. 2000) suggested that pericryptal myofibroblasts 
are lost in the inflamed mucosa of CD patients.  
To test this hypothesis, we used various preparations of myofibroblastic cells isolated from 
the human intestinal mucosa (Pinchuk et al. 2007, Teller et al. 2007, Vachon et al. 1993) as 
experimental cell models. Myofibroblasts are known to respond to various inflammatory 
signals (Otte et al. 2003, Saada et al. 2006) and have been shown to be altered in 
inflammatory bowel diseases (Fiocchi 1997b, Powell et al. 1999, Powell et al. 2005). For 
instance, mesenchymal cells isolated from the inflamed mucosa show higher levels of 
collagen production than their normal counterparts. We thus investigated the possibility 
that a loss of pericryptal myofibroblasts occurs in the inflamed regions of CD mucosa by 
testing myofibroblast susceptibility to the same panel of proinflammatory cytokines used 
above for epithelial cells (section 3.2). Individually, IL-1, IL-6, TNF and IFN as well as 
TGF exerted little or no effect on the growth and survival of intestinal myofibroblasts. 
However, cytokine combinations containing TNF and IFN induced significant caspase-
dependent apoptosis, suggesting that this mechanism may account for the loss of 
myofibroblasts in the inflamed CD mucosa. While not yet reported for myofibroblasts, the 
synergistic effect of TNF/IFN on various functions has been described in other cell types, 
namely intestinal epithelial cells (Begue et al. 2006, Francoeur et al. 2004, Ruemmele et al. 
1999, Wang et al. 2006, Warhurst et al. 1998).  
Interestingly, the pro-apoptotic effect of pro-inflammatory cytokines was only observed 
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mucosa being apoptosis-resistant (Francoeur et al. 2009). Distinct intrinsic properties of 
myofibroblasts isolated from inflammatory bowel disease vs non-inflammatory bowel 
disease patients remains to be elucidated but is not without precedent (Lawrance et al. 
2001). The contribution of bone marrow-derived myofibroblasts in the regenerative process 
in inflammatory bowel disease (Andoh et al. 2005, Brittan et al. 2007) may explain the 
resistance to cytokine-mediated apoptosis.  
The high levels of TGF in the inflamed mucosa may need to be further investigated 
considering its anti-inflammatory effect in inflammatory bowel diseases (Fiocchi 2001) and 
its promoting effect on myofibroblast differentiation (Simmons et al. 2002). Indeed, although 
not directly tested on myofibroblasts for apoptosis, TGF was found to significantly enhance 
SMA expression in intestinal myofibroblasts while all other cytokines reduced SMA 
expression. Interestingly, TGF completely reversed the down-regulation of SMA 
expression triggered by individual proinflammatory cytokines but failed to prevent the 
SMA down-regulation induced by the TNF/IFN combination, suggesting a 
dedifferentiation mechanism (Francoeur et al. 2009). 
In summary, these studies showed that the myofibroblasts of the intestinal pericryptal 
sheath are a target for proinflammatory cytokines in active inflammatory bowel diseases. 
The disappearance of laminin LM-211 and tenascin-C in the pericryptal region of the 
inflamed CD mucosa appears to be a direct consequence of the alteration of the 
myofibroblastic sheath. While proinflammatory cytokines appear to be responsible for the 
net reduction of the number of pericryptal myofibroblasts, the mechanisms involved include 
caspase-dependent apoptosis and dedifferentiation toward a fibroblastic phenotype. 
 
 
Fig. 4. Functional alterations of human intestinal epithelial-stromal components resulting 
from the synergistic effects of TNF and IFN. The TNF/IFN combination was found to 
trigger myofibroblast caspase-dependent apoptosis and myofibroblast dedifferentiation, 
which results in the disappearance of a significant portion of the pericryptal sheath (1) and, 
concomitantly, the loss of two extracellular matrix molecules specifically synthesized by 
these cells: laminin LM-211 and tenascin-C (Tn-C) (2). The TNF/IFN combination was 
found to also elicit caspase-dependent apoptosis in epithelial crypt cells (3) as well as 
induction of the expression of the laminins LM-332 and LM-511 (4), two laminins normally 
not expressed in the lower crypt. Expression of LM-511 may compensate for the 
disappearance of LM-211. 
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4. Conclusions  
It is becoming more and more evident that under inflammatory conditions, the intestinal 
immune response relies on a complex interplay between immune and nonprofessional 
immune cells (Fiocchi 1997b, Macdonald&Monteleone 2005). Proinflammatory cytokines, 
namely TNF and IFN in combination, were shown to induce human intestinal crypt 
epithelial cell apoptosis and altered expression and distribution of laminins LM-332 and 
LM-511 in the crypts (Francoeur et al. 2004), two events that contribute to the disruption of 
epithelial cell homeostasis (Bouatrouss et al. 2000, Teller&Beaulieu 2001). As summarized in 
Fig. 4, the proinflammatory conditions that prevail in the intestinal mucosa of patients 
affected with inflammatory bowel diseases also disrupt the pericryptal sheath, as shown by 
the loss of myofibroblasts and altered expression of laminin LM-211 and tenascin-C 
(Francoeur et al. 2009). Taken together, these data suggest that the entire epithelial-stromal 
interface is affected in the intestine under proinflammatory conditions.  
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1. Introduction 
Crohn’s disease is a chronic inflammation of the gut that affects an estimated 800,000 people in 
North-America alone. Crohn’s disease most commonly affects the ileum, and to a lesser extent, 
the colon, however can be found throughout the entire gastro-intestinal tract (Shanahan, 2002). 
The cause of this disease is as yet largely unknown, despite tremendous progress in research 
efforts over the last decade. It is increasingly clear that inflammation and disease progression 
involves a complex interplay between the environment, host genes and microbes (Baumgart 
and Carding, 2007). Increasingly, and predominantly based on genomic analyses, involvement 
of components of the innate immune system have been recognized in inflammatory bowel 
disease (Baumgart and Sandborn, 2007). The first major susceptibilty locus that was identified 
for Crohn’s disease was the IBD1 locus, encoding nucleotide oligomerization domain 2 or 
NOD2 (Hugot et al., 2001; Ogura et al., 2001). Various variations in genotypes and single 
nucleotide polymorphisms have been identifed in NOD2 that are strongly associated with 
Crohn’s disease development (Economou et al., 2004; Lesage et al., 2002). In a recent genome-
wide study, a total of 71 loci were identified to be associated with Crohn’s disease, with the 
potential involvement of more genes (Franke et al., 2010). Among the genes identified were the 
autophagy-related 16-1 or ATG16L1 gene and the interleukin-23 (IL-23) receptor gene. 
Autophagy is a mechanism that regulates protein degradation and is essential for immune 
balance. Disturbance of this mechanism may lead to inflammation or disease and therapeutic 
applications of manipulating this mechanism are under investigation (Fleming et al., 2011). 
The IL-23 receptor is a key feature of the Th17 subset of T helper cells which are a critical 
component of the antibacterial defense (Abraham and Cho, 2009). Both IL-17 and the IL-23 
receptor ligand are currently targeted for therapy (De Nitto et al., 2010). 
The epithelium of the gut is an important component of innate immunity. Epithelial cells 
perform an essential, yet selective barrier function, physically separating the gut lumen from 
underlying cells and tissues (Peyrin-Biroulet et al., 2008). This physical barrier limits the 
exposure of microbes and infectious agents to the underlying mucosal immune system, 
while at the same time allowing exchange and uptake of fluids and nutrients. More than a 
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form a critical link between mucosal immunity and the microbial intestinal flora via germ-
line encoded receptors and specific signaling pathways (Abreu, 2010; Koch and Nusrat, 
2009; Wells et al., 2010). For example, epithelial cells from distinct lineages express NOD2 or 
ATG16L1, critical for recognition and clearance of intracellular microbes and linked to 
Crohn’s disease as mentioned (Bevins, 2004, 2005; Kaser and Blumberg, 2011). Barrier 
functions of the gastro-intestinal tract is regulated by chemokines and cytokines released in 
underlying compartments as well (Zimmerman et al., 2008). The exact sites and mechanisms 
of how cytokines affect epithelial permeability is not known, however it involves mainly the 
Th1 cytokines tumor necrosis factor-α (TNF-α) and interferon-γ (IFN-γ). Therapy directed 
against these cytokines is currently widely applied in the clinic (Ford et al., 2011). 
Additionally, specialized epithelial cells have evolved in the gut that are critical in three 
areas: 1) Goblet cells secrete mucins and are a source of trefoil peptides, important for 
mucosal repair (McGuckin et al., 2011); 2) Paneth cells secrete antimicrobial peptides 
(Bevins, 2006; Ouellette, 2011); and 3) M cells transport antigen and micro-organisms, thus 
sampling the gut lumen (Miller et al., 2007). In this chapter, we will discuss in detail the 
active barrier function of the indivdual cellular components of the intestinal epithelium in 
context of immune homeostasis and Crohn’s disease. 
 
 
Fig. 1. Epithelial cells of the ileum. 
The ileum is predominantly populated by columnar enterocytes or columnar cells which 
provide essential barrier function to the gut, separating the lumen from underlying tissue. 
Specialized goblet cells produce mucus, the first line of defence against microorganisms, but 
also microhabitat for bacteria. Paneth cells produce a host of antimicrobial factors resulting 
in a relatively sterile environment in the crypt base. Poliplurent stem cells continually self-
replicate and differentiate to ensure high turnover rate of epithelial cells. M cells are 
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optimized for antigen sampling and transport and are in close proximity with underlying 
components of adaptive immunity.  
2. Goblet cells 
Goblet cells are glandular simple columnar epithelial cells that are found scattered among 
the epithelia of the intestinal and respiratory tracts, as well as the urogenital, visual, and 
auditory systems. The primary function of goblet cells is to secrete mucin into the lumen of 
the gut and airways. The majority of the cytoplasm of goblet cells is occupied by secretory 
granules containing a variety of proteins that form the mucus layer upon granule exocytosis. 
Rough endoplasmic reticulum, mitochondria, nucleus, and other organelles are located in 
the basal portion of the cell. The apical plasma membrane of goblet cells contains microvilli 
to increase the surface area for secretion.  
2.1 Mucus 
Mucus comprises a visoelastic layer of fluid that plays an important defensive role against 
foreign environmental substances. Mucus covers all exposed epithelia of mammals, as well 
as the epidermis of amphibians and the gills of fish. In addition to trapping and removing 
foreign substances, mucus serves to lubricate the some epithelial surfaces, principally those 
of the gastro-intestinal tract. A layer of mucus along the inner walls of the stomach is vital to 
protect gastric epithelial cells from the highly acidic environment. The average human body 
produces about one liter of mucus per day (Thorton, 2008). Mucus consists of water, salts 
and various macromolecules, including mucins, proteinases, proteinase inhibitors, 
proteoglycans, and defensive proteins. In the latter category are proteins such as lysozyme, 
lactoferrin, and immunoglobulins. Proper concentrations of these components are required 
for the optimum function of mucus, and an alteration in the quality or quantity of the 
individual constituents of mucus may lead to pathological conditions.  
2.2 Mucins 
Mucins are the primary protein constituents of mucus (Lillehoj and Kim, 2002). These high 
molecular weight glycoproteins contain variable numbers of tandem repeats (VNTRs) in 
which serine, threonine, and/or proline residues are highly enriched. Serines and threonines 
are responsible for extensive mucin glycosylation that contributes to size and charge 
heterogeneity of the molecules. Glycosylation within the VNTR takes place between the 
serine/threonine moieties of the peptide backbone and N-acetylgalactosamine of the 
oligosaccharides, characteristic of O-linked glycoproteins. In addition, a limited amount of 
N-linked glycosylation between asparagines residues of the protein backbone and N-
acetylglucosamine of the oligosaccharides also are present. Mucins can be broadly classified 
as either gel-forming/secreted mucins or membrane mucins. Gel-forming mucins are 
produced by goblet cells and account for the visoelastic property of the mucus layer as a 
result of protein cross-linking between mucin monomers. Cross-linking occurs following 
disulfide bonding between cysteine-rich D domains in the NH2- and COOH-termini of the 
proteins. Membrane mucins are expressed in a polarized fashion on the apical surface of all 
epithelial cells. Eighteen mucin (MUC) genes have been cloned and the particular 
distribution of mucin gene expression varies by epithelial type. In the gastro-intestinal tract, 
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(MUC2, MUC5AC, MUC5B, MUC7, and MUC19) and membrane (MUC1, MUC3, MUC4, 
MUC12, MUC13, MUC15, MUC16, and MUC17) mucins. 
2.2.1 MUC2, the major gel-forming mucin of the intestinal tract 
MUC2 is the major component of the secreted mucus barrier in the small and large 
intestines (Figure 2). MUC2 knockout mice spontaneously develop colitis, indicating that 
MUC2 is critical for colonic protection (Van der Sluis et al., 2006). The MUC2 gene product 
is a very large, greater than 5,100 amino acids in length, and contains two VNTRs with 
different amino acid sequences (Gum et al., 1994). The VNTR domain contains 50 -100 
threonine/proline-rich 23 amino acid continuous repeats, while the second is composed of a 
347 residue irregular and discontinuous serine/threonine/proline-rich repeat. MUC2 
contains four cysteine-rich D domains, three located at the NH2-terminus and the fourth at 
the COOH-terminus of the protein. This D domain organization is similar to that seen in von 
Willebrand factor, a glycoprotein involved in hemostasis. The MUC2 D domains contain a 
characteristic -cysteine-X-X-cysteine- sequence (where X is any amino acid) that mediates 
mucin oligomerization through disulfide bonding. The glycan moieties of MUC2 contain an 
equal fraction of neutral (40%) and sialylated (40%) residues with the remainder being 
sulphated (Karlsson et al., 1996). Mass spectrometry identified the sulfate group attached to 






Upper, MUC2 cDNA. D1, D2, D3 = dimerization domains; yellow = cysteine-rich regions; 
blue = cysteine knot. Lower, MUC2 protein. Tan = non-repeat NH2–terminal region; red = VNTRs; 
green = non-repeat COOH-terminal region. 
Fig. 2. Schematic structure of MUC2. 
2.2.2 MUC3, the major membrane mucin of the intestinal tract 
MUC3 is the most abundantly expressed membrane mucin in the small intestine (Kim and 
Ho). Here, MUC3 expression on epithelial cells shows a maturational gradient with 
increasing expression from the crypt to villus. The MUC3 protein consists of two subunits, 
an extracellular region containing heavily O-glycosylated VNTR domains and two 
epidermal growth factor (EGF)-like domains. The EGF-like regions are separated by a SEA 
(sperm protein, enterokinase, and agrin) module, containing a proteolytic cleavage site 
during biosynthesis. A membrane-spanning, hydrophilic region that is responsible for 
incorporation of MUC3 into the lipid bilayer and an intracellular cytoplasmic tail (CT) with 
potential phosphorylation sites involved in signalling, lie distal to the SEA domain. The 
MUC3 ectodomain may be shed from the cell surface by the activation of membrane-
associated metalloproteinases, by the separation of two subunits in the SEA domain, or by 
alternative splicing of its mRNA. Despite the mechanism involved, shed MUC3 contributes 
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to the mucus gel overlying the intestinal epithelium. In mice, the cysteine-rich EGF-like 
domains inhibit apoptosis and stimulate cell migration, implying a regulatory role in 
maintaining the structure and function of the intestinal epithelial layer. 
2.2.3 MUC1, a membrane mucin with signaling potential 
MUC1 was the first mucin gene to be cloned (Gendler et al., 1990; Lan et al., 1990). Several 
studies have provided evidence that MUC1 plays a critical role in the intestinal tract. First, 
mice deficient in MUC1 expression have reduced amounts of intestinal mucus (Parmley and 
Gendler, 1998). Second, lack of intestinal MUC1 mucin in knockout mice impairs cholesterol 
uptake and absorption (Wang et al., 2004). Similar to MUC3, MUC1 consists of a large 
extracellular domain which is heavily glycosylated through N-acetylgalactosamine O-
linkages, a single-pass transmembrane region, and a cytoplasmic CT (Figure 3). The MUC1 
ectodomain serves as a binding site for pathogenic microorganisms, including Pseudomonas 
aeruginosa (Kato et al.; Lillehoj et al., 2001), Helicobacter pyori (Linden et al., 2004; Linden et al., 
2009), Campylobacter jejuni (McAuley et al., 2007), Escherichia coli (Parker et al., 2010; Sando et 
al., 2009), and Salmonella enterica (Parker et al., 2010). During intracellular biosynthesis, the 
MUC1 ectodomain is autoproteolytically cleaved in its SEA domain to yield two 
noncovalently associated protein chains. The 72-amino acid CT domain of MUC1 contains 7 
evolutionally conserved tyrosine residues. Many of these tyrosines are phosphorylated, 
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Upper, the MUC1 gene is located on chromosome 1q21 between the genes for thrombospondin 3 
(THBS3) and tripartite motif containing 46 (TRIM46). Lower, the seven exon structure of the MUC1 
gene and corresponding protein regions. L, leader peptide; VNTR, variable number of tandem repeats; 
SEA, sperm protein, enterokinase, and agrin; TM, transmembrane; CT, cytoplasmic tail. 
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linkages, a single-pass transmembrane region, and a cytoplasmic CT (Figure 3). The MUC1 
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Upper, the MUC1 gene is located on chromosome 1q21 between the genes for thrombospondin 3 
(THBS3) and tripartite motif containing 46 (TRIM46). Lower, the seven exon structure of the MUC1 
gene and corresponding protein regions. L, leader peptide; VNTR, variable number of tandem repeats; 
SEA, sperm protein, enterokinase, and agrin; TM, transmembrane; CT, cytoplasmic tail. 





proteins, including phosphoinositide 3-kinase (PI3K), Shc, phospholipase C-γ (PLC-γ), c-Src, 
and Grb-2 (Hattrup and Gendler, 2008; Theodoropoulos and Carraway, 2007). Binding of 
PI3K, c-Src, and Grb-2 to the CT have been experimentally verified, while Shc and PLC-γ are 
only inferred based upon the presence of the predicted amino acid sequence motifs. Other 
proteins bind to non-tyrosine sites, including glycogen synthase kinase 3β (GSK3β), protein 
kinase C-δ (PKC-δ), and β-catenin. Consensus sequences resembling an ITAM 
(immunoreceptor tyrosine-based activation motif) and ITIM (immunoreceptor tyrosine-
based inhibitory motif) are also present in the MUC1 CT region. Estrogen receptor α (ERα), 
p53, p120ctn, ErbB1-4, adenomatous polyposis coli (APC), heat shock protein 70 (Hsp70), 
and Hsp90 also have been reported as binding partners of the CT, but specific amino acid 
residues have not been identified. Analysis of downstream signaling events indicated that 
the MUC1 CT activated a Ras → MEK1/2 → ERK1/2 pathway, but the mechanism is 
unclear. 
2.3 Mucus proteoglycans 
Proteoglycans are large molecular weight glycoconjugates characterized by variable 
numbers of glycan repeats (Meisenberg, 2006). The basic proteoglycan unit consists of a core 
protein with one or more covalently attached glycosaminoglycan chain(s) to a serine 
residue. The serine residue is generally in the sequence -serine-glycine-X-glycine-, although 
not every protein with this sequence has an attached glycan moiety. The chains are long, 
linear carbohydrate polymers that are negatively charged under physiological conditions, 
due to the occurrence of sulfate and uronic acid groups. As a result of the later 
modifications, proteoglycans are highly acidic in physiologic conditions allowing them to 
bind to cations, such as Na+, K+, and Ca2+. Three types of proteoglycans were shown to be 
secreted into mucus by epithelial cells cultured in vitro, hyaluronic acid containing 
proteoglycans, chondroitin sulfate containing proteoglycans and heparan sulfate containing 
proteoglycans (Kim, 1985; Paul et al., 1988; Wu et al., 1985). While the physiologic roles of 
proteoglycans in mucus remain largely unknown, suggested functions include epithelial 
development, remodeling, inflammation, and host defense (Forteza et al., 2001; Huang et al., 
1999; Ohkawara et al., 2000; Zhao et al., 1999). 
2.4 Mucus proteinases and proteinase inhibitors 
A number of proteinases are present in mucus, all of which known to be associated with 
inflammation and derived from inflammatory cells. Among these are elastase and various 
cathepsins from neutrophils and chymase and tryptase from mast cells. Neutrophil elastase 
has been shown to cause destruction of elastin (Snider et al., 1984), stimulate mucin release 
from goblet cells (Kim et al., 1987), and induce chemotaxis via production of IL-8 by the 
underlying epithelial cells ((Nakamura et al., 1992). Excess elastase released from 
neutrophils during injury and inflammation is balanced by several proteinase inhibitors, 
including α1-anti-trypsin, soluble leukocyte protease inhibitor (sLPI), and elafin 
((Perlmutter and Pierce, 1989; Sallenave et al., 1993; Thompson and Ohlsson, 1986). 
Attenuated induction of sLPI and elafin has been reported in Crohn's disease (Schmid et al., 
2007). Chymase and trypase are proteinases produced by mast cells, the former being 
responsible for disruption of the epithelial cell barrier allowing antigens and inflammatory 
mediators to enter the intestinal mucosa, while the latter is responsible for stimulating 
mucus secretion as well as TGF-β release from the extracellular matrix (Sommerhoff et al., 
1990; Taipale et al., 1995). 
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2.5 Trefoil peptides 
Trefoil peptides, or trefoil factors (TFFs), are a group of molecules that are characterized by 
having at least one copy of the trefoil motif, a 40-amino acid domain that contains three 
conserved disulfide bonds (Wong et al., 1999). Trefiol peptides are stable secretory proteins 
expressed in the gastro-intestinal tract. Their functions are not well defined, but they may 
protect the mucosa from insults, stabilize the mucus layer, and regulate healing of the 
epithelium. The close physical association between trefoil peptides and mucins supports 
these possible roles. The trefoil domain is found in a variety of extracellular eukaryotic 
proteins, including TFF1 (or protein pS), a protein secreted by the stomach mucosa, TFF2 (or 
spasmolytic polypeptide), a protein of about 115 residues that inhibits gastro-intestinal 
motility, and TFF3 (or intestinal trefoil factor, ITF). Other proteins with trefoil domains are 
Xenopus laevis stomach proteins xP1 and xP4, Xenopus integumentary mucins A.1 and C.1, 
Xenopus skin protein xp2, zona pellucida sperm-binding protein B (ZP-B), and intestinal 
sucrase-isomaltase. TFF1 and TFF3 contain one trefoil domain, TFF2 contains two domains, 
and the Xenopus proteins contain multiple copies. All three human proteins are clustered on 
chromosome 21q22.3. Overexpression of human TFF1 in mice was reported to reduce their 
susceptibility to dextran sodium sulfate (DSS)-induced colitis and TFF-deficient mice 
exhibited increased disease susceptibility (Mashimo et al., 1996; Playford et al., 1996). 
Unfortunately, however, these animal studies have not been translated into an effective 
clinical therapy (Mahmood et al., 2005). 
3. Paneth cell 
Paneth cells are specialized intestinal epithelial cells located at the base of ileal crypts in 
healthy individuals (Bevins, 2004; Ouellette, 2011). These cells are pivotal in maintaining the 
balance between the host and the microbiome. These cells act as sentinels for the detection of 
microbial molecules which are recognized by Toll-like receptors (TLRs), germ-line encoded 
receptors specific for bacterial and viral antigens. Genetic polymorphisms in these receptors 
and their signaling pathways affect Paneth cell function and have been associated with 
Crohn’s disease (Inohara et al., 2005; Kobayashi et al., 2005). Paneth cell function is regulated 
by two additional mechanisms, the so-called unfolded protein response or UPR and 
autophagy, a process involved in clearance of intracellular microbes. The process of 
autophagy is induced by stress in the endoplasmatic reticulum (ER), which in turn is 
activated by UPR. Genetic mutations in proteins involved in both of these mechanisms have 
been linked to Crohn’s disease as well. Variations in the autophagy protein ATG16L1 were 
identified in genome-wide studies and found to be associated with increased risk of disease 
development (Hampe et al., 2007; Rioux et al., 2007). Alterations in the gene encoding the 
UPR transcription factor protein Xbox-binding protein 1 or XBP-1 are signifiantly associated 
with inflammatory bowel disease in humans (Kaser et al., 2008). Further, loss of XBP-1 
decreases the number of Paneth cells and thus the antimicrobial capacity of the intestine and 
leads to spontaneous enteritis in mice (Kaser and Blumberg, 2009; Kaser et al., 2008). Paneth 
cells are equipped with a vast arsenal of antimicrobial agents which are deployed following 
the recognition of potential microbial threats. These include enzymes, such as lysozyme , 
trypsin, phospholipase A2 and matrix metalloproteases, cytokines such as TNF-α and IL-17, 
as well as the bactericidal defensin peptides (Figure 4). In the following sections, we will 
discuss in detail the role of defensins as effectors of the innate immune system and their 
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(Left) Light microscope image of isolated human ileal crypt. Paneth cells are localized at the base of the 
crypt as indicated. The box on the right lists confirmed compounds localized in dense secretory 
granules. 
Fig. 4. Localization and cellular contents of Paneth cells. 
3.1 Defensins 
Defensins constitute a major family of antimicrobial peptides that play a protective role 
against microbial invasion of various epithelial surfaces, including the skin, respiratory tract 
and gastro-intestinal tract. Primarily, these small cationic peptides act as effectors of the 
innate immune system with the ability to kill a variety of microbial pathogens, including 
bacteria, fungi and viruses (Ganz, 2003; Zasloff, 2002). Based on a difference in disulfide 
connectivity of six conserved cysteine residues, defensins have been divided in two families, 
termed  and . Both families are believed to have evolved from a common ancestral -
defensin gene (Patil et al., 2004; Schutte et al., 2002), and share similar tertiary structures 
despite low amino acid sequence identity (Hill et al., 1991; Pazgiera et al., 2006; Szyk et al., 
2006). In humans, -defensins are widely expressed in epithelial cells. Defensins of the -
family are expressed predominantly in neutrophils (termed human neutrophil peptides, or 
HNPs) or in ileal Paneth cells in the case of Human Defensin 5 and 6 (HD-5 and HD-6) 
(Porter et al., 2002; Selsted and Ouellette, 2005). 
In addition to their antimicrobial activities, increasing evidence suggests that defensins play 
a significant role in innate and adaptive immunity. Such functions include chemoattraction 
and immune cell activation and promotion of cell proliferation, often involving interactions 
with cellular receptors (Aarbiou et al., 2002; Biragyn et al., 2002; Grigat et al., 2007; Yang et 
al., 1999). The capacity to chemoattractant monocytes was first described for HNPs (Territo 
et al., 1989). Subsequently, HNPs were shown to chemoattract different subsets of T 
lymphocytes and immature dendritic cells (Chertov et al., 1997; Yang et al., 2000). Similar 
functions were reported for -defensins, which were shown to selectively chemoattract 
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immature dendritic cells and memory T lymphocytes (Yang et al., 1999; Yang et al., 2001). 
More recently, -defensins were shown to act as endogenous ligands for TLRs on immature 
dendritic cells directly. This interaction mediated signaling for dendritic cell maturation and 
triggered a polarized immune response in vivo (Biragyn et al., 2002). In the case of human -
defensin-2 (HBD-2), the observed chemotaxis of immature dendritic cells and memory T 
cells was shown to result from directly binding the chemokine receptor CCR6 (Yang et al., 
1999). Subsequently, a murine -defensin was shown to recruit tumor-infiltrating dendritic 
cell precursors through CCR6 also (Conejo-Garcia et al., 2004). In contrast to these earlier 
studies, it was reported recently that -defensins chemoattract mast cells and macrophages 
but not dendritic cells and lymphocytes and that CCR6 was not involved (Soruri et al., 2007). 
Specific receptors for the chemotactic activity of -defensins have not been identified. 
Several studies however have shown that also for -defensins this activity is blocked by 
pertussis toxin, indicating the involvement of Gi�-coupled receptors (Chertov et al., 1996; 
Yang et al., 2000). 
3.1.1 Alpha-Defensins and gastro-intestinal inflammation 
There is increasing evidence that aberrant defensin expression is correlated to inflammation 
of the gastro-intestinal tract. A specific deficiency of the enteric -defensin HD-5 was 
observed in patients suffering from ileal Crohn’s disease (Wehkamp et al., 2005b). 
Interestingly, the HD-5 deficiency was more pronounced in patients carrying loss-of-
function mutations in the cellular receptor NOD2, an intracellular receptor for the bacterial 
peptidoglycan component muramyl dipeptide (Inohara et al., 2005). NOD2 is 
predominantly expressed in the distal part of the ileum in a number of cell types including 
Paneth cells, which are the sole source of HD-5 (Bevins, 2006; Porter et al., 2002). In addition 
to recognition of bacterial ligands, NOD2 monitors the expression of enteric -defensins. 
Genetic polymorphisms in the NOD2/CARD15 gene have been identified to be tightly linked 
with susceptibility to Crohn’s disease (Hugot et al., 2001; Ogura et al., 2001) and with 
decreased defensin expression. 
A number of recent animal model studies have underscored the importance of NOD2 and 
defensin expression in relation to infection. Compared with wild-type mice, NOD2 deficient 
mice showed reduced expression of certain -defensins, resulting in increased susceptibility 
to oral infection by Listeria monocytogenes (Kobayashi et al., 2005). Similarly, mice that lack 
mature cryptdins (the murine orthologue for -defensins) are more susceptible to ileal 
colonization by non-invasive Escherichia coli (Wilson et al., 1999). Paneth cell expression of 
HD-5 rendered mice markedly resistant to oral, but not peritoneal, challenge with a virulent 
strain of Salmonella typhymurium (Salzman et al., 2003). Interestingly, HD-5 transgenic mice 
showed a striking loss of segmented filamentous bacteria and had fewer IL-17-producing 
lamina propria T cells (Salzman et al., 2010). These findings are in support of the notion that 
defensin deficiency may alter the microbiome, which in turn affects the adaptive immune 
response of the host. IL-17-producing T cells, however, were also observed in wild-type 
mice with functional defensins, in the specific absence of this class of bacteria. Additionally, 
HD-5 was shown to slightly improve mortality in lethal DSS-induced colitis in mice by 
intraperitoneal injection; however no effect on disease was noted when the defensin was 
administered orally (Ishikawa et al., 2009). This may suggest that HD-5 directly affects 
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A number of recent studies report on the role of ileal defensins in mucosal immunity and 
inflammation in humans. Single nucleotide polymorphisms in the gene encoding HD-5 have 
also been described recently in a New Zealand Caucasian population that may confer 
susceptibility to inflammatory bowel disease (Ferguson et al., 2008). Luminal processing of 
pro-HD-5 to its mature form was found to be impaired in Crohn’s patients specifically 
(Elphick et al., 2008). As in mice, human enteric defensins HD-5 and HD-6 are synthesized 
as pro-peptides in Paneth cells and processed after secretion by trypsin in humans (Ghosh et 
al., 2002). In the majority of Crohn’s disease patients, HD-5 appeared in a complex with its 
processing enzyme trypsin or chymotrypsin, thus rendering the peptide inactive (Elphick et 
al., 2008). Additionally, expression of HD-5 was markedly decreased in transplanted human 
small intestinal allografts (Fishbein et al., 2008). Rejection of allografts resembles Crohn’s 
disease clinically and pathologically (Podolsky, 2002; Shanahan, 2002). Notably, decrease in 
the expression of HD-5 preceded visible damage to the intestinal epithelium. Finally, 
expression of both HD-5 and HD-6 was reported to be non-significantly decreased in active 
ileal Crohn’s disease and decreased expression correlated positively with decreased Vil1 
expression, a marker for epithelial integrity (Arijs et al., 2009). 
3.1.2 Beta-Defensins and gastro-intestinal inflammation 
Impaired induction of -defensins in the mucosal epithelium has been predominantly linked 
to colonic Crohn’s disease (Fellermann and Stange, 2001; Wehkamp et al., 2002; Wehkamp et 
al., 2005a; Wehkamp et al., 2005c). The most widely studied -defensin in the context of gut 
inflammation is human -defensin-2 or HBD-2. Genetic polymorphisms (Fellermann et al., 
2006), and especially gene copy number of HBD-2 (Fellermann et al., 2006; Hollox, 2008; 
Hollox et al., 2003), have been identified as risk factors in colonic Crohn’s. More recently, 
expression of HBD-2 at both RNA and protein levels was found to be dysregulated in 
biopsies from colonic Crohn’s patients (Aldhous et al., 2009). Interestingly, in this study, 
HBD-2 expression correlated with IL-10 production, irrespective of variations in HBD-2 
gene copy number or variations in the HBD-2 promoter region. Additional studies on other 
members of the human -defensin family emphasize their involvement in mucosal defense. 
Expression of HBD-1 was found to be protective in colonic Crohn’s disease (Peyrin-Biroulet 
et al., 2010). Protective expression of HBD-1 occured via activation of the peroxisome 
proliferator-activated receptor (PPAR)-γ with rosiglitazone (Peyrin-Biroulet et al., 2010) or 
independently via a single nucleotide polymorphism in the HBD-1 gene promoter region 
(Kocsis et al., 2008). Two studies have reported on colonic Crohn’s association of gene copy 
number of the gene encoding HBD-2, however with contrasting results (Bentley et al., 2010; 
Fellermann et al., 2006). 
4. M cells 
M cells, or microfold cells, are specialized epithelial cells of the ileum that have evolved to 
sample the gut lumen and relay this information to the underlying tissues. They are located 
in a region of the epithelium that is commonly referred to as the follicle-associated 
epithelium, or FAE, comprising the Peyer’s patches and underlying lymphoid follicles 
(Figure 5). M cells exhibit microfolds, but not microvilli, and display a thin glycocalyx 
compare with absorptive enterocytes, making them more accessible to microbes (Gebert, 
1996; Kyd and Cripps, 2008). Sensing and transport of microbes by M cells is facilitated by 
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the expression of TLRs, integrins and microbial adhesion molecules such as galectin-9 (Kyd 
and Cripps, 2008; Pielage et al., 2007). 
 
 
Microfold (M) cells specialize in antigen sampling of the gut lumen and act as a selective conduit to 
underlying components of adaptive immunity without compromising epithelial barrier function. 
Fig. 5. Structure of the follicle-associated epithelium. 
M cells do not harbor many lysosomes and do not express major histocompatibility (MHC) 
class II molecules, suggesting that most antigens that are transported are not degraded 
(Owen et al., 1986; Pickard and Chervonsky, 2010). Because of their relatively weak defenses 
compared with other sites of the ileal mucosa, M cells are exploited by pathogens as a 
potential entry site for infection. Such pathogens include EHEC and EPEC strains of 
Escherichia coli (Fitzhenry et al., 2002; Phillips et al., 2000), as well as Shigella flexneri and 
Salmonella typhymurium (Jensen et al., 1998). Viruses may also use M cells as a point of entry 
and specific receptors for HIV (Fotopoulos et al., 2002) and reovirus (Helander et al., 2003) 
on M cells have been identified. 
4.1 M cells and gastro-intestinal inflammation 
It is technically challenging to study human M cells in vitro, mainly because of the absence 
of clear cellular markers. Differentiation of enterocytes into M cells likely requires epithelial 
cell-T lymphocyte cross-talk as indicated by a co-culture model of these two types of cells 
(Kerneis et al., 1997). Most of our current knowledge on M cells and their role in gastro-
intestinal disease comes from animal studies. Various models of chemically induced 
intestinal inflammation have been used to study M cells, the FAE and interplay with the 
underlying Peyer’s patches. In an indomethacin-induced enteritis model in rats, M cell 
numbers increased initially and showed increased apoptosis in inflamed tissue only 
(Kucharzik et al., 2000; Lugering et al., 2004). In the DSS-induced model of colitis in mice, 
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nodes, but not with mice lacking Peyer’s patches only (Spahn et al., 2002). Three further 
studies emphasize the role of epithelial cross-talk with the underlying mucosal tissue at the 
FAE. The SAMP1/Yit mouse strain develops spontaneous ileal inflammation (Matsumoto et 
al., 1998). In this model, as well as in a water avoidance stress-induced rat model, early 
inflammatory lesions were observed in the FAE (Kosiewicz et al., 2001; Velin et al., 2004). 
Very recently, the FAE and M cells were shown to be targeted specifically by adhesive-
invasive E. coli bacteria associated with Crohn’s disease (Chassaing et al., 2011). The 
interaction between these bacteria and Peyer’s patches of mouse and human was shown to 
depend on bacterial production of long, polar fimbriae. Such interactions may trigger the 
recruitment of subsets of dendritic cells or Th1 cells with increased potential for the 
production of TNF-α, as observed in mucosa of Crohn’s disease patients (de Baey et al., 
2003; Koboziev et al., 2010; Kudo et al., 2004). 
5. Conclusion 
It is becoming increasingly evident that intestinal health requires a controlled and balanced 
interplay between microbes and the host. The host provides microbes with a unique 
environment of constant nutrition and temperture, whereas microbes aid in food 
degradation and shape host immunity. In maintaining this balance, the epithelium stands 
guard, constantly sampling and relaying messages to elicit a rapid immune response if 
neccesary. At the same time, epithelial cells are continually self-renewing and differentiating 
to cope with the dynamics of this balance and have evolved into specialized, recognizable 
subsets. Together, these subsets form a selective barrier consisting of physical, chemical and 
biological components. In spite of harboring a tremendous arsenal of defensive agents, this 
barrier does have weaknesses which can be exploited by potentially harmful organisms. 
Some of these weaknesses have become apparent in an environment where the host is 
genetically predisposed. The inability of the host to timely recognize or eliminate microbes 
provides a window of opportunity for penetration of the epithlium, which may eventually 
lead to inflammation.  
In addition to chemical drug treatment, biological therapy has proven its efficacy in 
treatment of active Crohn’s disease. In particular, treatment to eliminate excess tumor 
necrosis factor alpha or decrease cell trafficking and adhesion by administration of 
monoclonal antibodies is clinically used in mild to severe cases. Both excess of tumor 
necrosis factor alpha as well as increased cell adhesion negatively affect the barrier function 
of the epithelium. Whether an epithelial imbalance is primarily caused by changes in innate 
or adaptive immunty is currently unclear and will likely vary between individuals. It is clear 
that disturbance of this delicate balance by environmental factors, pathogens or underlying 
genetic predispositions of the host may lead to inflammation. Clinically, an imbalance 
caused by one of these factors is often indistuinguishable from the other. For these reasons, 
having an understanding of the patients genetic background may help to determine the 
preferential clinical therapy. Restoration of epithelial barrier function will be an important 
goal of any therapy, either by strenthening the antibacterial capacity of the gut or by 
restoring the underlying inflammatory cascade. Additionally, as more and more is revealed 
about the "black box" which we refer to as the microbiome in the human intestinal tract, 
alternative approaches to restoration of immune balance may become apparent. 
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1. Introduction 
Crohn’s Disease (CD), together with ulcerative colitis (UC) belongs to inflammatory bowel 
diseases (IBD). Among its typical symptoms are inflammation, abdominal pain, melaena, 
diarrhea, ulcers and even fistulas. So far the etiology of CD remains unclear, but what is 
certain, is that it is multifactorial. Causing chronic inflammation and starting an 
immunological response requires both genetic factors, as well as environmental ones. What 
is more, CD is multigenetic – various genes could be a potential cause of the disease; among 
them are e.g. CARD15/NOD2, ATG16L1 and IL23R (Barrett et al., 2008; Cukovic-Cavka 2006, 
Cho 2008, Lesage 2002).  
2. Aim of the study 
The aim of this study was to investigate the polymorphisms in the CARD15/NOD2 
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correlations, or associations between the genotypes and alleles, and the localization of 
gastrointestinal and extra-intestinal symptoms of the disease.  
3. Materials and methods 
A total of 289 subjects took part in this study: 139 CD patients (60 women, 79 men) and 150 
individuals in a population based control group (73 women, 77 men). All the patients were 
patients of Poznan University of Medical Sciences, Poland, Department of Gastroenterology, 
Human Nutrition and Internal Diseases. Moreover, all the subjects participating in this 
research project were adults, who had agreed to take part in genetic testing. The population 
group came from the DNA bank of the Institute for Human Genetics at the Polish Academy 
of Science. Genotyping was performed for all the investigated individuals. If obtaining 
reliable result was impossible, a given probe was eliminated from further analysis. That is 
why,  the number of individuals in particular analyses may differ. In some cases, obtaining 
the data pertaining to the localization of the symptoms, as well as other co-existing 
symptoms was also impossible. Similarly, probes without an complete disease history were 
not included in further research. 
Peripheral blood samples were collected on EDTA in the amount of 5 ml.  Next, DNA was 
isolated from leukocytes, using the GTC (guanidine thiocyanate) and phenol-chlorophorm 
extraction method (Slomski et al, 2008). The isolates were dissolved in 1xTE buffer to obtain 
500ng/µl concentration.  
In the investigation of single nucleotide polymorphism (SNP) pyrosequencing was 
performed. A polymerase chain reaction (PCR) was performed for each probe with a set of 
primers: two for PCR, including a biothynylated one, and primer for sequencing. The 
sequences of the primers were designed with the use of computer software software 
dedicated to pyrosequencing (Table 1). 
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Table 2. Analyzed sequences. SNPs are marked. 
 
SNP Population group CD patients p 
CARD15_G908R Amount % Amount %  
CC 139 93,9 136 91,9 ns 
CG 9 6,1 11 7,4 ns 
GG 0 0,0 1 0,7 ns 
ATGrs2241879 Amount % Amount %  
GA 39 55,7 75 48,7 ns 
AA 19 27,1 48 31,2 ns 
GG 12 17,1 31 20,1 ns 
ATG16L1rs2241880 Amount % Amount %  
TC 46 47,9 74 47,4 ns 
CC 22 22,9 48 30,8 ns 
TT 28 29,2 34 21,8 ns 
IL23Rrs 7517847 Amount % Amount %  
GT 51 53,7 75 48,7 ns 
TT 33 34,7 62 40,3 ns 
GG 11 11,6 17 11,0 ns 
IL23Rrs 1004819 Amount % Amount %  
TT 4 4,3 18 15,9 ns 
TC 48 51,1 40 35,4 ns 
CC 42 44,7 55 48,7 ns 
Table 3. Genotype frequencies and statistical significance. 
Statistical analysis was performed using the exact Fisher test and the test for differences 
between two frequencies (odds ratio – OR). A p-value of less than 0.05 was accepted as 
statistically significant. 
Symptoms of CD can be localized in the area of the entire gastrointestinal tract (GIT), 
starting at the oral cavity and ending with the anus; however, extra-intestinal symptoms are 
also characteristic of this disease. The GIT symptoms were divided into: symptoms 
occurring in the oral cavity, esophagus, stomach and duodenum, small intestine, colon, and 





correlations, or associations between the genotypes and alleles, and the localization of 
gastrointestinal and extra-intestinal symptoms of the disease.  
3. Materials and methods 
A total of 289 subjects took part in this study: 139 CD patients (60 women, 79 men) and 150 
individuals in a population based control group (73 women, 77 men). All the patients were 
patients of Poznan University of Medical Sciences, Poland, Department of Gastroenterology, 
Human Nutrition and Internal Diseases. Moreover, all the subjects participating in this 
research project were adults, who had agreed to take part in genetic testing. The population 
group came from the DNA bank of the Institute for Human Genetics at the Polish Academy 
of Science. Genotyping was performed for all the investigated individuals. If obtaining 
reliable result was impossible, a given probe was eliminated from further analysis. That is 
why,  the number of individuals in particular analyses may differ. In some cases, obtaining 
the data pertaining to the localization of the symptoms, as well as other co-existing 
symptoms was also impossible. Similarly, probes without an complete disease history were 
not included in further research. 
Peripheral blood samples were collected on EDTA in the amount of 5 ml.  Next, DNA was 
isolated from leukocytes, using the GTC (guanidine thiocyanate) and phenol-chlorophorm 
extraction method (Slomski et al, 2008). The isolates were dissolved in 1xTE buffer to obtain 
500ng/µl concentration.  
In the investigation of single nucleotide polymorphism (SNP) pyrosequencing was 
performed. A polymerase chain reaction (PCR) was performed for each probe with a set of 
primers: two for PCR, including a biothynylated one, and primer for sequencing. The 
sequences of the primers were designed with the use of computer software software 
dedicated to pyrosequencing (Table 1). 
 




















Table 1. Primers used for analysis. 
Genotyping of CARD15/NOD2, ATG16L1 and IL23R Genes in Polish Crohn’s Disease (CD)  
Patients – Are They Related to the Localization of the Disease and Extra-Intestinal Symptoms? 
 
41 






Table 2. Analyzed sequences. SNPs are marked. 
 
SNP Population group CD patients p 
CARD15_G908R Amount % Amount %  
CC 139 93,9 136 91,9 ns 
CG 9 6,1 11 7,4 ns 
GG 0 0,0 1 0,7 ns 
ATGrs2241879 Amount % Amount %  
GA 39 55,7 75 48,7 ns 
AA 19 27,1 48 31,2 ns 
GG 12 17,1 31 20,1 ns 
ATG16L1rs2241880 Amount % Amount %  
TC 46 47,9 74 47,4 ns 
CC 22 22,9 48 30,8 ns 
TT 28 29,2 34 21,8 ns 
IL23Rrs 7517847 Amount % Amount %  
GT 51 53,7 75 48,7 ns 
TT 33 34,7 62 40,3 ns 
GG 11 11,6 17 11,0 ns 
IL23Rrs 1004819 Amount % Amount %  
TT 4 4,3 18 15,9 ns 
TC 48 51,1 40 35,4 ns 
CC 42 44,7 55 48,7 ns 
Table 3. Genotype frequencies and statistical significance. 
Statistical analysis was performed using the exact Fisher test and the test for differences 
between two frequencies (odds ratio – OR). A p-value of less than 0.05 was accepted as 
statistically significant. 
Symptoms of CD can be localized in the area of the entire gastrointestinal tract (GIT), 
starting at the oral cavity and ending with the anus; however, extra-intestinal symptoms are 
also characteristic of this disease. The GIT symptoms were divided into: symptoms 
occurring in the oral cavity, esophagus, stomach and duodenum, small intestine, colon, and 









The first aim of the project was to determine the differences in the genotype and allele 
frequencies, taking into consideration the two investigated groups of individuals: CD 
patients and the population group. 
A statistical analysis of the genotypes did not reveal any significant differences in genotype 
frequencies (Table 3), but the allele analysis revealed that the frequency of alleles in 
ATG_rs2241880 and IL23Rrs7517847 differs significantly between the CD subjects and the 
population group (Table 4). 
 
SNP CD patients Population group p 
CARD15_G908R Amount % Amount %  
G 12 7,55 9 5,66 ns 
C 147 92,45 148 93,08 ns 
ATGrs2241879 Amount % Amount %  
G 106 46,29 51 46,29 ns 
A 123 53,71 57 53,71 ns 
ATG_rs2241880 Amount % Amount %  
T 108 46,96 78 33,91 p=0,0775 
C 122 53,04 68 29,57 p=0,0017 
IL23Rrs7517847 Amount % Amount %  
T 137 59,83 84 36,68 p=0,0011 
G 92 40,17 62 27,07 p=0,0987 
IL23Rrs1004819 Amount % Amount %  
T 58 37,91 52 33,99 ns 
C 95 62,09 90 58,82 ns 
Table 4. Allele frequencies and statistical significance. 
4.2 The correlation between genotypes and the localization of GIT symptoms  
Symptoms were divided into: symptoms occurring in the oral cavity, esophagus, stomach 
and duodenum, symptoms displayed by the small intestine, colon, and the presence of 
fistulas. Genotype analysis and its relation to the localization of GIT symptoms  revealed 
that the only polymorphism that is connected with localization of the disease symptoms in 
the Polish CD population is IL23R rs7517847, and which is related to the symptoms localized 
in the small intestine.  
Genotyping of CARD15/NOD2, ATG16L1 and IL23R Genes in Polish Crohn’s Disease (CD)  











 small intestine  colon  perianal fistulas  
Geno-
type CC CG GG ∑ CC CG GG ∑ CC CG GG ∑ CC CG GG ∑ 
yes 4 1 0 5 40 3 0 43 50 6 0 56 22 0 0 22 
no 73 6 0 79 36 4 0 40 26 1 0 27 55 7 0 62 
Total 77 7 0 84 76 7 0 83 76 7 0 83 77 7 0 84 




ns CC vs GG p<0.0001 CC vs CG p< 0.001 ns ns 
 
Table 5. CARD15/NOD2 G908R genotype analysis and its relation with the localization of 
GIT symptoms. 
Statistical analysis did not indicate any significant discrepancies, but some tendencies were 
observed. A comparison of the genotypes proved that the CC genotype is statistically more 









 small intestine  colon  perianal fistulas  
Geno-
type GA AA GG ∑ GA AA GG ∑ GA AA GG ∑ GA AA GG ∑ 
yes 1 1 2 4 22 16 8 46 33 16 10 59 16 3 5 24 
no 43 25 16 84 22 9 10 41 11 9 8 28 29 22 13 64 
Total 44 26 18 88 44 25 18 87 44 25 18 87 45 25 18 88 




ns GA vs GG p=0.005 ns ns 
 
Table 6. ATG16L1 rs2241879 genotype analysis and its relation to the localization GIT 
symptoms. 
Genotype comparison revealed certain tendencies, i.e. that in the case of the ATG rs2241879 
polymorphism, among CD patients with symptoms localized in the small intestine, the GA 
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type TC CC TT ∑ TC CC TT ∑ TC CC TT ∑ TC CC TT ∑ 
yes 2 2 1 5 23 15 9 47 35 15 11 61 14 4 6 24 
no 44 24 18 86 23 10 10 43 11 10 8 29 33 21 13 67 
Total 46 26 19 91 46 25 19 90 46 25 19 90 47 25 19 91 




ns TCvsTTp=0.005 ns ns 
 
Table 7. ATG16L1 rs2241880 genotype analysis and its relation to the localization of GIT 
symptoms. 
The comparison of genotypes suggests, that among CD patients with symptoms localized in 
small intestine, as far as the ATG16L1 rs2241880 polymorphism is concerned, the TC 












types TT TC CC ∑ TT TC CC ∑ TT TC CC ∑ TT TC CC ∑ 
yes 1 1 1 3 3 17 20 40 8 22 25 55 2 9 11 22 
no 10 32 35 77 8 15 16 39 3 10 11 24 9 23 25 57 
Total 11 33 36 80 11 32 36 79 11 32 36 79 11 32 36 79 




ns TTvsCCp=0.005 ns ns 
 
Table 8. IL23R rs1004819  genotype analysis and its relation to the localization of GIT 
symptoms. 
Genotype comparison showed that, among CD patients, in the IL23R rs1004819 
polymorphism, the TT genotype is significantly more related to the localization of the 
symptoms in the small intestine than the CC genotype. 
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types TT GT GG ∑ TT GT GG ∑ TT GT GG ∑ TT GT GG ∑ 
yes 1 2 0 3 23 15 7 45 24 28 7 59 11 9 3 23 
no 36 37 11 84 14 23 4 41 13 10 4 27 26 30 8 64 
Total 37 39 11 87 37 38 11 86 37 38 11 86 37 39 11 87 










Table 9. IL23R rs7517847 genotype analysis and its relation with the localization of GIT 
symptoms. 
Statistical analysis demonstrates that the only polymorphism that can statistically be 
connected with intestinal localization of CD is rs7517847 in the IL23R gene (p=0.0364).   
What is more, genotype comparison revealed that the TT genotype is significantly more 
frequent than the GG one in the case of CD patients, whose symptoms are localized in the 







small intestine colon perianal fistulas 
CARD15 
_908 G C Σ G C Σ G C Σ G C Σ 
yes 1 5 6 3 43 46 6 56 62 0 22 22 
no 6 79 85 4 40 44 1 27 28 7 62 69 
Total 7 84 91 7 83 90 7 83 90 7 84 91 




ns C vs G p<0.001 C vs G p<0.001 C vs G p<0.001 
Table 10. CARD15/NOD2 G908R allele analysis and its relation to the localization of 
symptoms in the GI track. 
4.3 Correlation between alleles frequency and GIT symptoms localization 
For each of the investigated polymorphisms, allele distribution analysis was performed, as 
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localization of the symptoms in the GI track. The results are presented in tables 10 – 14. 
None of the alleles seem to be significantly related with the localization of the GI track 
symptoms. However, genotype comparison revealed certain tendencies, which are 
presented in the tables below.  
In CARD15/NOD2 G908R polymorphism, allele C was more frequent among patients with 







small intestine colon perianal fistulas 
ATGrs 
2241879 G A Σ G A Σ G A Σ G A Σ 
yes 3 2 5 30 38 68 43 49 92 21 19 40 
no 59 68 127 32 31 63 19 20 39 42 51 93 
Total 62 70 132 62 69 131 62 69 131 63 70 133 




ns ns ns ns 
 
Table 11. ATG16L1 rs2241879 alleles analysis and its relation to the localization of symptoms 







small intestine colon perianal fistulas 
ATGrs 
2241880 T C Σ T C Σ T C Σ T C Σ 
Yes 3 4 7 32 38 70 46 50 96 20 18 38 
No 62 68 130 33 33 66 19 21 40 46 54 100 
Total 65 72 137 65 71 136 65 71 136 66 72 138 




ns ns ns ns 
 
Table 12. ATG16L1 rs2241880 allele analysis and its relation to the localization of symptoms 
in the GI track. 
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small intestine colon perianal fistulas 
IL23Rrs 
7517847 T G Σ T G Σ T G Σ T G Σ 
yes 3 2 5 38 22 60 52 35 87 20 12 32 
no 73 48 121 37 27 64 23 14 37 56 38 94 
Total 76 50 126 75 49 124 75 49 124 76 50 126 




ns ns T vs G p<0.02 ns 
 
Table 13. IL23R rs7517847 allele analysis and it’s relation to the localization of symptoms in 
GI track. 
In IL23R rs7517847 what was observed, was the tendency for the predominant presence of 








small intestine colon perianal fistulas 
IL23Rrs 
1004819 T C Σ T C Σ T C Σ T C Σ 
yes 2 2 4 20 37 57 30 47 77 11 20 31 
no 42 67 109 23 31 54 13 21 34 32 48 80 
Total 44 69 113 43 68 111 43 68 111 43 68 111 




ns ns C vs T p<0.04 ns 
 
Table 14. IL23R rs1004819 alleles analysis and its relation to the localization of symptoms in 
GI track. 
In IL23R rs1004819, what was observed, was the tendency for allele C, rather than T to be 
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Table 14. IL23R rs1004819 alleles analysis and its relation to the localization of symptoms in 
GI track. 
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4.4 The correlation between the frequency of genotypes and  the localization of non-
GIT symptoms  
The second part of this research project was devoted to the analysis of the relations between 
the genotypes and extra-intestinal symptoms. Extra-intestinal symptoms were divided into: 
arthralgia, uveitis, iritis, stomatitis aphtosa, erythema nodosum, fatty liver or elevated body 
temperature. The results are presented in tables 15-24. 
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Table 15. Analysis of genotypes and their correlation with the extra-intestinal  symptoms. 
A comparison of the genotypes revealed the tendency for the CC genotype to be the 
statistically predominant one in all the investigated cases. 
 
 
 fatty liver  elevated body temperature  
CARD15 
G908R CC CG GG ∑ CC CG GG ∑ 
yes 4 1 0 5 35 6 0 41 
no 71 6 0 77 40 1 0 41 
Total 75 7 0 82 75 7 0 82 




ns  CCvsCG p<0.001 CCvsGG p<0.0001  
Table 16. Analysis of genotypes and their correlation with extra-intestinal symptoms. 
Genotype comparison revealed the tendency for the CC genotype to be statistically more 
frequent than GG and CG ones among patients declaring elevated body temperature. 
Although, in our opinion, elevated body temperature cannot be treated as a symptom 
specific to CD (rather as a symptom related to the chronic inflammation), the decision was 
made to include it into the group of extra-intestinal symptoms, since it was mentioned as a 
symptom by the patients. 
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rs2241879 GA AA GG ∑ G A AA GG ∑ GAAA GG ∑ G A AA GG ∑ GA AA GG ∑ 
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Total 45 25 17 87 44 25 17 86 44 25 17 86 44 25 17 86 44 25 17 86 
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Table 17. Analysis of the genotypes, and their correlation with extra-intestinal symptoms. 
Genotype comparison showed the tendency for the GA genotype to be the statistically 
prevailing one among patients declaring joint pain and erythema nodosum. 
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rs2241879 GA AA GG ∑ GA AA GG ∑ 
Yes 3 0 2 5 22 14 6 42 
no 41 25 15 81 22 11 11 44 
Total 44 25 17 86 44 25 17 86 
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Genotype 
comparison   GAvsGG p<0.001  
Table 18. Analysis of the genotypes, and their correlation with extra-intestinal symptoms. 
Genotype comparison showed a tendency for the GA genotype to be statistically more 
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Genotype comparison showed that in patients complaining of joint pain and erythema 
nodosum, the TC genotype was statistically the most common one. 
 
ATG 
rs2241880 fatty liver  elevated body temperature  
 TC CC TT ∑ TC CC TT ∑ 
Yes 3 0 2 5 22 14 8 44 
no 43 25 16 84 24 11 10 45 
Total 46 25 18 89 46 25 18 89 
p ns  ns  
Genotype 
comparison ns  TCvsTT p<0.01  
Table 20. Analysis of the genotypes, and their correlation with extra-intestinal symptoms. 
The TC genotype was more frequent than the TT one among patients with an elevated body 
temperature. 
 




rs7517 847 TT GT GG ∑ TT GT GG ∑ TT GT GG ∑ TT GT GG ∑ TT GT GG ∑ 
yes 24 21 8 53 7 3 2 12 4 5 1 10 10 10 4 24 6 8 5 19 
no 12 18 3 33 28 36 9 73 31 34 10 75 25 29 7 61 29 31 6 66 
Total 36 39 11 86 35 39 11 85 35 39 11 85 35 39 11 85 35 39 11 85 
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Table 21. Analysis of genotypes, and their correlation with extra-intestinal symptoms. 
Genotype comparison showed two tendencies: in patients complaining of joint pain, the TT 
genotype was statistically more frequent than the GG one, but GT was more frequent than GG. 
 
 fatty liver  elevated body temperature  
IL23R 
rs7517847 TT GT GG ∑ TT GT GG ∑ 
yes 2 3 0 5 22 14 5 41 
no 33 36 11 80 13 25 6 44 
Total 35 39 11 85 35 39 11 85 
p ns  ns  
Genotype 
comparison ns  
TTvsGG p<0.03 
GTvsGG p<0.01  
Table 22. Analysis of the genotypes, and their correlation with extra-intestinal symptoms. 
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Again, an elevated body temperature was related to the presence of the TT but not the GG 
genotype, as well as the GT but not GG genotype. However, as it was mentioned above, we 
do not believe it should be associated with CD specifically. 
 
 




rs1004 819 TT TC CC ∑ TT TC CC ∑ TT TC CC ∑ TT TC CC ∑ TT TC CC ∑ 
Yes 8 19 19 46 3 3 6 12 2 4 3 9 5 7 11 23 2 4 13 19 
no 3 13 17 33 8 29 30 67 9 28 33 70 6 25 25 56 9 28 23 60 
Total 11 32 36 79 11 32 36 79 11 32 36 79 11 32 36 79 11 32 36 79 




ns ns ns ns TTvsCC p<0.03 TCvsCC p<0.03 
 
Table 23. Analysis of the genotypes, and their correlation with extra-intestinal symptoms. 




 fatty liver  elevated body temperature  
IL23R 
rs1004819 TT TC CC ∑ TT TC CC ∑ 
Yes 2 2 1 5 8 11 18 37 
no 9 30 35 74 3 21 18 42 
Total 11 32 36 79 11 32 36 79 
p ns  P=0.078  
Genotype 
comparison ns  CCvsTT p<0.03  
 
Table 24. Analysis of the genotypes and their correlation with extra-intestinal symptoms. 
A comparison of the genotypes revealed the tendency for the CC genotype to be statistically 
more frequent than the TT one in patients declaring elevated body temperature. 
4.5 The correlation between allele frequency and the localization of non-GIT 
symptoms 
The analysis of allele frequency in exact polymorphisms among CD patients was correlated 
with extra-intestinal symptoms. Although no significant results were obtained, some 





Genotype comparison showed that in patients complaining of joint pain and erythema 
nodosum, the TC genotype was statistically the most common one. 
 
ATG 
rs2241880 fatty liver  elevated body temperature  
 TC CC TT ∑ TC CC TT ∑ 
Yes 3 0 2 5 22 14 8 44 
no 43 25 16 84 24 11 10 45 
Total 46 25 18 89 46 25 18 89 
p ns  ns  
Genotype 
comparison ns  TCvsTT p<0.01  
Table 20. Analysis of the genotypes, and their correlation with extra-intestinal symptoms. 
The TC genotype was more frequent than the TT one among patients with an elevated body 
temperature. 
 




rs7517 847 TT GT GG ∑ TT GT GG ∑ TT GT GG ∑ TT GT GG ∑ TT GT GG ∑ 
yes 24 21 8 53 7 3 2 12 4 5 1 10 10 10 4 24 6 8 5 19 
no 12 18 3 33 28 36 9 73 31 34 10 75 25 29 7 61 29 31 6 66 
Total 36 39 11 86 35 39 11 85 35 39 11 85 35 39 11 85 35 39 11 85 







ns ns ns ns 
Table 21. Analysis of genotypes, and their correlation with extra-intestinal symptoms. 
Genotype comparison showed two tendencies: in patients complaining of joint pain, the TT 
genotype was statistically more frequent than the GG one, but GT was more frequent than GG. 
 
 fatty liver  elevated body temperature  
IL23R 
rs7517847 TT GT GG ∑ TT GT GG ∑ 
yes 2 3 0 5 22 14 5 41 
no 33 36 11 80 13 25 6 44 
Total 35 39 11 85 35 39 11 85 
p ns  ns  
Genotype 
comparison ns  
TTvsGG p<0.03 
GTvsGG p<0.01  
Table 22. Analysis of the genotypes, and their correlation with extra-intestinal symptoms. 
Genotyping of CARD15/NOD2, ATG16L1 and IL23R Genes in Polish Crohn’s Disease (CD)  
Patients – Are They Related to the Localization of the Disease and Extra-Intestinal Symptoms? 
 
51 
Again, an elevated body temperature was related to the presence of the TT but not the GG 
genotype, as well as the GT but not GG genotype. However, as it was mentioned above, we 
do not believe it should be associated with CD specifically. 
 
 




rs1004 819 TT TC CC ∑ TT TC CC ∑ TT TC CC ∑ TT TC CC ∑ TT TC CC ∑ 
Yes 8 19 19 46 3 3 6 12 2 4 3 9 5 7 11 23 2 4 13 19 
no 3 13 17 33 8 29 30 67 9 28 33 70 6 25 25 56 9 28 23 60 
Total 11 32 36 79 11 32 36 79 11 32 36 79 11 32 36 79 11 32 36 79 




ns ns ns ns TTvsCC p<0.03 TCvsCC p<0.03 
 
Table 23. Analysis of the genotypes, and their correlation with extra-intestinal symptoms. 




 fatty liver  elevated body temperature  
IL23R 
rs1004819 TT TC CC ∑ TT TC CC ∑ 
Yes 2 2 1 5 8 11 18 37 
no 9 30 35 74 3 21 18 42 
Total 11 32 36 79 11 32 36 79 
p ns  P=0.078  
Genotype 
comparison ns  CCvsTT p<0.03  
 
Table 24. Analysis of the genotypes and their correlation with extra-intestinal symptoms. 
A comparison of the genotypes revealed the tendency for the CC genotype to be statistically 
more frequent than the TT one in patients declaring elevated body temperature. 
4.5 The correlation between allele frequency and the localization of non-GIT 
symptoms 
The analysis of allele frequency in exact polymorphisms among CD patients was correlated 
with extra-intestinal symptoms. Although no significant results were obtained, some 





 arthralgia Uveitis iritis stomatitis aphtosa 
Erythema 






G908R C G C G C G C G C G C G C G 
no 33 2 70 5 73 6 58 5 63 3 77 6 58 5 
yes 50 5 12 0 9 1 24 2 19 4 5 1 24 2 




C vs G 
p<0.001 ns ns ns ns ns 
C vs G 
p<0.01 
ATG 
rs2241879 A G A G A G A G A G A G A G 
yes 40 37 59 40 62 52 51 43 53 47 66 56 33 33 
no 30 25 10 11 7 9 18 18 16 14 3 5 36 28 




ns ns ns ns ns ns ns 
ATG 
rs2241880 T C T C T C T C T C T C T C 
yes 39 42 53 62 55 65 55 52 48 54 59 68 34 35 
no 26 30 11 9 9 6 19 19 16 17 5 3 30 36 




ns ns ns ns ns ns ns 
IL23R 
rs7517847 T G T G T G T G T G T G T G 
yes 45 29 64 45 65 44 54 36 60 37 69 47 38 31 
no 40 21 10 5 9 6 20 14 14 13 5 3 36 19 




T vs G 
p< 0.04 ns ns ns ns ns ns 
IL23R 
rs1004819 T C T C T C T C T C T C T C 
yes 27 38 37 59 37 61 31 50 37 51 39 65 24 39 
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no 16 30 6 9 6 7 12 18 6 17 4 3 19 29 
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Table 25. Correlation between allele frequency and the localization of non-GIT symptoms 
5. Discussion 
Crohn’s Disease (CD) has been known to physicians for many decades. In 1904 Antoni 
Leśniowski, already tried to characterize the disease, and in later years his efforts were 
undertaken by many other researchers. Unfortunately, up to this day we know very little 
about CD. There are numerous descriptions of clinical cases presenting different localization 
of disease symptoms, descriptions of symptoms localized solely in the digestive tract, as 
well as symptoms accompanying the disease, typical for CD, but not necessarily associated 
with the digestive tract. Since the second half of XX century it has also been known that CD 
is conditioned by genetic factors. However, these do not act independently, but instead need 
to overlap with immunological and environmental factors, resulting in an onset of the 
disease. All this information sheds much light on the etiology of inflammatory bowel 
disease (IBD), including CD, but does not entirely solve the puzzle constituted by this 
complex condition. Genetic research initiated by the discovery of the IBD1 region, and later 
the CARD15/NOD2 gene lying in its vicinity, appears to have provided answers to the 
numerous questions and doubts of researchers: What is the cause of CD? What increases the 
risk of the disease developing and what is the protective factor? Why is its clinical picture so 
diverse and complex, and what is it determined by? Is it hereditary and if so how? It quickly 
became clear that what seemed to have provided the answer and cleared all doubts, only 
opened new perspectives for ascertaining the possible causes of CD, but still did not solve 
the problem. Today CD is thought to be polygenic, which means that complicated 
dependencies related to numerous genes lie at its basis. Until recently, it was assumed that a 
group of 40 genes are involved as possible determinants of the disease, but the most recent 
findings point to a number twice as large. 
While planning this research project, the idea which emerged, was to research the genotype 
distribution within the human genome, amongst Polish patients diagnosed with Crohn’s 
disease. Although the clinical course might be similar everywhere, research as to the genetic 
factors underlying CD differs depending on the population which patient stems from. 
Consequently, we decided to define the span of genotypes and alleles for the Polish 
population. What is more, having the information about the clinical course of the disease,  it 
seemed interesting to study whether any dependencies exist between a particular genome 
and the clinical course, as well as localization of the disease symptoms.  
Recently, some information surfaced related o the dependency between the localization of 
the disease symptoms and the particular genotypes. The  latest of these studies, (Jurgens et 
al., 2010),   carried out by German researchers on patients with  CD, showed that there is a 
clear dependency between the presence of homozygotic mutations in the CARD15/NOD2 
gene and the occurrence of fistulas and simultaneously  post-inflammatory intestinal 
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(G908R) in CARD15/NOD2 gene was studied. However, it did not show a statistically 
significant change in the frequency of occurrence of particular genotypes and alleles in the 
patient group, as compared to the healthy population. None the less, certain tendencies 
were observed, which pointed to a relation between the presence of the CC genotype iand 
an intestinal localization of the disease (both the small intestine, as well as the colon). Our 
research also confirmed the association of perianal fistulas with the presence of the CC 
genotype, in this respect, confirmed the results of the above-mentioned German research 
project. What is more, our studies also indicated certain tendencies with respect to the 
occurrence of specific disease symptoms not related to the gastrointestinal tract, such as joint 
pain, iritis, erythema nodosum, or aphtous ulcerations in the mouth (these symptoms were 
predominant in patients with the CC genotype). This aspect of the research presented here 
seems to supplement our current knowledge in an interesting way, as it has not been taken 
into account in the German study and therefore is in itself innovative and unique.  
In this research project two polymorphic changes, located in the IL23R gene 
(IL23Rrs7517847, as well as IL23Rrs1004819) were analyzed. In the case of the former, 
statistically significant changes were observed in the frequency of occurrence of the alleles, 
as compared with the population group (allele T p=0,0011, allele G p=0,0987). This points to 
the fact that polymorphism IL23Rrs7517847 can be associated with an increased risk of 
morbidity in significant way. Studies conducted as part of this research project 
demonstrated the tendency for the development of the disease related changes in the small 
intestine and colon. Similarly, for IL23Rrs7517847, the TT genotype was significantly more 
frequent in patients with intestinal changes, while the TG genotype was most frequent in the 
case of changes within the colon. Although our research does not show any significant 
association of the IL23R gene with the occurrence of fistulas, it does bear out the results of 
the German publication cited above.  
Another study on the relation between the CARD15/NOD2 gene with the course of the 
disease is the one conducted on a Croatian group of patients from 2006 (Cukovic-Cavka et 
al., 2006). They reported that mutations in the CARD15/NOD2 gene were associated with 
an increased risk of developing CD, and were also  responsible for an earlier diagnosis on 
the disease (the patients were diagnosed at an earlier age) as well as the need for surgical 
intervention (a more severe disease course). As part of the research conducted on Croatian 
patients three most common mutations/polymorphisms (Arg702Trp, Gly908Arg, 
Leu1007fsinsC) occurring in CARD15/NOD2 gene were studied. The research published by 
Annese i et al. (2005) corroborates the results of the work published above and proves that 
the existence of even one of the key mutations/polymorphisms is responsible for an 
aggressive course of the disease. Possibly, because only one analysis, of the mentioned 
polymorphisms - Gly908Arg –was planned in the project no similar dependence was shown. 
According to the literature data, the largest impact as far as increasing the risk of developing 
CD is concerned, as well as a more severe course of the disease is caused by insertional 
mutation. Although it was not studied as part of this research project as of yet, we do plan to 
carry out research focussing on this aspect in the future.  
Another publication, which confirms the association of the CARD15/NOD2 gene with the 
clinical symptoms of the disease, is a study by Mendoza et al. from 2003 who scrutinized 
this dependence in the Spanish population. One aspect makes it particularly interesting; not 
only does this research point to the influence of the three main SNP changes in the 
CARD15/NOD2 gene on the occurrence of the intestinal disease symptoms, but also proves 
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that carriers of the G908R mutation show a disease type characterized by intestinal 
strictures, which additionally requires more frequent surgical interventions, including 
appendectomy. The results of the study presented here do confirm the Spanish data 
pertaining to the association of G908R mutation with the intestinal localization of the 
disease; however, the remaining aspects discussed by Mendoza et. al. are not analyzed in 
this project, and, therefore, cannot be compared. The need for more frequent surgical 
intervention associated with the presence of a CARD15/NOD2 gene mutation, was also 
confirmed in 2010, when pediatric cases of CD were analyzed (Lacher et al., 2010). It was 
discovered that in the case of children under the age of 17, surgical interventions were more 
common in those who displayed the presence of the mutation. 
A very interesting scientific publications surfaced in 2008, when Barrett et al., performed a 
GWAS analysis (genome-wide association studies) on a group of 3230 CD patients, as well 
as a control group of 4829 subjects (GWAP studies include the analysis of a huge number of 
polymorphisms in the research (patient) group and a subsequent comparison of the same 
types of changes in the control/ population group; the differences in the occurrence of 
changes in both of these groups (presented mainly through a very precise and thorough 
statistical analysis) point to a relation between the potential polymorphisms associations 
with the disease studied. These studies showed that within the human genome there are at 
least 32 genes associated with predisposition for CD (11 loci mentioned in earlier 
publications were confirmed, and 21 new ones were identified). This lends support to the 
currently held belief that CD may be conditioned by 30-35 different genes.  
The reports presented above clearly point to the fact that for a number of years worldwide 
research has been resorting to multilocus studies. These are not aimed at determining one 
particular mutation or polymorphism conditioning a given disease, but rather at discovering 
complex inter-genetic dependencies. Similarly, this research project strives to follow these 
global trends, at least to an extent. Of course the authors realize that the relatively small 
patient group (compared to large-scale research projects) is not a match for the reports 
presented above; nevertheless, we believe it is still an interesting attempt at investigating the 
described dependencies in the Polish patient population.  
Not all of the polymorphisms studied in this doctoral thesis have been analyzed previously 
in reference to the clinical course of the disease. In Poland this kind of research is quite 
innovative, although studies of this type have surfaced on the international stage. Most 
frequently it is the CARD15/NOD2 gene that is subject to analysis as so far, it has seemed to 
be most closely associated CD. However, recent studies have pointed to other susceptibility 
genes, for example ATG16L1 or IL23R, which may shed more light on the results obtained 
so far  
In this research project the authors decided to scrutinize those genes which were most 
frequently linked to CD in publications appearing over the course of last several years. In 
the planning process of the study presented here we decided to concentrate on the analysis 
of three chosen genes, as well as the polymorphisms present within them, in order to 
eventually uncover certain dependencies. We were fortunate to observe certain tendencies 
in the occurrence of disease symptoms related to a particular genotype; however, we found 
no relation which might be crucial in explaining the mystery of CD. It is possible that the 
reason for this is either the absence of such a dependency, or the insufficient size of the 
research group. Although 160 patients seem to constitute a rather substantial sample, 
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that carriers of the G908R mutation show a disease type characterized by intestinal 
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Unfortunately, conducting such large-scale study in Poland is extremely problematic; 
therefore, a project based on a group of even 160 patients, yet featuring an analysis of 10 
polymorphic loci, might be considered a success.  
When this research project was still in its infancy, the topic of multilocus analyses of both 
clinical symptoms and the course of the disease was entirely innovative in Poland; what is 
more, foreign studies of this type were also extremely scarce. In recent years, the topic has 
attracted much attention worldwide; nevertheless, in Poland, a genetic multilocus study 
complemented by an analysis of the clinical symptoms and demonstrating such a wide 
scope remains a rarity. It is also worth mentioning that despite the fact the relevant genetic 
dependencies underlying CD remain undiscovered, such a possibility is not unattainable in 
the future. Global research aimed at unearthing its causes is being carried out as we speak, 
and it is the authors' firm belief that Polish researchers will also participate in this trend. 
After all, CD is a complex condition, and the research project presented here does not 
exhaust all the possible hypotheses pertaining to its etiology. 
6. Conclusions 
In this research project, 139 patients with Crohn’s Disease were analyzed taking into 
consideration 5 single nucleotide polymorphisms (SNPs): 
 CARD15/NOD2 G908R,  
 ATG16L1 rs2241879,  
 ATG16L1 rs2241880,  
 IL23R rs7517847,  
 IL23R rs1004819,  
The obtained results were compared to an adequate population group.  
All SNPs were polymorphic in the Polish population, which has been described in detail in 
the previous section of this publication. Unfortunately, no statistically significant differences 
in the distribution of particular genotypes were observed. However, the analysis of alleles 
showed, that: 
- in the ATG16L1 gene (rs2241880), allele C was statistically significantly more frequent 
among CD patients than in the population group (p=0.0017, for allele T p=0.0775). 
- in the IL23R gene (rs7517847), allele T was statistically significantly more frequent 
among CD patients than in the population group (p=0.0011, for allele G p=0.0987). 
Due to these results, it is possible that allele C for ATG16L1 Thr300Ala (rs2241880) and T for 
IL23R (rs7517847) are connected with a higher risk of developing CD.  
The second part of this research project focused on alleles and genotypes; in particular, on 
their relation to the localization of symptoms. It revealed that there are certain tendencies 
that can predict some predispositions to exact disease symptoms: 
- among the CD patients, in the CARD15/NOD2 gene G908R, genotype CC and allele C 
were the most frequent ones, which is connected with the localization of the symptoms 
in the area of intestines and the presence of perianal fistulas.  
- the analysis of the extra-intestinal symptoms also revealed some interesting 
dependences: patients with joint pain, uveitis, stomatitis aphtosa, erythema nodosum, 
or elevated body temperature have statistically more frequent alleles C and the CC 
genotype. 
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- in the ATG16L1 gene (rs2241879), patients with symptoms localized in the small 
intestine more frequently displayed the GA genotype; what is more, the same genotype 
was observed more often among patients with joint pain and erythema nodosum. 
Unfortunately, the allele analysis did not reveal statistically significant dependences. 
- in the ATG16L1 gene (rs2241880), the TC genotype  was observed more frequently for 
patients with  symptoms localized in the small intestine, arthralgia and erythema 
nodosum. Allele analysis did not reveal any statistically significant dependences. 
- in the IL23R gene (rs1004819), the TT genotype  was  statistically the predominant one 
in CD patients with the disease symptoms manifested in the small intestine; however, 
allele analysis revealed that the presence of allele T alone may be crucially connected 
with the colonic symptoms as well. What is more, the TT and TC genotypes were 
statistically more frequent among patients declaring the presence of erythema 
nodosum.  
- in the IL23R gene (rs7517847) the TT genotype  was statistically prevalent among CD 
patients with symptoms localized in the small intestine. Together with the GT 
genotype, the TT genotype was statistically more frequent among individuals 
complaining of joint pain.  
Although this research project did not reveal statistically significant differences in the 
distribution of particular genotypes in CD patients and the population group, some 
tendencies have been observed. They can be helpful when predicting the development of 
the disease, but they cannot be treated as a diagnostic parameter; rather, they indicate 
certain predispositions to the development of the disease. As a result, currently patient 
history, physical examinations, colonoscopy, histopathology and radiological studies (e.g. 
USG examination) still remain the main sources of the diagnosis. 
It needs to be noted that although spectacular genetic dependencies underlying the causes 
of CD have not been discovered as of yet, it is still feasible in the future. Indeed, with every 
next research project – including this one – new advances are made in the field; therefore, it 
is possible that the genetic background of CD will be determined in the coming years which 
would constitute a significant advantage for patients. 
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1. Introduction 
Crohn's disease (CD) and chronic ulcerative colitis (UC) are considered as two distinct forms 
of inflammatory bowel disease (IBD). In IBDs, the first clinical signs of disease begin typically 
between adolescence and the third decade of life (Andres & Friedman 1999; Baldassano & 
Piccoli 1999). CD is a non-specific granulomatous inflammatory disease affecting the lower 
end of the ileum and often involving the colon and other parts of the intestinal tract (Podolsky 
2002). CD was first reported by B. Crohn and his colleagues in 1932 and called Regional 
Enteritis (Matsuura et al. 1993). CD is diagnosed in four patients per 100 000 in the Northern 
Europe and the incidence and prevalence is rising (Elson et al. 1995). UC is a chronic disease of 
unknown etiology characterized by inflammation of the mucosa and sub-mucosa of the 
rectum (altimes) with a continuous extension to upper parts of the colon without healthy 
mucosa between inflammatory mucosa, which can be limited to the rectum (proctitis) to the 
colon below the lefts angle (left colitis), beyond the left angle (extensive colitis) or affect all the 
colon (pancolitis). UC is mostly characterized by bloody diarrhea. UC may have a prevalence 
of 100 case per 100 000 population in Northern Europe (Satsangi et al. 1996) 
The causes of CD and UC remain to be clarified. However, genetic factors in combination 
with environmental factors are suspected to be involved in the pathogenesis of Crohn's 
disease (Baker et al. 1981; Podolsky 2002). Inadequate or prolonged activation of the 
intestinal immune system plays an important role in the pathophysiology of chronic 
mucosal inflammation (Elson et al. 1995; Matsuura et al. 1993). 
CD and UC are characterized by periods of remission followed by episodes of clinical 
relapse, characterized by an increase in symptoms usually due to acute intestinal 
inflammation. Treatment is primarily aimed at reducing inflammation during relapse and 
secondarily at prolonging the time-spent remission. Conventionally both of these aims are 
governed by consideration of clinical symptoms rather than objective evidence of 
inflammatory activity. Gastroenterologists are often faced with the difficulty of 
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inflammation. Treatment is primarily aimed at reducing inflammation during relapse and 
secondarily at prolonging the time-spent remission. Conventionally both of these aims are 
governed by consideration of clinical symptoms rather than objective evidence of 
inflammatory activity. Gastroenterologists are often faced with the difficulty of 
differentiating patients with irritable bowel syndrome from those with organic intestinal 
 
Crohn's Disease 60
pathologies, in particular inflammatory bowel disease. Many symptoms are common to 
both conditions including abdominal pain, bloating, excessive flatus and altered bowel habit 
while other clinical features such as a predominance of diarrhea and rectal bleeding will 
increase the likelihood of organic disease. Although symptoms are a surprisingly good 
guide to a diagnosis, most clinicians proceed to and rely on laboratory tests to aid in the 
differential diagnosis. The two main forms of IBD are both characterized by an aberrant 
immune response of intestinal mucosa. The enormous complexity of pathophysiology 
mandates a systematic approach to identify the molecular events that cause and perpetuate 
these chronic, relapsing inflammatory disorders. The ability to quantitate the global 
expression profiles at the level of RNA using oligonucleotide microarrays has recently been 
applied to investigate transcriptional signatures present in CD peripheral blood and CD 
gastrointestinal tissue (Lawrance et al. 2001; Warner & Dieckgraefe 2002). These studies 
identified genes involved in inflammatory response generally up-regulated in IBD and 
showed that the gastrointestinal tissue transcriptome obtained from UC and CD patients 
were quite distinct, with gene sets identified that appear to distinguish UC from CD tissue. 
In contrast to biopsies, peripheral blood is a much more accessible tissue source to 
distinguish between UC and CD. Circulating peripheral blood mononuclear cells (PBMCs) 
are responsible for the comprehensive surveillance of the body for signs of infection and 
disease. PBMCs may therefore serve as a surrogate tissue for evaluation of disease induced 
gene expression as biomarker of disease status or severity (Rockett et al. 2004). 
 











Biopsies Physiological state Age of donor Gender of donor 
CD5 Inflamed 23 F 
CD6ni Non inflamed 24 F 
CD6i Inflamed 24 F 
CD7 Inflamed 21 F 
CD8 Inflamed 31 F 
UC1 Inflamed 45 F 
UC2ni Non inflamed 20 F 
UC2i Inflamed 20 F 
IBS 1 Inflamed 28 M 
IBS 2 Inflamed 59 F 
C6 Non inflamed 55 M 
Table 1. Origin of PBMCs and biopsies. CD = Crohn's Disease patient; UC = Ulcerative 
colitis patient; IBS = Irritable Bowel Syndrome patient, C = Disease free individual. 
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We here explored expression profiles of PBMCs from four CD patients compared to age and 
gender matched healthy individuals. We monitored as well the expression profiles of 
biopsies obtained by endoscopy from five CD patients, three UC, two intestinal disorders 
functional and one disease free individual (Table 1). To study the transcriptome we used 
“Taqman Low Density Arrays” microfluidic cards (Applied Biosystems), based on the 
technology of real-time PCR and Taqman probes. Such strategy is particularly attractive due 
to the quality of measurements of gene expression, the simplicity of implementation and the 
384 wells format thus covering the whole family of G Protein-Coupled Receptor (GPCR) on 
one plate. In this project, we used cards dedicated to study the GPCR transcriptome and this 
in two configurations. Card #1 was designed in 2004 by professor J. Haiech (UMR 7200 
CNRS, Faculty of Pharmacy, Illkirch). This card contained 355 GPCR, 16 housekeeping 
genes and 10 genes belonging to various categories. Card #2, used for monitoring biopsies, 
is produced as it by Applied Biosystems (ref. 4365295). This second card, designed two years 
later, takes in account updates on GPCR's annotation; it contained 365 GPCR including 4 
olfactory GPCR, 14 housekeeping genes and 2 genes of various functions. These two cards 
have 352 genes in common, including 10 housekeeping genes with 30 genes specific to each 
card. 
2. Materials and methods 
2.1 Blood and tissues culture 
Healthy donors with no clinical history were selected for PBMCs and tissues studies. 
Patients blood and tissues were obtained from CD patients at the Gastroentetology units 
from Strasbourg and Caen Universities hospitals (France). This work was approved by an 
authorized ethics committee (CPP Nord Ouest 2, Amiens, France), and carried out according 
to international guidelines. A fragment of each tissue specimen (colon, ileum, small 
intestine) was used for histopathological studies. The other part was immediately frozen on 
solution D (Chomczynski and Sacchi 1987) and stored at -70°C. PBMCs from healthy donors 
were separated as previously described (Boyum 1968). 
Peripheral blood diluted in Ca2+ and Mg2+ free HBSS (CMF-HBSS) containing 100 IU 
heparin/ml was layered over Histopaque-1077 and centrifuged for 30 min at 400g (20°C). 
Cells harvested at the interface were washed 3 times in CMF-HBSS and resuspended at a 
final concentration of 5x105 cells/ml in RPMI 1640 supplemented by 10% heat-inactivated 
fetal bovin serum (FBS). PBMCs were seeded on 24-well culture plates at a final 
concentration of 5.105 cells/ml in RPMI-1640 supplemented with 10% heat-inactivated 
FBS (v/v) and penicillin–streptomycin (100g/ml). Control cells and CD patients cells 
were activated, or not, by LPS (5g/ml) for 2 hours 30 min at 37°C. PBMCs were 
centrifuged and the pellets were pooled, frozen in liquid nitrogen and kept at –80°C until 
testing. 
2.2 Flow cytometry 
Flow cytometry was performed on a Guava EasyCyte Plus System (Merck/Millipore/ 
Guava, Hayward, USA) equipped with a 488 nm laser that illuminates each cell then 
fluorescence is collected at different wavelength (530 ± 15 nm, 575 ± 13 nm and 660 ± 10 nm). 
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2.3 TNF- secretion tests 
Human PBMCs were incubated in 24 well culture plates in culture medium at 5x105 cells/ml 
for 24 h at 37°C in a humidified 5% CO2 / 95% air atmosphere in presence of increasing 
concentrations of the somatostatin analogues ranging from 10-7M to 10-5M, with or without 
activation by LPS (5g/ml). Compounds were dissolved in water. Control samples always 
contained the same amount of water (without compounds). For ELISA, plates were 
centrifuged after incubation for 15 min at 200xg (20°C). Supernatants were stored at -80°C 
until testing. For coating, human TNF- antibody 0,5mg/ml (BD Pharmingen, Le Pont de 
Claix, France) was diluted to 1/100 in Binding Solution (Na2HPO4 0,1M+NaH2PO4 0,1M à 
pH9) and added in the 96 wells plate (Nunc Maxisorp 96-wells, VWR, Val de Fontenay, 
France). The plate was sealed to prevent evaporation, and incubated overnight at 4°C. The 
96-wells plate was then washed once with PBS 1x/Tween 0,05% then saturated by addition 
of 200µl PBS/milk 5% during 2 hours at room temperature. After two washes with PBS 
1x/Tween 0,05%, PBMC supernatants were added. TNF- protein standard 1g/ml (BD 
Pharmingen, Le Pont de Claix, France) with dilutions (10000, 3333, 1111, 370, 123, 41 and 
5pg/ml) was added in corresponding standard wells for the statistic correlation. The 
detection was done with Human TNF- biotin 0,5mg/ml (BD Pharmingen, Le Pont de 
Claix, France) during one hour at room temperature. The plate was washed four times with 
PBS 1x/Tween 0,05%. Peroxydase/streptavidin 1,25 mg/ml (Zymed, In Vitrogen, Cergy 
Pontoise, France) was added and the plate incubated for one hour at room temperature. The 
plate was washed four times in PBS 1x/Tween 0,05%, and OPD (Sigma, Lyon, France) was 
used to determine the amount of TNF-detected in each well. The plate was then analysed 
in a spectrophotometer at 450nm (Molecular Devices, VersaMax Tunable Microplate Reader, 
Sunnyvale, USA). 
2.4 RNA Extraction of tissues and PBMCs 
The tissues were defrosted 15 minutes on ice (Chomczynski & Sacchi 1987). The cells were 
broken with a sterile piston, and put in sodium acetate 2M pH 4, phenol pH 4 saturated and 
chloriform/isoamylic alcool (49:1). After shaking, the membranes were incubated 15 
minutes on ice and centrifuged 20 minutes at 12000g at 4°C. Aqueous phase with the RNA 
were kept and precipitated with isopropanol one hour at -20°C. The RNA were centrifuged 
20 minutes 12000g at 4°C, and washed with 500µl of ethanol 70% stored at -20°C. They were 
centrifuged 5 minutes 12000g at 4°C and washed again three times. The RNA were dried 
with Speed Vac, and added with sterile water. RNA was isolated from PBMC cells pellet 
(5.106 cells) with Tri reagent (Molecular Research Center, Inc., Cincinnati, Ohio, USA) 
according to the manufacturer's instructions. 
Total mRNA were checked for integrity and concentration using the RNA 6000 LabChip kit 
on the Agilent 2100 bio analyzer (ratios of 28S RNA/18S RNA were above 1.6) and for 
purity by reading the absorbance at 260 and 280 nm (ratios A260/A280 were comprised 
between 1.8 and 2.0). 
2.5 Real-Time RT-PCR and PCR 
Five g of total RNA is reversely transcribed to single-stranded cDNA using the "High-
Capacity cDNA AUCive™ Kit" (Applied Biosystems, Foster City, California, USA). RNA is 
pre-incubated at 25ºC for 10 min, followed by 2 hours at 37ºC, according to the 
manufacturer’s recommendations (Applied Biosystems, Foster City, California, USA). 
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Subsequently, cDNA was kept at –20 °C until used. An aliquot of cDNA (850 ng) was mixed 
carefully in 850µL TaqMan Universal PCR Master Mix (PE Applied Biosystems).  On the 
card keeped at room temperature, 105µL of the sample were loaded into each of 8 ports on 
the TaqMan Low-Density Array (Applied Biosystems, Foster City, CA). The TaqMan Low-
Density Array microfluidic card #1 consists of a preconfigured in a 384-well format to assess 
the expression of 355 GPCR genes. The card #2 has 365 GPCR genes as well as 4 olfactives 
GPCR. The cards were then centrifuged twice in custom Buckets (Applied Biosystems, CA 
USA) in a Heraeus centrifuge (Kendro Scientific, Asheville, NC, USA) for 1 min at 1200 rpm. 
The cards were immediately sealed with the TaqMan Low-Density Array Sealer (Applied 
Biosystems, CA USA) to prevent any cross-contamination. Real-time RT-PCR is then 
performed on an ABI Prism 7900 (Applied Biosystems, Foster City, CA). Thermal cycling, to 
activate uracil-DNA glycosylase, is carried out for 2 min at 50°C, 10 min at 94.5°C then 40 
cycles of 30 s at 97 °C and 60 s at 59.7 °C. Each reaction contained cDNA derived from 
around 1.5 ng of total RNA. 
2.6 Statistics 
Real-time RT-PCR data were quantified using the SDS 2.2.1 software package (Applied 
Biosystems). Results were quantified in a relative comparative study, using an automatic 
baseline and threshold to record the cycle thresholds (Cts) setting and the 18S rRNA gene 
expression as a reference for normalization (ΔCts). Student's t-test was used with a 
significance threshold of P < 0.05. ELISA data are expressed as a percentage of the basal 
cytokine secretion level or as means (± SE); ‘n’ refers to the number of experiments. Results 
were compared using the non-parametric Mann–Whitney U test. The level of statistical 
significance was fixed at P < 0.05. 
3. Results  
By monitoring non-orphan RCPGs (i.e. 279 among the 382 RCPGs tested) in PBMCs of 10 
healthy donors and 10 CD patients we found that the data obtained were highly dependent 
on RNA integrity. The integrity of RNA molecules is of paramount importance for 
experiments that try to reflect the snapshot of gene expression at the moment of RNA 
extraction. The RNA integrity number (RIN) is an important tool regrettably often 
disregarded, in conducting valid gene expression measurement experiments as real-time 
PCR or DNA microarray (Schroeder et al. 2006). After RIN determination of our 20 samples, 
only 4 CD patients and 4 paired healthy donors could be considered reliable due to sample 
degradation yet with handling and shipping in dry ice from the hospital to the laboratory. 
3.1 Standardization 
Figure 1 represented a Dot Blot reflecting dispersion of 10 Housekeeping genes (PBMCs and 
biopsies). Before standardization, values (Ct) of 10 genes presented a distribution around 
50% of the median of the samples. However gene GUSB had weaker variance and 
symmetrical distribution compared to median. The distribution of ARNr 18S values is 
relatively good compared to whole of other Housekeeping genes excepting two samples 
presenting extreme values. The literature relates that genes of the sugar metabolism were 
found deregulated in biopsies of IBD patients  (Dieckgraefe et al. 2000) this fact encouraged 
us to choose 18S RNA to standardize our samples. After standardization, genes generally 
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Fig. 1. Dot blot of 10 Housekeeping genes before (A) and after (B) standardization to 18S 
RNA. 
showed a weaker dispersion, but we noticed that several genes like PGK1, RPLP0 and B2M 
presented extreme values. The fact that 3 genes out of 10 Housekeeping genes are not 
standardized the same manner, states clearly that genes are connected to different ways of 
metabolism which ways are affected by cell deregulation. For example, many reports on 
ratios show that the level of GAPDH messenger does not remain constant. Even if the 
GAPDH gene was considered for years as a reference in genetic organization, expression 
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and regulation studies, recent evidences demonstrate that mammalian GAPDH displays a 
number of diverse activities unrelated to its glycolytic function. For example, GAPDH 
messenger variations of enzymatic activity are implied in many mechanisms as varied as 
replication of DNA, transport of nuclear ARN and organization of cytoskeletal (Sirover 
1999) as well as neurodegenerative diseases.(Tatton et al. 2000) 
3.2 Gene clustering 
Before seeking genes differentially expressed in statistical systems with two classes, we 
wanted to know if it is possible to group samples in classes that characterize them with 
profile genes and type of pathology of patient to differentiate CD and UC. We followed a 
supervised approach which data groups without existing classes. Procedure of clustering 
consists in classifying a whole of data in several subsets according to their similarities. Data 
of expression form a matrix whose lines correspond to genes, here genes common to both 
cards, and columns with 17 samples. First, data were filtered so general average of form of 
genes is lower than 38 Ct, then standardized compared to ARNr 18S. 
The tree diagram or dendrogram illustrates the arrangement of clusters produced by 
hierarchical clustering. The individuals who resemble the most to each other are gathered in 
the bottom of the tree. The length of the branches is proportional to their distance among 
each other. The matrix of expression data is coloured coded according to the relative level of 
gene expression of genes: colours go from green for level of high expression to red for level 
of low expression, with black for intermediate level (units expressed in Ct). 
Figure 2 shows an ascending hierarchical classification by using Pearson's coefficient of 
correlation to measure the distance between two points. This distance reflects proximity or 
similarity between two points. Using Euclidean distance, which measures dissimilarity 
between two points and is more sensitive to amplitude of variations between data, produces 
regrouping of the data as illustrated into Figure 3. 
The data regrouping are obtained in form of two dendrograms, for genes and for 
individuals for each card. Classification distributes samples in 2 principals groups, PBMCs 
and biopsies. This first scission marks differences related nature of tissues. Then within each 
one of these 2 regroupings, we distinguish sub-groups: 
- for the PBMC group: the subgroup of healthy individuals differs markedly from that of 
patients with CD, each of these subgroups appear marginally affected by treatment 
with LPS. 
- for the biopsy group: the formation of sub-groups is less obvious, as is the 
interpenetration of these sub-groups: healthy subjects, healthy areas of patients with 
CD, healthy areas of patients with UC and inflammatory areas in patients with CD , 
inflammatory areas in patients with UC, and finally mucosa of patients with IBS. This 
behavior is certainly due to an insufficient number of samples representing each class, 
including healthy people and healthy areas of patients. These ambiguous groupings of 
biopsies outside their own classes indicate a high level of variation in gene expression 
in samples. 
In addition, dispersion curves (fig. 4 and 5) illustrate the heterogeneity of genes form in 
samples supposed to represent the same IBS. The correlation curves expression data of 
biopsies from inflammatory areas of patients with UC show a large dispersion of values in 
contrast to results obtained with patients CD. Indeed, the correlation coefficient of patients 
with UC or IBS is much lower (near 0.6) than that obtained with the data on three areas of 
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In addition, dispersion curves (fig. 4 and 5) illustrate the heterogeneity of genes form in 
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Fig. 2. GPCRs expression profile by ascending hierarchical classification of the samples. 
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Fig. 3. Ascending hierarchical classification using Euclidean distance to measure 
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Fig. 4. Gene dispersion curves for CD (A) and IBS (B) biopsies. 
 
 
            (A)              (B) 
Fig. 5. Gene dispersion curves for CD (A) and UC (B) biopsies. 
The origins of these dispersions are many. First, in a technical point of view, the collection is 
a delicate operation to achieve in the bowel (colonoscopy) and the removal of the tissue 
requires expertise to pick the exact target area by damaging the minimum completeness of 
tissue removed. On the other hand, in a biological point of view, the heterogeneity of 
individuals (age, sex, treatment, diet, etc..) And the exact position where the taking is in the 
intestinal tract, are major sources of heterogeneity. The difficulty of our work was to remove 
background noise genes specifically associated with CD. In addition, changes in profiles of 
biopsies may represent different levels of evolution and development of the disease. Indeed, 
there may be a great variability of samples supposed to represent a single disease state or 
biological replicas considered in the statistical analysis. To achieve this level of 
interpretation, the data should be obtained on a large number of individuals in a population 
well characterized.  
This grouping study provides assurance that the GPCR expression profiles in PBMCs can 
distinguish CD from healthy subjects. It shows, however, the existence of heterogeneity of 
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expression profiles of GPCR and a large variance in the expression of genes in the biopsies, 
this should not be overlooked when analysing the data. 
3.3 Normal distribution of data 
Parametric statistical tests on the means involve the estimation of parameters such as 
variance. These tests are generally more powerful than nonparametric tests, but require as a 
condition for applying the normality of data distribution of the mean. Although the tests 
called parametric tests are quite robust, i.e. are insensitive to a deviation from normality (as 
long as you estimate the variance) and are often used as the mode of data distribution 
deviates slightly of normality, it is useful to test the normality of data distribution. 
We used the correlation test of Ryan-Joiner, similar to the Shapiro-Wilk test, as proposed in 
the Minitab software. The test generates a line of Henry and performs a hypothesis test to 
see if the observations are normally distributed. The assumptions of the test are: H0, the 
data follow a normal distribution against H1, the data do not follow a normal distribution. 
Using this test, we submitted the data from 9 housekeeping genes (Table 2) thru the 27 








RPLP0 Hs99999902_m1 Ribosomal protein, large, P0 NM_053275 12 
PPIA Hs99999904_m1 Peptidylprolyl isomerase A (cyclophilin A) NM_203430 7 
GAPD Hs99999905_m1 Glyceraldehyde-3-phosphate dehydrogenase NM_002046 12 
HIST1H1C Hs00271185_s1 Histone 1, H1c NM_005319 6 
HPRT1 Hs99999909_m1 Hypoxanthine phosphoribosyltransferase 1 NM_000194 X 
HSPCA Hs00743767_sH Heat shock 90kDa protein, 1 alpha NM_005348 14 
PGK1 Hs99999906_m1 Phosphoglycerate kinase 1 NM_000291 X 
K-ALPHA-1 Hs00744842_sH Tubulin, alpha, ubiquitous NM_006082 12 
RARS Hs00259879_m1 Arginyl-tRNA synthetase NM_002887 5 
ACTB Hs99999903_m1 Actin, beta NM_001101 7 
B2M Hs99999907_m1 Beta-2-microglobulin NM_004048 15 
CYC1 Hs00357717_m1 Cytochrome c-1 NM_001916 8 
GUSB Hs99999908_m1 Glucuronidase, beta NM_000181 7 
TFRC Hs99999911_m1 Transferrin receptor (p90, CD71) NM_003234 3 
NUP62 Hs00383013_m1 Nucleoporin 62kDa NM_153719 19 
18S  Ribosomal RNA 18S   
Table 2. Housekeeping list presents in the Applied Biosytem microfluidic card. 
Of the nine genes tested, 7 of them verify the hypothesis H0, the data follow the normal 
distribution, the risk of first type  of 0.01 (Figure 6). Only two genes, PGK1 and B2M have p 
values less than 0.01. These results can be linked with the dispersal rate of expression of 
these genes, as was noted earlier. The test results are for a normal distribution of data and 
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Fig. 6. Test of normality by the Ryan-Joiner test of correlation. The vertical axis represents 
scale of probabilities and horizontal axis scale of data. A line of least squares is adjusted at 
raised points and is traced on graph for reference. The line represents an estimate of 
function of pattern of settlement from where data are extracted. The estimates of parameters 
average and standard deviations of population are posted under graph. 
3.4 Gene expression in PBMCs of CD patients versus control 
It is now widely accepted that GPCRs, including cytokine receptors play a critical role in 
controlling the inflammatory response (Luther & Cyster 2001; Onuffer & Horuk 2002; 
Thelen 2001). It has been shown that immune cells express many receptors of neuropeptides 
and neurotransmitters, highlighting the role of mediators in the neuroendocrine modulation 
of immune response. In addition, there is a bundle of evidence indicating the existence of 
relationship between GPCR signaling pathways and answers related to antigen receptor of T 
cells and interleukin-2. Thus, prostaglandins produced by activated macrophages during 
the immune response can inhibit both cytokine production and proliferation of T cells 
(Baker et al. 1981). These observations motivated us to work with PBMCs, a more 
homogeneous cell population much less restrictive than the colon biopsies of patients. In our 
study on PBMCs taken from four healthy subjects and four patients with CD in remission, 
the expression profiles of GPCRs were obtained on card #1. 
The genes were previously filtered to eliminate those not expressed in any of the samples, so 
that they are about 85 genes remaining. The were two reason of this operation: i) reduce 
variance brought by genes not expressed during calculation of ∆Ct since these genes have Ct 
equal to 40; ii) avoid null denominators in calculations in particular standard deviations. This 
does not mean that all 296 selected genes are expressed. Values are normalized to 18S rRNA in 
each sample. The differentially expressed genes between the normal subjects and CD patients 
were obtained from the p-value of the Student test at risk of type  equal to 0.05. The 
difference in expression between the two classes of individuals was determined from the 
difference between the average ΔCt healthy subjects and the average ΔCt of CD patients. 
∆∆Ct = (∆Cthealthy- ∆CtCD) 
The data of the 22 differentially expressed genes were subjected to a nonparametric test, 
more robust and less sensitive to extreme values. The Mann-Whitney test for unpaired data 
with Minitab software calculates the value p and focuses on the equality of medians of two 
groups. Figure 7 shows two examples of the report of the results for Minitab for gene SSTR5 
and ADRA2B for a threshold of the first kind  of 0.05. The data of the first gene name can 
reject the hypothesis H0 while those of ADRA2B does not allow it. 
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Hs00664150_s1 MRGPRE MAS-related GPR, member E 0.007 9.8 2.10 Rejection 
Hs00265647_s1 SSTR5 somatostatin receptor 5 0.038 9.6 2.50 Rejection 
Hs00664166_s1 GPR142 G protein-coupled receptor 142 0.011 9.5 2.22 Rejection 
Hs00270999_s1 GPR4 G protein-coupled receptor 4 0.018 8.4 2.15 Rejection 
Hs00266671_s1 FY Duffy blood group 0.020 7.8 2.26 Rejection 
Hs00265617_s1 SSTR1 somatostatin receptor 1 0.024 7.8 2.10 Rejection 
Hs00664089_s1 GPR148 G protein-coupled receptor 148 0.023 7.6 2.19 Rejection 
Hs00275980_s1 PPYR1 pancreatic polypeptide receptor 1 0.022 7.3 2.39 Rejection 
Hs00271049_s1 GPR20 G protein-coupled receptor 20 0.017 7.2 2.35 Rejection 
Hs00265195_s1 CHRM1 cholinergic receptor, muscarinic 1 0.035 6.7 2.15 Rejection 
Hs00271017_s1 GPR7 G protein-coupled receptor 7 0.030 6.3 2.16 Rejection 
Hs00271023_s1 GPR8 G protein-coupled receptor 8 0.002 6.1 1.52 No rejection 
Hs00664201_s1 BDKRB1 bradykinin receptor B1 0.049 5.8 2.19 No rejection 
Hs00271008_s1 GPR6 G protein-coupled receptor 6 0.044 5.5 2.03 No rejection 
Hs00706455_s1 CCR10 chemokine (C-C motif) receptor 10 0.015 5.3 2.02 No rejection 
Hs00268954_s1 FZD9 frizzled homolog 9 (Drosophila) 0.016 5.3 1.86 No rejection 
Hs00265090_s1 ADRA2B adrenergic, alpha-2B-, receptor 0.047 4.5 1.96 No rejection 
Hs00265286_s1 HTR1B 5-hydroxytryptamine (serotonin) receptor 1B 0.026 4.1 1.57 No rejection 
Hs00184657_m1 BAI2 brain-specific angiogenesis inhibitor 2 0.041 -2.4 1.44 No rejection 
Hs00222094_m1 HRH4 histamine receptor H4 0.050 -2.5 1.57 No rejection 
Hs00181231_m1 ADORA1 adenosine A1 receptor 0.028 -3.3 1.74 No rejection 
Hs00173471_m1 OPRL1 opiate receptor-like 1 0.004 -5.1 1.71 Rejection 
Table 3. Results of p-values for 22 genes. 
The results of the p-values have been reported in Table 3: 14 of 22 genes confirmed the 
results of the parametric test (MRGPRE, SSTR5, GPR142, GPR4, FY, SSTR1, GPR148, PPYR1, 
GPR20, CHRM1, GPR7, FZD9, and HTR1B OPRL1). 
The Mann-Whitney, which addresses to data from samples drawn randomly and 
independently in two populations of the same variance, is limited here by the low number 
of individuals tested. Having duplicate data, that is to say to increase the "NR" to 8 instead 
of 4 and keeping the same values of the medians, produces a p-value less than 0.05. All 
genes in Table 3 for which the hypothesis H0 could be rejected for NR equal to 4, are 
regarded significantly different by the mere fact of double samples. This is proven by a ratio 
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Knowing that the signed rank test 2-sample is slightly less powerful than the test samples 
with 2 grouping of sample variance when the populations are normal, and taking into 
account the recommendations of Minitab software for populations with different standard 
deviations, we have privileged a 2-sample t test without pooling the variances for the 
analysis of differential genes. 
Of the 22 genes differentially expressed in PBMC of CD patients compared to normal subjects, 
18 were overexpressed, while four are under-expressed. The overexpressed genes are mostly 
induced in the disease except ADRA2B and GPR8 receptors that are expressed in PBMCs of 
normal subjects. Among these genes are receptors involved in the inflammatory and immune 
(SSTR5, SSTR1, CHRM1, CCR10, FY, BDKRB1, HTR1B) in other processes (MRGPRE, PPYR1, 
FZD9) and unknown functions (7 orphan receptors: GPR4, GPR142, GPR148, GPR20, GPR7, 
GPR8, GPR6). In a similar approach, Burczynski ME and collaborators research in PBMC gene 
expression signatures to discriminate CD of UC. They used the Affymetrix microarray 
platform HG-U133A that allows you to query more than 22 000 genes with a sample of 42 
normal individuals and 59 CD patients (Burczynski et al. 2006). Their data were deposited in 
the database of microarrays GEO "Gene Expression Omnibus" at NCBI and are available to the 
community in the form of CEL files. CEL files are files that contain Affymetrix raw data. The 
site also allows to directly visualize the expression profile of a gene selected from across all 
samples as a histogram. Out of the 22 genes on the TLDA microfluidic cards, 16 are present on 
the chip. By submitting data at the same t-test that was used at the threshold 0.05, 5 genes 
appear differentially expressed in CD patients compared to normal individuals (FZD9, SSTR1, 
CCR10, HTR1B, OPRL1) with reports of expression ranging from 1.83 (FZD9) and 0.75 
(OPRL1). The very low expression of these 16 genes on the chip confirms the absence of 
expression observed in real-time PCR in healthy individuals (SSTR5, SSTR1, FZD9, CCR10, 
HTR1B, GPR6, FY, ADORA1, BDKRB1, PPYR1, GPR20, GPR4). The discrepancy concerning the 
magnitude of changes in expression levels (less than 2 with the microarray against values 
higher then 16 in real-time PCR) between the two sets of data can be related to the difference in 
sensitivity of two technologies, real-time PCR being much more sensitive than the 
oligonucleotide hybridization technique. 
 
 
           (A)              (B) 
Fig. 7. Validation of results obtained by real-time PCR in 96 well plates as compared to 
LDTA card. (A) Correlation curve for SSTR5 data. (B) Ratio of expression rates between CD 
patient and disease free individuals for 3 somatostatin receptors for data obtained by using 
microfluidic cards or 96 plates technology.. 
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The presence among this group of receptor genes in the same family, SSTR1 and SSTR5, 
which in addition show a strong increase of expression in CD patients, is interesting. This 
prompted us to conduct a new measurement of the expression of these genes by real-time 
PCR but using 96-well plate format. This makes it possible to assess the performance of the 
microfluidic card system, i.e. if the differences of expression come from technology, 
rheology, the depot of the tests in the cards, etc. Complementary DNA has been a 
resynthesized from total RNA and PCR was conducted under the same conditions of 
reagents on the ABI Prism 7000 thermocycler. We add to the experience another 
somatostatin receptor, SSTR3, whose expression is unchanged in microfluidic card TLDA. 
The histogram in Figure 7 confirms the results achieved with the microfluidic card and the 
curve (Fig.7A) shows good correlation between measurements of two technologies. 
3.5 Healthy subjects and CD patients with LPS activation 
We tested the ability of PBMC from healthy individuals and CD patients with to induce the 
production of TNF- in response to LPS stimulation. After 24 hours incubation with LPS, we 
measured the release of TNF-. We observed a production of TNF-α in the two groups of 
people consolidating us on the effectiveness of PBMC to respond to LPS. PBMCs of CD 
patients produce TNF- twice as much as healthy subjects (data not shown).  
Concerning gene expression, the data analysis was performed using an approach similar to 
the one described before. However, we applied here more strict filters by removing genes 
whose mean Ct was greater than 37. In this area of values measuring variations are 
significant. They are due on the one hand to the lack of reproducibility of withdrawals that 
is related to the Gaussian distribution of the sample in a solution containing a small number 
of copies of cDNA, and secondly, the SDS software that assigns a Ct of 40 to genes for which 
the amplification curve does not reach a plateau, as they cross the threshold between the 
37th and 40th cycle. 
Values were first normalized to 18S rRNA then for each individual, the difference of ∆Cts, 
the ∆∆Cts between the PBMC stimulated or not by LPS was computed. We also calculated 
the average values of ∆∆Cts obtained from four individuals. The genes whose expression is 
regulated by the activation of PBMC by LPS in normal subjects were selected on the one 
hand for an average of ∆∆Cts values greater than 1.5 and less than -1.5, and to the other 
from the p-value of Student's test for paired data at risk of Type  equal to 0.05. We obtained 
18 genes (Table 4) whose expression is significantly LPS dependent, of which 4 are 
overexpressed and 14 repressed. With the exception of GPRC5A the three overexpressed 
genes (GPR155, SSTR3, H963) are well expressed in the non-activated PBMC from healthy 
subjects. Among these genes are many receptors known to be involved in the inflammatory 
process and immune response (EDG2, EMR2, EMR3, CCR1, GPR35, FPr1, CCR3, CMKLR1, 
C5R1, FPRL2, P2RY2, GPBAR1) with two orphan receptors (GPR77, GPR162). 
The same experiment conducted with PBMC from CD patients, stimulated or not with LPS, 
shows a profile of genes regulated by LPS very similar to that obtained in healthy subjects, 
but with a more important difference between those genes induced and repressed (1 for 19 
genes) (Table 5). The appearance of genes such as CCR5, EDG3, EDNRB and IL8RB 
strengthens families of genes already controlled by LPS in healthy subjects. We also observe 
an effect of LPS on the expression of neuropeptide receptors, BAI1, and HTR1A NTSR1. 
Conversely, LPS does not seem to affect the expression of GPRC5A, SSTR3, H963, EMR2 and 
EMR1 genes in CD patients. 
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deviations, we have privileged a 2-sample t test without pooling the variances for the 
analysis of differential genes. 
Of the 22 genes differentially expressed in PBMC of CD patients compared to normal subjects, 
18 were overexpressed, while four are under-expressed. The overexpressed genes are mostly 
induced in the disease except ADRA2B and GPR8 receptors that are expressed in PBMCs of 
normal subjects. Among these genes are receptors involved in the inflammatory and immune 
(SSTR5, SSTR1, CHRM1, CCR10, FY, BDKRB1, HTR1B) in other processes (MRGPRE, PPYR1, 
FZD9) and unknown functions (7 orphan receptors: GPR4, GPR142, GPR148, GPR20, GPR7, 
GPR8, GPR6). In a similar approach, Burczynski ME and collaborators research in PBMC gene 
expression signatures to discriminate CD of UC. They used the Affymetrix microarray 
platform HG-U133A that allows you to query more than 22 000 genes with a sample of 42 
normal individuals and 59 CD patients (Burczynski et al. 2006). Their data were deposited in 
the database of microarrays GEO "Gene Expression Omnibus" at NCBI and are available to the 
community in the form of CEL files. CEL files are files that contain Affymetrix raw data. The 
site also allows to directly visualize the expression profile of a gene selected from across all 
samples as a histogram. Out of the 22 genes on the TLDA microfluidic cards, 16 are present on 
the chip. By submitting data at the same t-test that was used at the threshold 0.05, 5 genes 
appear differentially expressed in CD patients compared to normal individuals (FZD9, SSTR1, 
CCR10, HTR1B, OPRL1) with reports of expression ranging from 1.83 (FZD9) and 0.75 
(OPRL1). The very low expression of these 16 genes on the chip confirms the absence of 
expression observed in real-time PCR in healthy individuals (SSTR5, SSTR1, FZD9, CCR10, 
HTR1B, GPR6, FY, ADORA1, BDKRB1, PPYR1, GPR20, GPR4). The discrepancy concerning the 
magnitude of changes in expression levels (less than 2 with the microarray against values 
higher then 16 in real-time PCR) between the two sets of data can be related to the difference in 
sensitivity of two technologies, real-time PCR being much more sensitive than the 
oligonucleotide hybridization technique. 
 
 
           (A)              (B) 
Fig. 7. Validation of results obtained by real-time PCR in 96 well plates as compared to 
LDTA card. (A) Correlation curve for SSTR5 data. (B) Ratio of expression rates between CD 
patient and disease free individuals for 3 somatostatin receptors for data obtained by using 
microfluidic cards or 96 plates technology.. 
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The presence among this group of receptor genes in the same family, SSTR1 and SSTR5, 
which in addition show a strong increase of expression in CD patients, is interesting. This 
prompted us to conduct a new measurement of the expression of these genes by real-time 
PCR but using 96-well plate format. This makes it possible to assess the performance of the 
microfluidic card system, i.e. if the differences of expression come from technology, 
rheology, the depot of the tests in the cards, etc. Complementary DNA has been a 
resynthesized from total RNA and PCR was conducted under the same conditions of 
reagents on the ABI Prism 7000 thermocycler. We add to the experience another 
somatostatin receptor, SSTR3, whose expression is unchanged in microfluidic card TLDA. 
The histogram in Figure 7 confirms the results achieved with the microfluidic card and the 
curve (Fig.7A) shows good correlation between measurements of two technologies. 
3.5 Healthy subjects and CD patients with LPS activation 
We tested the ability of PBMC from healthy individuals and CD patients with to induce the 
production of TNF- in response to LPS stimulation. After 24 hours incubation with LPS, we 
measured the release of TNF-. We observed a production of TNF-α in the two groups of 
people consolidating us on the effectiveness of PBMC to respond to LPS. PBMCs of CD 
patients produce TNF- twice as much as healthy subjects (data not shown).  
Concerning gene expression, the data analysis was performed using an approach similar to 
the one described before. However, we applied here more strict filters by removing genes 
whose mean Ct was greater than 37. In this area of values measuring variations are 
significant. They are due on the one hand to the lack of reproducibility of withdrawals that 
is related to the Gaussian distribution of the sample in a solution containing a small number 
of copies of cDNA, and secondly, the SDS software that assigns a Ct of 40 to genes for which 
the amplification curve does not reach a plateau, as they cross the threshold between the 
37th and 40th cycle. 
Values were first normalized to 18S rRNA then for each individual, the difference of ∆Cts, 
the ∆∆Cts between the PBMC stimulated or not by LPS was computed. We also calculated 
the average values of ∆∆Cts obtained from four individuals. The genes whose expression is 
regulated by the activation of PBMC by LPS in normal subjects were selected on the one 
hand for an average of ∆∆Cts values greater than 1.5 and less than -1.5, and to the other 
from the p-value of Student's test for paired data at risk of Type  equal to 0.05. We obtained 
18 genes (Table 4) whose expression is significantly LPS dependent, of which 4 are 
overexpressed and 14 repressed. With the exception of GPRC5A the three overexpressed 
genes (GPR155, SSTR3, H963) are well expressed in the non-activated PBMC from healthy 
subjects. Among these genes are many receptors known to be involved in the inflammatory 
process and immune response (EDG2, EMR2, EMR3, CCR1, GPR35, FPr1, CCR3, CMKLR1, 
C5R1, FPRL2, P2RY2, GPBAR1) with two orphan receptors (GPR77, GPR162). 
The same experiment conducted with PBMC from CD patients, stimulated or not with LPS, 
shows a profile of genes regulated by LPS very similar to that obtained in healthy subjects, 
but with a more important difference between those genes induced and repressed (1 for 19 
genes) (Table 5). The appearance of genes such as CCR5, EDG3, EDNRB and IL8RB 
strengthens families of genes already controlled by LPS in healthy subjects. We also observe 
an effect of LPS on the expression of neuropeptide receptors, BAI1, and HTR1A NTSR1. 
Conversely, LPS does not seem to affect the expression of GPRC5A, SSTR3, H963, EMR2 and 
EMR1 genes in CD patients. 
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Hs00173681_m1 GPRC5A retinoic acid induced 3 0.023 4.9 
Hs00400624_m1 GPR155 G protein-coupled receptor 155 0.026 2.2 
Hs00265633_s1 SSTR3 somatostatin receptor 3 0.005 1.6 
Hs00664328_s1 H963 platelet activating receptor homolog 0.027 1.5 
Hs00173500_m1 EDG2 endothelial differentiation, lysophosphatidic acid GPCR 2 0.036 -1.7 
Hs00203752_m1 EMR2 egf-like module containing, mucin-like, hormone receptor-like 2 0.006 -1.8 
Hs00261470_m1 EMR3 egf-like module containing, mucin-like, hormone receptor-like 3 0.028 -2.1 
Hs00174298_m1 CCR1 chemokine (C-C motif) receptor 1 0.016 -2.2 
Hs00271114_s1 GPR35 G protein-coupled receptor 35 0.005 -2.4 
Hs00181830_m1 FPR1 formyl peptide receptor 1 0.002 -2.9 
Hs00266213_s1 CCR3 chemokine (C-C motif) receptor 3 0.031 -2.9 
Hs00356604_m1 CMKLR1 chemokine-like receptor 1 0.034 -3.0 
Hs00356609_g1 C5AR1 complement component 5 receptor 1 (C5a ligand) 0.006 -3.7 
Hs00266666_s1 FPRL2 formyl peptide receptor-like 2 0.011 -3.9 
Hs00175732_m1 P2RY2 purinergic receptor P2Y, G-protein coupled, 2 0.011 -4.4 
Hs00218495_m1 GPR77 G protein-coupled receptor 77 0.038 -4.5 
Hs00248078_m1 GPR162 likely ortholog of mouse gene rich cluster, A gene 0.004 -5.0 
Hs00544894_m1 GPBAR1 G protein-coupled bile acid receptor 1 0.008 -5.4 
Table 4. Genes differentially expressed between PBMCs of control subjects stimulated or not 
by LPS. Test ID: test Taqman Applied Biosystems identification; T-TEST: value p of the test 
of Student for paired data; Average of ΔΔCts: average of the difference of ΔΔCt (ΔCthealthy - 
ΔC Cthealthy +LPS) for each individual. The average of ΔΔCts is positive for overexpressed 
genes and negative for under-expressed genes. 
To search for genes regulated by LPS in a different manner in healthy individuals and 
patients with CD, we used a t test for unpaired data. Table 6 shows the three genes: P2RY2 
gene is repressed by LPS in healthy subjects while remaining unaffected in CD patients, 
CCR5 gene is repressed only in CD patients, the gene GPR4 appears for a regulation in the 
opposite direction depending on whether LPS acts on PBMC from healthy individuals or 
CD patients. The difference of expression of GPR4 between patients and healthy becomes 
significant. It is interesting to note that the GPR4 gene was increased in PBMC of CD 
patients without LPS treatment. To these genes we might add the genes that appear only 
with the healthy or disease group like SSTR3, H963, GPRC5A, EMR2 and EMR3for the 
healthy or NTSR1, EDG3 and GPRAR for CD patients, but there is not enough statistical 
evidence at this level of the study to consider these genes differentially expressed between 
healthy subjects and patients. 
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Assay ID Gene Symbol Gene Name T-TEST 
Average 
Cts 
Hs00400624_m1 GPR155 G protein-coupled receptor 155 0.031 1.8 
Hs00181777_m1 BAI1 brain-specific angiogenesis inhibitor 1 0.025 -1.7 
Hs00173500_m1 EDG2 endothelial differentiation, lysophosphatidic acid GPCR 2 0.039 -1.8 
Hs00265014_s1 HTR1A 5-hydroxytryptamine (serotonin) receptor 1A 0.018 -1.8 
Hs00152917_m1 CCR5 chemokine (C-C motif) receptor 5 0.003 -1.9 
Hs00174304_m1 IL8RB interleukin 8 receptor, beta 0.004 -2.2 
Hs00265090_s1 ADRA2B adrenergic, alpha-2B-, receptor 0.041 -2.2 
Hs00266213_s1 CCR3 chemokine (C-C motif) receptor 3 0.007 -2.3 
Hs00356604_m1 CMKLR1 chemokine-like receptor 1 0.021 -2.3 
Hs00181830_m1 FPR1 formyl peptide receptor 1 0.034 -2.6 
Hs00174298_m1 CCR1 chemokine (C-C motif) receptor 1 0.007 -3.4 
Hs00173592_m1 NTSR1 neurotensin receptor 1 (high affinity) 0.008 -3.6 
Hs00220561_m1 GPR84 G protein-coupled receptor 84 0.033 -3.7 
Hs00266666_s1 FPRL2 formyl peptide receptor-like 2 0.000 -3.8 
Hs00356609_g1 C5AR1 complement component 5 receptor 1 (C5a ligand) 0.004 -4.0 
Hs00218495_m1 GPR77 G protein-coupled receptor 77 0.003 -4.0 
Hs00245464_s1 EDG3 endothelial differentiation, sphingolipid GPCR 3 0.003 -4.1 
Hs00240747_m1 EDNRB endothelin receptor type B 0.010 -4.3 
Hs00544894_m1 GPBAR1 G protein-coupled bile acid receptor 1 0.026 -5.2 
Hs00248078_m1 GPR162 likely ortholog of mouse gene rich cluster, A gene 0.014 -6.9 
Table 5. Genes differentially expressed between PBMC of CD patients stimulated or not by 
LPS. Test ID: Taqman Applied Biosystems identification test; T-TEST: value p of the test of 
Student for paired data; Average of Cts: average of the difference of Ct (CtCD - C 
CtCD+LPS) for each individual. The average of Cts is positive for overexpressed genes and 
negative if under-expressed. 
 





Hs00175732_m1 P2RY2 purinergic receptor P2Y, G-protein coupled, 2 0.049 3.4 
Hs00152917_m1 CCR5 chemokine (C-C motif) receptor 5 0.003 -1.5 
Hs00270999_s1 GPR4 G protein-coupled receptor 4 0.028 -5.7 
Table 6. Genes differentially expressed in PBMCs stimulated by LPS between control and 
CD patients. 
3.6 Expression profiles in biopsies 
Biopsies from healthy subjects, CD, UC and IBS patients were analyzed. Data were obtained 
with the microfluidic card#2 dedicated to GPCR transcriptome. The results presented were 
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Hs00400624_m1 GPR155 G protein-coupled receptor 155 0.026 2.2 
Hs00265633_s1 SSTR3 somatostatin receptor 3 0.005 1.6 
Hs00664328_s1 H963 platelet activating receptor homolog 0.027 1.5 
Hs00173500_m1 EDG2 endothelial differentiation, lysophosphatidic acid GPCR 2 0.036 -1.7 
Hs00203752_m1 EMR2 egf-like module containing, mucin-like, hormone receptor-like 2 0.006 -1.8 
Hs00261470_m1 EMR3 egf-like module containing, mucin-like, hormone receptor-like 3 0.028 -2.1 
Hs00174298_m1 CCR1 chemokine (C-C motif) receptor 1 0.016 -2.2 
Hs00271114_s1 GPR35 G protein-coupled receptor 35 0.005 -2.4 
Hs00181830_m1 FPR1 formyl peptide receptor 1 0.002 -2.9 
Hs00266213_s1 CCR3 chemokine (C-C motif) receptor 3 0.031 -2.9 
Hs00356604_m1 CMKLR1 chemokine-like receptor 1 0.034 -3.0 
Hs00356609_g1 C5AR1 complement component 5 receptor 1 (C5a ligand) 0.006 -3.7 
Hs00266666_s1 FPRL2 formyl peptide receptor-like 2 0.011 -3.9 
Hs00175732_m1 P2RY2 purinergic receptor P2Y, G-protein coupled, 2 0.011 -4.4 
Hs00218495_m1 GPR77 G protein-coupled receptor 77 0.038 -4.5 
Hs00248078_m1 GPR162 likely ortholog of mouse gene rich cluster, A gene 0.004 -5.0 
Hs00544894_m1 GPBAR1 G protein-coupled bile acid receptor 1 0.008 -5.4 
Table 4. Genes differentially expressed between PBMCs of control subjects stimulated or not 
by LPS. Test ID: test Taqman Applied Biosystems identification; T-TEST: value p of the test 
of Student for paired data; Average of ΔΔCts: average of the difference of ΔΔCt (ΔCthealthy - 
ΔC Cthealthy +LPS) for each individual. The average of ΔΔCts is positive for overexpressed 
genes and negative for under-expressed genes. 
To search for genes regulated by LPS in a different manner in healthy individuals and 
patients with CD, we used a t test for unpaired data. Table 6 shows the three genes: P2RY2 
gene is repressed by LPS in healthy subjects while remaining unaffected in CD patients, 
CCR5 gene is repressed only in CD patients, the gene GPR4 appears for a regulation in the 
opposite direction depending on whether LPS acts on PBMC from healthy individuals or 
CD patients. The difference of expression of GPR4 between patients and healthy becomes 
significant. It is interesting to note that the GPR4 gene was increased in PBMC of CD 
patients without LPS treatment. To these genes we might add the genes that appear only 
with the healthy or disease group like SSTR3, H963, GPRC5A, EMR2 and EMR3for the 
healthy or NTSR1, EDG3 and GPRAR for CD patients, but there is not enough statistical 
evidence at this level of the study to consider these genes differentially expressed between 
healthy subjects and patients. 
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Assay ID Gene Symbol Gene Name T-TEST 
Average 
Cts 
Hs00400624_m1 GPR155 G protein-coupled receptor 155 0.031 1.8 
Hs00181777_m1 BAI1 brain-specific angiogenesis inhibitor 1 0.025 -1.7 
Hs00173500_m1 EDG2 endothelial differentiation, lysophosphatidic acid GPCR 2 0.039 -1.8 
Hs00265014_s1 HTR1A 5-hydroxytryptamine (serotonin) receptor 1A 0.018 -1.8 
Hs00152917_m1 CCR5 chemokine (C-C motif) receptor 5 0.003 -1.9 
Hs00174304_m1 IL8RB interleukin 8 receptor, beta 0.004 -2.2 
Hs00265090_s1 ADRA2B adrenergic, alpha-2B-, receptor 0.041 -2.2 
Hs00266213_s1 CCR3 chemokine (C-C motif) receptor 3 0.007 -2.3 
Hs00356604_m1 CMKLR1 chemokine-like receptor 1 0.021 -2.3 
Hs00181830_m1 FPR1 formyl peptide receptor 1 0.034 -2.6 
Hs00174298_m1 CCR1 chemokine (C-C motif) receptor 1 0.007 -3.4 
Hs00173592_m1 NTSR1 neurotensin receptor 1 (high affinity) 0.008 -3.6 
Hs00220561_m1 GPR84 G protein-coupled receptor 84 0.033 -3.7 
Hs00266666_s1 FPRL2 formyl peptide receptor-like 2 0.000 -3.8 
Hs00356609_g1 C5AR1 complement component 5 receptor 1 (C5a ligand) 0.004 -4.0 
Hs00218495_m1 GPR77 G protein-coupled receptor 77 0.003 -4.0 
Hs00245464_s1 EDG3 endothelial differentiation, sphingolipid GPCR 3 0.003 -4.1 
Hs00240747_m1 EDNRB endothelin receptor type B 0.010 -4.3 
Hs00544894_m1 GPBAR1 G protein-coupled bile acid receptor 1 0.026 -5.2 
Hs00248078_m1 GPR162 likely ortholog of mouse gene rich cluster, A gene 0.014 -6.9 
Table 5. Genes differentially expressed between PBMC of CD patients stimulated or not by 
LPS. Test ID: Taqman Applied Biosystems identification test; T-TEST: value p of the test of 
Student for paired data; Average of Cts: average of the difference of Ct (CtCD - C 
CtCD+LPS) for each individual. The average of Cts is positive for overexpressed genes and 
negative if under-expressed. 
 





Hs00175732_m1 P2RY2 purinergic receptor P2Y, G-protein coupled, 2 0.049 3.4 
Hs00152917_m1 CCR5 chemokine (C-C motif) receptor 5 0.003 -1.5 
Hs00270999_s1 GPR4 G protein-coupled receptor 4 0.028 -5.7 
Table 6. Genes differentially expressed in PBMCs stimulated by LPS between control and 
CD patients. 
3.6 Expression profiles in biopsies 
Biopsies from healthy subjects, CD, UC and IBS patients were analyzed. Data were obtained 
with the microfluidic card#2 dedicated to GPCR transcriptome. The results presented were 
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obtained from 11 biopsies taken from a sampling of heterogeneous individuals: one biopsy 
of healthy individuals, four zones of patients with inflammatory CD and a healthy area of a 
patient with CD, inflammatory zone 2 of patients with UC and a healthy area of a patient 
with UC, and 2 from patients with IBS. The results presented were obtained from 11 
biopsies taken heterogeneous individuals: 1 biopsy of healthy individual only, 4 inflamed 
zones of CD patients and one healthy zone of CD patients, 2 inflamed zones of UC patients 
and a healthy zone of UC patient, and 2 inflamed zones of IBS patients. 
Due to the heterogeneity and the small number of individuals studied, we tried to present 
here the most interesting results in spite of all possible combinations. It seemed wise to seek 
for receptors that expressed specifically in inflamed CD tissue relative to all other samples, 
biopsy of the healthy individual and those of patients with UC or IBS. This procedure is like 
comparing the inflammatory tissue of CD with background noise resulting from the 
combination of all other tissues. To do this, we used the same approach of comparing 
expression profiles of PBMCs from healthy subjects and patients with a Student test for 
unpaired data (α equal to 0.05) and the calculation of ∆∆Ct averages of two classes (∆∆Ct = 
(∆Ct non-CD- ∆Ct CD)). The genes were filtered with the criteria of an average of Cts lower than 
37 and selected for ∆∆Ct higher than 1.5. Thus Table 8 shows 37 genes differentially 
expressed between biopsies from inflamed zone of CD patients and all the other biopsies 
(healthy individual, healthy area of CD patient, areas of healthy and inflammatory UC 
patients and IBS). All 37 genes are overexpressed in CD. 
Given the large number of genes revealed, we relied on the David software to highlight the 
functional categories appropriately represented in an expression profile. David is a Web 
application of NCBI that uses the NCBI GO terms (Gene Ontology) a vocabulary structured 
to describe role of genes and their products (The Gene Ontology Consortium, 2001). David 
interprets terms GO associated with differentially found genes and alternatively compares 
them with whole of functional categories of genes present on card#2, alternately against the 
studied genome. Under "immune response", appeared a group of seven genes, including 
many chemokine receptors (ADORA1, BLR1, CNR2, CCR6, CCR7, CCR8, IL8RA, IL8RB). This 
group corresponds to an ontology enrichment of a factor 2 (8/33 compared to 49/362 in 
map 2). One can note the strong representation of genes related to neuropeptides, receptor 
proteins are 17 out of 33 (33 of the 37 gene list have a GO term). However, these receptors do 
not represent enrichment since they are 162 listed in this category. 
We looked for genes characteristic of different types of inflammation of the intestine: IBS, 
UC and CD. To do this we compare the three groups of tissue two by two and used the 
criteria previously used to identify "differential" genes. Tables 8 to 11 represent the genes 
obtained. Table 11 shows a greater number of "differential" genes between inflamed zones 
between IBS patients and CD patients. All 19 genes are increasing in CD up to several orders 
of magnitude. These genes are composed in a large majority of neuropeptides receptors. 
There are also many orphan receptors, like the TAAR family ("Trace Amine Associated 
Receptor"), for which ligands are likely to have similarities with the metabolites of amino 
acids as neurotransmitters. 
Table 12 shows 4 "differential" genes between UC and IBS: 3 orphan receptors are increased 
in UC biopsies whereas receptor of chemokine CCBP2 is reduced. Between biopsies of UC 
and CD (table 10), there are very few genes that are significantly "differently" expressed. 
Note that among four neuropeptide receptors, two are receptors for peptides from the brain 
(vasopressin and parathyroid hormone). These hormone receptors may reflect a special 
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relationship of inflammatory bowel area with the central nervous system.  Those genes are 
the significantly different between UC and CD. 
 
Assay ID Gene Symbol Gene Name T-TEST Average 
Cts 
Hs00609865_m1 EDNRA endothelin receptor type A 0.002 6.6 
Hs00174146_m1 IL8RA interleukin 8 receptor, alpha 0.035 6.0 
Hs00218495_m1 GPR77 G protein-coupled receptor 77 0.008 5.3 
Hs00167241_m1 HTR2A 5-hydroxytryptamine (serotonin) receptor 2A 0.007 4.4 
Hs00223340_m1 GPR147 G protein-coupled receptor 147 0.006 4.2 
Hs00174304_m1 IL8RB interleukin 8 receptor, beta 0.044 3.8 
Hs00173855_m1 GPR putative G protein coupled receptor 0.002 3.6 
Hs00176122_m1 AVPR1A arginine vasopressin receptor 1A 0.002 3.4 
Hs00200681_m1 ADMR adrenomedullin receptor 0.049 3.3 
Hs00542381_m1 GPR114 G protein-coupled receptor 114 0.015 3.2 
Hs00174895_m1 PTHR1 parathyroid hormone receptor 1 0.007 3.1 
Hs00171054_m1 CCR7 chemokine (C-C motif) receptor 7 0.001 3.0 
Hs00332805_m1 MRGPRF MAS-related GPR, member F 0.003 3.0 
Hs00736776_m1 P2RY8 purinergic receptor P2Y, G-protein coupled, 8 0.002 3.0 
Hs00212116_m1 GPRC5B GPCR, family C, group 5, member B 0.009 3.0 
Hs00168765_m1 PTGIR prostaglandin I2 (prostacyclin) receptor (IP) 0.027 2.9 
Hs00174764_m1 CCR8 chemokine (C-C motif) receptor 8 0.016 2.9 
Hs00361490_m1 CNR2 cannabinoid receptor 2 (macrophage) 0.028 2.7 
Hs00266671_s1 FY Duffy blood group 0.040 2.7 
Hs00391810_m1 GPR116 G protein-coupled receptor 116 0.009 2.6 
Hs00237052_m1 CXCR4 chemokine (C-X-C motif) receptor 4 0.006 2.4 
Hs00272624_s1 CYSLTR1 cysteinyl leukotriene receptor 1 0.040 2.4 
Hs00174910_m1 TSHR thyroid stimulating hormone receptor 0.030 2.4 
Hs00168763_m1 PTGFR prostaglandin F receptor (FP) 0.028 2.3 
Hs00187982_m1 F2RL2 coagulation factor II (thrombin) receptor-like 2 0.047 2.3 
Hs00173499_m1 EDG1 endothelial differentiation, sphingolipid  GPCR 1 0.010 2.2 
Hs00173527_m1 BLR1 Burkitt lymphoma receptor 1, GTP binding protein (chemokine (C-X-C motif) receptor 5) 0.022 2.2 
Hs00184657_m1 BAI2 brain-specific angiogenesis inhibitor 2 0.035 2.2 
Hs00170665_m1 SMO smoothened homolog (Drosophila) 0.043 2.1 
Hs00262150_m1 GPR124 G protein-coupled receptor 124 0.026 2.1 
Hs00274326_s1 P2RY10 purinergic receptor P2Y, G-protein coupled, 10 0.034 2.0 
Hs00181231_m1 ADORA1 adenosine A1 receptor 0.042 2.0 
Hs00246222_s1 NPY6R neuropeptide Y receptor Y6 (pseudogene) 0.026 2.0 
Hs00168362_m1 HTR2B 5-hydroxytryptamine (serotonin) receptor 2B 0.038 1.9 
Hs00173787_m1 CALCRL calcitonin receptor-like 0.028 1.9 
Hs00169258_m1 F2R coagulation factor II (thrombin) receptor 0.030 1.8 
Hs00270873_s1 AGTRL1 angiotensin II receptor-like 1 0.026 1.8 
Hs00171121_m1 CCR6 chemokine (C-C motif) receptor 6 0.009 1.8 
 
Table 7. Genes differentially expressed between biopsies of inflamed zone CD patients and 
biopsies of colon (healthy individual, healthy zone of the CD patient, healthy and inflamed 
zones of UC patients, inflamed zones of IBS patients). 
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obtained from 11 biopsies taken from a sampling of heterogeneous individuals: one biopsy 
of healthy individuals, four zones of patients with inflammatory CD and a healthy area of a 
patient with CD, inflammatory zone 2 of patients with UC and a healthy area of a patient 
with UC, and 2 from patients with IBS. The results presented were obtained from 11 
biopsies taken heterogeneous individuals: 1 biopsy of healthy individual only, 4 inflamed 
zones of CD patients and one healthy zone of CD patients, 2 inflamed zones of UC patients 
and a healthy zone of UC patient, and 2 inflamed zones of IBS patients. 
Due to the heterogeneity and the small number of individuals studied, we tried to present 
here the most interesting results in spite of all possible combinations. It seemed wise to seek 
for receptors that expressed specifically in inflamed CD tissue relative to all other samples, 
biopsy of the healthy individual and those of patients with UC or IBS. This procedure is like 
comparing the inflammatory tissue of CD with background noise resulting from the 
combination of all other tissues. To do this, we used the same approach of comparing 
expression profiles of PBMCs from healthy subjects and patients with a Student test for 
unpaired data (α equal to 0.05) and the calculation of ∆∆Ct averages of two classes (∆∆Ct = 
(∆Ct non-CD- ∆Ct CD)). The genes were filtered with the criteria of an average of Cts lower than 
37 and selected for ∆∆Ct higher than 1.5. Thus Table 8 shows 37 genes differentially 
expressed between biopsies from inflamed zone of CD patients and all the other biopsies 
(healthy individual, healthy area of CD patient, areas of healthy and inflammatory UC 
patients and IBS). All 37 genes are overexpressed in CD. 
Given the large number of genes revealed, we relied on the David software to highlight the 
functional categories appropriately represented in an expression profile. David is a Web 
application of NCBI that uses the NCBI GO terms (Gene Ontology) a vocabulary structured 
to describe role of genes and their products (The Gene Ontology Consortium, 2001). David 
interprets terms GO associated with differentially found genes and alternatively compares 
them with whole of functional categories of genes present on card#2, alternately against the 
studied genome. Under "immune response", appeared a group of seven genes, including 
many chemokine receptors (ADORA1, BLR1, CNR2, CCR6, CCR7, CCR8, IL8RA, IL8RB). This 
group corresponds to an ontology enrichment of a factor 2 (8/33 compared to 49/362 in 
map 2). One can note the strong representation of genes related to neuropeptides, receptor 
proteins are 17 out of 33 (33 of the 37 gene list have a GO term). However, these receptors do 
not represent enrichment since they are 162 listed in this category. 
We looked for genes characteristic of different types of inflammation of the intestine: IBS, 
UC and CD. To do this we compare the three groups of tissue two by two and used the 
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(vasopressin and parathyroid hormone). These hormone receptors may reflect a special 
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relationship of inflammatory bowel area with the central nervous system.  Those genes are 
the significantly different between UC and CD. 
 
Assay ID Gene Symbol Gene Name T-TEST Average 
Cts 
Hs00609865_m1 EDNRA endothelin receptor type A 0.002 6.6 
Hs00174146_m1 IL8RA interleukin 8 receptor, alpha 0.035 6.0 
Hs00218495_m1 GPR77 G protein-coupled receptor 77 0.008 5.3 
Hs00167241_m1 HTR2A 5-hydroxytryptamine (serotonin) receptor 2A 0.007 4.4 
Hs00223340_m1 GPR147 G protein-coupled receptor 147 0.006 4.2 
Hs00174304_m1 IL8RB interleukin 8 receptor, beta 0.044 3.8 
Hs00173855_m1 GPR putative G protein coupled receptor 0.002 3.6 
Hs00176122_m1 AVPR1A arginine vasopressin receptor 1A 0.002 3.4 
Hs00200681_m1 ADMR adrenomedullin receptor 0.049 3.3 
Hs00542381_m1 GPR114 G protein-coupled receptor 114 0.015 3.2 
Hs00174895_m1 PTHR1 parathyroid hormone receptor 1 0.007 3.1 
Hs00171054_m1 CCR7 chemokine (C-C motif) receptor 7 0.001 3.0 
Hs00332805_m1 MRGPRF MAS-related GPR, member F 0.003 3.0 
Hs00736776_m1 P2RY8 purinergic receptor P2Y, G-protein coupled, 8 0.002 3.0 
Hs00212116_m1 GPRC5B GPCR, family C, group 5, member B 0.009 3.0 
Hs00168765_m1 PTGIR prostaglandin I2 (prostacyclin) receptor (IP) 0.027 2.9 
Hs00174764_m1 CCR8 chemokine (C-C motif) receptor 8 0.016 2.9 
Hs00361490_m1 CNR2 cannabinoid receptor 2 (macrophage) 0.028 2.7 
Hs00266671_s1 FY Duffy blood group 0.040 2.7 
Hs00391810_m1 GPR116 G protein-coupled receptor 116 0.009 2.6 
Hs00237052_m1 CXCR4 chemokine (C-X-C motif) receptor 4 0.006 2.4 
Hs00272624_s1 CYSLTR1 cysteinyl leukotriene receptor 1 0.040 2.4 
Hs00174910_m1 TSHR thyroid stimulating hormone receptor 0.030 2.4 
Hs00168763_m1 PTGFR prostaglandin F receptor (FP) 0.028 2.3 
Hs00187982_m1 F2RL2 coagulation factor II (thrombin) receptor-like 2 0.047 2.3 
Hs00173499_m1 EDG1 endothelial differentiation, sphingolipid  GPCR 1 0.010 2.2 
Hs00173527_m1 BLR1 Burkitt lymphoma receptor 1, GTP binding protein (chemokine (C-X-C motif) receptor 5) 0.022 2.2 
Hs00184657_m1 BAI2 brain-specific angiogenesis inhibitor 2 0.035 2.2 
Hs00170665_m1 SMO smoothened homolog (Drosophila) 0.043 2.1 
Hs00262150_m1 GPR124 G protein-coupled receptor 124 0.026 2.1 
Hs00274326_s1 P2RY10 purinergic receptor P2Y, G-protein coupled, 10 0.034 2.0 
Hs00181231_m1 ADORA1 adenosine A1 receptor 0.042 2.0 
Hs00246222_s1 NPY6R neuropeptide Y receptor Y6 (pseudogene) 0.026 2.0 
Hs00168362_m1 HTR2B 5-hydroxytryptamine (serotonin) receptor 2B 0.038 1.9 
Hs00173787_m1 CALCRL calcitonin receptor-like 0.028 1.9 
Hs00169258_m1 F2R coagulation factor II (thrombin) receptor 0.030 1.8 
Hs00270873_s1 AGTRL1 angiotensin II receptor-like 1 0.026 1.8 
Hs00171121_m1 CCR6 chemokine (C-C motif) receptor 6 0.009 1.8 
 
Table 7. Genes differentially expressed between biopsies of inflamed zone CD patients and 
biopsies of colon (healthy individual, healthy zone of the CD patient, healthy and inflamed 
zones of UC patients, inflamed zones of IBS patients). 
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Hs00174146_m1 IL8RA interleukin 8 receptor, alpha 0.002 10.8 
Hs00218495_m1 GPR77 G protein-coupled receptor 77 0.035 8.4 
Hs00220561_m1 GPR84 G protein-coupled receptor 84 0.023 7.9 
Hs00174304_m1 IL8RB interleukin 8 receptor, beta 0.025 6.1 
Hs00223340_m1 GPR147 G protein-coupled receptor 147 0.010 5.9 
Hs00271072_s1 GPR23 G protein-coupled receptor 23 0.043 5.8 
Hs00181830_m1 FPR1 formyl peptide receptor 1 0.035 5.1 
Hs00256749_s1 P2RY13 purinergic receptor P2Y, G-protein coupled, 13 0.012 4.0 
Hs00266213_s1 CCR3 chemokine (C-C motif) receptor 3 0.034 3.7 
Hs00261470_m1 EMR3 egf-like module containing, mucin-like, hormone receptor-like 3 0.040 3.6 
Hs00269446_s1 EDG6 endothelial differentiation, G-protein-coupled  receptor 6 0.046 3.6 
Hs00252658_s1 CYSLTR2 cysteinyl leukotriene receptor 2 0.015 3.1 
Hs00171054_m1 CCR7 chemokine (C-C motif) receptor 7 0.012 2.9 
Hs00542381_m1 GPR114 G protein-coupled receptor 114 0.031 2.8 
Hs00274326_s1 P2RY10 purinergic receptor P2Y, G-protein coupled, 10 0.027 2.4 
Hs00252888_s1 VN1R1 vomeronasal 1 receptor 1 0.040 1.7 
Hs00176738_m1 MATK megakaryocyte-associated tyrosine kinase 0.041 -1.3 
Hs00191104_m1 GPR37L1 G-protein coupled receptor 37 like 1 0.039 -4.8 
Table 8. Genes differentially expressed between biopsies of inflamed zone of CD patients, 
and biopsies of healthy individual and patients having IBS. 
 
Assay ID Gene Symbol Gene Name T-TEST Average Cts 
Hs00266671_s1 FY Duffy blood group 0.040 2.7 
Hs00184657_m1 BAI2 brain-specific angiogenesis inhibitor 2 0.035 2.2 
Hs00181231_m1 ADORA1 adenosine A1 receptor 0.042 2.0 
Table 9. Common genes differentially expressed between biopsies of inflamed zone and 
PBMCs of CD patients. 
 
Assay ID Gene Symbol Gene Name T-TEST Average Cts 
Hs00174895_m1 PTHR1 parathyroid hormone receptor 1 0.001 3.9 
Hs00176122_m1 AVPR1A Arginine vasopressin receptor 1A 0.007 2.7 
Hs00184657_m1 BAI2 brain-specific angiogenesis inhibitor 2 0.029 2.2 
Hs00265081_s1 ADRA2A adrenergic, alpha-2A-, receptor 0.044 2.1 
Hs00174304_m1 IL8RB interleukin 8 receptor, beta 0.004 -2.2 
Hs00266213_s1 CCR3 chemokine (C-C motif) receptor 3 0.007 -2.3 
Hs00181830_m1 FPR1 formyl peptide receptor 1 0.034 -2.6 
Hs00220561_m1 GPR84 G protein-coupled receptor 84 0.033 -3.7 
Hs00218495_m1 GPR77 G protein-coupled receptor 77 0.003 -4.0 
Table 10. Genes differentially expressed between biopsies of inflamed zone of CD patients 
and biopsies of inflamed zone of UC patients. 
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Hs00601815_s1 TAAR9 trace amine associated receptor 9 0.010 11.7 
Hs00365019_s1 MRGPRX2 MAS-related GPR, member X2 0.009 11.4 
Hs00265296_s1 HTR1F 5-hydroxytryptamine (serotonin) receptor 1F 0.012 11.2 
Hs00609865_m1 EDNRA endothelin receptor type A 0.026 11.1 
Hs00174146_m1 IL8RA interleukin 8 receptor, alpha 0.006 11.1 
Hs00265208_s1 CHRM2 cholinergic receptor, muscarinic 2 0.000 9.9 
Hs00220561_m1 GPR84 G protein-coupled receptor 84 0.012 9.4 
Hs00269590_s1 TAAR5 trace amine associated receptor 5 0.001 9.3 
Hs00754695_s1 MRGPRX3 MAS-related GPR, member X3 0.043 8.8 
Hs00265081_s1 ADRA2A adrenergic, alpha-2A-, receptor 0.036 8.6 
Hs00664049_s1 GPR150 G protein-coupled receptor 150 0.017 8.4 
Hs00274365_s1 TAAR2 trace amine associated receptor 2 0.002 7.4 
Hs00271072_s1 GPR23 G protein-coupled receptor 23 0.002 7.3 
Hs00664166_s1 GPR142 G protein-coupled receptor 142 0.044 6.9 
Hs00267157_s1 MAS1 MAS1 oncogene 0.003 6.2 
Hs00266671_s1 FY Duffy blood group 0.030 5.8 
Hs00271877_s1 CD4R Melanocortin 4 receptor 0.046 5.1 
Hs00269446_s1 EDG6 endothelial differentiation, G-protein-coupled receptor 6 0.029 4.5 
Hs00168567_m1 NPY2R Neuropeptide Y receptor Y2 0.032 3.3 
Table 11. Genes differentially expressed between biopsies of inflamed zone of CD patients 
and IBS patients. 
 
Assay ID Gene Symbol Gene Name T-TEST 
Average 
Cts 
Hs00220561_m1 GPR84 G protein-coupled receptor 84 0.044 8.0 
Hs00664166_s1 GPR142 G protein-coupled receptor 142 0.042 7.5 
Hs00542396_m1 GPR110 G protein-coupled receptor 110 0.008 4.9 
Hs00174299_m1 CCBP2 chemokine binding protein 2 0.039 -2.8 
Table 12. Genes differentially expressed between biopsies of inflamed zone of FGD patients 
and UC patients. 
4. Conclusion 
Studying the expression of GPCRs in PBMCs has highlighted a number of deregulated 
genes in CD. In general, among these deregulated genes, the majority is accepted to be 
involved in mechanisms of inflammation or immune response. After a closer examination of 
their function, these genes appear to have an opposite contribution in the inflammatory 
process. Surprisingly, receptor expression is regulated more in favor of a repressor or 
suppressor effect of a malfunction of inflammatory cells rather than in a pro-inflammatory 
activity like SSTR5 whose role is to reduce intestinal inflammation.  
Expression profiles of PBMC's GPCR distinguish CD patients from healthy donors are 
represented in Figure 10. The expression of a reduced number of genes makes it even clearly 
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feasible to differentiate PBMCs from healthy individuals and CD patients (Figure 11). These 
receptors could be a signature for CD, but it remains necessary to test this group of genes 
with other known genes, for healthy and CD PBMCs, and so to check if clustering classifies 
correctly these samples. It would be also interesting to compare these profiles with those 
obtained from PBMCs of patients developing IBS or UC. 
Our study activation of PBMCs by LPS shows that PBMCs are able to induce in vitro an 
immunizing response in answer to exposure to bacterial lipopolysaccharide of production 
and release in medium of TNF-, principal mediator of inflammatory answer. This 
activation of monocytes by LPS was amply described and used in routine way in 
laboratories to test capacity of monocytes to answer pathogenic microorganisms. Majority of 
human cells answer molecular signals of microbial invasion of installing locally mechanisms 
of defense, then by recruiting and activating specialized cells of immune system. 
 
 
Fig. 10. Signature of GPCR expression in PBMCs from CD patients (CD) versus healthy 
donors (H). Ascending hierarchic classification was carried out using the software Dchip (Li 
and Wong 2001) using a correlation matrix of distances and centroid grouping. The matrix 
of expression data is converted into a thermal colored map according to the relative level of 
expression of each gene.  The colors range from blue to a high level of expression to red for a 
low level of expression through an intermediate white (values expressed in ∆Ct). 
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Fig. 11. Signature of expression of GPCRs in biopsies of CD patients (MCxx), UC patients 
(RHCxx) and IBS patients (TFIxx). 
As has been described before, the recognition of TRL4 receptors on the surface of monocytes 
by a bacterial product such as LPS leads to a cascade of reactions within the cells and release 
of cytokines TNF-, but also IL-1, IL-3, I-6, IL-10, and colony stimulating factors (CSFs), 
chemokines such as IL-8 and macrophage inflammatory proteins (MIFs). The main 
mechanism underlying the induction of these proteins is at the level of transcription, 
particularly under the control of the transcription factor NF-B. We studied here the effect of 
bacterial stimuli in an original way, first by examining its effect on the expression of almost 
all GPCRs, second using a macro-arrays technology by real-time PCR. Our results indicate 
that activation of PBMC by LPS is reflected mainly by a repression of GPCR expression. In a 
similar approach conducted with larger arrays, the same trend was observed i.e. LPS 
represses 1125 genes out of 1868 differentially expressed genes (Wurfel et al. 2005). Among 
the overexpressed genes, these authors note the presence of key players in the inflammatory 
response, primarily cytokines and chemokines. In our hands the only GPCR in the list of 15 
genes selected in each category is the chemokine receptor 2 (CCR2) the 2nd most strongly 
repressed. If we noticed no decrease in CCR2, the experimental condition, origin of LPS, 
exposure time and concentration of LPS may explain this divergence of results. It is 
interesting to note that among genes repressed by LPS common to healthy individuals and 
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CD patients, two families of receptor are represented: chemokine receptors (CCR1, CCR3, 
CMKLR1, C5AR1) and formylated peptides receptors (FPR1, FPRL2). The receptors 
involved in chemotaxis and recognition of bacterial peptides (CCR1, CMKLR1, RPF) have 
been extensively documented for their repression following LPS activation of PBMCs 
(Boldrick et al. 2002; Nau et al. 2002; Parker et al. 2004). Others observed similar expression 
profiles in PBMCs (Boldrick et al. 2002). In addition, they noticed that the induction and 
repression are LPS dose dependent and there are some differences in the profiles along the 
microorganism and their virulence, suggesting that some pathogens have developed 
strategies to foil the defense mechanism of host cells. However we observe a suppression of 
two other chemokine receptors: CCR3, known to have high affinity for eotaxin, a chemokine 
produced by eosinophil in broncho-alveolar fluid in the animal model of asthma (Jose, 
Griffiths-Johnson et al. 1994) and C5AR1 studied in neutrophil chemotaxis and linked to 
many diseases immune complex. Other receptors whose function is less known (EDG2, 
GPBAR1) and especially 2 orphan receptors (GPR155 one of rare genes activated by LPS and 
GPR162 repressed by more than 100 times in CD patients) could provide new elements in 
understanding the signaling pathways that control the inflammatory response. 
The decrease in gene expression essential for the defense of an organism, while it is in 
contact with the invader, may seem paradoxical. One hypothesis is that these mechanisms of 
repression and induction of certain genes have a regulatory role for antigen-presenting cells 
(APC). This repression of genes, without which the massive amplification of defense 
systems quickly destroy infectious agents, allows the APC time to present antigens to T 
cells, not only at the site of infection but also in secondary lymphoid tissues. 
It should be noted that parallel to repression of certain receptors, most of their ligands, 
cytokines and chemokines, are increased by LPS (Boldrick et al. 2002). This hypothesis 
reinforces the concept of immune defense mechanism tightly controlled and orchestrated at 
the transcriptional level as highlighted by studying expression profiles over time. Thus, in 
monocytes, LPS controls temporally and alternately increase and decrease of expression of 
different groups of gene (Sharif et al. 2007). In the context of a specific program of control of 
gene expression, it is not surprising that the time, the origin and the dose of LPS are factors 
that influence the expression profile. It is interesting to note that in the work of Sharif and 
coll., 4 receptors of our repertory are among the 72 genes controlled by LPS: after 1 hour of 
exposure, only ADORA1 is slightly increased but returns to its original level at 4 hours, after 
four hours, while CCR7 is increased CCR2 and CXR4 are repressed. Our results for these 
genes obtained after 2 hours 30 of exposure are compatible and consistent with those 
described before (Sharif et al. 2007). In Table 6 are represented the 3 receptors whose 
expression varies significantly for CD patients. Why and how genes are regulated in the 
context of healthy individuals or with the disease and how they are connected to other 
receptors deregulated in CD patients, are questions difficult to be answered at this level of 
study. However, the large number of genes controlled by LPS in both healthy subjects and 
CD patients, compared to three genes differentially controlled, suggests that PBMC from the 
two populations have the capacity to respond very similarly to LPS activation, suggesting 
that CD patients PBMCs are only moderately disturbed in response to a bacterial infection. 
However, we can not exclude that one of the 3 receptors that differentiate two groups of 
individuals in response to bacterial stimuli, could control a signaling pathway involved, 
directly or indirectly, in CD. For example, disability and loss of immunological tolerance 
vis-à-vis certain species of commensal bacteria in the intestine is characteristic of CD 
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patients and are often put forward to explain the chronicity of the inflammatory state (Sartor 
2003). The expression profiles of GPCR in inflamed zones of Crohn patients clearly suggest a 
close relationship between the inflammatory process and the nervous system. Our results 
have shown unequivocally chemokine receptors (ADORA1, BLR1, CCR6, CCR7, CCR8, 
IL8RA, IL8RB) many neuropeptide receptors and neurotransmitter in the disease. 
Neuropeptide receptors and neurotransmitter occupy an essential place in the nervous 
system to ensure the function of the intestinal wall. The nervous system is complex: the 
autonomous nervous system consists of a network of nerve fibers connected to the plexus 
that connect the different layers of the wall and sympathetic and parasympathetic fibers that 
make synapses in small intramural ganglia. The autonomous nervous system ensures 
glandular secretion, vasodilation and vasoconstriction, and motility of smooth muscle fibers. 
The colon wall is also controlled by the vegetative nervous system under the control of the 
hypothalamic-adrenal-hypophysio-surrenal axis. It is through him that emotions, stress and 
fatigue affect the functioning of the digestive system (Taylor & Keely 2007). 
The presence of chemokine receptors, neuropeptides and neurotransmitters suggests a close 
relationship and communication between nerve cells, the intestinal lining cells and immune 
cells in the inflammatory zone. These links are illustrated by the endocrine cells, for 
example, the colonic epithelium that secrete polypeptide hormones and neurotransmitters 
such as gastrin, cholecystokinin (CCK), VIP (vasoactive intestinal peptide), substance P, 
bombesin and somatostatin and serotonin, which also act as neurotransmitters. If the effect 
of the ligands is relatively well documented in all functions related to the nervous system, 
transmission potential, secretion, muscle contractility, the role of receptors is more complex. 
The increase in receptors in the inflammatory tissue of CD is consistent with a general 
increase in neuronal signaling, described in the literature in terms of neuropeptides and 
neurotransmitters. At this stage of the study, interpretation of the increase in these receptors 
and their role in the inflammation is difficult without information on the characteristics of 
cells in which they are overexpressed. 
These increases can be linked to altered activity of nerve cells under the influence of 
inflammatory mediators or a nervous system response to restore tissue to a normal state. 
The histology of the intestinal mucosa, as we observed on our CD biopsies, must be 
accompanied by a remodeling of the enteric system so that it can perform its functions. It is 
a set of elements that are responsible for these changes: neuronal plasticity, all of these 
neuronal modulations, changes in morphology, the number and development of new 
dendrites for connective, but the emergence of new nerve cells (Geboes & Collins 1998). The 
increase of certain nerve cells may explain the increase in receptors. Enterochromaffin cells 
contain many neuroactive substances such as serotonin, bradykinin, tachykinin and 
prostaglandin that are released by multiple stimuli, mechanical, chemical and nervous. The 
release of serotonin, which has many roles (such as the increase in intestinal motility, 
vasoconstriction, synaptic transmission), is controlled at the level of enterochromaffin cells 
by receptors some of which have a stimulatory activity (HTR1, HTR2, MCR3) while others 
have an inhibitory activity (HTR3, type purinergic receptor P2Y, histamine, neurokinin, 
somatostatin). In these cells, two receptors HTR2 A and B increased in Crohn's disease, have 
a role rather amplifier of the disease. It would be the same level of sensory nerves that 
express a wide range of receptor on their surface. Neuronal activity is controlled mainly by 
receptor of natural substances such as VIP or substance P, but the activity can be altered by 
the presence of inflammatory products (serotonin, bradykinin, prostaglandin leukotriene, 
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CD patients, two families of receptor are represented: chemokine receptors (CCR1, CCR3, 
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CD patients, compared to three genes differentially controlled, suggests that PBMC from the 
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that CD patients PBMCs are only moderately disturbed in response to a bacterial infection. 
However, we can not exclude that one of the 3 receptors that differentiate two groups of 
individuals in response to bacterial stimuli, could control a signaling pathway involved, 
directly or indirectly, in CD. For example, disability and loss of immunological tolerance 
vis-à-vis certain species of commensal bacteria in the intestine is characteristic of CD 
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patients and are often put forward to explain the chronicity of the inflammatory state (Sartor 
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have shown unequivocally chemokine receptors (ADORA1, BLR1, CCR6, CCR7, CCR8, 
IL8RA, IL8RB) many neuropeptide receptors and neurotransmitter in the disease. 
Neuropeptide receptors and neurotransmitter occupy an essential place in the nervous 
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transmission potential, secretion, muscle contractility, the role of receptors is more complex. 
The increase in receptors in the inflammatory tissue of CD is consistent with a general 
increase in neuronal signaling, described in the literature in terms of neuropeptides and 
neurotransmitters. At this stage of the study, interpretation of the increase in these receptors 
and their role in the inflammation is difficult without information on the characteristics of 
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inflammatory mediators or a nervous system response to restore tissue to a normal state. 
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a set of elements that are responsible for these changes: neuronal plasticity, all of these 
neuronal modulations, changes in morphology, the number and development of new 
dendrites for connective, but the emergence of new nerve cells (Geboes & Collins 1998). The 
increase of certain nerve cells may explain the increase in receptors. Enterochromaffin cells 
contain many neuroactive substances such as serotonin, bradykinin, tachykinin and 
prostaglandin that are released by multiple stimuli, mechanical, chemical and nervous. The 
release of serotonin, which has many roles (such as the increase in intestinal motility, 
vasoconstriction, synaptic transmission), is controlled at the level of enterochromaffin cells 
by receptors some of which have a stimulatory activity (HTR1, HTR2, MCR3) while others 
have an inhibitory activity (HTR3, type purinergic receptor P2Y, histamine, neurokinin, 
somatostatin). In these cells, two receptors HTR2 A and B increased in Crohn's disease, have 
a role rather amplifier of the disease. It would be the same level of sensory nerves that 
express a wide range of receptor on their surface. Neuronal activity is controlled mainly by 
receptor of natural substances such as VIP or substance P, but the activity can be altered by 
the presence of inflammatory products (serotonin, bradykinin, prostaglandin leukotriene, 
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ATP) and usually results in hyper excitability. Generally, treatment uses antagonists of these 
receptors (Hansen 2003). 
All nerve cells do not have the same contribution in the development of the disease. For 
example, in terms of motility disorders, due to alterations in signal transmission at synapses 
of the enteric nerves, it was shown that motility of the intestine is controlled by the 
adrenergic sympathetic fibers that decrease while the parasympathetic fibers stimulate the 
cholinergic (Smith & Smid 2005). Studies show that agents which promote parasympathetic 
activity also tend to reduce the severity of the disease, and conversely for sympathetic 
activity (Miceli & Jacobson 2003). It would be interesting to know the repertoire of these 
receptors in nerve cells and identify those that are deregulated in order to use agonists or 
antagonists to restore gut motility. 
Results reported here are encouraging nevertheless they remain preliminary. It will be 
necessary to analyze a larger number of samples, identify exactly the biopsy position in the 
colon and obtain relevant information on individuals before hoping to get molecular 
signatures of the different types of bowel diseases. In a therapeutic point of view, our results 
on the transcriptome of GPCRs from Crohn's disease biopsies offer a wide range of potential 
therapeutic targets, for functions as diverse as those related to the immune response, 
hormonal regulations, transfers of nervous information nerve, or blood clotting. 
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1. Introduction 
Nowadays, there is still no gold standard test for Inflammatory Bowel Disease (IBD). Many 
etiologies are responsible of an inflammation of the gut. When a patient presents with signs 
suggestive of IBD (abdominal pain, diarrhea, and sometimes fever), the clinician had to 
establish whether the patient suffers from an IBD or from one of the numerous alternative 
diseases. The use of immunosuppressive agents and biotherapies in IBD treatment enforces 
the necessity to distinguish them from infectious diseases, particularly from tuberculosis. 
Clinical signs of IBD are not specific. This review will focus on the differential diagnosis of 
Crohn’s Disease (CD) and on the helpful tests for the diagnosis. Histopathological findings 
are sometimes insufficient to establish the diagnosis, granuloma is not specific and 
inconstant in CD (only in 15 to 60 % of cases). Serological assays (perinuclear antineutrophil 
antibodies pANCA and anti-Saccharomyces cerevisae antibodies ASCA) are contributing to 
the diagnosis, but their sensitivity and specificity are too weak for a gold standard. This 
review will be divided in 2 parts: first, a review of etiologies inducing granulomas in the gut 
(infections, systemic diseases, drug related disorder…), second, a review of controversies in 
the distinction between ulcerative colitis (UC) and CD. This review will contribute to 
provide to clinicians a strategy for differential diagnosis of CD (infection, systemic disease, 
neoplasm, drug related disorders, non specific inflammation…). Therefore, sensible and 
specific biomarkers are needed to facilitate the diagnosis of IBD in the future.  
Crohn’s disease is an Inflammatory Bowel Disease (IBD), able to affect all the gut mucosa. 
Crohn disease may induce lesion of epithelioid granuloma. However, this type of lesion 
may be associated with others affections, certain of these affections are infectious diseases, 
and contra-indicate formally the immunotherapy. Nowadays, there is no gold standard 
assay to make the etiological diagnosis of granuloma of the gastrointestinal (GI) tract.  
2. How differentiate CD from tuberculosis? 
The differential diagnosis of CD and tuberculosis of the digestive tract is challenging, as the 
incidence of CD is dramatically increasing in countries where TB is too prevalent, and as TB 
epidemic restarts in the developed countries. Since the presence of a caseation necrosis in 
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endoscopic biopsies confirms TB, this histological findings stay uncommon in the most cases 
of digestive TB. Surgical biopsies are more efficient to establish the diagnosis of TB (1). A 
confusion between TB and CD is not Exceptional. In a saoudian  study, 21% of the patients 
treated for a digestive TB, were really affected by CD (2). Clinically, the differential 
diagnosis is uneasy. Digestive TB is induced by hematogenous spread after the inhalation of 
the bacillus or by ingestion of mycobacterium bovis. In case of an infection by mycobacterium 
tuberculosis, the association with a pulmonary TB is unconsistent. Certain localizations for 
lesion are more frequent in TB than in CD. Preponderant localizations are presented in table 
1. After a comparison between 53 patients with CD and 53 others with digestive TB, 
Makharia et al. establish a clinical, endoscopic et histological score to differentiate TB (3). In 
this study, chronic diarrhea, blood in the stools, perianal disease and extraintestinal 
manifestations were significantly more frequent in CD than in TB. On the other side, 
abdominal pain, constipation, intestinal obstruction, loss of appetite, and weight loss were 
associated with TB. Sites of CD involvement were more often rectum, sigmoid, ascending 
and descending colon. The type of lesions in endoscopy was also different in the two 
groups: skip lesions, friability, aphtous, linear and superficial ulcers, and cobblestoning 
were more often observed in the CD group. Nodular lesions were more frequent in the TB 
group. Histological examination found more and larger granulomas per section in TB, and 
more often lesion of focally enhanced colitis in CD. The developed score is: -2,5*Involvement 
of sigmoïd colon-2,1* blood in stool+2,3*weight loss-2,1*focally enhanced colitis+7 where 
each characteristics were given 1 if present and 0 if absent. With a cutt-off of 5,1, this score 
demonstrated a good sensibility, a good specificity and a good ability to correctly classify 
the two diseases. The area under the receiver operating curve (AUC-ROC) was 89,2. 
Endoscopic examination is really helpful to differentiate TB from CD. Considering that 
anorectal lesions, longitudinal ulcers, aphtous ulcers cobblestone appearance were typical in 
CD, and that involvement of fewer than four segments, a patulous ileocecal valve, 
transverse ulcers, and scars of pseudopolypes were typical of intestinal TB, Lee et al. 
hypothesized that CD diagnostic could be made when the number of parameters 
characteristic of CD was greater than parameters associated with TB (4). With these 
assumptions, diagnosis was correctly made in 87,5 % of the patients. Histological 
examination is also useful. However, characteristic lesions of TB as confluent granulomas, 
more than 10 granulomas per biopsy sites, and caseous necrosis are present in only a limited 
number of TB cases (50%, 33%, 22% respectively)(5). Mycobacterium is found by direct 
examination of biopsy in only 20 to 50% of intestinal TB cases.  
 








Table 1. Principal localisations of granuloma in CD and TB 
Serological test to differentiate CD and ulcerative colitis (UC) as detection of perinuclear 
anti-neutrophil antibodies (p-ANCA), and anti-saccharomyces cerevisae antibodies (ASCA) 
are not useful to differentiate CD from TB. Several studies had shown that IgA and/or IgG 
level of ASCA was not different between patients with CD and intestinal tuberculosis. P-
ANCA was also similar in patients with CD than in patients with intestinal TB. Nowadays, 
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serological test with p-ANCA & ASCA are not helpful to differentiate TB from CD. 
Intradermoreaction with tuberculin is not enough sensible or enough specific to make the 
diagnosis of intestinal TB, as it can be positive in the case of infections due to others 
Mycobacteriae and after vaccination and negative in immunocompromised patients. 
Quantiferon is a blood test of reactivity of lymphocytes T to TB antigens with production of 
interferon gamma which is not influenced by vaccination. Up today, no study is published 
on the diagnosis value of quantiferon TB for differentiating between TB and CD. There are 
only cases reports about positive quantiferon in case of intestinal TB. However, quantiferon 
is often negative in cases of extrapulmonar TB as osteitis due to Mycobacteria.  
Cultures of Mycobacteria are difficult and long (3 to 8 weeks). Polymerase Chain Reaction 
(PCR) in intestinal biopsy, or in stools might be a good tool. Yet, the sensibility of the PCR 
Mycobacterium tuberculosis varies from 31 to 60% in biopsies (6). A positive PCR was less 
frequent than caseation necrosis, and presence of bacillus after Ziehl and Neelsen staining. 
A PCR positive in stools might help to make the diagnosis of intestinal TB, with a sensibility 
of 79% and a good specificity, however, this PCR may be positive in case of pulmonary TB 
without intestinal involvement (7).  
3. Non tuberculous mycobacteria: Another cause of intestinal granuloma or 
an agent for CD? 
In immuno-compromised patients (particularly HIV-positive subjects and transplanted 
patients), Mycobacterium avium paratuberculosis (MAP) is often incriminated in intestinal 
granulomatous disorders. However, several authors hypothesized that it might be a causal 
agent of CD. Long term blood culture from a great number of CD patients are positive for 
MAP, yet a great proportion of healthy controls exhibit positive blood culture. The 
frequency of MAP positive blood culture is greater in the groups of CD patients (8). 
However, these results are insufficient to conclude that MAP is a causal agent for CD. It 
might be a consequence of a modified commensal microbiota. A defective sensing and 
killing of bacteria (due to mutation in pattern-recognition receptors) might contribute to the 
onset of the disease (9). The only temporary efficacy of anti-tuberculous therapy in patients 
with CD is not in favor of a causal role of MAP in CD (10).  
4. Helicobacter pylori (HP): An under-estimated agent of granulomatous 
gastritis 
HP is a potential agent for granulomatous gastritis. Its frequency might be under-estimated. 
In 18 patients with granulomatous gastritis, HP was found in 14 cases, diagnosis of CD was 
made in only 1 case (11). For others, infection with HP is only concomitant of CD (12).  
5. Gastro-intestinal histoplamosis: A difficult but urgent diagnosis 
Histoplasma capsulatum (HC) is a mold which is common in mid-western USA, and south 
America. The most of patients with a disseminated histoplasmosis exhibits HC in 
gastrointestinal tract. First, HC is inhaled and disseminated in the all organism. Risk factors 
for HC are immunodepression: AIDS, CD4 lymphopenia, immunosuppressive agents. 
Gastrointestinal involvement may occur as a result of the adjacent mediastinal adenitis or 
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bleeding, broncho-oesophageal fistula, abdominal pain, weight loss, lower GI bleeding, 
intestinal occlusion in the case of an intestinal involvement. However, GI involvement of 
HC may be asymptomatic. Diagnosis can be made after periodic acid Schiff (PAS) stain, 
antigen detection in blood and urine, serology and cultures are useful to establish the 
diagnosis as they are often positive in patients with histoplasmosis (13). This pathology is 
uncommon, but in the most of cases, no travel in endemic zone is identified. Other 
manifestations can be seen as hyperferritinemia, macrophagic activation syndrome, 
pancytopenia. The presence of these extradigestive manifestations in immunocompromised 
patients may encourage physicians to look for histoplasmosis.  
6. Tropheryma whipplei (TW): A “real” pathogen with frequent asymptomatic 
carriers  
Whipple’s disease is unfrequent. Nine percent of the patients with manifestations of 
Whipple’s disease had duodenal biopsies with granulomatous gastritis without caseation 
necrosis. Clinical manifestations are malabosrption, chronic diarrhea associated with 
arthritis, arthralgia, neurological disorders: supranuclear ophtalmoplegia, cognitive 
disorders. PCR for T. Whipplei is helpful to make the diagnosis. However, as this PCR is 
positive in 1 on 174 healthy patients, the diagnosis is definitive when the PAS staining and 
the PCR are positive, in association with evocating clinical manifestations. Furthermore, this 
PCR is positive in duodenal biopsies in stools of respectively 5 % and 11% of the patients 
with gastric disorders. There are many subjects who are asymptomatic carriers of TW (14).  
7. GI granuloma: Do not forget Syphilis? 
At the secondary and tertiary stage of Treponema Pallidum infection, GI involvement is 
possible with granulomatous lesions (15). Gastric ulcers and upper GI bleeding may be seen. 
Diagnosis is made with serologies TPHA, VDRL, PCR, and immunofluorescence staining in 
biopsies. Differential diagnosis are gastric lymphoma and linitis.  
8. Yersinia: A frequent agent for granulomatous appendicitis 
Yersinia enterolitica and pseudotuberculosis may cause granulomatous appendicitis, ileitis, 
mesenteric adenitis and colitis. The cultures are positive in around 25% of granulomatous 
appendicitis(16). The contamination is due to the ingestion of the bacteria. Some authors 
hypothesized that the defects in mucosal barrier induced by CD favors infection by Yersnia 
(17).  
9. Sarcoïdosis: Rare but not impossible granulomatous involvement of 
digestive tract 
Sarcoïdosis is a systemic granulomatosis, which rarely involves in the gastrointestinal tract 
(almost 3% of the patients). This is a disease, affecting people from 20 to 40 years old; the 
incidence is more frequent in blacks and north Europeans. Gastric lesions and extrinsic 
compression by mediastinal lymphadenopathy are the most frequent (18). Furthermore, any 
cases were reported of, small bowel polyps and colonic obstruction(19,20). Small bowel 
involvement may cause a real enteropathy. To confirm the diagnostic, physicians needs to 
obtain two biopsies from two different sites positive for giant granuloma without caseum, 
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and after having exluded all the other potential diagnosis. Skin biopsies, lymphadenectomy, 
bronchoscopy with biopsy, 18-fluoro-desoxy-glucose scintigraphy may be useful to confirm 
the diagnosis. The dosage of the angiotensin converting enzyme (ACE) is not really helpful 
as every granuloma are secreting (21), as there is a polymorphism for its gene (22), with 
individuals with low level of ACE, even with sarcoidosis. 
10. Other systemic granulomatous disorders: a more frequent GI involvement 
Wegener’s granulomatosis and Churg-Strauss syndrome affects in 80 % of the cases the GI 
tract. Clinically, patients exhibit abdominal pains, nausea, diarrhea and digestive 
hemorrhage (23). Gastroduodenal ulcers may be found. Granuloma is not always found in 
biopsy. Clinically, asthma is always found in Churg-Strauss syndrome and associated with 
hypereosinophilia. The dosage of antineutrophil cytoplasmic antibodies is interesting for the 
diagnosis as the sensibility is almost 70 to 80 % and a similar specificity (23). Anti-PR3 are 
associated with Wegener’s granulomatosis. 
11. Other anecdotic etiologies  
Gastric lymphoma may represent an alternative diagnosis for a gastric granulomatous 
lesion (12). It is often T cells lymphoma or, lymphoma of the gut associated lymphoid tissue. 
Necrosis could be seen in this situation. In Shapiro’s study, 2 patients on 42- with a gastric 
granuloma- were affected by a lymphoma. They also described in this retrospective study, 
cases of adenocarcinoma of the distal oesophagea. Some toxic agents may cause granuloma; 
yet, digestive involvement is rare. These agents are beryllium, -interferon, BCG therapies 
for bladder cancer, and allopurinol. Taeniasis may be associated with granuloma of GI tract.  
There is a genetic disease, which causes immunodeficiency and systemic granulomatosis. 
Chronic septic granulomatosis is often linked to X-chromosome. Patients are susceptible to 
bacterian and fungal infections; it’s the consequence of a modified NADPH-oxydase in 
macrophages. Granulomatous lesions of GI tract are frequent, particularly in colon(24).  
12. Which strategy adopting when histopathological examination is not 
sufficient to make the diagnosis?  
First line, second and third line, laboratory assays helpful to make a diagnosis are presented 
in table 2, 3 and 4. In many cases, the etiological diagnosis is made with all clinical and 
biological arguments. Finally, when the diagnosis stays difficult, an anti-TB treatment might 
be started and its efficacy might lead physicians to conclude for a diagnosis of TB.  
13. Clinical diagnosis with Crohn’s disease among various forms of intestinal 
inflammation 
These diagnosis depend about the anatomic localization of the process  
Ileitis:  
A variety of conditions may mimic Crohn’s iletis. Table 5 report differential diagnosis of 
ileitis. Some others rare aetiologies can be explain ileitis. Infiltrative diseases (amyloidosis 
and eosinophilic gastroenteritis), lymphoid nodular hyperplasia and radiation enteritis must 
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Laboratory assays Diagnostic orientation Diagnostic value 





Inflammatory syndrome in 
all cause of digestive 
granuloma 
No sensibility, No specificity 
C-reactive protein Confirmes inflammation No sensibility, no specificity 
Lactate deshydrogenase May orientate to lymphoma 
if increase 
No sensibility, no specificity 
Creatinine, albumine in 
urine/creatinine ratio 
An associated nephropathy 





Tuberculin test Tuberculosis, sarcoidosis if 
asynergy 
No specificity (past 




Chest radiography Tuberculosis Only 30% patients with TB of 
GI tract have a pulmonary 
TB 
Testing for HIV by 
serological assay 
Orientate to opportunistic 
infection : histoplasmosis or 
non tuberculosis mycobacteria 
Sensible and specific for HIV 




examination of the stools 
Yersinia, parasites Sensible 
Helicobacter pylori culture 
in biopsies, or Hp serology
Hp infection Culture may be negative if 





Table 2. First line biological examination in patients with evidence of a GI tract granuloma 
 





Laboratory assays Diagnostic orientation Diagnostic value 
Quantiferon TB gold Tuberculosis Not evaluated in digestive 
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Tuberculosis Not enough sensible in 
biopsies, lack of specificity 
in stools as it may be 
positive in pulmonary TB 




Good sensibility, good 
specificity for these three 
etiologies 
ASCA detection Crohn disease Not specific, may be 
positive in TB 
Angiotensin Converting 
enzyme 
sarcoidosis Not sensible, not specific 
and genetic polymorphism 
18-FDG scintigraphy May guide some deep 
biopsies 
Sensible but not specific 
Chest and abdominal 
tomodensitometry 
Search other sites of 
involvement to orientate 
the diagnosis as infiltrative 
pneumopathy 
Not specific 





Laboratory assays Diagnostic orientation Diagnostic value 
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in biopsies, or Hp serology
Hp infection Culture may be negative if 
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Table 5. Differential diagnosis of ileitis 
Proctitis: 
In addition to ulcerative proctitis, proctitis may also occasionally be the presentation of 
crohn’s disease. The other differential diagnosis are breaf (Table 6). 
Colitis:  
The causes of colitis are legion.  
Numerous infectious agents may cause a transient colitis, but the clinical course of most 
enteric infections is usually complete within 2 weeks of onset. The most important infections 
are: Cytomegalovirus, Shigella, Campylobacter, Clostridium difficile, Salmonella, 
Aeromonas pleisioides, Amebiasis, Enterohemorrhagic E. coli (EHEC), Mycobacterium 
tuberculosis, Yersinia enterocolitica, Schistosomiasis and strongylidosis. Nevertheless, 
others aetiologies must be evocated in function of associated symptoms and patient: 
Ischemic colitis, diverticulitis, microscopic colitis, diversion colitic or radation, Behçet 
disease and sarcoidosis. 
 






Herpes simplex type II 
Neisseria gonorrhoeae 





Solitary rectal ulcer 
Trauma 
Chemical injury 
Table 6. Differential diagnosis of Crohn’s disease or ulcerative proctitis 
Drug related colitis must be researched: NSAIDs, gold, penicillamine) or toxic like cannabis; 
Some aetiologies are rare and must be evocated after these hypothesis: Chronic 




 Ulcerative colitis Crohn’s disease 
Distribution Continuous, symmetric, 
and diffuse, with 
granularity or ulceration 
found in entire involved 
segments; 
Often discontinuous and 
asymmetric with skipped 
segments, normal 
intervening mucosa, 
Rectum Typically involving rectum 
and distributed proximally 
Complete or, more often, 
relative rectal sparing may 
be present 
Mucosal lesions Microulcers more common, 
larger ulcers possible, 
pseudopolyps more 
common 
Aphthous ulcers common 
in early disease; late disease 
notable for ulcers with 
stellate, “rake,” “bear-
claw,” linear or serpiginous 
ulcers; cobblestonin 
Depth of inflammation Mucosal, not transmural 
except in fulminant disease 
Submucosal, mucosal, and 
transmural 
Histology Crypt abscesses and ulcers 
are the defining lesion 
Crypt abscesses may be 
present Ulceration on a 
background of inflamed 
mucosa 
Crypt abscesses may be 
present Ulceration on a 
background of inflamed 
mucosa Hallmark is focally 
enhanced inflammation, 
often on a 
normal background 
Complications Parianal findings not 
prominent 
Parianal lesions (40%), 
strictures, fistulas 



























Neoplasm Drug related Vascular 






























Table 5. Differential diagnosis of ileitis 
Proctitis: 
In addition to ulcerative proctitis, proctitis may also occasionally be the presentation of 
crohn’s disease. The other differential diagnosis are breaf (Table 6). 
Colitis:  
The causes of colitis are legion.  
Numerous infectious agents may cause a transient colitis, but the clinical course of most 
enteric infections is usually complete within 2 weeks of onset. The most important infections 
are: Cytomegalovirus, Shigella, Campylobacter, Clostridium difficile, Salmonella, 
Aeromonas pleisioides, Amebiasis, Enterohemorrhagic E. coli (EHEC), Mycobacterium 
tuberculosis, Yersinia enterocolitica, Schistosomiasis and strongylidosis. Nevertheless, 
others aetiologies must be evocated in function of associated symptoms and patient: 
Ischemic colitis, diverticulitis, microscopic colitis, diversion colitic or radation, Behçet 
disease and sarcoidosis. 
 






Herpes simplex type II 
Neisseria gonorrhoeae 





Solitary rectal ulcer 
Trauma 
Chemical injury 
Table 6. Differential diagnosis of Crohn’s disease or ulcerative proctitis 
Drug related colitis must be researched: NSAIDs, gold, penicillamine) or toxic like cannabis; 
Some aetiologies are rare and must be evocated after these hypothesis: Chronic 




 Ulcerative colitis Crohn’s disease 
Distribution Continuous, symmetric, 
and diffuse, with 
granularity or ulceration 
found in entire involved 
segments; 
Often discontinuous and 
asymmetric with skipped 
segments, normal 
intervening mucosa, 
Rectum Typically involving rectum 
and distributed proximally 
Complete or, more often, 
relative rectal sparing may 
be present 
Mucosal lesions Microulcers more common, 
larger ulcers possible, 
pseudopolyps more 
common 
Aphthous ulcers common 
in early disease; late disease 
notable for ulcers with 
stellate, “rake,” “bear-
claw,” linear or serpiginous 
ulcers; cobblestonin 
Depth of inflammation Mucosal, not transmural 
except in fulminant disease 
Submucosal, mucosal, and 
transmural 
Histology Crypt abscesses and ulcers 
are the defining lesion 
Crypt abscesses may be 
present Ulceration on a 
background of inflamed 
mucosa 
Crypt abscesses may be 
present Ulceration on a 
background of inflamed 
mucosa Hallmark is focally 
enhanced inflammation, 
often on a 
normal background 
Complications Parianal findings not 
prominent 
Parianal lesions (40%), 
strictures, fistulas 





When a causative agent is not identified, the issue of sorting out a first presentation of IBD 
from an acute self-limited colitis arises. Such a distinction relies strongly on histologic rather 
than endoscopic findings. Once a diagnosis of IBD has been established, Crohn’s disease 
should be distinguished from ulcerative colitis. 
14. Controversies in the distinction between ulcerative colitis and Crohn’s 
disease 
Many distinctions—clinical, anatomic, histologic—have been drawn between the 2 major 
forms of IBD (Table 7). A gold standard of diagnosis has yet to be attained, however. 
Some clinical distinctions challenged by careful observation. Theorycally, ileum is not 
involved, except as “backwash” ileitis in panulcerative colitis. Conversely, ileum is often 
involved in chron’s disease. Backwash ileitis has long been recognized as a feature of pan-
ulcerative colitis but may yet throw even the experienced diagnostician off the trail if more 
than a few centimeters of ileal inflammation are present. When ileitis in the setting of 
pancolitis is more extensive than this, careful appraisal of the ileocecal valve may be helpful. 
A patulous valve with extensive backwash is more convincing as a feature of ulcerative 
colitis than lengthy ileitis behind a constricted, stenotic valve, more suggestive of Crohn’s 
disease. 
Complications are very frequent in the natural history of Crohn’s disease. The 20-year 
cumulative rate of all complications is more than a population-based cohort (25); CD 
evolution relates to disease location. Small bowel involvement might be complicated at 
diagnosis or during the first years after diagnosis by an abcess or fistula, or by a stricture 
followed by formation of a fistula, whereas colonic disease can remain uncomplicated or 
inflammatory for many years. Stricturing and penetrating lesions can coexist in the same 
individual or even within the same intestinal segment. Conversly, in UC perianal findings 
are not prominent. If fissure or fistula have been present, they shouhd be uncomplicated. 
Strictures are rarely present and are suggestive of adenocarcinoma. Moreover, fistulas are 
not present, except for rare occurrence of rectovaginal fistula. In CD, about 20%-30% of 
patients present with perianal lesions and 15%-20% have or had a fistula (26). Another 
diagnostic criterion challenged by careful observation is the classic observation of 
continuous involvement of colonic mucosa without skip areas in ulcerative colitis. Although 
this distinction is generally true, care must be taken in interpreting the finding of skip areas. 
Topical therapies may lead to a false impression of “rectal sparing,” whereas oral or 
systemic therapies may result in patchy healing, depending on the timing of endoscopy or 
completeness of response (27). Accordingly, the most accurate diagnosis may be made at the 
earliest evaluation, before anatomy and histology have been confounded by treatment.  
Given this limitation, it is not surprising that, in some cases, it will be impossible to 
distinguish between ulcerative colitis and Crohn’s disease, with potential implications for 
prognosis and treatment. Prospective, population-based studies suggest that approximately 
1 in 20 patients with IBD will have a diagnosis of indeterminate colitis (28). Subsequent 
follow-up leads to a firmly established diagnosis of ulcerative colitis in one third of these 
cases, whereas 17% are assigned a diagnosis of Crohn’s disease (29). The clinical value of 
pANCA or ASCA testing in patients presenting with non-specific gastrointestinal symptoms 
is limited because of inadequate sensitivity. Thus tests are infrequently positive in 
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individuals who do not have IBD. With the addition the latest panel of 7 antibodies has 
improved the positive and negative values of serologies. Using all of the serologic markers 
reported for CD, the sensitivity for diagnosing CD is greater than 80% and the positive 
predictive value is over 90% but only when the prevalence of CD is high, 38% (30). ANCA 
positivity has been observed in other colitides, such as eosinophilic and collagenous colitis. 
The specificity of ASCA seems to be higher, but ASCA positivity has been observed in 
patients with Behçet’s disease, primary biliary cirrhosis, autoimmune hepatitis, and celiac 
disease. The cost effectiveness of serologic tests in the sequential diagnostic testing of IBD in 
children has been shown to avoid unnecessary and costly evaluations (31), but it has not 
been confirmed by other studies (32).  
Serologic evaluation of ANCAs and ASCAs could be of help in patients with indeterminate 
colitis (33). In these patients, early knowledge of the exact diagnosis could be of clinical 
importance with regard to therapeutic decisions and prognosis (34). Patients who are 
pANCA positive and ASCA negative are 19 times more likely to have UC, whereas patients 
who are ASCA positive and pANCA negative are 16 times more likely to have CD (35). A 
remarkable finding is that patients who do not have antibodies, to either ASCAs or ANCAs, 
are remaining indeterminate colitis after a mean duration of 9.9 years (33). Further 
refinement of serologic tests and/or the combination of serologic testing with routine 
laboratory and fecal tests testing and noninvasive imaging may offer efficient cost-effective 
screening in the future. 
15. Conclusion 
The increases in incidence and prevalence of IBD over the last 15 years and its emergence in 
developing countries indicate a role of the environment in pathogenesis. Their diagnosis 
may be difficult and are clinical, endoscopic and histologic assessment. The issue remains 
that no gold standard test exists for the diagnosis of IBD. For these reasons, diagnosing 
crohn’s disease and ulcerative colitis continues to be a more than occasional challenge to the 
practicing gastroenterologists. In the time of biotherapies, a casual diagnosis of IBD may 
result in critical errors in management in that incorrect diagnosis may result in 
inappropriate or even contraindicated treatment.  
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1. Introduction 
Human biological diversity involves interindividual variability in morphology, behavior, 
physiology, development, susceptibility to disease and response to stressful stimuli and 
drug therapy (phenotypes). Although the human DNA sequence is 99.9% identical among 
individuals, the variations may greatly affect a person's disease susceptibility. Many 
common diseases, and many individual responses to injury, drugs, and non-pharmacologic 
therapies are genetically complex, characteristically involving an interplay of many genetic 
variations in molecular and biochemical pathways (1).  
The year 2007 marked the publication of adequately powered and successfully replicated 
genome-wide association studies that identified significant genetic contributors to the risk of 
common polygenic disease (e.g., coronary artery disease, MI, types I and II diabetes, atrial 
fibrillation, obesity, asthma, common cancers, rheumatoid arthritis, Crohn’s disease and others) (1). 
Crohn’s disease affects a younger age group, with a peak incidence between 10 and 40 years 
of age. The reported incidence of disease is reported to be 5 to 10 per 100,000/yr (2). Despite 
advances in medical treatment, many patients still require surgery. The mainstay of 
management is medical treatment, usually aminosalicylates and steroids. Other immune-
modifying agents are used in severe disease. This chapter is going to focus on the 
relationship between Crohn’s disease (disease and used drugs) and anesthetic medicine. 
2. What is Crohn’s disease? 
Crohn's disease causes a chronic, nonspecific, transmural inflammation of the intestine that 
found throughout the GI tract, from the oropharynx to the anus. Crohn's disease also 
manifests itself in many extraintestinal symptoms of eyes, skin, and joints. The severity and 
relapsing nature of these symptoms severely affect a patient's quality of life and require 
dependence on long-term medical therapy (3). 
Crohn's disease is incurable, and the natural course of the disease is different for each 
patient. Patients will have episodes of disease exacerbation followed by periods of relative 
or complete remission. In a minority of patients, the disease is unrelenting, depending on 
the location and severity of the disease. The primary treatment of Crohn's disease is medical. 
Although the time course may vary, at least 75% of patients will require surgery after 20 
years with the disease. Surgery is indicated for those who do not respond adequately to 
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3. Interaction beetween anti-Crohn’s drugs and anesthetic drugs 
3.1 Aminosalicylates 
Sulfasalazine and mesalamine are the two aminosalicylates used for Crohn's disease. The 
primary antiinflammatory, antipyretic, and analgesic actions of salicylates such as aspirin 
are due to blockade of prostaglandin synthesis by inhibition of the cyclooxygenase 1 and 2 
enzymes. These are effective in maintaining remission in patients with mild-to-moderate 
diseases (4). Studies demonstrate that both mesalamine and sulfasalazine are efficacious at 
inducing and maintaining remission, and are often used as long-term maintenance 
treatments. The improved side effect profile of mesalamine has enabled the use of doses that 
are much higher in amount than doses possible with sulfasalazine. However, a number of 
cases of 5-ASA-induced nephrotoxicity have been reported in patients with inflammatory 
bowel disease (IBD) (5, 6). Several case reports have reported renal impairment in the forms 
of dose-dependent ‘analgesic nephropathy’, inhibition of cyclooxygenases or hypersensitivity 
leading to reversible interstitial nephritis in humans. The incidence of renal impairment in 
patients with IBD treated with 5-ASA is estimated to be one in 100 patients, and interstitial 
nephritis occurs in one in 500 patients (7, 8).  
Mahmud et al, were unable to show nephrotoxicity after six months of mesalamine 
treatment in patients with ulcerative colitis using a low dose of 1.2 g/day (9). Similarly, Van 
Staa et al, were not able to demonstrate a relationship between the dose or type of 5-ASA 
and the incidence of renal disease among 19,025 IBD patients on 5-ASA (10). Based on their 
findings, interstitial nephritis related to 5-ASA use appears to be a rare event. Although 
interstitial nephritis occurs infrequently, renal function can be compromised over time with 
the use of 5-ASA. According to a recent report, de Jong et al, did not find a significant 
change in creatinine clearance (CrCl) over an 11-year interval in 200 patients with Crohn’s 
disease (11). However, the mean duration of treatment with 5-ASA was 8.6 years, much 
shorter than the interval that CrCl was measured. This may reflect why the decline in CrCl 
was reported to be within the expected physiological decline in renal function associated 
with aging. Fortunately, the kidneys have the capacity to regain function after an insult; 
thus, creatinine measurements need to be taken at the onset and end of treatment rather 
than time points outside of the actual treatment interval. Also, no case of interstitial 
nephritis was reported by same author (11). In brief, the time of development of renal 
impairment is variable and may be seen as late as after several years. There is also a risk of 
developing irreversible renal disease if not recognized early, in which discontinuation of 5-
ASA could result in recovery of renal function. Monitoring serum creatinine provides an 
easy and inexpensive way to prevent a detrimental side effect. 
3.2 Corticosteroids 
For patients with exacerbations leading to moderate or severe Crohn's disease, steroids are 
the primary therapy. However, they do not help maintain remission and are detrimental 
when used for long-term treatment. The synthetic analogs of cortisol have been developed 
with the primary goal of maximizing glucocorticoid activity while minimizing 
mineralocorticoid effects and decreasing the adverse effects of high quantities of 
systemically active glucocorticoid. Effects of glucocorticoids that are well documented 
include inhibition of the production of proinflammatory cytokines such as tumor necrosis 
factor alpha (TNF-α) and interleukin-l (IL-l) and chemokines such as IL-8; repression of the 
transcription of the genes for certain enzymes such as inducible nitric oxide synthase, 
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phospholipase A2, and cyclooxygenase 2; and blockade of adhesion molecule expression. 
These molecular actions of glucocorticoids result in a blockade of leukocyte migration and 
function and inhibit the effects of numerous important peptide and lipid-derived mediators 
of inflammation (3). 
Corticosteroids can induce clinical remission in Crohn's disease (60% success rate compared to 
30% placebo response). The side effects of corticosteroids are extensive and include 
osteonecrosis, osteoporosis, cataracts, glaucoma, hyperglycemia, hyperlipidemia, 
hypertension, psychosis, and skin changes (3). 
Corticosteroids and its side effects are important in anesthetic practice. Primarily, anesthetist 
must be aware of the need for corticosteroid replacement not only in patients who have 
primary adrenal insufficiency but also in patients who have adrenal insufficiency resulting 
from long-term corticosteroid therapy. Without adequate knowledge, the anesthetist may 
fail to prepare the patient to withstand the stress of surgery and may open the way for life-
threatening hemodynamic abnormalities that accompany inadequate amounts of 
corticosteroids (12). 
Secondly, its known that a long-term medication with prednisolone resulted in a shorter 
duration of an atracurium-induced neuromuscular block in patients with ulcerative colitis 
or Crohn's disease. The underlying chronic IBD itself did not influence the time course of the 
neuromuscular block. Although the mechanism is not fully understood, several possible 
sites of interaction of steroids with neuromuscular transmission have been suggested: (i) 
glucocorticoids have been shown to possess a direct facilitatory effect on the impulse 
generating end of the motor nerve axon; (ii) corticosteroids act presynaptically stimulating 
synthesis, spontaneous release, and stimulated release of acetylcholine; (iii) however, at 
large concentrations, corticosteroids might possess a post-synaptic depressant effect on 
neuromuscular transmission (13). 
On the other hand, medication with prednisolone was associated with a prolonged onset 
time and attenuated maximum block of rocuronium (14). These data are in contrast to the 
results of the study mentioned in the previous paragraph. The reasons for the differences 
between atracurium and rocuronium might be alterations in drug metabolism mediated by 
the glucocorticoid (14). Alternatively, the presence of chronic IBD itself might influence the 
effect of the neuromuscular blocking drug: in an experimental model of systemic 
inflammation, resistance to atracurium was attributed to increased drug binding to a1-acid 
glycoprotein. Changes in acetylcholine receptor expression in systemic inflammation could 
was not be observed (15). 
A reliable effect of neuromuscular blocking drugs is important to all anaesthesiologists in 
their clinical routine. A delayed recovery from a neuromuscular block might contribute to 
severe complications; even increased mortality could be proved previously (16). However, 
an unexpectedly decreased effect of the drug might also lead to intraoperative complications 
as a result of coughing or sudden movements. Additionally, it might increase laryngeal 
morbidity, i.e. injuries of the vocal cords (17). 
Thirdly; adolescent or child patients, receiving chronic steroid therapy for IBD underwent 
major intestinal surgery, can develop vasodilation during anesthesia (especially induction of 
anesthesia). Systemic hypotension can occur in patients and we can treate them by large 
volumes of intravenous crystalloid solution which cause intraoperative and postoperative 
water retention with resultant hypertension as well as occasional pulmonary edema and 
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calculated fluid losses should be given with caution to children/adolescent receiving high-
dose steroids who undergo major intestinal surgery. Perioperative fluid retention under 
those circumstances may be treated best with early diuretic administration (18). 
3.3 Antibiotics 
Although antibiotics are not used to treat specific bacterial organisms, they have been found 
to be effective in the treatment of Crohn's disease, especially for the perianal area. 
Metronidazole is the most common agent employed, although ciprofloxacin has also been 
used. By decreasing the amount of bacterial flora in the intestinal lumen, they act to prevent 
the infectious complications of Crohn's disease, such as abscesses and fistulas (3). Clinical 
trials have shown their efficacy in inducing remission (19, 20).  
Although rare, prolonged and high-dose administration of metronidazole may induce 
cerebellar lesions. Increased awareness of this phenomenon is important, as these lesions are 
reversible with discontinuation of this drug (21). Therefore, metronidazole dosages should 
be reduced in patients with liver dysfunction to prevent the accumulation of metronidazole, 
which can lead to CNS dysfunction and peripheral neuropathy (22). 
Knorr et al reported a case of Q-T interval prolongation in a pediatric patient with no known 
risk factors (including hypokalemia, hypomagnesemia, hypocalcemia, bradycardia, starvation etc.) 
for the development of a long Q-T syndrome (LQTS) (23). After 48 hours of ciprofloxacin 
administration, the patient became bradycardic. Antimicrobial therapy was changed to 
ampicillin and ciprofloxacin was discontinued. The patient’s bradycardia persisted for three 
days after the initial detection, and his Q-T prolongation was deemed resolved six days after 
detection; no other cardiac abnormalities have been reported after this day. The patient's Q-
T interval was normalized within seven days of ciprofloxacin discontinuation. The patient 
did not have any further cardiac anomalies.  
The pharmacologic mechanism of drug-induced LQTS is proposed to be via the blockade of 
delayed rectifier potassium channels of the ventricular myocardium during the 
repolarization phase. This blockade prolongs the cardiac action potential and allows early 
afterdepolarization (EAD), which results in the development of a second action potential. 
The second action potential may create a premature ventricular complex on an ECG, and if 
this dysrhythmia becomes self-sustaining, the resulting pattern of EADs reveals itself as a 
“twisting of the points” on the ECG. With the development of dysrhythmia, the patient may 
be asymptomatic or may present with syncope, palpitations, ventricular tachycardia, or 
sudden death (24, 25). Fluoroquinolone-induced Q-T prolongation is most commonly 
associated with gatifloxacin, moxifloxacin, and the withdrawn agents sparifloxacin and 
grepafloxacin (26). This case demonstrated that the use of ciprofloxacin in patients (esp. 
pediatric) should be restricted to situations in which there is no other safe and effective 
alternative to treat the infection. It is important for clinicians to familiarize themselves with 
the drugs that may propagate Q-T prolongation as well as the risk factors that increase the 
probability of developing drug-induced LQTS (23). 
3.4 Immunosuppressive drugs 
As the increasing number of of evidence points to an immunological etiology of IBD, efforts 
have been made to utilize various immunotherapies. The drugs most commonly used are 
azathioprine and its metabolite, 6-mercaptopurine (6-MP), and antimetabolites that inhibit 
DNA synthesis (27). After administration of azathioprine or 6-MP, the 6-thioguanine 
 
Crohn's Disease: From an Anesthetist’s Perspective 
 
107 
nucleotides accumulate intracellularly and are believed to mediate the biological actions of 
these drugs (3). 
Despite over 50 years of investigation, the precise molecular basis for the therapeutic effects 
of the purine analogs is not known. However, intracellular accumulation of 6-thioguanine 
nucleotides causes inhibition of the pathways of purine nucleotide metabolism and DNA 
synthesis and repair, resulting in inhibition of cell division and proliferation. It is plausible, 
but not proven, that antiproliferative or functionally inhibitory actions on cells of the 
immune system, such as lymphocytes, underlie the immunosuppressive actions of 
azathioprine and 6-MP (3). Their value was established in a study that showed 67% of 
patients with a clinical response compared to 8% in the placebo group, although the effect 
was delayed by 3 to 6 months. In addition, 75% of patients were able to discontinue or 
reduce their steroid doses (27). A metaanalysis of nine trials revealed that azathioprine and 
6-MP are effective in patients with an active disease, while the adverse side effects 
approached 10% (28). 
Two categories of adverse effects to azathioprine and 6-MP have been described: allergic, 
occurring early during treatment; and dose-related, generally occurring later. Allergy to 
these drugs can manifest as pancreatitis, fever, rash, nausea, diarrhea, and an allergic 
hepatitis. Approximately 50% of the IBD population beginning treatment with azathioprine 
or 6-MP will experience an allergic reaction to the drug, which can be confirmed by 
rechallenge if necessary. Dose-related toxicities of azathioprine or 6-MP include bone 
marrow depression leading to leukopenia (10% cumulative risk), anemia, thrombocytopenia, 
and hepatic toxicity. If severe, leukopenia can potentially cause profound immune 
suppression and thus predispose to opportunistic infections or neoplasms. If leukopenia 
and a serious infection develop in a patient receiving azathioprine or 6-MP, reversal of bone 
marrow suppression is usually possible with granulocyte colony-stimulating factor. 
Decreases in the white blood cell (WBC) or elevations in liver function tests (LFTs) are 
common and generally respond to small dose reductions if needed, without discontinuation. 
The most important criteria for the success of azathioprine and 6-MP include adequate 
dosing and duration of treatment and individual metabolism of these drugs based on 
detectable thiopurine methyltransferase activity (29). Withdrawal of drug has shown a 70% 
relapse rate (28). 
Methotrexate is a folate analog that inhibits purine and pyrimidine synthesis and has been 
shown in a number of trials to be effective in treating Crohn's disease (30). The principal 
biochemical action of methotrexate, and the mechanism that is believed to be responsible for 
the drug's cytotoxic activity, is inhibition of dihydrofolate reductase. It has alternatively 
been proposed that the antiinflammatory action of methotrexate may be mediated by 
inhibition of cytokine release or by increased release of the endogenous antiinflammatory 
autocoid adenosine. Methotrexate may also have effects on activated T lymphocytes, a 
critical part of the inflammatory infiltrate in IBD. However, this drug has significant side 
effects, including hepatotoxicity. and bone marrow suppression, and thus is reserved for 
patients wIth severe Crohn's that is refractory to other therapies (3). 
The latest class of drugs that has resulted in huge advancements in the treatment of Crohn's 
disease are the anti-tumour necrosis factor alpha (TNF-α) agents. Levels of TNF-α are 
increased in Crohn's disease, and in a study of its efficacy, it was noted to produce fistula 
healing (3). Infliximab, a monoclonal antibody against TNF-α, is licensed for the 
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nucleotides accumulate intracellularly and are believed to mediate the biological actions of 
these drugs (3). 
Despite over 50 years of investigation, the precise molecular basis for the therapeutic effects 
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patients whose condition has not responded adequately to treatment with a corticosteroid 
and a conventional immunosuppressant or who are intolerant of them (31). It has been 
associated with acute demyelination of the central nervous system (32-34). Recently, 
Drummonad at al. reported profound postoperative muscle weakness in a patient who had 
been treated with infliximab (35). However, reports in literature suggesting interactions 
between infliximab and any anaesthetic drugs are unavailable. It is possible that the 
immunosuppressive effect of the hydrocortisone bolus (given at the induction of anesthesia) or 
simply of the surgery itself may have interacted with the infliximab, hastening the onset of 
symptoms. Therefore every patients recently treated with infliximab should have a 
neurological examination documented at pre-operative assessment in order to provide a in 
case should problems occur postoperatively. 
On the other hand; it is well known that infliximab can worsen congestive heart failure. The 
preliminary results of a study assessing the heart function (by means of electro-and 
echocardiogram) during infliximab therapy, in twelve paediatric IBD patients (9 Crohn's 
disease, 3 ulcerative colitis), have been published (36). Seven out of 12 patients showed cardiac 
disturbances consisting of dilation of the cardiac cavities (5 cases) and septal hypertrophy (2 
cases), with a direct correlation between the length of Q–T interval and the systolic and 
diastolic diameter of the left ventricle. These findings point to an increased risk of 
developing arrhythmias in these patients. However, further and more complete studies 
should be done before recommendations about cardiologic work-up required before 
surgery. 
Vitamin B12 (cyanocobalamin) is an integral component of two biochemical reactions in 
humans: the conversion of L-methylmalonyl coenzyme A into succinyl coenzyme A and the 
formation of methionine by methylation of homocysteine. The transmethylation reaction is 
essential to DNA synthesis and to the maintenance of the myelin sheath by the methylation 
of myelin basic protein. Active vitamin B12 contains cobalt in its reduced form (Co+). 
Nitrous oxide produces irreversible oxidation to the Co++ and Co forms that renders 
vitamin B12 inactive. The etiologies of vitamin B12 deficiency include many situations such 
as malabsorption (because of celiac disease, colitis, etc.). Patients with vitamin B12 deficiency 
are exceedingly sensitive to neurologic deterioration following nitrous oxide anesthesia. If 
unrecognized, the neurologic deterioration becomes irreversible and may result in death 
(37). 
4. Certain circumstances in Crohn's disease which may affect anesthesia 
4.1 Anemia 
Anemia is the most common systemic complication of IBD (38). Anemia in IBD is a 
prototype of a combination of iron deficiency and anemia of inflammation (i.e. anemia of 
chronic disease) which is caused by negative effects of an activated immune system at 
different levels of erythropoiesis. Inflammation affects three major steps essential for normal 
erythropoiesis and can, therefore, lead to the development of anemia of inflammation. These 
effects are: (i) an immunity-driven diversion of iron traffic leading to retention of the metal 
in macrophages and thus to iron-deficient erythropoiesis; (ii) blunting of the biological 
activity of erythropoietin, the major erythropoiesis-stimulating hormone; and (iii) inhibition 
of the differentiation and proliferation of erythroid progenitor cells (39).  
Anemia in IBD can also be induced by deficiency of vitamins, such as cobalamin and folic 
acid, a condition which further impairs the proliferation of hematopoietic progenitor cells 
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(40), or by certain medications, such as thiopurine analogs (6-mercaptopurine, azathioprine), 
sulfasalazine and methotrexate, most of which can inhibit erythropoiesis directly (41). 
The severity of anemia in IBD varies considerably (42). The lower hemoglobin levels below 
which anemia was defined as present were those proposed by the World Health 
Organization (non-pregnant women, 12.0 g/dL; men 13.0 g/dL). Most patients with IBD have 
mild to moderate anemia (hemoglobin above 10.0g/dL), but in the presence of bleeding 
episodes, the hemoglobin concentration may decrease further (41, 43).  
The persistence of anemia is associated with impaired cardiac and renal function, reduced 
systemic oxygen delivery, decreased physical activity, fatigue, and impaired quality of life 
or ability to work (41, 43, 44). However, anemia is a comorbid condition which is associated 
with other diseases (such as transfusion associated hepatitis C) or even death (45).  
Preoperative anemia is a major risk factor for adverse outcome in major surgery and, it’s 
also one of the most important risk factor for perioperative blood transfusions (46). With 
various multivariate statistics and propensity score matching in some studies, the authors 
unanimously found that preoperative anemia and perioperative allogeneic blood 
transfusions (ABT) were both independent risk factors for postoperative mortality, ischemia, 
and infections (47). 
The question of what hemoglobin/hematocrit (Hb/Hct) level justifies the risks associated 
with the administration of blood has been widely discussed. The inviolable “10-30” rule has 
been abandoned. Experience with several patient subpopulations (renal failure, military 
casualties, Jehovah's Witnesses) and systematic study has revealed that considerable greater 
degrees of anemia can be well tolerated and that, in many situations, morbidity and 
mortality rates did not increase until Hb levels fell below 7 g/dL (48, 49). As significant as 
the identification of a 7 g/dL threshold for increased morbidity was the observation that 
stable general medical-surgical managed to a target Hb of 10g/dL fared less well than a 
parallel group managed with a transfusion trigger of 7 g/dL (48). That observation implies 
an adverse effect of transfusion. Accordingly, the contemporary transfusion trigger for 
stable general medical-surgical patients is 21%/7.0 g/dL (Hct/Hb). However, there is 
evidence that the threshold for patients with cardiac disease should be higher (48). That 
evidence includes an investigation supporting a threshold of 30%/10 g/dL (Hct/Hb) in 
patients who have suffered a recent acute myocardial infarction (50), and an observational 
study suggests better outcomes in patients with several cardiac diagnoses (cardiac and 
vascular surgery, ischemic heart disease, dysrhythmias) above a threshold of 9.5g/dL (51). The 
Practice Guidelines for Blood Component Therapy developed by the American Society of 
Anesthesiologists (ASA) state that “red blood cell transfusion is rarely indicated when the 
hemoglobin concentration is greater than 10 g/dL and is almost always indicated when it is less than 
6 g/dL. The indications for autologous transfusion may be more liberal than for allogeneic 
(homologous) transfusion”(52). 
Blood transfusions are widely used as an immediate intervention for rapid correction of 
severe or life-threatening anemia. However, such transfusions do not correct the underlying 
pathology and do not have a lasting effect. The decision on whether to administer blood 
should not, therefore, be based only on the hemoglobin level, but should also take clinical 
symptoms and co-morbidity into account. Whether blood transfusions affect immune 
function and whether they are cause-effectively linked to mortality in patients undergoing 
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The clinician's responsibility is to anticipate, on a patient-by-patient basis, the minimum Hb 
level (probably in the range of 7 to 10 g/dL) that will avoid organ damage due to oxygen 
deprivation. Determining this individual “transfusion trigger” requires reference to the many 
elements of patient condition that determine demand for the delivery of oxygen and the 
physiologic reserve (54), including ongoing blood loss and the potential for sudden blood 
loss. Ultimately, the decision to transfuse red blood cells (RBCs) should be made on the basis 
of the clinical judgment that the oxygen-carrying capacity of the blood must be increased to 
prevent oxygen consumption from outstripping oxygen delivery. That judgment is based on 
an understanding of the physiologic mechanisms that compensate for anemia and the limits 
of those mechanisms. 
4.2 Respiratory problems 
The pathogenesis of IBD-associated respiratory lesions is unknown. The inflammatory 
lesions seen beneath the bronchial epithelium are similar to those observed beneath the 
colonic epithelium in IBD. Both epithelia have columnar structures and mucosal glands, and 
both sites are challenged constantly by foreign antigens. There are two possible hypotheses: 
(i) a systemic immunologically-mediated phenomenon originating from the intestinal 
inflammatory process underlies the bronchial/parenchymal changes in the lungs; or (ii)  a 
defect in the regulation of local immune response which is evident in both gastrointestinal 
and respiratory tract in response to as yet unknown antigens (55).  
While clinically apparent bronchopulmonary disease complicating IBD is rare, the function 
of the small airways and the diffusion capacity of the lungs has been shown to be affected in 
IBD patients without any clinical respiratory involvement (56, 57). Heatley et al. Reported 
reduced diffusion capacity for carbon monoxide in 25%, and spirometric abnormalities in 
50%, of 102 patients with IBD (58). Adenis et al., using clearance of 99mTechnitium isotopic 
DTPA, suggested that patients with Crohn’s disease may have increased pulmonary 
vascular permeability due to latent alveolitis (57). 
Respiratory symptoms can occur at any time in the history of IBD. Most interstitial lung 
diseases associated with IBD start gradually with weeks or months of breathlessness 
associated with cough. Bronchiolitis can progress unrecognised as there is no distinctive 
pattern of physical signs (59). Despite exertional dyspnoea, there may be no audible signs on 
auscultation. Radiological signs are also variable. Chest radiographs may show diffuse or 
patchy infiltrates but can be normal. Computed tomography scan is more helpful in 
demonstrating diffuse nodular or ground glass opacities which maybe patchy or uniform 
(60). Pulmonary function tests usually show a restrictive defect in interstitial lung 
involvement with reduced gas transfer and resting/exercise hypoxaemia. Broncho-alveolar 
lavage, useful in ruling out infectious causes, generally shows lymphocytosis. A lung biopsy 
is usually necessary to confirm the diagnosis and may aid in indicating prognosis (61) 
Drug-induced interstitial lung disease has been well-reported in IBD, with clinical features 
very similar to IBD-associated interstitial lung diseases. Most cases have been attributed to 
salicylates and mesalazine therapy (62).  Salicylates (sulphasalazine and 5-ASA) can induce 
different lung diseases such as bronchiolitis obliterans, bronchiolitis obliterans with 
organising pneumonia (BOOP), and interstitial pneumonitis with the most common being 
eosinophilic pneumonitis. 
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Drug-induced lung disease can be confirmed by drug rechallenge and improvement has 
occurred following drug withdrawal. Generally, prognosis is favourable in the majority of 
salicylate-induced interstitial lung diseases, but fatal outcomes due to irreversible lung 
fibrosis and rapidly progressive interstitial lung disease have been described (63). 
Hypersensitivity pneumonitis may occur with methotrexate. This is a serious complication, 
occasionally fatal, with a reported prevalence of 3.1 to 11.6% in patients receiving long-term 
low-dose therapy (64, 65). The clinical features include dyspnoea, fever and cough with 
diffuse alveolar and interstitial shadowing on chest X-ray. Treatment requires the 
immediate withdrawal of methotrexate and high dose corticosteroids. A few cases of 
azathioprine-induced interstitial lung diseases have been reported in non-IBD patients. 
Opportunistic infections have been described in patients treated with immunosuppressants, 
particularly cyclosporin, and most recently, infliximab (66, 67). 
Most respiratory disease associated with IBD responds well to corticosteroids with the 
exception of constrictive bronchiolitis obliterans (68). But, in some patients, pathological 
changes such as bronchiectasis and bronchiolitis obliterans are irreversible. Initial treatment 
of airways inflammation is with inhaled corticosteroids. Systemic corticosteroids are used to 
treat parenchymal disease (BOOP, interstitial pneumonitis and necrotic nodules). Methotrexate 
or salicylates should be withdrawn as potential causes of interstitial lung disease. The 
duration and dosage of corticosteroid treatment should be guided by symptomatic response 
and pulmonary function tests. In the case of BOOP, the duration of corticosteroid treatment 
is usually six months and clinical improvement can be seen within days to weeks (69). 
4.3 Renal problems 
Secondary amyloidosis (SA) is a rare but serious complication of IBD, generally seen in 
Crohn's disease. Indeed SA is frequently described as a major cause of death in patients with 
Crohn’s disease (70). At least 1% of patients with Crohn's disease develop SA. In literature, 
the time lapse between the onset of Crohn's disease and the diagnosis of SA has been 
reported to range from one to 21 years. In most patients, protein-uria heralded the onset of 
renal involvement from amyloid and occurred from three to 15 years after Crohn's disease 
diagnosis (71). Renal failure is the most common clinical presentation of SA, ranging from 
nephrotic syndrome and impaired renal function–to renal failure, with a potential for high 
morbidity (72).   
So far no effective treatment for SA has been identified. Multiple therapeutic strategies have 
been employed with discouraging results, including colchicine and immunosuppressive 
drugs such as tumor necrosis factor alpha inhibitors The therapeutic approach to these 
patients should be dual. On the one hand it aims at minimizing the activity of the 
underlying disease in order to mitigate or prevent serum amyloid A (SAA) production, the 
precursor of plasma amyloid that is deposited in tissues and will be responsible for their 
malfunction. On the other hand it is aimed at treating the disease once it is established. The 
treatment of SA has two pillars: a) improvement of renal dysfunction; and b) reduction of 
inflammation, the constant source of SAA, thus trying to prevent the formation of amyloid, 
and hence curb the progression of disease (73, 74). Dialysis and renal transplantation are 
reserved for patients with end-stage renal failure. Survival rates for these patients have 
improved in recent years with the introduction of these drugs, but there is still no 
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reported to range from one to 21 years. In most patients, protein-uria heralded the onset of 
renal involvement from amyloid and occurred from three to 15 years after Crohn's disease 
diagnosis (71). Renal failure is the most common clinical presentation of SA, ranging from 
nephrotic syndrome and impaired renal function–to renal failure, with a potential for high 
morbidity (72).   
So far no effective treatment for SA has been identified. Multiple therapeutic strategies have 
been employed with discouraging results, including colchicine and immunosuppressive 
drugs such as tumor necrosis factor alpha inhibitors The therapeutic approach to these 
patients should be dual. On the one hand it aims at minimizing the activity of the 
underlying disease in order to mitigate or prevent serum amyloid A (SAA) production, the 
precursor of plasma amyloid that is deposited in tissues and will be responsible for their 
malfunction. On the other hand it is aimed at treating the disease once it is established. The 
treatment of SA has two pillars: a) improvement of renal dysfunction; and b) reduction of 
inflammation, the constant source of SAA, thus trying to prevent the formation of amyloid, 
and hence curb the progression of disease (73, 74). Dialysis and renal transplantation are 
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4.4 Pain problems 
Pain is a common component of IBD, especially during acute inflammatory episodes. The 
substances involved in visceral hyperalgesia are present throughout the gastrointestinal 
tract and their synthesis is increased during acute clinical episodes of IBD (76-79). On the 
other hand, opioid-binding proteins are involved as acutephase reactants and their 
concentrations are elevated in IBD (80), and the modulation of pain during this disease is 
therefore unclear.  
However, medical management of IBD remains challenging and cannot always control all 
aspects of the disease. Even with therapy, patients frequently suffer not only from diarrhea 
and rectal bleeding but also from abdominal pain, cramps and arthralgia. Although the 
established disease activity indices only include abdominal pain as one variable, pain occurs 
throughout the body with pain attacks severely diminishing the patient’s health-related 
quality of life (HRQOL) and interfering with their social and occupational habits. 
Localization of pain is a matter of great interest because of the different treatment options 
for abdominal pain and arthralgia. While the treatment of arthralgia could be composed of 
physical therapy, steroids or sulfasalazine, abdominal pain requires a more effective anti-
inflammatory therapy. In cases of persistent pain despite remission, IBS-like symptoms, 
depression or drug-related side effects must also be considered (81). 
The use of analgesics and their dosage is difficult to gauge and should be well evaluated. 
Pain killers have a variety of known effects and side effects. Given the gastrointestinal side 
effects and the possibility of aggravating mucosal inflammation, non-steroidal anti-
inflammatory drugs (NSAID) should be avoided in IBD. However, opioids might also 
worsen pain in IBD patients because long-term use of opioids may also be associated with 
the development of abnormal sensitivity to pain and a progressive decline in plasma cortisol 
levels (82). Consequently, Smith and coworkers recently showed that treatment with low-
dose naltrexone improved disease course and HRQOL of Crohn’s disease (83). An 
alternative explanation for the discrepancy between use of analgesics and perception of pain 
might be the high prevalence of functional somatic symptoms (IBS-like symptoms) among 
IBD patients (84). 
Previous studies have demonstrated an increase in opioid requirements and a large 
variability in patients with Crohn’s disease or ulcerative colitis compared with controls 
undergoing abdominal major surgery. Two recent studies have indicated the existence of 
diffuse hyperalgesia during an intestinal inflammatory process (85, 86). Verne and 
colleagues confirmed that patients with functional bowel disorder have visceral cutaneous 
hyperalgesia that are distributed over a considerable rostro-caudal distance but are yet 
optimally expressed in lumbosacral dermatoma (87). Also, that study demonstrate that the 
inflammatory status seems to influence opioid requirements during surgery for IBD. 
Inflammation induces visceral and cutaneous hyperalgesia that may explain the decrease in 
opioid requirements in patients with quiescent IBD compared with those who have an 
active IBD. On the other hand, during surgery, pain stimulation was much more related to 
painful stimuli to the abdominal wall than to direct stimuli to the inflammatory bowel. 
Hence, we may speculate that increased opioid requirements during abdominal wall 
stimulation are linked to this somatic hyperalgesia in lumbosacral referred dermatoma. 
However, the decrease in opioid consumption may also be related to changes in 
pharmacokinetic factors due to the inflammation (88). 
 




We are faced with the Crohn’s disease in practice of anesthesia. We usually pay attention to 
the type of surgery. However, our patients's clinical status (nutrition, blood protein level, etc.), 
interactions between anesthetic drugs and patient used drugs are impotant too. Thus we can 
help prevent complications, early discern to negative signals and start effective treatments.  
Nothing is simple, nothing is resolved. 
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1. Introduction 
Mycobacterium avium subsp. paratuberculosis is an acid fast rod, extremely slow growing and 
mycobactin-dependent for its in vitro growth. This mycobacterium is the etiological agent of 
the chronic enteritis that affects domestic and wild ruminants, well-known as 
paratuberculosis or Johne’s disease. In humans, a possible M. avium subsp. paratuberculosis 
infection has been suggested to be involved in the pathogenesis of Crohn’s disease [1, 2], 
sarcoidosis; and recently sarcoidosis-like multisystem autosomal-dominant granulomatous 
disorder (Blau syndrome) [3, 4]. 
Crohn’s disease encompasses a spectrum of clinical and pathological patterns manifested by 
focal, asymmetric, transmural, and, chronic granulomatous inflammation affecting the 
gastrointestinal tract with the potential for systemic and extraintestinal complications. The 
etiology of Crohn’s disease is thought to be multifactorial, involving an interaction between 
genetic susceptibility, environmental triggers, and immune-mediated tissue injury. In this 
regard, there is considerable suggestive evidence to support an environmental factor, such 
as M. avium subsp. paratuberculosis infection. This evidence includes similarity of the macro 
and microscopic injuries, bacteriological isolation and molecular biology tests which have 
allowed the detection of this mycobacterium in intestine, milk and peripheral blood of 
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patients with Crohn’s disease [5, 6, 7]. Despite this; M. avium subsp. paratuberculosis is still 
not recognized as a human pathogen. 
Cronh’s disease has a high prevalence in North America, and Northern and Western Europe 
is less so in South Africa, Australia, and South and Middle Europe. It is considered a rare 
disease in Asia, Africa and Latin America. However, recently an increase in the incidence of 
Crohn’s disease has been noted in Spain and Latin American countries, such as Puerto Rico 
and Brazil [10, 11]. These populations are very similar to the Mexican population, mainly 
composed by Mexican Mestizo individuals which have a proportion of 56% Native 
American Indian genes, 40% Caucasian genes (the most common European ancestry are the 
Spaniards), and 4% Afro-American genes [12]. In 2010, 14,706 persons were diagnosed with 
tuberculosis in Mexico (1.39% of them suffering meningitis), unfortunately the prevalence of 
other mycobacteriosis remains unknown [13]. The present study used in situ hybridization 
to detect a fraction of M. avium subsp. paratuberculosis specific sequence IS900, it was carried 
out to determine the presence of M. avium subsp. paratuberculosis on formalin fixed intestinal 
samples of Mexican patients with Crohn’s disease, and in samples of ruminants with 
paratuberculosis. 
2. Material and methods 
2.1 Samples origin and characteristics 
Twenty three paraffin blocks with intestinal samples from 14 patients with clinical and 
histopathological diagnosis of Crohn’s disease were included. All patients underwent 
surgical resection of the small and/or large bowel segments for disease at the Medical 
Sciences and Nutrition National Institute "Salvador Zubirán". A sample of human intestine 
diagnosed with intestinal tuberculosis and ulcerative colitis was included as a negative 
control; this case was kindly facilitated by the National Institute of Pediatrics. Paraffin 
blocks with intestine samples from 1 bovine, 2 goats and 9 ovines, previously diagnosed 
with paratuberculosis by ELISA, histopathology and tissue culture were used, as controls. 
2.2 Test area selection 
Histopathological evaluation to characterize the inflammatory disease and select 
appropriate target areas for the application of the hybridisation probe was performed on all 
the intestine samples after staining with hematoxilin and eosin (HE); and Ziehl-Neelsen 
(ZN). The Criteria for group formation, was to consider the presence or absence of acid fast 
bacilli after ZN stain, accordingly we separated the animal tissues into two paratuberculosis 
groups: Group A with 8 samples showing a granulomatous reaction and ZN (+); and group 
B with 4 samples showing granulomatous reaction but ZN (-).  
All Crohn’s disease cases were negative to the ZN stain. Group C included those Crohn’s 
disease cases in which at histopathological examination we observed transmural 
inflammatory infiltrate with the presence of macrophages, epitheliod cells and sometimes 
giant Langhans cells; and considered as granulomatous. Whereas group D consisted of 
those cases in which infiltration was predominantly lymphocytic with plasma cells or mixed 
with some granulocytes at mucosal or transmural level which were considered as non 
granulomatous. In a single case with multiple samples, one was classified within group C 
and another one in group D. Group C consisted of 7 patients and 10 samples, whereas group 
D comprised 8 patients with 13 samples. 
Detection of Mycobacterium avium subsp. paratuberculosis in  




Fig. 1. Case of paratuberculosis from group A. ISH, DAB. 40x. Positive reaction inside 
macrophages in ileal submucosa. 
2.3 In situ hybridization (ISH) 
The biotinylated probe used consists in 25 bases: TAGGACTGGTCGGCTGCAAGGTAG. 
This sequence belongs to the region 639-664 of the 3' chain of IS900. Sections of 2 m of 
thickness were placed in positive charged and pre-cleaned slides (FisherBiotech, USA). The 
slides were baked for 30 min at 60°C and submerged 5 min in xylol, rehydrated through 
graded alcohol (2 x 100%, 96%, 70%, 3 min each step) and air dried. Sections were incubated 
with proteinase K (DakoCytomation, USA) for 10 min at 42°C. Sections were washed twice 
with distilled water and H2O2 0.3% were added and placed 5 min at room temperature (RT). 
By capillarity, 5-10 l of the probe at 17.04 g/ml was added (depending on the large of the 
sample). Slides were placed in termoblock for 10 min at 94.5°C. Hybridization was allowed 
overnight at 37°C. Sections were washed 4 times with Tris Buffered Solution (TBS, pH 7.5). 
Immediately, 50 l of the stringent wash solution (0.015 M NaN3) were added on each slide 
and they were placed in termoblock, 30 min at 40°C and Finally TBS-washing for 4 times. 
2.4 Signal detection 
Two systems of signal detection were used. Catalyzed signal amplification system (CSA). 50 
l of primary streptavidin-HRP was added and slides were placed in termoblock 20 min at 
37°C. Slides were washed 4 times with TBS. Then, the slides were incubated with a drop of 
Biotinyl-tyramide 20 min at RT. Slides were washed 4 times with TBS and a drop of 
secondary streptavidin-HRP was added to the sections and incubated 15 min at RT. 
Reaction was revealed with 20 l of 1:50 dilution of diaminobenzidine tetrahydrochloride 
(DAB). The reaction was observed in the microscope and it was stopped rinsing slides with 
distilled water. 
2.5 Alkaline peroxidase system (AP) 
Alkaline streptavidin phosphatase (DakoCytomation, USA) was added and incubated 30 
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drops of N2 N-dimethylformamide (NBT/BCIP) to the 1.7%. Every 10 min the reaction was 
observed in the microscope and finally stopped rinsing slides with distilled water. Finally 
the reaction was counterstained with light green at 3%. Slides were rinsed with alcohol 96%; 
air dried and submerged in xylol to adhere them a cover slip with entellan resin. The results 
were submitted to a difference between proportions test in the program Statistica 6.0 
(Statsoft, Tulsa Ok. EU), to verify the difference between groups A and B, as well as between 
groups C and D, with a confidence level of 95%. A p value of less than 0.05 was considered 
to be significant. 
3. Results  
In the ruminant groups A and B, as expected, all the samples were positive by in situ 
hybridization. In humans (groups C and D), overall positivity for M. avium subsp. 
paratuberculosis by in situ hybridization was 64.28% (n= 9). According to the groups 
distribution, all 7 patients (100%) in group C were positive for M. avium subsp. 
paratuberculosis by in situ hybridization, compared to 3/8 (37.5%) patients in group D; this 
difference was statistically significant (p= 0.0239).  
 
 
Fig. 2. Case of Crohn’s disease from group C, ISH, NBCT/BCIP. 40x. Positive reaction inside 
macrophages in the colonic submucosa. 
Of the 8 patients in which more than one sample was analyzed, 3 of them were positive, 2 
(25%) showed one positive and one negative sample and in 3 cases (37.5%) all were 
negative.  
After in situ hybridization M. avium subsp. paratuberculosis was observed intracellularly 
within macrophages, epithelioid cells and giant cells in the intestinal mucosa and 
submucosa. In groups A, B and C the positive signal was observed within granulomas, 
whereas in group D it was seen within little macrophages that contribute to the 
inflammatory infiltrate. The positive signals were granular and intracytoplasmatic. In group 
A, the cases in group A with abundant intracellular Mycobacteria; the reaction coalesces and 
looks diffuse in the cytoplasm. 
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4. Discussion  
Crohn’s disease is a chronic inflammatory bowel disease of as yet unknown and possibly 
heterogeneous etiology. Diet, infections, immune dysregulation, and other unidentified 
environmental factors, all working under the influence of a genetic predisposition, have 
been suspiciously regarded. Among these, one of the most enduring hypotheses has been 
that M. avium subsp. paratuberculosis could be the causative agent of Crohn’s disease. 
By bacteriological isolation, serology and techniques of molecular biology several authors 
have been able to detect the presence of M. avium subsp. paratuberculosis in a great 
proportion of patients with Crohn’s disease [2, 3, 5-7]. Even more, some authors have 
reported clinical remission of Crohn’s disease patients who received anti-mycobacterial 
therapy which included macrolide antibiotics [8].  
However, early results were inconsistent so that the role of this chronic enteric pathogen in 
the pathogenesis of Crohn’s disease is not yet clearly established. The disparity in the earlier 
results can be due to several factors; among them the application of different 
methodologies.Successful isolations have been achieved by bacteriologists in veterinary 
laboratories since human medicine laboratories do not routinely culture mycobactin 
dependent mycobacteria, and therefore, don’t necessary have adequate media for the 
isolation of these very difficult and slow growing organisms. In addition, when culture has 
been successful, the primary isolation consists on ZN-negative cell wall deficient forms 
which require long incubation times; which can extend for years to revert to bacillary forms 
[1]. In this study all cases showed a granular and intracytoplasmatic stain pattern, as 
expected for intracellular bacteria like mycobacteria and Chlamydophila in agreement with 
the previous work described by Hulten et al and Meijer et al. [12, 14-15].  
In the veterinary group A, the tissues were from multibacillary Johne’s disease, with the 
labeled probe therefore hybridizing to the bacillary forms of M. avium subsp. 
paratuberculosis. In group B, as well as in the cases of Crohn’s disease in groups C and D; the 
labeled probe hybridized in situ to the ZN-negative form of these versatile pathogens 
showing that this technique is capable of recognizing the cell wall deficient phenotype.  
Therefore, the protocol of in situ hybridization used identifies both forms of M. avium subsp. 
paratuberculosis. The enzymatic digestion treatment is apparently able to permeabilise the 
mycobacterial cellular wall without altering intestine tissue architecture in ruminants and 
humans. 
The identification, by in situ hybridization of positive cases to M. avium subsp. 
paratuberculosis in groups B, C and D is consistent with the findings of the study of Hulten et 
al in which they identify spheroplasts of this mycobacterium in paucibacillary cases of 
Johne´s disease in ovines [14], as well as their later study when they demonstrated the 
presence of spheroplasts in 7 of 37 (18.91%) of the Crohn’s disease patients [15]. In the same 
way, Sechi et al demonstrated by in situ hybridization, the presence of M. avium subsp. 
paratuberculosis spheroplasts in 35 of 48 (72.91%) of Crohn’s disease patients, despite the fact 
that on this occasion they did not find M. avium subsp. paratuberculosis by PCR IS900 in the 
same samples [17]. However, these authors did identify M. avium subsp. paratuberculosis by 
PCR in subsequent work using improved sample processing procedures [18]. 
Although some literature classifies patients with Crohn’s disease according to the fistulous 
or obstructive phenotype, in our present series of clinical cases we observed that the same 
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method of classification is in our view uncertain. Most of the studies of the molecular 
pathology in Crohn’s disease do not differentiate between patients with the granulomatous 
and non granulomatous presentation. The results obtained in the present study indicate that 
a greater proportion of patients with granulomatous disease are M. avium subsp. 
paratuberculosis positive by in situ hybridization. This observation agrees with those of 
Hulten et al. However; we found the positive in situ hybridization signal particularly in 
relation to the granulomas in Crohn’s disease patients.  
Greenstein suggested that the identification of M. avium subsp. paratuberculosis DNA in the 
tissues of patients with Crohn’s disease cannot be taken as proof of a causal association 
between this mycobacterium with Crohn’s disease. It could be a coincidence of M. avium 
subsp. paratuberculosis DNA being in the intestinal lumen of people who had ingested cow’s 
milk containing these pathogens [19]. In the present study using an in situ diagnostic 
procedure we were able to confirm the presence of M. avium subsp. paratuberculosis within 
the inflamed gut wall and related to the granulomatous lesions. In this situation M. avium 
subsp. paratuberculosis is most unlikely to be a transient food-borne contaminant. It is much 
more likely that is well characterized multi-host chronic enteric pathogen is related to the 
causation of the chronic inflammatory intestinal disease.  The exact mechanism is not know 
but one theory is that M. avium subsp. paratuberculosis either can infect the host and cause a 
primary infection responsible for the development of the disease, or it is a secondary 
opportunistic infection that could perpetuate the cycle of inflammation and cytokine release. 
Regarding the Crohn’s disease pathogenesis, there is no doubt that Crohn’s disease is a 
result of immune dysregulation, where an excessive TH1-driven, cell-mediated immune 
response is elicited and persists. In this context, chronic intracellular M. avium subsp. 
paratuberculosis infection may be the trigger for this excessive TH1 immune response that 
results in the clinical, endoscopic, radiological, and histological manifestation known as 
Crohn’s disease. 
Even if M. avium subsp. paratuberculosis is not causally linked with Crohn’s disease, the 
presence of DNA from M. avium subsp. paratuberculosis and other bacteria within the 
mucosa might have secondary clinical implications. Some studies have proved that bacterial 
DNA has immunomodulatory activity by signaling via pattern recognition receptors such as 
toll-like receptor 9 on host epithelial cells [20]. Further studies are needed, and it is 
imperative that researchers adopt standardized methods and techniques, including 
appropriate controls, and search for intracellular bacteria other than M. avium subsp. 
paratuberculosis. The availability of these tests could influence the therapeutic approach of 
these patients; antimycobacterial therapy may include macrolide antibiotics which have 
been beneficial for remission of intestinal lesions [8].  
Although previous epidemiological studies have suggested that the incidence of 
inflammatory bowel disease is lower in Latin American populations, recent studies have 
demonstrated that the incidence is increasing and may be higher than suspected. For 
example, Appleyard et al  showed that in Puerto Rico, an Hispanic predominant population; 
the total incidence of IBD increased significantly between 1996 and 2000 (3.07/100,000 to 
7.74/100,000; p <0.001), being significantly higher for Crohn’s disease (four-fold increase, p 
< 0.01), but not for ulcerative colitis (1.7-fold increase) [10]. Puerto Ricans are genetically 
complex and comprised of various proportions of Native American, African, and European 
genetic origins, as our Mexican population. Although the reasons for this are unclear, the 
data suggest several possible explanations such as changes in health care system, movement 
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from rural areas to urban cities, a more Westernized and fairly high carbohydrates and fat 
diet, and decrease in the incidence of intestinal parasites; which have  a protective effect via 
regulation of the immune response. 
5. Conclusion 
In conclusion, despite the obvious need to evaluate a greater number of Mexican patients 
with and without inflammatory bowel disease these initial results remark the exposure of 
the Mexican population to M. avium subsp. paratuberculosis and provide further evidence in 
support of the zoonotic features of this agent. Taking on account the public health relevance 
of the issue as well as its economic impact, wider studies are needed in Mexico. 
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1. Introduction  
Crohn's disease (CD) is a chronic inflammatory bowel disease, with the potential to affect 
any segment of the gastrointestinal tract. Despite the great advances in recent decades, 
which provided a better understanding of the pathogenesis of the disease, it is yet to be 
completely elucidated. Presence of genetic factors, luminal factors such as microflora and 
factors related to the intestinal barrier and immunoregulation are pieces that interact with 
each other and with environmental factors. The possibility of an infectious etiology has 
always been widely discussed. In this context, Mycobacterium avium subspecies 
paratuberculosis (MAP) has attracted the interest of many researchers because of the 
similarity between paratuberculosis and CD. In 1913, two decades before the description of 
CD in 1932, T. K. Dalziel made associations between chronic cases of enteritis in humans 
and paratuberculosis in cattle (Behr and Kapur, 2008). 
Some genetic studies also support the role of MAP in CD and susceptibility genes have been 
identified, which encode proteins involved in the innate immunity defense against 
intracellular bacteria. However, no study is conclusive about a causal relationship. It is not 
possible to conclude that a single agent is solely responsible for the etiology of CD: a 
multifactorial cause is much more likely (Grant et al., 2001). 
Whereas the causal relationship has not been established, therapeutic implications require 
further studies. Results of these studies could help answer questions about the role of MAP 
in the etiology of CD. 
2. Mycobacterium avium subspecies paratuberculosis 
Mycobacterium avium subspecies paratuberculosis (MAP) is a small bacillus, Gram-positive, 
intracellular, acid-resistant bacterium belonging to the Mycobacteriacea family. It grows 
slowly and when observed under an optic microscope, usually appears to form small 
clusters (Fig.1). Like other mycobacteria, this microorganism has a thick cell wall, composed 
mainly of lipids, which determines its acid-resistant, hydrophobicity and high resistance to 
chemical processes, such as chlorination of water, and physical processes, such as 
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chemical processes, such as chlorination of water, and physical processes, such as 
pasteurization (Harris and Barletta, 2001). 
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Fig. 1. Mycobacterium avium subspecies paratuberculosis (MAP) stained by Ziehl-Neelsen. 
Optical microscopy (1000x). 
The first observation of the microorganism was made in 1895 by Johne and Frothingham, 
who isolated an acid-resistant bacterium from the ileum of animals with chronic 
granulomatous inflammation. The disease was called paratuberculosis, according to its 
similarity with intestinal tuberculosis. Although the disease had been reported in 1895, 
identification of the agent was assigned by Twort in 1910 who could grow the 
microorganism for the first time in laboratory (Cocito et al., 1994). 
Morphology of MAP colonies depends on the medium used for growth. In Herrold Egg 
Yolk Medium (HEYM), colonies are small, measuring about 1 to 2 mm, generally white, 
convex and smooth, while in Middlebrook Agar they become more wrinkled. Even under 
optimal conditions, colonies may take 3 to 4 months or longer to become visible (Harris and 
Barletta, 2001). Other features of MAP, which serve to differentiate it from other bacteria, are 
its dependence on mycobactin J for in vitro growth, a compound extracted from 
mycobacterial cells that helps in iron uptake, and the presence of insertion element IS900, 
which appears as 14 to 18 copies within the genome (Green et al., 1989). 
The complete genome of MAP K-10 was sequenced in 2004 by researchers at the University 
of Minnesota, USA. Analysis showed that MAP K-10 has a circular sequence of 4,829,781 
base pairs with 69.3% G+C. When comparing the genome of MAP and other mycobacteria, 
researchers have suggested two hypotheses to explain the extremely slow growth of MAP. 
Firstly, the presence of an insertion sequence, MAP0028c/IS1311, much closer to oriC in 
MAP compared to M. tuberculosis, would be detrimental to chromosomal replication, 
leading to a wider range of generation. The second theory is the presence of the gene 
map0638, with a higher replacement rate compared to M. tuberculosis. This gene is 
responsible for regulating synthesis of purine and therefore has a role in rate of protein 
synthesis and cell growth (Li et al., 2005). 
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3. Paratuberculosis 
Mycobacterium avium subspecies paratuberculosis (MAP) is the causative agent of 
paratuberculosis or Johne's disease, a chronic infectious enteritis, characterized by the 
presence of persistent diarrhea and progressive weight loss, which mainly affects domestic 
and wild ruminants worldwide and may also affect several other species of mammals, 
including primates.  
In the USA, bovine paratuberculosis is well documented and it is estimated that economic 
losses for the dairy industry are of the order of millions of dollars annually. These losses are 
due to decreased production, reduced protein content of milk, premature culling, increased 
susceptibility to other diseases, reduced fertility and increased health costs (Hendrick et al., 
2005).  
Under natural conditions, the transmission of the microorganism is usually horizontal, by 
ingesting food or water contaminated with MAP. Transmission can also occur vertically by 
intrauterine infection, colostrum from females infected or contaminated semen.  
Paratuberculosis usually manifests in young adult cattle. After an incubation period of 
about 2 to 5 years clinical symptoms begin to appear. However, infected animals eliminate 
the microorganism in their stools and in minor amounts in milk even before the onset of 
clinical signs, which contributes to the spread of the agent. Confinement contributes to the 
infection of animals and can be one of the reasons for higher prevalence of the disease in 
dairy cattle herds compared to meat cattle. The long incubation period has great importance 
in the economic impact of disease because infected animals are responsible for the unnoticed 
spread of the agent and, therefore, of the disease in herds.  
In vivo, the primary target of MAP infection is the M cells from Peyer's patches and the 
primary lesions occur on the walls of the small intestine and mesenteric lymph nodes. The 
multiplication of the microorganism leads to the extent of injury to the ileum, jejunum, 
cecum and colon, interfering with the intestinal metabolism. The main gross lesions are 
characterized by thickening of the intestinal mucosa, which presents an aspect grid with 
transverse folds, well-exposed and enlarged mesenteric lymph nodes, and the main 
histopathological findings consist of enteritis and granulomatous lymphangitis and 
lymphadenitis associated with the presence of acid-fast bacilli resistant into macrophages.  
Typical clinical signs of the disease are rapid and progressive weight loss (Fig. 2) and 
intermittent diarrhea, which becomes progressively more severe. Animals continue with a 
normal appetite but cannot effectively absorb nutrients. Lower body condition scores are 
generally found. In the final stage, chronic diarrhea of animals becomes untreatable and 
then, they will die in cachectic state. During the early stages of paratuberculosis, the 
immunity is characterized by a strong cell-mediated immune response and in the later 
stages there is a humoral immune response. Antibody concentrations become higher with 
the progression of the disease when the lesions become more extensive, reflecting the 
amount of antigen present.  
Diagnosis can be based on the detection of the etiologic agent or detection of immune 
response to this agent. Several methods have been used to diagnose the disease such as fecal 
culture, immunological tests, histopathological tests and molecular tests.  
MAP isolation by fecal culture is considered the "gold standard" for diagnosis of 
paratuberculosis, despite having low sensitivity and requiring up to 16 weeks until the first 
colonies can be seen. To detect infected animals in the early stages of the disease by this 
method is very difficult due to the slow growth of MAP. The agent is grown on specific 
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immunity is characterized by a strong cell-mediated immune response and in the later 
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the progression of the disease when the lesions become more extensive, reflecting the 
amount of antigen present.  
Diagnosis can be based on the detection of the etiologic agent or detection of immune 
response to this agent. Several methods have been used to diagnose the disease such as fecal 
culture, immunological tests, histopathological tests and molecular tests.  
MAP isolation by fecal culture is considered the "gold standard" for diagnosis of 
paratuberculosis, despite having low sensitivity and requiring up to 16 weeks until the first 
colonies can be seen. To detect infected animals in the early stages of the disease by this 
method is very difficult due to the slow growth of MAP. The agent is grown on specific 
 
Crohn's Disease 132 
medium and confirmation of the identity of the colonies is done by its dependence of 
micobactin J or targeting the insertion sequence IS900 on molecular tests, an element pattern 
that enables the genetic identification of MAP.  
 
 
Fig. 2. Animal with paratuberculosis showing low body score 
Several serological tests have been used for rapid detection of infected animals including 
complement fixation, agar gel immunodiffusion and ELISA. However, because disease 
immunity is mediated by cells in the early stages and humoral in the later stages, these tests 
generally have high sensitivity in infected animals showing clinical signs, and low 
sensitivity in animals that do not. Therefore they are most useful in the clinical stages of 
disease. Among the serological tests, ELISA is the most commonly used for its high 
sensitivity and acceptable specificity. Despite the low sensitivity and specificity, intradermal 
tests have also been used. Infected animals show a cellular response when in contact with 
purified MAP proteins. These tests are not recommended because it may cause cross-
reactivity of these proteins with tuberculin during the tuberculin test, leading to false 
positive results. This is a test performed by control programs for diagnosis of tuberculosis, a 
disease caused by M. bovis in countries where this disease is present. 
Rapid detection of microorganisms of slow growth has become possible through use of 
molecular biology techniques. Discovery of insertion sequence IS900 in the MAP genome 
and the development of the polymerase chain reaction (PCR) revolutionized this field. 
PCR is used successfully to detect MAP DNA in samples of pasteurized milk and fresh 
milk and is more sensitive than fecal culture. Using PCR it is possible to detect 
concentrations as low as 10UFC/mL milk. It is a highly sensitive and specific technique 
for the detection of MAP, as well as fast, and can reduce diagnosis time from months to 
just two days. PCR is also very versatile, considering that it can be used in stool, tissues, 
milk, blood and semen. There is currently no satisfactory treatment for animals affected 
by MAP. Vaccines currently available against MAP do not protect animals completely and 
there is also the aforementioned problem of possible cross-reactions. Thus, vaccination is 
not recommended. 
General management measures such as general hygiene facilities, separating animals by age, 
and identification and disposal of infected animals can be cited as preventative measures. 
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3.1 Paratuberculosis in Brazil 
In Brazil, the first notification of paratuberculosis occurred in Rio de Janeiro, in an imported 
animal (Dupont, 1915). Afterwards, the disease was reported in the Southeastern (Santos 
and Silva, 1956; Dacorso Filho et al., 1960; Silva, 1961; Nakajima et al., 1991; Ristow et al., 
2007; Costa et al., 2010), Southern (Portugal et al., 1979; Ramos et al., 1986; Driemeier et al., 
1999), Mid-western (Brautingam et al., 1996; Acypreste et al., 2005), and Northeastern (Mota 
et al., 2010; Oliveira et al., 2010) regions of the country in animals born and raised in Brazil. 
The first report in raw milk samples is recent (Carvalho et al., 2009). 
The first report of the presence of MAP in milk samples in the country was fairly recent. 
Although researches on paratuberculosis in Brazil have increased considerably, the studies 
published in the area are still few and the economic impact of the disease has not been 
measured in the country. In Brazil, the estimated prevalence of paratuberculosis is higher 
than in other countries. Further studies are needed to subsidize control measures in the 
national herd, since, in Brazil, there is no health program for this disease. 
4. Crohn’s disease 
Crohn's disease (CD) is an inflammatory bowel disease of unknown etiology, which is 
characterized by chronic, focal, asymmetric, transmural and granulomatous inflammation, 
and can affect any segment of the digestive tract, from mouth to anus, although with 
preference for the distal small intestine and proximal large intestine. The disease has three 
phenotypes which are: stenosing, penetrating, and not stenotic and non-penetrating. 
Incidence and prevalence of CD varies greatly with geographic location. USA, Britain, 
Scandinavia (especially Norway and Sweden), Italy and countries of northern Europe are 
considered areas with greater impact. Intermediate incidence areas are represented by the 
countries of southern Europe, South Africa, Australia and New Zealand. Low incidence is 
reported in Asia and South America. 
The disease can affect individuals of any age, but occurs with greater frequency in patients 
between 20 and 40 years old. It affects people in their most productive period, with an 
enormous impact on quality of life of patients. A second peak in incidence, less obvious, is 
described in patients between 60 and 80 years old, setting a bimodal presentation. The 
disease has no predilection for sex. 
Pathogenesis of CD, although not fully understood, fundamentally involves four aspects 
that interact with each other and with environmental factors: a) genetic factors; b) luminal 
factors related to the intestinal microbiota, its antigens, metabolic products and food 
antigens; c) factors related to the intestinal barrier, including aspects related to innate 
immunity and intestinal permeability; and d) factors related to immunoregulation, based on 
the adaptive or acquired immunity. 
CD is characterized by periods when the disease is active and others where it is in 
remission. Symptoms depend on the severity and location of intestinal involvement. In 
approximately one third of patients, CD involves the small intestine, especially ileum, and 
in some cases the jejunum. About 20% to 25% of cases present only colonic lesions. The 
isolated involvement of the jejunum is rare, as well as cases involving the esophagus, 
stomach and duodenum. The most common clinical manifestations are abdominal pain, 
diarrhea and weight loss. CD progresses with periods of remission and exacerbation, even 
after surgical resection of the affected areas. It has a high percentage of complications with 
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formation of abscesses, fistulas, stenosis, cavity free perforation and anoperineal 
involvement (Fig. 3). About 70% of individuals affected by the CD undergo surgery and 30% 
suffer from repeated bowel resections. This disease may be associated with extraintestinal 
manifestations, and rheumatological, dermatological, ophthalmological, and hepatobiliary 
nephrology manifestations are the most frequent. 
Diagnosis of the disease represents a major challenge, especially when it comes to early 
diagnosis. It is based on a combination of clinical, laboratory, radiological, endoscopic and 
histopathological findings. There is no pathognomonic test for the diagnosis of CD. 
To date there is no medical or surgical treatment that provides healing of CD. As 
inflammation is the maximum expression of the disease pathophysiology, clinical therapy, 
which involves different groups of medications such as aminosalicylates, corticosteroids, 
immunomodulators and biologic therapy are aimed at blocking the inflammatory cascade 
and ending the inflammation and scarring of the intestinal mucosa. 
 
 
Fig. 3. Endoscopic appearance of Crohn's disease (CD). A: bleeding ulcerated lesion; B: 
serpiginous ulcerations in the mucosa showing cobblestones appearence. Surgical 
specimens. C: ileum with extensive ulcerated lesion, D: intestinal wall thickening and 
opening of the fistulous orifice (arrow). 
Although it is a benign disease with low mortality rate, CD is accompanied by high 
morbidity, with an unpredictable course and the phases of activity, exteriorized through 
uncomfortable manifestations and/or complications, even when the best care and 
treatments are implemented.  Patients have to live for a long time with limitations that affect 
directly their daily lives, impacting greatly on the quality of life (Sands, 2006; Brand, 2009). 
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4.1 Crohn’s disease in Brazil 
Brazil is located in South America, a region considered to have a low incidence of CD. 
Despite the paucity of epidemiological studies that allow us to know the real incidence and 
prevalence of the disease, reports of cases, predominantly from universities, have shown 
that this disease is not rare, and that its incidence had increased in recent decades. This 
epidemiological profile, now recognized in Brazil, has been previously observed in different 
countries with a high incidence. Nowadays, these countries have been evolving for stability 
in the frequency of the disease. For the different areas of Brazil, CD is most frequently 
observed in states located in the south and southeast, areas with higher socioeconomic 
development. Currently, there is a joint effort of hospitals for inflammatory bowel diseases 
to collect reliable statistical data that would serve as an international database. 
In one follow up study, researchers evaluated 100 patients with CD in university referral 
center for inflammatory bowel disease. The mean follow-up was 47.3 months, with 
variations from one month to 9.5 years. As for gender distribution, 59% were female and 
41% male. Age of patients ranged from 16 to 69 years old, with an average of 29.9 and a 
median of 27 years old. 5% of patients had a family history of ulcerative colitis or CD. 
Among the clinical manifestations, abdominal pain was the most common symptom 
observed in 98% of cases, followed by chronic diarrhea in 83% and weight loss in 82% of 
patients. Regarding the behavior of the disease, stenosing form was observed in 35% of 
cases, followed by non-penetrating and not stenosing form in 34% of cases and fistulizing 
form was described in 31% of cases. Of the extraintestinal manifestations, rheumatological 
manifestation was the most frequently observed, followed by skin and eyes manifestations. 
50% of patients underwent surgical procedures and 63% were hospitalized at least once. The 
authors conclude that the profile of CD in evaluated patients was similar to that described in 
the literature, and these data were corroborated by other Brazilian authors (Faria et al., 2004; 
Santana et al., 2008; Torres et al., 2010). 
5. Mycobacetrium avium subspecies paratuberculosis vs Crohn’s disease 
Paratuberculosis and Crohn's disease (CD) are two diseases that share many clinical and 
histopathological similarities. Both diseases are characterized by chronic inflammation, 
weight loss and there is no cure. 
While there have been, in recent years, various hypotheses about the etiology of CD and the 
mechanisms that trigger it may be cited as diet, environmental factors, genetic 
predisposition and autoimmune responses, the two main causal theories are infection and 
the autoimmune response. Mycobacterium avium subspecies paratuberculosis (MAP) has been 
cited as the leading candidate from the point of view of infection. 
Considering the high prevalence of MAP in dairy herds and the resistance of 
microorganisms to disinfectants and pasteurization, several countries have created 
programs to control the disease considering its possible zoonotic potential. 
5.1 Facts that support MAP in Crohn’s disease 
Despite extensive research and large and important advances in the past few decades, the 
etiology of Crohn's disease (CD) remains unknown, hindering the development of a specific 
therapy. Due to the similarity of clinical signs and histopathological findings between the 
two diseases, associations between paratuberculosis in cattle and chronic ileocolitis in 
humans have been made. Interest in participation in the infectious etiology of CD has 
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increased with the isolation and detection of DNA of Mycobacterium avium subspecies 
paratuberculosis (MAP) in samples from patients with the disease. MAP is not classified as a 
zoonotic agent, but it represents a major concern in the field of public health because of the 
associations that have been made. 
The controversial zoonotic potential of CD grows as more research has been seeking an 
association between MAP and CD. In recent studies, MAP strains were isolated from human 
intestinal tissues and blood from patients with CD. It is known that patients with CD are 
substantially more positive for MAP, regardless of method used, when compared with 
individuals with ulcerative colitis or individuals without inflammatory bowel disease. The 
isolation of MAP and detection of MAP DNA from breast milk of nursing mothers with a 
diagnosis of CD has also been reported and a possible maternal-fetal transmission of MAP 
may be suggested. These results, however, were not replicated by other researchers and 
there is no evidence of increased frequency of CD in children of mothers with CD (Naser et 
al., 2000; Schwartz et al., 2000; Bull et al., 2003; Naser et al., 2004).  
In several published reports, presence of antibodies against MAP has also been 
demonstrated in serum samples from patients with CD by serological tests. Using these 
tests, there are also significant differences when compared with sera from patients with CD, 
ulcerative colitis and control patients. This is another fact that supports the association of 
MAP with CD (Olsen et al., 2009; Rosenfeld and Bressler, 2010).  
Molecular techniques have been used for providing faster results than conventional 
diagnostic techniques. Using PCR-based sequence IS900, MAP DNA has also been found in 
a significantly higher proportion of patients with CD than in patients with ulcerative colitis 
or patients without inflammatory bowel disease (Abubakar et al., 2008).  
Besides all this evidence, CD’s patients have been treated successfully using antimycobacterial 
drugs. If MAP is involved in the etiology of CD, it is expected that antimycobacterial drugs 
should improve the clinical status of affected patients (Hermon-Taylor, 2002).   
Contaminated milk would be the main, but not the only, vehicle of transmission of MAP 
from animals to human beings. Infected animals can eliminate the organism in this way and 
furthermore can occur a milk contamination with via fecal material, a route through which 
the organism is eliminated at higher concentrations. It is known that occurrence of MAP in 
milk is well documented and several studies have shown that the microorganism can 
remain viable after being subjected to standard conditions of pasteurization and processes 
used to produce cheese if it is present in large concentrations. In addition, although not 
recommended, it is known that raw milk is consumed fresh in many parts of the world, 
besides being used for the manufacture of several dairy products. A causal association of 
MAP with CD would have important implications for the processing of milk and other 
dairy products (Grant et al., 2001).  
There is no doubt therefore that there is a potential source of zoonotic infection, considering 
(1) the widespread dissemination of MAP in dairy herds in Europe, America and Australia, 
(2) the elimination of MAP in milk of infected animals, (3) the relative strength of MAP to 
pasteurization process used currently and (4) the recovery of viable MAP in milk samples, 
water and beef, other potential sources of transmission of MAP. So, considering the 
association between CD and MAP infection to be correct, the fact that MAP has been 
detected in foods could be a public health problem.  
It is known that the vast majority of studies using many different techniques have detected 
MAP DNA or cultured the microorganism most frequently in tissue from patients with CD, 
rather than in those with ulcerative colitis and other disorders. These results are consistent 
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with two possibilities: either MAP infection could cause CD in a subgroup of patients that 
are selectively exposed to this microorganism or are genetically susceptible to infection, or 
alternatively, this microorganism, relatively common in the diet, can colonize selectively to 
ulcerated mucosa of patients with CD, but not initiate or perpetuate intestinal inflammation 
(Behr and Kapur, 2008; Hermon-Taylor, 2009; Rosenfeld and Bressler, 2010).  
The most plausible theory that would explain a role for MAP in the etiology of CD is related 
to the recipient NOD2/CARD15. NOD2/CARD15 is an intracellular receptor for muramyl 
dipeptide (MDP), the smallest immunologically active component of bacterial 
peptidoglycan. The binding of MDP to the receiver NOD2/CARD15 activates nuclear factor 
kB. This may contribute to the elimination of intracellular bacterial infection and secretion of 
α defensins by Paneth cells, which constitutively express NOD2/CARD15. The three most 
common polymorphisms of this gene lead to a defective activation of nuclear factor kB by 
the MDP and they are found in 35% of Caucasian patients with CD. NOD2/CARD15 
mutations in CD are associated with a decreased expression of α defensins in the mucosa. 
Thus, a plausible explanation linking NOD2/CARD15 to CD is that a defect in this gene 
could not result in elimination of intracellular infection by MAP and decreased secretion of 
luminal α defensins in the mucosa, allowing a greater adhesion and epithelial invasion by 
the microorganisms ingested (Sartor, 2005). 
Despite all the evidence implying an association of MAP with CD, it is not possible to 
conclude that a single agent is solely responsible for the cause of CD - a multifactorial cause 
is more likely. The role of MAP in the etiology of CD cannot yet be confirmed or refuted 
with certainty. The organism can act as a causative agent, it may have a role in the context of 
infection, it can exacerbate the disease, or it may be non-pathogenic. Clearly, more studies 
are needed to determine whether MAP infection causes the disease or whether this 
environmental contaminant innocently lodges in ulcerated mucosa. Well-designed studies 
are needed to definitively resolve this debate. 
5.2 Facts that do not support MAP in Crohn’s disease 
It has been suggested that a relationship between MAP infection and Crohn’s exists due to 
the clinical and pathological similarities between Crohn’s disease (CD) in human patients 
and paratuberculosis in animals. However, there are also many arguments against MAP 
being the causative agent of CD. Despite the similarities between clinical signs and 
histopathological features of both diseases, there may be differences in clinical and 
pathological responses between both diseases, which are not expected if both diseases are 
caused by the same microorganism.  
Another important factor to be considered is the lack of epidemiological support 
considering the infection’s transmission. If animals eliminate MAP in large quantities in 
feces and milk, it would be expected that the prevalence of CD in people in direct contact 
with animals infected with MAP was great if the association between the CD and 
paratuberculosis is true. These facts have not yet been reported (Jones et al., 2006).  
Not all patients with CD respond well to treatment with anti-MAP. The failure of treatment 
in such cases can be attributed to the fact that CD can exist in two forms: one form caused or 
triggered by infection with MAP and otherwise, induced by some other unknown cause. If 
this is true, the treatment may be ineffective due to inability to identify patients infected 
with MAP before the start of treatment. There is not enough evidence to assert the effects of 
antimycobacterial therapy in patients with CD, but it is suggested that this therapy can help 
maintain remission of clinical signs of disease (Selby et al., 2007).  
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milk is well documented and several studies have shown that the microorganism can 
remain viable after being subjected to standard conditions of pasteurization and processes 
used to produce cheese if it is present in large concentrations. In addition, although not 
recommended, it is known that raw milk is consumed fresh in many parts of the world, 
besides being used for the manufacture of several dairy products. A causal association of 
MAP with CD would have important implications for the processing of milk and other 
dairy products (Grant et al., 2001).  
There is no doubt therefore that there is a potential source of zoonotic infection, considering 
(1) the widespread dissemination of MAP in dairy herds in Europe, America and Australia, 
(2) the elimination of MAP in milk of infected animals, (3) the relative strength of MAP to 
pasteurization process used currently and (4) the recovery of viable MAP in milk samples, 
water and beef, other potential sources of transmission of MAP. So, considering the 
association between CD and MAP infection to be correct, the fact that MAP has been 
detected in foods could be a public health problem.  
It is known that the vast majority of studies using many different techniques have detected 
MAP DNA or cultured the microorganism most frequently in tissue from patients with CD, 
rather than in those with ulcerative colitis and other disorders. These results are consistent 
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with two possibilities: either MAP infection could cause CD in a subgroup of patients that 
are selectively exposed to this microorganism or are genetically susceptible to infection, or 
alternatively, this microorganism, relatively common in the diet, can colonize selectively to 
ulcerated mucosa of patients with CD, but not initiate or perpetuate intestinal inflammation 
(Behr and Kapur, 2008; Hermon-Taylor, 2009; Rosenfeld and Bressler, 2010).  
The most plausible theory that would explain a role for MAP in the etiology of CD is related 
to the recipient NOD2/CARD15. NOD2/CARD15 is an intracellular receptor for muramyl 
dipeptide (MDP), the smallest immunologically active component of bacterial 
peptidoglycan. The binding of MDP to the receiver NOD2/CARD15 activates nuclear factor 
kB. This may contribute to the elimination of intracellular bacterial infection and secretion of 
α defensins by Paneth cells, which constitutively express NOD2/CARD15. The three most 
common polymorphisms of this gene lead to a defective activation of nuclear factor kB by 
the MDP and they are found in 35% of Caucasian patients with CD. NOD2/CARD15 
mutations in CD are associated with a decreased expression of α defensins in the mucosa. 
Thus, a plausible explanation linking NOD2/CARD15 to CD is that a defect in this gene 
could not result in elimination of intracellular infection by MAP and decreased secretion of 
luminal α defensins in the mucosa, allowing a greater adhesion and epithelial invasion by 
the microorganisms ingested (Sartor, 2005). 
Despite all the evidence implying an association of MAP with CD, it is not possible to 
conclude that a single agent is solely responsible for the cause of CD - a multifactorial cause 
is more likely. The role of MAP in the etiology of CD cannot yet be confirmed or refuted 
with certainty. The organism can act as a causative agent, it may have a role in the context of 
infection, it can exacerbate the disease, or it may be non-pathogenic. Clearly, more studies 
are needed to determine whether MAP infection causes the disease or whether this 
environmental contaminant innocently lodges in ulcerated mucosa. Well-designed studies 
are needed to definitively resolve this debate. 
5.2 Facts that do not support MAP in Crohn’s disease 
It has been suggested that a relationship between MAP infection and Crohn’s exists due to 
the clinical and pathological similarities between Crohn’s disease (CD) in human patients 
and paratuberculosis in animals. However, there are also many arguments against MAP 
being the causative agent of CD. Despite the similarities between clinical signs and 
histopathological features of both diseases, there may be differences in clinical and 
pathological responses between both diseases, which are not expected if both diseases are 
caused by the same microorganism.  
Another important factor to be considered is the lack of epidemiological support 
considering the infection’s transmission. If animals eliminate MAP in large quantities in 
feces and milk, it would be expected that the prevalence of CD in people in direct contact 
with animals infected with MAP was great if the association between the CD and 
paratuberculosis is true. These facts have not yet been reported (Jones et al., 2006).  
Not all patients with CD respond well to treatment with anti-MAP. The failure of treatment 
in such cases can be attributed to the fact that CD can exist in two forms: one form caused or 
triggered by infection with MAP and otherwise, induced by some other unknown cause. If 
this is true, the treatment may be ineffective due to inability to identify patients infected 
with MAP before the start of treatment. There is not enough evidence to assert the effects of 
antimycobacterial therapy in patients with CD, but it is suggested that this therapy can help 
maintain remission of clinical signs of disease (Selby et al., 2007).  
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Genetic profiles of different strains already isolated have been outlined and possible 
epidemiological associations between the species from which they were isolated has been 
studied. Studies have shown that human isolates have profiles more similar to those isolated 
from sheep and goats than to those isolated from cattle. This fact also contrasts with the idea 
that cow's milk would be the main source of transmission of MAP from cattle to human 
beings. In contrast to this fact, there are studies reporting that both animals and humans are 
susceptible to infection by MAP isolates with similar genotypes (Jones et al., 2006).  
Just as there are several research groups associating MAP to CD using detection of MAP 
DNA in samples of intestinal tissues and blood of patients with CD, other groups have 
shown the opposite: the same levels of detection of MAP in patients with CD compared 
with patients with ulcerative colitis or patients without inflammatory bowel diseases. 
Moreover, the absence of MAP DNA in patients with CD was also reported. Data are very 
variable for all groups. There is a variation from 0 to 100% of MAP by PCR detection 
(Abubakar et al., 2008).  
Another argument against a possible etiology of MAP in CD is related to the observation of 
a good response from patients with CD undergoing immunosuppressive therapy. 
5.3 Conditions in Brazil that could facilitate the transmission from MAP to humans 
MAP has been detected in several states in the Southeast, South, Midwest and Northeast 
regions of Brazil. Despite reports of paratuberculosis in several states, few research groups 
working in this field are still doing surveys on the disease. In addition to bovine 
paratuberculosis, there are some groups in the country researching the presence of MAP in 
goats and sheep.  
Although there is a strong and effective control program for tuberculosis in the country, 
there is not a control program for paratuberculosis. Research into this disease is still 
preliminary and there has been no survey even made, even superficially, about the 
economic losses caused by the disease.  
Currently, Brazil is the sixth largest milk producing country, with a volume that 
corresponds to approximately 4.5% of world production (IBGE, 2006). The Southeast region 
is the largest producing region, accounting for 38.4% of all domestic production. Despite the 
high production, productivity of dairy herds in Brazil is low. The milk industrial chain is 
important from the standpoint of economic and social development, generating significant 
income and jobs in all sectors. Despite all these factors, no studies in the country are aimed 
at detection of MAP in dairy products and the first detection of MAP in milk was quite 
recent. MAP was detected by PCR using primers based on the IS900 sequence in an initial 
survey about the disease in the Southeast region (Carvalho et al., 2009).  
Brazil has also not been reported the presence of MAP in pasteurized milk. A survey in this 
sense, in the same region where it was detected MAP DNA in raw milk samples, is already 
in the early stages. In parallel, the resistance of MAP to pasteurization temperatures in the 
laboratory is being tested.  
Brazil has a volume estimated at around 112 billion cubic meters of fresh water of the planet. 
Moreover, in Brazilian subsoil there is the Brazilian Guarani aquifer, the largest subsoil 
reservoir of freshwater on the planet. This enormous underground wealth extends over an area 
of 1.6 million square kilometers, of which two thirds are in Brazilian territory. Even with all that 
water, there have been no studies in the country to verify the presence of MAP in water. 
There are no studies about the possible association between MAP infection and Crohn's 
disease (CD). A first attempt of an association between MAP infection and CD is being 
performed. Intestinal biopsies of patients with CD, ulcerative colitis patients and patients 
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without inflammatory bowel disease are being collected with the aim of isolating MAP 
and/or detection of DNA of the microorganism for molecular tests.  
6. Future prospects 
Historically, one of the ways to make the connection between a potential agent of an 
infectious disease and the disease itself was considering whether Koch's postulates were 
true. For the relationship between MAP infection and Crohn's disease (CD), postulates “The 
organism can be isolated from a sick patient” and “The organism can be cultured in the 
laboratory” can still be controversial, but are true. “If the causative microorganism is 
introduced into another susceptible host, the same disease should be generated” is a 
postulate a little harder to prove. Disease results from interaction between infection and 
immune response by the microorganism that causes it. Clinical manifestations of infection 
depend on several variables such as genetics of the host and the state of the immune system, 
among others (Rosenfeld and Bressler, 2010). 
CD certainly involves host genetic influences and environmental influences that interact to 
cause clinically evident disease. It is known that MAP is widely present in the human food 
chain and that MAP DNA can be recovered from intestinal samples of patients with CD. 
Although existing data do not necessarily involve MAP as a causative agent of CD, this 
possibility cannot be definitively excluded. 
Besides this, there is the difficulty in obtaining experimental models for studies involving 
human pathogens or potential human pathogens. Such studies are complicated to 
performed, since although the relationship between MAP and CD is not yet established, it is 
reckless inoculate MAP in human patients for testing. 
There is still much to be learned about MAP and diseases that it can cause in humans. CD 
may be a syndrome with multiple etiologies that result in clinical, endoscopic, radiological 
and pathological findings that define the disease. MAP may be one of the etiologies of this 
syndrome. 
7. Conclusion 
Some studies have shown that the etiology of Crohn's disease (CD) may involve a variety of 
viral and bacterial agents, including MAP, or an immunological origin. Evidence supports an 
interaction between a persistent environmental stimulus, such as a microbial antigen, and 
genetic factors that regulate an immune response or a function of the intestinal mucosa. Recent 
discoveries in many research fields have generated favorable results suggesting an association 
between CD and MAP, but that does not necessarily indicate that the microorganism is 
involved in the etiology of the disease. It is not possible to conclude that a single agent is solely 
responsible for the cause of CD as a multifactorial cause is more likely. For patients and their 
physicians, a clear answer on this association is an important step toward establishing control 
measures and treatment for this debilitating disease. Theories of mycobacterial and 
autoimmune etiologies of CD should be seen as complementary rather than mutually 
exclusive. The causal association between CD and MAP infection remains unanswered.  
If MAP is responsible for a subset of CD, public health measures should be implemented to 
eliminate the source of infection in the human food chain and food processing practices 
must be modified. If there is no evidence of a causal association of MAP and CD, we must 
direct resources to other research fields. This controversy has persisted for too long and 
needs to be resolved.  
 
Crohn's Disease 138 
Genetic profiles of different strains already isolated have been outlined and possible 
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that cow's milk would be the main source of transmission of MAP from cattle to human 
beings. In contrast to this fact, there are studies reporting that both animals and humans are 
susceptible to infection by MAP isolates with similar genotypes (Jones et al., 2006).  
Just as there are several research groups associating MAP to CD using detection of MAP 
DNA in samples of intestinal tissues and blood of patients with CD, other groups have 
shown the opposite: the same levels of detection of MAP in patients with CD compared 
with patients with ulcerative colitis or patients without inflammatory bowel diseases. 
Moreover, the absence of MAP DNA in patients with CD was also reported. Data are very 
variable for all groups. There is a variation from 0 to 100% of MAP by PCR detection 
(Abubakar et al., 2008).  
Another argument against a possible etiology of MAP in CD is related to the observation of 
a good response from patients with CD undergoing immunosuppressive therapy. 
5.3 Conditions in Brazil that could facilitate the transmission from MAP to humans 
MAP has been detected in several states in the Southeast, South, Midwest and Northeast 
regions of Brazil. Despite reports of paratuberculosis in several states, few research groups 
working in this field are still doing surveys on the disease. In addition to bovine 
paratuberculosis, there are some groups in the country researching the presence of MAP in 
goats and sheep.  
Although there is a strong and effective control program for tuberculosis in the country, 
there is not a control program for paratuberculosis. Research into this disease is still 
preliminary and there has been no survey even made, even superficially, about the 
economic losses caused by the disease.  
Currently, Brazil is the sixth largest milk producing country, with a volume that 
corresponds to approximately 4.5% of world production (IBGE, 2006). The Southeast region 
is the largest producing region, accounting for 38.4% of all domestic production. Despite the 
high production, productivity of dairy herds in Brazil is low. The milk industrial chain is 
important from the standpoint of economic and social development, generating significant 
income and jobs in all sectors. Despite all these factors, no studies in the country are aimed 
at detection of MAP in dairy products and the first detection of MAP in milk was quite 
recent. MAP was detected by PCR using primers based on the IS900 sequence in an initial 
survey about the disease in the Southeast region (Carvalho et al., 2009).  
Brazil has also not been reported the presence of MAP in pasteurized milk. A survey in this 
sense, in the same region where it was detected MAP DNA in raw milk samples, is already 
in the early stages. In parallel, the resistance of MAP to pasteurization temperatures in the 
laboratory is being tested.  
Brazil has a volume estimated at around 112 billion cubic meters of fresh water of the planet. 
Moreover, in Brazilian subsoil there is the Brazilian Guarani aquifer, the largest subsoil 
reservoir of freshwater on the planet. This enormous underground wealth extends over an area 
of 1.6 million square kilometers, of which two thirds are in Brazilian territory. Even with all that 
water, there have been no studies in the country to verify the presence of MAP in water. 
There are no studies about the possible association between MAP infection and Crohn's 
disease (CD). A first attempt of an association between MAP infection and CD is being 
performed. Intestinal biopsies of patients with CD, ulcerative colitis patients and patients 
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without inflammatory bowel disease are being collected with the aim of isolating MAP 
and/or detection of DNA of the microorganism for molecular tests.  
6. Future prospects 
Historically, one of the ways to make the connection between a potential agent of an 
infectious disease and the disease itself was considering whether Koch's postulates were 
true. For the relationship between MAP infection and Crohn's disease (CD), postulates “The 
organism can be isolated from a sick patient” and “The organism can be cultured in the 
laboratory” can still be controversial, but are true. “If the causative microorganism is 
introduced into another susceptible host, the same disease should be generated” is a 
postulate a little harder to prove. Disease results from interaction between infection and 
immune response by the microorganism that causes it. Clinical manifestations of infection 
depend on several variables such as genetics of the host and the state of the immune system, 
among others (Rosenfeld and Bressler, 2010). 
CD certainly involves host genetic influences and environmental influences that interact to 
cause clinically evident disease. It is known that MAP is widely present in the human food 
chain and that MAP DNA can be recovered from intestinal samples of patients with CD. 
Although existing data do not necessarily involve MAP as a causative agent of CD, this 
possibility cannot be definitively excluded. 
Besides this, there is the difficulty in obtaining experimental models for studies involving 
human pathogens or potential human pathogens. Such studies are complicated to 
performed, since although the relationship between MAP and CD is not yet established, it is 
reckless inoculate MAP in human patients for testing. 
There is still much to be learned about MAP and diseases that it can cause in humans. CD 
may be a syndrome with multiple etiologies that result in clinical, endoscopic, radiological 
and pathological findings that define the disease. MAP may be one of the etiologies of this 
syndrome. 
7. Conclusion 
Some studies have shown that the etiology of Crohn's disease (CD) may involve a variety of 
viral and bacterial agents, including MAP, or an immunological origin. Evidence supports an 
interaction between a persistent environmental stimulus, such as a microbial antigen, and 
genetic factors that regulate an immune response or a function of the intestinal mucosa. Recent 
discoveries in many research fields have generated favorable results suggesting an association 
between CD and MAP, but that does not necessarily indicate that the microorganism is 
involved in the etiology of the disease. It is not possible to conclude that a single agent is solely 
responsible for the cause of CD as a multifactorial cause is more likely. For patients and their 
physicians, a clear answer on this association is an important step toward establishing control 
measures and treatment for this debilitating disease. Theories of mycobacterial and 
autoimmune etiologies of CD should be seen as complementary rather than mutually 
exclusive. The causal association between CD and MAP infection remains unanswered.  
If MAP is responsible for a subset of CD, public health measures should be implemented to 
eliminate the source of infection in the human food chain and food processing practices 
must be modified. If there is no evidence of a causal association of MAP and CD, we must 
direct resources to other research fields. This controversy has persisted for too long and 
needs to be resolved.  
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When appropriate methods are used, most patients with CD are detected and there is no data 
showing that MAP is harmless to human patients. More epidemiological studies seeking to 
rigorously analyze both diseases are needed. While CD is likely to be a multifactorial 
condition, MAP can be a primary etiologic agent or a significant secondary invading agent. It 
is well documented that MAP is present in humans and that there are many routes of 
transmission and consumption of milk and dairy products are the main, and perhaps the 
biggest, problem link on the subject, since it has been shown that the microorganism can resist 
milk pasteurization processes and also the chlorination processes of drinking water. Therefore, 
until MAP is declared as a non-pathogenic agent for humans, it should be treated as such. 
8. Acknowledgments 
The authors would like to thank Pró-Reitoria de Extensão e Cultura from Federal University 
of Viçosa (UFV), CNPq (Conselho Nacional de Desenvolvimento Científico e Tecnológico), 
CAPES (Coordenação de Aperfeiçoamento de Pessoal de Nível Superior) and FAPEMIG 
(Fundação de Amparo à Pesquisa do Estado de Minas Gerais) for financial support. 
9. References 
Abubakar, I., Myhill, D., Aliyu, S.H.& Hunter, P.R. (2008). Detection of Mycobacterium avium 
subspecies paratuberculosis from patients with Crohn's disease using nucleic acid-
based techniques: A systematic review and meta-analysis. Inflammatory Bowel 
Diseases, Vol.14, No.3, pp.401-410  
Acypreste, C.S., Juliano, R.S., Riveira, F.E.B., Silva, L.A.F., Fioravanti, M.C.S.& Filho, F.C.D. 
(2005). Uso da técnica do ELISA indireto na detecção de anticorpos anti-Mycobacterium 
paratuberculosis em vacas em lactação. Ciência Animal Brasileira, Vol.6, pp. 41-45  
Behr, M.A.& Kapur, V. (2008). The evidence for Mycobacterium paratuberculosis in Crohn's 
disease. Current Opinion in Gastroenterology, Vol.24, No.1, pp.17-21  
Brand, S. (2009). Crohn's disease: Th1, Th17 or both? The change of a paradigm: new 
immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn's 
disease. Gut, Vol.58, No.8, pp.1152-1167 1468-3288 (Electronic) 0017-5749 (Linking) 
Brautingam, F.E., Glass, R.& Mendy, W., 1996. Levantamento sorológico utilizando a técnica 
de ELISA para paratuberculose em cinco rebanhos de corte do Mato Grosso do Sul 
e quatro rebanhos de leite do Estado de São Paulo. In:  XV Congresso 
Panamericano de Ciências Veterinárias, Campo Grande, MT, p. 271. 
Bull, T.J., McMinn, E.J., Sidi-Boumedine, K., Skull, A., Durkin, D., Neild, P., Rhodes, G., 
Pickup, R.& Hermon-Taylor, J. (2003). Detection and verification of Mycobacterium 
avium subsp. paratuberculosis in fresh ileocolonic mucosal biopsy specimens from 
individuals with and without Crohn's disease. Journal of Clinical Microbiology, 
Vol.41, No.7, pp.2915-2923  
Carvalho, I.A., Silva, A., Jr., Campos, V.E.& Moreira, M.A. (2009). Short communication: 
detection of Mycobacterium avium subspecies paratuberculosis by polymerase chain 
reaction in bovine milk in Brazil. Journal of Dairy Science, Vol.92, No.11, pp.5408-
5410, ISSN 1525-3198 (Electronic) 0022-0302 (Linking) 
Cocito, C., Gilot, P., Coene, M., de Kesel, M., Poupart, P.& Vannuffel, P. (1994). 
Paratuberculosis. Clinical Microbiology Reviews, Vol.7, No.3, pp.328-345  
Costa, J.C.M., Pieri, F.A., Souza, C.F., Espeschit, I.F., Felippe, A.G., Santos, G.M., Tobia, F.L., 
Silva Jr., A.& Moreira, M.A.S. (2010). Levantamento sorológico de Mycobacterium 
 
Mycobacterium avium ssp. paratuberculosis vs Crohn’s Disease 141 
avium subesp. paratuberculosis em bovinos leiteiros no estado do Espírito Santo. 
Arquivo Brasileiro de Medicina Veterinária e Zootecnia, Vol.62, No.6, pp.1491-1494  
Dacorso Filho, P., Campos, I.O.N., Faria, J.F.& Langenegger, J. (1960). Doença de Johne 
(Paratuberculose) em bovinos nacionais. Arquivos do Instituto Biológico, Vol.3, 
pp.129-139  
Driemeier, D., Cruz, C.E.F., Gomes, M.J.P., Corbellini, L.G., Lorett, A.P.& Colodel, E.M. 
(1999). Aspectos clínicos e patológicos da paratuberculose em bovinos no Rio 
Grande do Sul. Pesquisa Veterinária Brasileira, Vol.19, No.3/4, pp.109-115  
Dupont, O. (1915). Jornal do Commercio, pp.8  
Faria, L.C., Ferrari, M.L.A.& Cunha, A.S. (2004). Aspectos clínicos da doença de Crohn em 
um centro de referência para doenças intestinais GED Gastroenterologia e Endoscopia 
Digestiva, Vol.23, No.4, pp.151-163  
Grant, I.R., Rowe, M., Dundee, L.& Hitchings, E. (2001). Mycobacterium avium ssp. 
paratuberculosis: its incidence, heat resistance and detection in milk and dairy 
products. International Journal of Dairy Technology, Vol.54, No.1,  
Green, E.P., Tizard, M.L., Moss, M.T., Thompson, J., Winterbourne, D.J., McFadden, J.J.& 
Hermon-Taylor, J. (1989). Sequence and characteristics of IS900, an insertion 
element identified in a human Crohn's disease isolate of Mycobacterium 
paratuberculosis. Nucleic Acids Research, Vol.17, No.22, pp.9063-9073  
Harris, N.B.& Barletta, R.G. (2001). Mycobacterium avium subsp. paratuberculosis in Veterinary 
Medicine. Clinical Microbiology Reviews, Vol.14, No.3, pp.489-512  
Hendrick, S.H., Kelton, D.F., Leslie, K.E., Lissemore, K.D., Archambault, M.& Duffield, T.F. 
(2005). Effect of paratuberculosis on culling, milk production, and milk quality in 
dairy herds. Journal of the American Veterinary Medical Association, Vol.227, No.8, 
pp.1302-1308 0003-1488 (Print) 0003-1488 (Linking) 
Hermon-Taylor, J. (2002). Treatment with drugs active against Mycobacterium avium 
subspecies paratuberculosis can heal Crohn's disease: more evidence for a neglected 
public health tragedy. Digestive and Liver Disease, Vol.34, No.1, pp.9-12  
Hermon-Taylor, J. (2009). Mycobacterium avium subspecies paratuberculosis, Crohn's disease 
and the Doomsday scenario. Gut Pathogens, Vol.1, No.1, pp.15 1757-4749 
(Electronic) IBGE, 2006. Produção da Pecuária Municipal. Online available: 
http://www.cnpgl.embrapa.br/nova/informacoes/estatisticas/producao_leite/in
dex.php. Acessed: 5 Nov 2006 
Jones, P.H., Farver, T.B., Beaman, B., Cetinkaya, B.& Morgan, K.L. (2006). Crohn's disease in 
people exposed to clinical cases of bovine paratuberculosis. Epidemiology and 
Infection, Vol.134, No.1, pp.49-56 0950-2688 (Print) 0950-2688 (Linking) 
Li, L., Bannantine, J.P., Zhang, Q., Amonsin, A., May, B.J., Alt, D., Banerji, N., Kanjilal, S.& 
Kapur, V. (2005). The complete genome sequence of Mycobacterium avium 
subspecies paratuberculosis. Proceedings of the National Academy of Sciences of the 
United States of America, Vol.102, No.35, pp.12344-12349  
Mota, R.A., Peixoto, P.V., Yamasaki, E.M., Medeiros, E.S., Costa, M.M., Peixoto, R.M.& Brito, 
M.F. (2010). Ocorrência de paratuberculose em búfalos (Bubalus bubalis) em 
Pernambuco. Pesquisa Veterinária Brasileira, Vol.30, No.3,  
Nakajima, M., Maia, F.C.L.& Mota, P.M.P.C., 1991. Diagnóstico da Paratuberculose em 
Minas Gerais. In:  IV Simpósio Brasileiro em Micobactérias, Bauru, São Paulo. 
Naser, S.A., Ghobrial, G., Romero, C.& Valentine, J.F. (2004). Culture of Mycobacterium avium 
subspecies paratuberculosis from the blood of patients with Crohn's disease. The 
Lancet Infectious Diseases, Vol.364, No.9439, pp.1039-1044  
 
Crohn's Disease 140 
When appropriate methods are used, most patients with CD are detected and there is no data 
showing that MAP is harmless to human patients. More epidemiological studies seeking to 
rigorously analyze both diseases are needed. While CD is likely to be a multifactorial 
condition, MAP can be a primary etiologic agent or a significant secondary invading agent. It 
is well documented that MAP is present in humans and that there are many routes of 
transmission and consumption of milk and dairy products are the main, and perhaps the 
biggest, problem link on the subject, since it has been shown that the microorganism can resist 
milk pasteurization processes and also the chlorination processes of drinking water. Therefore, 
until MAP is declared as a non-pathogenic agent for humans, it should be treated as such. 
8. Acknowledgments 
The authors would like to thank Pró-Reitoria de Extensão e Cultura from Federal University 
of Viçosa (UFV), CNPq (Conselho Nacional de Desenvolvimento Científico e Tecnológico), 
CAPES (Coordenação de Aperfeiçoamento de Pessoal de Nível Superior) and FAPEMIG 
(Fundação de Amparo à Pesquisa do Estado de Minas Gerais) for financial support. 
9. References 
Abubakar, I., Myhill, D., Aliyu, S.H.& Hunter, P.R. (2008). Detection of Mycobacterium avium 
subspecies paratuberculosis from patients with Crohn's disease using nucleic acid-
based techniques: A systematic review and meta-analysis. Inflammatory Bowel 
Diseases, Vol.14, No.3, pp.401-410  
Acypreste, C.S., Juliano, R.S., Riveira, F.E.B., Silva, L.A.F., Fioravanti, M.C.S.& Filho, F.C.D. 
(2005). Uso da técnica do ELISA indireto na detecção de anticorpos anti-Mycobacterium 
paratuberculosis em vacas em lactação. Ciência Animal Brasileira, Vol.6, pp. 41-45  
Behr, M.A.& Kapur, V. (2008). The evidence for Mycobacterium paratuberculosis in Crohn's 
disease. Current Opinion in Gastroenterology, Vol.24, No.1, pp.17-21  
Brand, S. (2009). Crohn's disease: Th1, Th17 or both? The change of a paradigm: new 
immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn's 
disease. Gut, Vol.58, No.8, pp.1152-1167 1468-3288 (Electronic) 0017-5749 (Linking) 
Brautingam, F.E., Glass, R.& Mendy, W., 1996. Levantamento sorológico utilizando a técnica 
de ELISA para paratuberculose em cinco rebanhos de corte do Mato Grosso do Sul 
e quatro rebanhos de leite do Estado de São Paulo. In:  XV Congresso 
Panamericano de Ciências Veterinárias, Campo Grande, MT, p. 271. 
Bull, T.J., McMinn, E.J., Sidi-Boumedine, K., Skull, A., Durkin, D., Neild, P., Rhodes, G., 
Pickup, R.& Hermon-Taylor, J. (2003). Detection and verification of Mycobacterium 
avium subsp. paratuberculosis in fresh ileocolonic mucosal biopsy specimens from 
individuals with and without Crohn's disease. Journal of Clinical Microbiology, 
Vol.41, No.7, pp.2915-2923  
Carvalho, I.A., Silva, A., Jr., Campos, V.E.& Moreira, M.A. (2009). Short communication: 
detection of Mycobacterium avium subspecies paratuberculosis by polymerase chain 
reaction in bovine milk in Brazil. Journal of Dairy Science, Vol.92, No.11, pp.5408-
5410, ISSN 1525-3198 (Electronic) 0022-0302 (Linking) 
Cocito, C., Gilot, P., Coene, M., de Kesel, M., Poupart, P.& Vannuffel, P. (1994). 
Paratuberculosis. Clinical Microbiology Reviews, Vol.7, No.3, pp.328-345  
Costa, J.C.M., Pieri, F.A., Souza, C.F., Espeschit, I.F., Felippe, A.G., Santos, G.M., Tobia, F.L., 
Silva Jr., A.& Moreira, M.A.S. (2010). Levantamento sorológico de Mycobacterium 
 
Mycobacterium avium ssp. paratuberculosis vs Crohn’s Disease 141 
avium subesp. paratuberculosis em bovinos leiteiros no estado do Espírito Santo. 
Arquivo Brasileiro de Medicina Veterinária e Zootecnia, Vol.62, No.6, pp.1491-1494  
Dacorso Filho, P., Campos, I.O.N., Faria, J.F.& Langenegger, J. (1960). Doença de Johne 
(Paratuberculose) em bovinos nacionais. Arquivos do Instituto Biológico, Vol.3, 
pp.129-139  
Driemeier, D., Cruz, C.E.F., Gomes, M.J.P., Corbellini, L.G., Lorett, A.P.& Colodel, E.M. 
(1999). Aspectos clínicos e patológicos da paratuberculose em bovinos no Rio 
Grande do Sul. Pesquisa Veterinária Brasileira, Vol.19, No.3/4, pp.109-115  
Dupont, O. (1915). Jornal do Commercio, pp.8  
Faria, L.C., Ferrari, M.L.A.& Cunha, A.S. (2004). Aspectos clínicos da doença de Crohn em 
um centro de referência para doenças intestinais GED Gastroenterologia e Endoscopia 
Digestiva, Vol.23, No.4, pp.151-163  
Grant, I.R., Rowe, M., Dundee, L.& Hitchings, E. (2001). Mycobacterium avium ssp. 
paratuberculosis: its incidence, heat resistance and detection in milk and dairy 
products. International Journal of Dairy Technology, Vol.54, No.1,  
Green, E.P., Tizard, M.L., Moss, M.T., Thompson, J., Winterbourne, D.J., McFadden, J.J.& 
Hermon-Taylor, J. (1989). Sequence and characteristics of IS900, an insertion 
element identified in a human Crohn's disease isolate of Mycobacterium 
paratuberculosis. Nucleic Acids Research, Vol.17, No.22, pp.9063-9073  
Harris, N.B.& Barletta, R.G. (2001). Mycobacterium avium subsp. paratuberculosis in Veterinary 
Medicine. Clinical Microbiology Reviews, Vol.14, No.3, pp.489-512  
Hendrick, S.H., Kelton, D.F., Leslie, K.E., Lissemore, K.D., Archambault, M.& Duffield, T.F. 
(2005). Effect of paratuberculosis on culling, milk production, and milk quality in 
dairy herds. Journal of the American Veterinary Medical Association, Vol.227, No.8, 
pp.1302-1308 0003-1488 (Print) 0003-1488 (Linking) 
Hermon-Taylor, J. (2002). Treatment with drugs active against Mycobacterium avium 
subspecies paratuberculosis can heal Crohn's disease: more evidence for a neglected 
public health tragedy. Digestive and Liver Disease, Vol.34, No.1, pp.9-12  
Hermon-Taylor, J. (2009). Mycobacterium avium subspecies paratuberculosis, Crohn's disease 
and the Doomsday scenario. Gut Pathogens, Vol.1, No.1, pp.15 1757-4749 
(Electronic) IBGE, 2006. Produção da Pecuária Municipal. Online available: 
http://www.cnpgl.embrapa.br/nova/informacoes/estatisticas/producao_leite/in
dex.php. Acessed: 5 Nov 2006 
Jones, P.H., Farver, T.B., Beaman, B., Cetinkaya, B.& Morgan, K.L. (2006). Crohn's disease in 
people exposed to clinical cases of bovine paratuberculosis. Epidemiology and 
Infection, Vol.134, No.1, pp.49-56 0950-2688 (Print) 0950-2688 (Linking) 
Li, L., Bannantine, J.P., Zhang, Q., Amonsin, A., May, B.J., Alt, D., Banerji, N., Kanjilal, S.& 
Kapur, V. (2005). The complete genome sequence of Mycobacterium avium 
subspecies paratuberculosis. Proceedings of the National Academy of Sciences of the 
United States of America, Vol.102, No.35, pp.12344-12349  
Mota, R.A., Peixoto, P.V., Yamasaki, E.M., Medeiros, E.S., Costa, M.M., Peixoto, R.M.& Brito, 
M.F. (2010). Ocorrência de paratuberculose em búfalos (Bubalus bubalis) em 
Pernambuco. Pesquisa Veterinária Brasileira, Vol.30, No.3,  
Nakajima, M., Maia, F.C.L.& Mota, P.M.P.C., 1991. Diagnóstico da Paratuberculose em 
Minas Gerais. In:  IV Simpósio Brasileiro em Micobactérias, Bauru, São Paulo. 
Naser, S.A., Ghobrial, G., Romero, C.& Valentine, J.F. (2004). Culture of Mycobacterium avium 
subspecies paratuberculosis from the blood of patients with Crohn's disease. The 
Lancet Infectious Diseases, Vol.364, No.9439, pp.1039-1044  
 
Crohn's Disease 142 
Naser, S.A., Schwartz, D.& Shafran, I. (2000). Isolation of Mycobacterium avium subsp 
paratuberculosis from breast milk of Crohn's disease patients. American Journal of 
Gastroenterology, Vol.95, No.4, pp.1094-1095  
Oliveira, D.M., Riet-Correa, F., Galiza, G.J.N., Assis, A.C.O., Dantas, A.F.M., Bandarra, 
P.M.& Garino Jr, F. (2010). Paratuberculose em caprinos e ovinos no Brasil. Pesquisa 
Veterinária Brasileira, Vol.30, No.1,  
Olsen, I., Tollefsen, S., Aagaard, C., Reitan, L.J., Bannantine, J.P., Andersen, P., Sollid, L.M.& 
Lundin, K.E. (2009). Isolation of Mycobacterium avium subspecies paratuberculosis 
reactive CD4 T cells from intestinal biopsies of Crohn's disease patients. PLoS ONE, 
Vol.4, No.5, pp.e5641 1932-6203 (Electronic) 
Portugal, M.A.S.C., Pimentel, J.N., Saliba, A.M., Baldassi, L.& Sandoval, E.F.D. (1979). 
Ocorrência de paratuberculose no estado de Santa Catarina. O Biológico, Vol.4, 
No.1/2, pp.19-24  
Ramos, E.T., Poester, F.P., Correa, B.L., Oliveira, S.J., Rodrigues, N.C.& Canabarro, C.E. 
(1986). Paratuberculose em bovinos no Estado do Rio Grande do Sul. A Hora 
Veterinária, Vol.34, No.6, pp.28-32  
Ristow, P., Marassi, C.D., Rodrigues, A.B., Oelemann, W.M., Rocha, F., Santos, A.S., 
Carvalho, E.C., Carvalho, C.B., Ferreira, R., Fonseca, L.S.& Lilenbaum, W. (2007). 
Diagnosis of paratuberculosis in a dairy herd native to Brazil. The Veterinary 
Journal, Vol.174, No.2, pp.432-434  
Rosenfeld, G.& Bressler, B. (2010). Mycobacterium avium paratuberculosis and the etiology of 
Crohn's disease: a review of the controversy from the clinician's perspective. The 
Canadian Journal of Gastroenterology, Vol.24, No.10, pp.619-624 0835-7900 (Print) 
0835-7900 (Linking) 
Sands, B.E., 2006, Crohn’s Disease, In: Feldman, M.e.a. (Ed.), Sleisenger and Fordtran's 
Gastrointestinal and liver Disease, Saunders Elsevier, Philadelphia, pp. 2459-2498. 
Santana, G.O., Souza, L.R., Azevedo, M., Sá, A.C., Bastos, C.M.& Lyra, A.C. (2008). 
Application of the Vienna classification for Crohn's disease to a single center from 
Brazil. Arquivos de Gastroenterologia, Vol.45, pp.64-68  
Santos, J.A.& Silva, N.L. (1956). Sobre a 1ª observação da paratuberculose no Brasil. Boletim 
da Sociedade Brasielira de Medicina Veterinária, Vol.24, pp.5-14  
Sartor, R.B. (2005). Does Mycobacterium avium subspecies paratuberculosis cause Crohn's 
disease? Gut, Vol.54, No.7, pp.896-898, ISSN 0017-5749 (Print) 0017-5749 (Linking) 
Schwartz, D., Shafran, I., Romero, C., Piromalli, C., Biggerstaff, J., Naser, N., Chamberlin, 
W.& Naser, S.A. (2000). Use of short-term culture for identification of 
Mycobacterium avium subsp. paratuberculosis in tissue from Crohn's disease patients. 
Clinical Microbiology and Infection, Vol.6, No.6, pp.303-307 1198-743X (Print) 1198-
743X (Linking) 
Selby, W., Pavli, P., Crotty, B., Florin, T., Radford-Smith, G., Gibson, P., Mitchell, B., Connell, 
W., Read, R., Merrett, M., Ee, H.& Hetzel, D. (2007). Two-year combination 
antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn's 
disease. Gastroenterology, Vol.132, No.7, pp.2313-2319  
Silva, N.M. (1961). Estudos sôbre a paratuberculose. Arquivos do Instituto Biológico, Vol.4, 
pp.169-173  
Torres, U.S., Rodrigues, J.O., Junqueira, M.S., Uezato, S.& Netinho, J.G. (2010). The Montreal 
classification for Crohn's disease: Clinical application to a Brazilian single-center 
cohort of 90 consecutive patients. Arquivos de Gastroenterologia, Vol.47, No.3, pp.279-
284  
Part 3 
Treatment of Crohn's Disease 
 
Crohn's Disease 142 
Naser, S.A., Schwartz, D.& Shafran, I. (2000). Isolation of Mycobacterium avium subsp 
paratuberculosis from breast milk of Crohn's disease patients. American Journal of 
Gastroenterology, Vol.95, No.4, pp.1094-1095  
Oliveira, D.M., Riet-Correa, F., Galiza, G.J.N., Assis, A.C.O., Dantas, A.F.M., Bandarra, 
P.M.& Garino Jr, F. (2010). Paratuberculose em caprinos e ovinos no Brasil. Pesquisa 
Veterinária Brasileira, Vol.30, No.1,  
Olsen, I., Tollefsen, S., Aagaard, C., Reitan, L.J., Bannantine, J.P., Andersen, P., Sollid, L.M.& 
Lundin, K.E. (2009). Isolation of Mycobacterium avium subspecies paratuberculosis 
reactive CD4 T cells from intestinal biopsies of Crohn's disease patients. PLoS ONE, 
Vol.4, No.5, pp.e5641 1932-6203 (Electronic) 
Portugal, M.A.S.C., Pimentel, J.N., Saliba, A.M., Baldassi, L.& Sandoval, E.F.D. (1979). 
Ocorrência de paratuberculose no estado de Santa Catarina. O Biológico, Vol.4, 
No.1/2, pp.19-24  
Ramos, E.T., Poester, F.P., Correa, B.L., Oliveira, S.J., Rodrigues, N.C.& Canabarro, C.E. 
(1986). Paratuberculose em bovinos no Estado do Rio Grande do Sul. A Hora 
Veterinária, Vol.34, No.6, pp.28-32  
Ristow, P., Marassi, C.D., Rodrigues, A.B., Oelemann, W.M., Rocha, F., Santos, A.S., 
Carvalho, E.C., Carvalho, C.B., Ferreira, R., Fonseca, L.S.& Lilenbaum, W. (2007). 
Diagnosis of paratuberculosis in a dairy herd native to Brazil. The Veterinary 
Journal, Vol.174, No.2, pp.432-434  
Rosenfeld, G.& Bressler, B. (2010). Mycobacterium avium paratuberculosis and the etiology of 
Crohn's disease: a review of the controversy from the clinician's perspective. The 
Canadian Journal of Gastroenterology, Vol.24, No.10, pp.619-624 0835-7900 (Print) 
0835-7900 (Linking) 
Sands, B.E., 2006, Crohn’s Disease, In: Feldman, M.e.a. (Ed.), Sleisenger and Fordtran's 
Gastrointestinal and liver Disease, Saunders Elsevier, Philadelphia, pp. 2459-2498. 
Santana, G.O., Souza, L.R., Azevedo, M., Sá, A.C., Bastos, C.M.& Lyra, A.C. (2008). 
Application of the Vienna classification for Crohn's disease to a single center from 
Brazil. Arquivos de Gastroenterologia, Vol.45, pp.64-68  
Santos, J.A.& Silva, N.L. (1956). Sobre a 1ª observação da paratuberculose no Brasil. Boletim 
da Sociedade Brasielira de Medicina Veterinária, Vol.24, pp.5-14  
Sartor, R.B. (2005). Does Mycobacterium avium subspecies paratuberculosis cause Crohn's 
disease? Gut, Vol.54, No.7, pp.896-898, ISSN 0017-5749 (Print) 0017-5749 (Linking) 
Schwartz, D., Shafran, I., Romero, C., Piromalli, C., Biggerstaff, J., Naser, N., Chamberlin, 
W.& Naser, S.A. (2000). Use of short-term culture for identification of 
Mycobacterium avium subsp. paratuberculosis in tissue from Crohn's disease patients. 
Clinical Microbiology and Infection, Vol.6, No.6, pp.303-307 1198-743X (Print) 1198-
743X (Linking) 
Selby, W., Pavli, P., Crotty, B., Florin, T., Radford-Smith, G., Gibson, P., Mitchell, B., Connell, 
W., Read, R., Merrett, M., Ee, H.& Hetzel, D. (2007). Two-year combination 
antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn's 
disease. Gastroenterology, Vol.132, No.7, pp.2313-2319  
Silva, N.M. (1961). Estudos sôbre a paratuberculose. Arquivos do Instituto Biológico, Vol.4, 
pp.169-173  
Torres, U.S., Rodrigues, J.O., Junqueira, M.S., Uezato, S.& Netinho, J.G. (2010). The Montreal 
classification for Crohn's disease: Clinical application to a Brazilian single-center 
cohort of 90 consecutive patients. Arquivos de Gastroenterologia, Vol.47, No.3, pp.279-
284  
Part 3 
Treatment of Crohn's Disease 
 9 
Manipulation of Intestinal Flora as  
a Way to Treat Crohn's Disease: The Role of 
Probiotics, Prebiotics and Antibiotics  
Petra Zadravec, Borut Štrukelj and Aleš Berlec 
Jožef Stefan Institute 
Slovenia  
1. Introduction  
Crohn’s disease (CD) is a chronic gastrointestinal disorder which, together with ulcerative 
colitis, is known as Inflammatory Bowel Disease (IBD). CD is characterized by transmural 
inflammation of the entire gastrointestinal tract, from oral cavity to anus. The most common 
symptoms are chronic diarrhea and abdominal pain, which are often accompanied by 
anorexia, malaise, weight loss, fever and extra-intestinal manifestations. The latter can 
involve almost every organ system (Macfarlane et al., 2009). CD can cause the formation of 
strictures, abscesses or fistulas. For that reason, surgical resection in CD patients is very 
common.  
Regardless of the vast amount of data gathered on the etiology and the course of CD, the 
actual cause is still unknown. The interplay of various factors is blamed for the disease 
outbreak. These factors include genetic predisposition, environmental influences (e.g. 
smoking), imbalance in immune response and changes in intestinal flora. Given the 
complexity of the disease, some factors may be the consequence of others.  
Genetic predisposition has received the most research attention in recent years. Family 
studies have shown that more than 50% concordance of CD can be expected in monozygotic 
twins. These findings indicate that the pathogenesis of CD is not based only on one gene but 
on a polygenic risk profile (Vavricka & Rogler, 2009). In 2001, two independent groups of 
researchers discovered one of the most important susceptibility genes for CD, a gene for 
NOD2/CARD15 (Hugot et al., 2001; Ogura et al., 2001). Its mutation is present in about one 
third of all CD patients. Patients with mutated NOD2/CARD15 variants could have a 
deficient response to bacterial LPS which could lead to the development of CD (Ogura et al., 
2001). Several other genes that can contribute to susceptibility to CD have been identified. 
These include IBD5, IL23R, ATG16L1, Chr5p13.1, Chr5q33.1 and Chr10q21.1 (Xavier & 
Podolsky, 2007). They are involved in the maintenance of barrier function and regulation of 
innate and adaptive immunity. 
There are several environmental factors that have been predicted to be involved in the 
development of CD. The single most important environmental risk factor for the 
development of CD is tobacco smoking. Further environmental risk factors are related to 
living in urban areas of developed western countries with stressful lifestyle. There is also 
some evidence that diet could influence the risk for CD. Uptake of fatty acids and sugar, 
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which has increased in the last decades in developed countries, has been linked to an 
increase in the incidence of CD (Hanauer, 2006).  
Dysregulated immune response and exaggerated response to exogenous factors, including 
the intestinal microbiota, is also an important contributor to CD. Immune response at the 
intestinal mucosa is mediated by epithelial and mucosal immune cells. They recognize 
molecules of bacterial origin via Toll-like and NOD-like receptors. Receptor binding leads to 
activation of the NF-κB pathway, which is a crucial regulator of the inflammatory response. 
In epithelial Paneth cells, NF-κB activation leads to the production of defensins. In antigen 
presenting cells, activation of NF-κB leads, with the involvement of procaspase 1, to the 
production of proinflammatory cytokines, which stimulate further inflammation events 
(Xavier & Podolsky, 2007). Increased expression of Th1 cytokines, mainly IFNγ, IL-12, 
TNFα, IL-1β and IL-6, has been considered fundamental in maintaining the inflammation. 
Other cytokines, such as IL-8, IL-18 and IL-23 have also been involved (Dharmani & Chadee, 
2008). 
Even though the actual role of bacteria in the pathogenesis of CD is still unknown, the 
differences in the composition of intestinal flora between healthy individuals and CD 
patients are today a well established fact. They have recently been confirmed by the 
metagenomic sequencing of the intestinal microbiome (Manichanh et al., 2006; Qin et al., 
2010). The difference is characterized by the reduction of species diversity from the phylum 
Firmicutes and an increase in the concentration of enterobacteriaceae, especially Escherichia 
coli. Interestingly, no significant differences in flora composition were observed between 
inflamed and non-inflamed intestinal mucosa of CD patients (Vasquez et al., 2007). CD is 
often associated with the presence of specific microorganisms (adherent and invasive E. coli, 
Mycobacterium avium subsp. paratuberculosis; described below) and lack of others 
(Faecalibacterium prausnitzii). F. prausnitzii is a member of Firmicutes which has been observed 
to be present in lower quantities in patients with endoscopic recurrence of CD six months 
after the surgery, in comparison to patients that were still in remission after surgery. Anti-
inflammatory effects of F. prausnitzii have been demonstrated in in vitro and in vivo mouse 
models (Sokol et al., 2008). Taken together, it has been hypothesized that either a single 
pathogen, increased mucosal permeability, or imbalance between “good” and “bad” 
bacteria (dysbiosis) contribute to the CD onset. 
The hypothesis of a single pathogen is based on the assumption that M. avium subsp. 
paratuberculosis (MAP) could be the causative agent of CD, and has been supported by a 
considerable body of evidence. Investigators were able to isolate MAP from the inflamed 
tissue and peripheral blood of CD patients, detect anti-MAP antibodies and also prove its 
presence using molecular analysis (De Hertogh et al., 2008; Macfarlane et al., 2009). 
However, this was not enough to prove MAP as causative agent of CD, especially since 
treatment with drugs against MAP had no effect on the improvement of CD. Several other 
bacteria have also been associated with CD pathogenesis. These include Listeria 
monocytogenes, Pseudomonas maltophilia, M. kansasii, Bacteroides fragilis and adherent invasive 
E. coli (AIEC) (De Hertogh et al., 2008; Macfarlane et al., 2009). The latter is a specific 
pathovar that has been shown to colonize intestinal mucosa of 36.4% of patients with ileal 
CD. It is able to replicate in macrophages and cause the release of large amounts of TNFα 
(Rolhion & Darfeuille-Michaud, 2007). There is also evidence that AIEC plays an important 
role in the formation of granulomas which are a histological characteristic of CD. 
Colonization with AIEC was recently linked to the previously mentioned NOD2/CARD15 
mutation, (Barnich & Darfeuille-Michaud, 2007; Rolhion & Darfeuille-Michaud, 2007).  
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A second hypothesis is based on an increased permeability of intestinal mucosa which can 
cause translocation of bacteria and their metabolites from the gastrointestinal tract to 
mesenteric lymph nodes and other internal organs (De Hertogh et al., 2008). Occurrence of 
such bacterial translocation in patients with CD after surgery has been documented and has 
caused systemic inflammatory septic response. E. coli, Enteroccoccus ssp, Bact. fragilis, and 
Klebsiella pneumoniae were among the bacterial species which translocated to the greatest 
extent (Takesue et al., 2002). 
A third, dysbiosis theory suggests a broken equilibrium between “good” and “bad” 
intestinal bacteria as a cause of CD (Tamboli et al., 2004). The hypothesis is based on a 
number of studies of faecal and mucosal associated microflora which were found to differ 
between CD patients and healthy individuals (reviewed by Tamboli et al., (2004)). The data 
obtained with classic bacteriological culturing techniques was recently substantiated by 
metagenomic sequencing (Qin et al., 2010). Faecal microflora from patients with CD contains 
decreased numbers of butyrate producing Firmicutes, especially the Clostridium leptum group 
(Manichanh et al., 2006). Ribosomal DNA sequence analysis of mucosa associated bacteria in 
patients with CD has shown increased levels of facultative bacteria (e. g. E. coli) in colonic 
mucosa. In small intestinal mucosa, decreased levels of C. leptum and Prevotella nigrescens 
subgroups were observed, as well as increased level of the Ruminococcus gnavus subgroup 
(Prindiville et al., 2006). These results speak in favor of the dysbiosis theory and make the 
single pathogen theory less likely.  
The aim of this chapter is to introduce ways of interference with the diversity and 
abundance of intestinal bacteria, which are important in CD pathogenesis. Clinical efficacy 
of various strategies will also be presented. 
2. Probiotics 
The Food and Agriculture Organization and the World Health Organization have defined 
probiotics as “live microorganisms which, when administrated in adequate amounts as part 
of food, confer a health benefit on the host”. Probiotics usually belong to the genera 
Lactobacillus or Bifidobacterium. These are gram positive bacteria with fermentative 
metabolism, in which lactic acid is a major product. They are obligatory or facultative 
anaerobes and are non-motile. Among lactobacilli, strains with probiotic properties are Lb. 
acidophilus, including strain LA-5, Lb. crispatus, Lb. johnsonii LA1, Lb. gasseri PA16, Lb. casei, 
Lb. paracasei, strains “shirota” and “defensis”, Lb. rhamnosus GG, Lb. reuteri and Lb. plantarum. 
Among bifidobacteria, B. longum, strains BB536 and SP07/3, B. bifidum MF20/5, B. infantis, 
B. animalis, B. adolescentis and B. breve, have been considered probiotic. Some other bacteria 
and yeasts can also have probiotic properties. These include Enterococcus faecalis, 
Streptococcus thermophilus, Propionibacteria, E. coli Nissle 1917 and yeast Saccharomyces 
boulardii (de Vrese & Schrezenmeir 2008). Probiotics have many potential beneficial health 
effects, which are more or less well documented. The effective use of probiotics for 
significant improvement of lactose digestibility, childhood infectious gastroenteritis, 
diarrhea associated with either antibiotics, rotavirus infection, or chemotherapy, as well as 
traveller’s diarrhea has been well documented (Schrezenmeir & de Vrese, 2001; Walker et 
al., 2006). Probiotics can stimulate humoral or cellular immune systems. They can cause a 
decrease in unfavourable metabolites (e. g. ammonium) in the colon. There are fewer reports 
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inflammatory effects of F. prausnitzii have been demonstrated in in vitro and in vivo mouse 
models (Sokol et al., 2008). Taken together, it has been hypothesized that either a single 
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bacteria (dysbiosis) contribute to the CD onset. 
The hypothesis of a single pathogen is based on the assumption that M. avium subsp. 
paratuberculosis (MAP) could be the causative agent of CD, and has been supported by a 
considerable body of evidence. Investigators were able to isolate MAP from the inflamed 
tissue and peripheral blood of CD patients, detect anti-MAP antibodies and also prove its 
presence using molecular analysis (De Hertogh et al., 2008; Macfarlane et al., 2009). 
However, this was not enough to prove MAP as causative agent of CD, especially since 
treatment with drugs against MAP had no effect on the improvement of CD. Several other 
bacteria have also been associated with CD pathogenesis. These include Listeria 
monocytogenes, Pseudomonas maltophilia, M. kansasii, Bacteroides fragilis and adherent invasive 
E. coli (AIEC) (De Hertogh et al., 2008; Macfarlane et al., 2009). The latter is a specific 
pathovar that has been shown to colonize intestinal mucosa of 36.4% of patients with ileal 
CD. It is able to replicate in macrophages and cause the release of large amounts of TNFα 
(Rolhion & Darfeuille-Michaud, 2007). There is also evidence that AIEC plays an important 
role in the formation of granulomas which are a histological characteristic of CD. 
Colonization with AIEC was recently linked to the previously mentioned NOD2/CARD15 
mutation, (Barnich & Darfeuille-Michaud, 2007; Rolhion & Darfeuille-Michaud, 2007).  
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A second hypothesis is based on an increased permeability of intestinal mucosa which can 
cause translocation of bacteria and their metabolites from the gastrointestinal tract to 
mesenteric lymph nodes and other internal organs (De Hertogh et al., 2008). Occurrence of 
such bacterial translocation in patients with CD after surgery has been documented and has 
caused systemic inflammatory septic response. E. coli, Enteroccoccus ssp, Bact. fragilis, and 
Klebsiella pneumoniae were among the bacterial species which translocated to the greatest 
extent (Takesue et al., 2002). 
A third, dysbiosis theory suggests a broken equilibrium between “good” and “bad” 
intestinal bacteria as a cause of CD (Tamboli et al., 2004). The hypothesis is based on a 
number of studies of faecal and mucosal associated microflora which were found to differ 
between CD patients and healthy individuals (reviewed by Tamboli et al., (2004)). The data 
obtained with classic bacteriological culturing techniques was recently substantiated by 
metagenomic sequencing (Qin et al., 2010). Faecal microflora from patients with CD contains 
decreased numbers of butyrate producing Firmicutes, especially the Clostridium leptum group 
(Manichanh et al., 2006). Ribosomal DNA sequence analysis of mucosa associated bacteria in 
patients with CD has shown increased levels of facultative bacteria (e. g. E. coli) in colonic 
mucosa. In small intestinal mucosa, decreased levels of C. leptum and Prevotella nigrescens 
subgroups were observed, as well as increased level of the Ruminococcus gnavus subgroup 
(Prindiville et al., 2006). These results speak in favor of the dysbiosis theory and make the 
single pathogen theory less likely.  
The aim of this chapter is to introduce ways of interference with the diversity and 
abundance of intestinal bacteria, which are important in CD pathogenesis. Clinical efficacy 
of various strategies will also be presented. 
2. Probiotics 
The Food and Agriculture Organization and the World Health Organization have defined 
probiotics as “live microorganisms which, when administrated in adequate amounts as part 
of food, confer a health benefit on the host”. Probiotics usually belong to the genera 
Lactobacillus or Bifidobacterium. These are gram positive bacteria with fermentative 
metabolism, in which lactic acid is a major product. They are obligatory or facultative 
anaerobes and are non-motile. Among lactobacilli, strains with probiotic properties are Lb. 
acidophilus, including strain LA-5, Lb. crispatus, Lb. johnsonii LA1, Lb. gasseri PA16, Lb. casei, 
Lb. paracasei, strains “shirota” and “defensis”, Lb. rhamnosus GG, Lb. reuteri and Lb. plantarum. 
Among bifidobacteria, B. longum, strains BB536 and SP07/3, B. bifidum MF20/5, B. infantis, 
B. animalis, B. adolescentis and B. breve, have been considered probiotic. Some other bacteria 
and yeasts can also have probiotic properties. These include Enterococcus faecalis, 
Streptococcus thermophilus, Propionibacteria, E. coli Nissle 1917 and yeast Saccharomyces 
boulardii (de Vrese & Schrezenmeir 2008). Probiotics have many potential beneficial health 
effects, which are more or less well documented. The effective use of probiotics for 
significant improvement of lactose digestibility, childhood infectious gastroenteritis, 
diarrhea associated with either antibiotics, rotavirus infection, or chemotherapy, as well as 
traveller’s diarrhea has been well documented (Schrezenmeir & de Vrese, 2001; Walker et 
al., 2006). Probiotics can stimulate humoral or cellular immune systems. They can cause a 
decrease in unfavourable metabolites (e. g. ammonium) in the colon. There are fewer reports 





specific probiotic strain, or to a combination of two or more strains (Schrezenmeir & de 
Vrese, 2001; Walker et al., 2006; Thomas & Greer, 2010). 
Due to the implication of intestinal bacteria in the CD, probiotics were also suggested as a 
possible treatment for CD. Among probiotics, Lb. rhamnosus GG, Lb. johnsonii LA1, B. lactis, 
Str. thermophilus, E. coli Nissle 1917 and yeast S. boulardii have been tested for the treatment 
of CD. 
2.1 Mechanism of action 
Several mechanisms by which probiotics exert beneficial effects in treatment of CD have 
been suggested (Boirivant & Strober, 2007; Dharmani & Chadee, 2008; Guandalini, 2010; Ng 
et al., 2009). Probiotics are supposed to improve the epithelial cell barrier function, decrease 
the load of “bad” bacteria by direct or indirect antibacterial effects or exert direct effects on 
epithelial and immune cells by, among other things, affecting their cytokine expression 
profiles. These effects are intertwined to a large extent and the contribution of an individual 
effect is therefore hard to establish. Besides, an individual probiotic bacterium is probably 
not capable of exerting the entire spectrum of activities. Instead, it is more likely to be 
responsible for a specific effect. 
2.1.1 Effects on epithelial cell barrier function 
The layer of epithelial cells that lines the intestinal tract constitutes a physical barrier that 
prevents intestinal bacteria from entering into the organism. The mix of probiotic organisms, 
VSL#3, was able to normalize barrier integrity in IL-10 deficient mice, as shown by the 
measurements of several parameters (conductivity, mannitol flux) on excised tissue 
(Madsen et al., 2001). Barrier function is reinforced by the layer of mucus, which is secreted 
by goblet epithelial cells. It has been shown that some probiotic bacteria are capable of 
modifying the expression of proteins that are involved in mucin production. Lb. plantarum 
299v was able to increase MUC2 and MUC3 mRNA expression in the epithelial cell line 
(Mack et al., 1999), while VSL#3 and E. coli Nissle 1917 increased MUC2, MUC3 and 
MUC5AC protein expression (Otte & Podolsky, 2004). The epithelial layer is also responsible 
for the active transport of nutrients, electrolytes and water. Impaired ability for reabsorption 
of sodium and water from the distal colon leads to diarrhea that usually accompanies CD 
(Zeissig et al., 2007). Str. thermophilus and Lb. acidophilus were able to increase trans-
epithelial resistance, but also alleviate electrolyte transport by increasing chloride secretion 
(Resta-Lenert & Barrett, 2009). Probiotics were also reported to influence the maintenance of 
tight junction proteins by influencing the cytoskeleton architecture. VSL#3 prevented the 
redistribution of tight junction protein ZO-1 (Otte & Podolsky, 2004) and Lb. acidophilus was 
able to prevent the rearrangement of F-actin upon exposure to pathogenic E. coli (Liévin-Le 
Moal et al., 2002). Probiotics can even prevent apoptosis of epithelial cells, as was shown for 
Lb. rhamnosus GG, which was able to activate anti-apoptotic and inhibit pro-apoptotic 
proteins (Yan & Polk, 2002). 
2.1.2 Antibacterial effects 
Probiotics influence the composition of intestinal flora by competing for the available space 
(e. g. available binding sites for adhesion) and for available essential nutrients. They can also 
exert antimicrobial effects by either direct or indirect means. Direct means include 
productions of inhibitory substances like bacteriocins, hydrogen peroxide and organic acids. 
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Bacteriocins are diverse group of low molecular weight peptides, usually produced by 
strains from genus Lactobacillus, and by some other lactic acid bacteria, including Lactoccocus 
lactis. Bacteriocins have antimicrobial activity against several bacteria, but are especially 
effective against Gram positive bacteria. Similar substances are produced in probiotic strains 
of Bifidobacteria, and are active against both Gram negative and Gram positive bacteria 
(Guandalini, 2010). Organic acids such as lactic acid, propionic acid and butyric acid are 
produced in fermentative metabolism of probiotics and are responsible for a decrease in pH 
in the gastrointestinal tract, which is harmful to acid sensitive intestinal bacteria. Probiotics 
can also exert indirect antibacterial effects, by stimulating the production of defensins. 
Defensins are human endogenous cationic antimicrobial peptides with antimicrobial activity 
against Gram negative and Gram positive bacteria. They are secreted by specialized 
epithelial Paneth cells. Deficiency in defensins could play an important role in the 
pathogenesis of colonic and ileal CD (Wehkamp et al., 2009). Low expression of β-defensin 
occurs in patients with colonic CD and affects the structure of colonic mucosa. In patients 
with ileal CD, decreased level of Paneth cells α-defensin has been observed and these 
patients also had the NOD2 mutation. These results suggest that there is a connection 
between NOD2 function and expression of α-defensin and that this connection has an 
important implication in the development of ileal CD (Wehkamp et al., 2009). 
2.1.3 Immunomodulative effects on epithelial and immune cells 
Probiotic bacteria can modulate the activity of epithelial and immune cells including 
dendritic cells, monocytes, macrophages, T cells, B cells and NK cells. The immune response 
is mediated by pattern recognition receptors, such as toll-like receptors, which recognize 
specific bacterial features, termed pathogen-associated molecular patterns. These include 
peptidoglycan, lipopolysaccharides, flagellin and DNA variants, such as unmethylated CpG 
motifs. Probiotic bacteria can induce regulatory T cells by stimulating the dendritic cells to 
produce anti-inflammatory cytokines IL-10 and TGFβ, as was demonstrated with the 
treatment with VSL#3 (Hart et al., 2004) and with several other bifidobacterial strains 
(Young et al., 2004). The activation of regulatory T cells can be initiated by direct binding of 
probiotics to dendritic cells via the DC-SIGN molecule (Smits et al., 2005). This can cause the 
diversion of the immune response toward noninflammatory tolerogenic pattern. Probiotics 
can downregulate the Th1 response by inhibition of the production of proinflammatory 
cytokines by dendritic cells, including the production of IL-12, TNFα and IFNγ. 
Downregulation of the production of TNFα was demonstrated in ex vivo treatment of 
intestinal tissue from CD patients with probiotics (Borruel et al., 2002). Probiotics can also 
decrease T cell proliferation and their production of IL-2, IL-4 and IL-10 cytokines, as 
demonstrated with Lb. rhamnosus. This increased T cell hypo-responsiveness was also 
induced in vivo in CD patients and in healthy individuals (Braat et al., 2004). Involvement of 
different mechanisms of action is highlighted by the fact that some strains of lactobacilli not 
only downregulate, but also upregulate the production of IL-12 (Mohamadzadeh et al., 
2005) and switch towards the Th1 response.  
2.2 Clinical trials with probiotics for the treatment of CD 
Probiotics have been tested for their ability to treat CD in several clinical trial settings. Some 
basic data on clinical trials is summarized in Table 1. Some probiotic strains or mixtures of 
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tested in more than one clinical trial. Almost all the trials were designed to be randomized 
and placebo controlled, and more than half were double blind. Four studies were designed 
for the maintenance of remission in CD and five for the prevention of postoperative 
recurrence of CD. One study was designed for the treatment of one of the common extra-
intestinal manifestations of CD, arthralgia, and one for evaluation of the impact of intestinal 
permeability in patients with CD.  
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Table 1. Clinical studies investigating the effects of probiotics in the maintenance of 
remission in CD or in the prevention of postoperative recurrence of CD (adapted from 
(Isaacs & Herfarth, 2008)). 
For maintenance of remission of the CD, 28 patients with active colonic CD were treated 
with synthetic corticosteroid prednisone and non-pathogenic probiotic E. coli strain Nissle 
1917, or with placebo (Malchow, 1997). From the results of remission rate we can conclude 
that a similar proportion of patients entered in remission in the two groups. More patients 
from the placebo group (63.6%) had relapse, when compared with the probiotic group, in 
which 33.3% of patients relapsed after 12 months of treatment. Even though these results 
were not statistically significant, a better outcome was reached in the probiotic group, which 
indicated some beneficial effect of E. coli Nissle 1917 on the maintenance of remission in 
colonic CD. Because of the small number of participants in this study, the authors suggested 
that larger study should be performed.  
Guslandi et al. investigated possible therapeutic benefits of non-pathogenic yeast S. boulardii 
in the maintenance of remission in CD (Guslandi et al., 2000). In this study, 32 patients with 
CD in clinical remission were divided randomly into two groups. The first group was 
treated with mesalamine two times a day and with S. boulardii once a day. The second group 
was treated only with mesalamine three times a day. The study was ended after 6 months of 
treatment. In the mesalamine group, 6 of 16 (37.5%) patients had clinical relapse after 6 
months while, in the group treated with mesalamine and S. boulardi, only 1 patient in 16 
(6.25%) had clinical relapse. This difference is statistically significant and demonstrates that 
S. boulardii, in combination with anti-inflammatory drug, could have beneficial effects in the 
maintenance of remission in CD. 
The efficacy of S. boulardii in the treatment of CD was again evaluated in a study of the 
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Vilela et al., 2008). The study was carried out on 34 patients who received either placebo or 
S. boulardii for 3 months. Additionally, patients received standard therapy with 
corticosteroids, anti-inflammatory drugs or antibiotics. Intestinal permeability was 
evaluated by measuring lactulose/mannitol ratio. The ratio was 0.005 +/- 0.0037 in healthy 
volunteers, and 0.021 +/- 0.01 in patients with CD. After 3 months of treatment, 
lactulose/mannitol ratio increased by 0.004 +/- 0.010 in the placebo group and decreased by 
0.008 +/- 0.006 in the S. boulardii group. These results demonstrated that S. boulardii, in 
combination with standard therapy for CD, could improve intestinal integrity in patients 
with CD. 
Probiotic Lb. rhamnosus GG was also tested for the ability to maintain the remission of CD 
(Schultz et al., 2004). Probiotic therapy with Lb. rhamnosus GG was tested in eleven patients 
with moderate to active CD. Patients were first treated with antibiotics for two weeks, 
followed by probiotic therapy for 6 months. Relapse occurred in 2 of 5 patients in the 
probiotic group, as well as in 2 of 6 patients in the placebo group. Two patients from each 
group achieved and maintained remission. No difference between probiotic and placebo 
group was thus observed and no benefit of Lb. rhamnosus GG could be reported. Small 
sample size was suggested as a reason why no difference was observed. 
More than 70% of CD patients will undergo at least one surgery in their life, and recurrence 
of CD in patients after surgical intestinal resection is very common (Marteau et al., 2006). 
Endoscopic recurrence of CD in patients is usually observed within one year after surgery 
and is followed by clinical recurrence. Around one quarter of patients will require further 
surgery in the following years, if no postoperative treatment of the disease will take place 
(Doherty et al., 2009). Prevention of postoperative CD is therefore another important target 
of probiotic treatment. This approach was first tested with probiotic mixture VSL#3 in 
combination with antibiotic rifaximin in a randomized controlled clinical trial with 28 
patients (Campieri et al., 2000). Half of the patients received rifaximin dose for the first three 
months, which was followed by probiotic dose for the next 9 months. The control group 
received 4 g of mesalamine per day for 12 months. Probiotic mixture VSL#3 contains 4 
strains of lactobacilli, 3 strains of bifidobacteria and Str. thermophilus. No side effects were 
reported during the study. At the end of the treatment, 4 of 20 patients had endoscopic 
recurrence, while in the placebo group, 8 patients had endoscopic recurrence. The authors 
concluded that the combination of VSL#3 and rifaximin is effective in preventing 
postoperative endoscopic recurrence of CD. The effectiveness of probiotic mixture VSL#3 
alone in preventing postoperative recurrence of CD was later confirmed in a larger 
randomized, double blind, placebo controlled multicenter study on 120 patients (Madsen et 
al., 2008). Patients receiving VSL#3 for 3 months showed less endoscopic recurrence (9,3% of 
patients) compared with placebo group (15,7% recurrence). Results were substantiated with 
measurements of mucosal pro-inflammatory cytokine levels. 
Beside VSL#3, which is a mixture of probiotic strains, some Lactobacillus strains were tested 
by themselves for the ability to prevent postoperative recurrence of CD. Probiotic strain 
Lactobacillus rhamnosus GG was tested for prevention of postoperative recurrence in a 
randomized double blind and placebo controlled study (Prantera et al., 2002). 23 patients 
received Lb. rhamnosus GG and 22 received placebo daily for one year. No side effects were 
reported, however 13 patients, from the two groups, did not finish the study. At the end of 
the study, 15 patients from Lb. rhamnosus GG group and 17 patients from the placebo group 
showed clinical remission. Among the patients with clinical remission, 9 of 15 patients in the 
probiotic group, and 6 of 17 patients in the placebo group had endoscopic recurrence of CD. 
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Clinical recurrence was observed in 3 patients from the Lactobacillus GG group and in two 
from the placebo group. No benefit of Lactobacillus rhamnosus GG in the postoperative 
treatment of CD could thus be observed. It was suggested that the study should be 
considered as a pilot one because of small number of patients, different demographic and 
different disease background. 
Lb. johnsonii LA1 is another Lactobacillus strain that was used in clinical trials for the prevention 
of postoperative CD. The first double blind, placebo controlled clinical trial with Lb. johnsonii 
LA1 was reported in 2006 (Marteau et al., 2006). 98 patients that underwent ileocolonic, colonic 
or ileal CD surgery were involved. Patients were administered 2x109 colony forming units 
(CFU) Lb. johnsonii LA1 or placebo twice a day for 6 months. Endoscopic recurrence was 
observed in 49% of patients in the probiotic group and in 64% of patients in the placebo group. 
Clinical recurrence was noted in four patients in the probiotic group and in three in the 
placebo group. Results were not statistically significant and beneficial effects of Lb. johnsonii 
LA1 on postoperative recurrence in patients with CD could not be established. 
A second clinical trial of the effectiveness of probiotic Lb. johnsonii LA1 in preventing 
endoscopic postoperative recurrence of CD was conducted with 70 patients that underwent 
curative ileo-caecal resection (Van Gossum et al., 2007). Clinical trial was designed as a 
randomized, double blind, placebo controlled multicenter study. Patients were treated 
either with 1x1010 CFU Lb. johnsonii LA1 daily or with placebo for 12 weeks. No difference in 
measured parameters or in clinical relapse between placebo group and Lb. johnsonii group 
was observed. Clinical relapse was observed in 4 patients in Lb. johnsonii group and in 2 
patients in the placebo group after 12 weeks of treatment.  
Some limited research has also been done on the use of probiotics in pediatric CD. A small 
pilot study was conducted with Lb. rhamnosus GG in children with active CD (Gupta et al., 
2000). Four patients were involved in the study, two with ileocolonic CD and two with 
gastrocolonic CD. Report has shown significant improvement after treatment with 1010 CFU 
of probiotic. Patients were also receiving standard therapy for CD. This study was later 
followed by a randomized, double blind, placebo controlled trial with Lb. rhamnosus GG 
strain which was given in addition to standard therapy for the maintenance of remission in 
children with CD (Bousvaros et al., 2005). 75 children with CD in remission were involved in 
the study for the period of two years. Results of the study have shown no significant 
difference between probiotic and placebo group in the time of relapse of CD. These results 
substantiated the results of a previous study on adults which also showed the 
ineffectiveness of Lb. rhamnosus GG in maintaining remission in CD. Because the 
effectiveness of probiotics in the treatment of CD was not established, treatment of CD with 
probiotics is not recommended for children (Thomas & Greer, 2010).  
Extra-intestinal manifestations like arthralgia and arthritis are common complications of 
CD. They are reported to occur in 10-35% of patients. Since beneficial effects of probiotics 
were observed in the treatment of ulcerative colitis and sometimes of CD, the treatment of 
arthralgia with probiotics mixture VSL#3 was also suggested (Karimi et al., 2005). Of 29 
patients with IBD involved in the study, only 16 patients ended the 3 months study and 9 of 
them were CD patients. After three months of treatment, the status of arthralgia differed 
between patients with peripheral arthralgia and axial arthralgia. Only patients with 
peripheral arthralgia reported improvements in their general well being and joint 
complaints. There was no relapse reported in patients after 3 months of treatment. The 
results of the study were shown for all IBD patients together. The results for patients with 
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can only be concluded that probiotic mixture VSL#3 had beneficial effects on arthralgia in 
patients with IBD, and possibly also in the subgroup of patients with CD. 
2.3 Recombinant probiotic bacteria for the treatment of CD 
Health effects of probiotic bacteria can be strengthened by genetic engineering which 
enables incorporation of new, defined traits into the existing bacterial repertoire. 
Recombinant bacteria can be used as a vector for the delivery of therapeutic proteins to the 
intestinal mucosa. Potential synergistic effects between existing probiotic and introduced 
therapeutic properties can be envisaged. Genetically modified probiotics will enable the 
selection of the desired protein, selection of the localization of protein expression 
(intracellular, secreted) and selection of the conditions required for the induction of the 
expression. It may also be possible to obtain a long term effect with colonizing strains 
(Marteau et al., 2009). 
To date, the focus has been on lactic acid bacterium Lactococcus lactis. It does not have a 
probiotic status and does not colonize the intestine, but is well studied and is readily 
amenable for genetic modification. L. lactis strains with the ability to produce anti-
inflammatory cytokine IL-10 or to bind pro-inflammatory cytokine TNFα have been 
constructed.  
Genetically modified L. lactis secreting cytokine IL-10 was engineered and tested in two 
murine colitis mouse models (Steidler et al., 2000). Results of intragastric administration of 
L. lactis secreting IL-10 showed 50% reduction in DSS-induced colitis and prevention of 
colitis in IL-10 knockout mice. In further research, the authors presented genetically 
modified L. lactis, which was engineered by replacing the thymidylate synthase gene thyA 
with synthetic human IL-10 gene (Steidler et al., 2003). This recombinant bacterium (LL-
Thy12) was able to produce human IL-10 and was not able to survive in the environment 
without thymidine or thymine. This enabled the biological containment of the bacterium 
and markedly decreased the safety concerns. Such a strain is appropriate for human use and 
the effectiveness of LL-Thy12 was investigated in a phase I trial on patients with CD (Braat et 
al., 2006). Results of the trial have demonstrated safety of the strain. Only minor adverse 
effects were noted and some beneficial effects on the disease activity were observed.  
Two recent studies have introduced another approach for the treatment of intestinal 
inflammations by binding the pro-inflammatory cytokine TNFα. The first study used 
engineered L. lactis which secreted TNFα-neutralizing nanobody (camelid heavy chain 
fragment). Its efficacy was demonstrated in two mouse models of colitis (Vandenbroucke et 
al., 2010). In another study, different binding TNFα-binding molecule was applied. TNFα-
binding affibody was expressed and immobilized on the surface of engineered L. lactis 
(Ravnikar et al., 2010).  
As noted earlier, besides IL-10, transforming growth factor beta (TGFβ) has often been 
described as an anti-inflammatory cytokine in CD. Commensal gut Gram-negative 
bacterium Bact. ovatus was engineered to express TGFβ1 under the control of xylan. Xylan is 
a dietary fiber which is important for the safety of this system. Results of the study have 
shown significant improvement of acute colitis in mice (Hamady et al., 2010).  
Initial studies of the concept of recombinant probiotic bacteria have shown promising 
results, but were mostly obtained in the animal studies of the treatment of ulcerative colitis. 
Further research will show whether recombinant probiotics have the capacity to be 
considered as an alternative in the treatment of CD.  
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Prebiotics were first defined by Gibson and Roberfroid as “nondigestible food ingredients 
that beneficially affect the host by selectively stimulating the growth and/or activity of one 
or a limited number of bacteria in the colon and thus improve host health” (Gibson & 
Roberfroid, 1995). An updated definition of probiotics was later suggested as follows: “A 
prebiotic is a selectively fermented ingredient that allows specific changes, both in the 
composition and/or activity of the gastrointestinal microflora, that confers benefits upon 
host wellbeing and health” (Gibson et al., 2004). In the past, many food ingredients were 
classified as potential prebiotics. However, in sensu stricto, the following criteria have to be 
fulfilled for a substance to be classified as prebiotic (Gibson et al., 2004):  
 resistance to gastric acidity, to hydrolysis by mammalian enzymes and to 
gastrointestinal absorption; 
 fermentability by intestinal microflora; 
 selective stimulation of the growth and/or activity of intestinal bacteria associated with 
health and wellbeing. 
These criteria are fulfilled by only three food ingredients that were marked as prebiotics: 
fructo-oligosaccharides (inulin and oligofructose), transgalacto-oligosaccharides and 
lactulose. All three prebiotics are carbohydrates; however, according to the definition, non-
carbohydrates can also be classified as prebiotics. According to other authors, even the 
prebiotic status of lactulose can be opposed, because the first criterion for prebiotic 
classification is not totally fulfilled (Roberfroid, 2007). Nevertheless, lactulose prebiotic 
status is substantiated by a lot of data from human studies. Other carbohydrates that are 
good candidates for prebiotics are isomalto-oligosaccharides, lactosucrose, xylo-
oligosaccharides, soybean oligosaccharides and gluco-oligosaccharides (Gibson et al., 2004; 
Roberfroid, 2007). These are already considered as probiotics by some authors.  
Fructo-oligosaccharides, which are represented by inulin and oligofructose, occur in nature 
in different plants, such as chicory, leek, onion, garlic, and asparagus (Leenen & Dieleman, 
2007). In 2006, results of a small study on clinical, immunological and microbiological effects 
of fructo-oligosaccharides in patients with active CD were published (Lindsay et al., 2006). 
In this study, 10 patients with active ileocolonic CD were treated with 15 g of fructo-
oligosaccharides per day for 21 days. The results of the study showed that prebiotics 
oligofructose and inulin have beneficial effects on the activity of CD. This was demonstrated 
by increased intestinal bifidobacterial content and by enhanced expression of IL-10 and 
TLRs in dendritic cells. The authors suggested further investigation of immunological and 
microbiological effects of these prebiotics, and a larger randomized double-blind placebo-
controlled trial was indeed published in 2011. 103 patients with active CD were enrolled. 
They received 15 g of fructo-oligosaccharides or placebo per day in a period of 4 weeks 
(Benjamin et al., 2011). No significant differences in faecal bifidobacteria concentration 
between the placebo and prebiotic groups after 28 day of prebiotic treatment could be 
observed and no clinical benefits could be recorded. The results of the pilot study therefore 
could not be reproduced in the larger setting.  
The use of prebiotics is usually focused on stimulation of the growth or activity of 
bifidobacteria and lactobacilli because of their well known beneficial health effects. For that 
reason, probiotics and prebiotics are often used together in the treatment of active CD and 
other gastrointestinal disorders. The product that contains both probiotics and prebiotics is 
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multicenter, randomized, double-blind, placebo-controlled study to prevent postoperative 
recurrence of CD (Chermesh et al., 2007). Synbiotic 2000 is composed of 4 probiotics (1010 
Pediacoccus pentoseceus, 1010 Lb. raffinolactis, 1010 Lb. paracasei subsp. paracasei 19, and 1010 Lb. 
plantarum 2362) and 4 prebiotics (2.5 g β-glucans, 2.5 g inulin, 2.5 g pectin and 2.5 g resistant 
starch). The clinical trial involved 30 patients with CD who were treated, after surgery, 
either with Synbiotic 2000 or with placebo once a day for up to 24 months. Only 9 patients 
completed the study, 7 from Synbiotic 2000 group and 2 from placebo group. No difference 
between the two groups in clinical, laboratory and endoscopic results could be confirmed 
and it was concluded that Synbiotic 2000 is not effective in preventing postsurgical 
recurrence of CD (Chermesh et al., 2007). Because of relatively small group of patients 
involved in this clinical trial more research was suggested, involving a larger setup and 
different synbiotic mixtures.  
Another synbiotic therapy was reported in a clinical trial with 35 patients with active CD 
(Steed et al., 2010). The synbiotic product in this instance contained 2x1011 CFU of probiotic 
bacterium B. longum and 6 g of prebiotic Synergy 1, which is the commercial name for 
oligofructose-enriched inulin. Patients had received synbiotic or placebo twice a day for six 
months. Treatment with synbiotic improved clinical symptoms and histological score in 
treated patients with active CD. A significant reduction of TNFα expression in patient 
treated with synbiotic was observed after three months, however after six months, the 
reduction was no longer significant. A beneficial effect of synbiotic could also be observed in 
the significant increase of the level of bifidobacteria in treated patients.   
4. Antibiotics 
The use of antibiotics in the primary treatment of CD is again based on the theory of 
involvement of bacteria in the pathogenesis of the disease (Lal & Steinhart, 2006). CD could 
be caused by an aggressive immune response to antigens in the gut of genetically 
susceptible individuals (Prantera, 2009). Antibiotics in CD have been used for the 
nonspecific reduction of intestinal bacterial load. In clinical trials, several antibiotics were 
used for the treatment of CD (Prantera, 2009): 
 antibiotics with antimycobacterial activity (clofazimin, clarithromycin, rifabutin) 
 metronidazole (active against anaerobic bacteria) 
 ciprofloxacin (active against E. coli)  
 rifaximin.  
Antibiotics have shown some effectiveness in the treatment of CD, mostly in reducing post-
operative recurrence of CD. Their benefits however have to be balanced by the side effects 
they cause (Doherty et al., 2010).  
4.1 Antimycobacterial therapy 
The earlier described single pathogen hypothesis suggests M. avium subsp. paratuberculosis 
as a causative agent for CD. For that reason, antibiotics against mycobacteria have been 
tested in the treatment of CD. In 2007, a prospective, parallel, placebo-controlled, double-
blind, randomized clinical trial in patients with active CD was reported. The authors used 
the combination of clarithromycin, rifabutin, and clofazimine for two years (Selby et al., 
2007). They concluded that this combination of antibiotics against M. paratuberculosis 
showed no benefits in the treatment of CD. This could serve as another piece of evidence 
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against the single pathogen hypothesis with M. avium subsp. paratubercolosis. Nevertheless, 
further studies should be performed to confirm or disprove these findings. 
4.2 Metronidazole and ciprofloxacin 
Metronidazole and ciprofloxacin are the most popular antimicrobial drugs used in the 
treatment of CD. They exert antimicrobial activity against Gram negative and Gram positive 
bacteria (Dharmani & Chadee, 2008). Metronidazole is a nitromidazole antibiotic, and 
ciprofloxacin belongs to a group of fluoroquinolone antibiotics. Both antibiotics, alone or in 
combination, were used in several clinical trials for active CD treatment. Antibiotics have 
been effective in preventing the remission of CD; however their benefits have to be balanced 
by the side effects they cause.  One of the reports describes the use of a combination of 
metronidazole and ciprofloxacin therapy in patients with active ileal or colonic CD. The 
therapy was well tolerated and showed beneficial effects with symptomatic improvement in 
patients with active CD, especially in the colon (Greenbloom et al., 1998). Only five of 72 
patients required withdrawal of the therapy because of side effects. The authors speculated 
that only metronidazole is to be held responsible for side effects (e. g. neuropathy, nausea 
and anorexia), as those have already been reported in previous studies on metronidazole 
treatment of CD (Greenbloom et al., 1998; Prantera et al., 1996). 
4.3 Rifaximin 
Rifaximin is a rifamycin-based antibiotic with a broad spectrum of antimicrobial activity. 
This covers Gram positive and Gram negative bacteria, and includes both aerobic and 
anaerobic bacteria. Rifaximin is poorly absorbed from the gastrointestinal tract and therefore 
has less systemic effects. It has an excellent safety profile, minimal drug interaction, and 
negligible impact on the intestinal microbiome. For those reasons, it has a great potential in 
the treatment of gastrointestinal diseases, including active CD. Rifaximin is approved in 
more than 30 countries for a variety of gastrointestinal disorders, including the treatment of 
traveler’s diarrhea, caused by noninvasive diarreagenic E. coli (Koo & DuPont, 2010).  
In recent years, several studies have reported rifaximin effectiveness in the treatment of CD. 
In 2006, a multicenter, double blind, randomized, placebo-controlled study was reported. 
Rifaximin gastroresistant granules (800 mg once a day or 800 mg twice a day) were given 
orally to 83 patients with mildly to moderately active CD for 12 weeks (Prantera et al., 2006). 
Rifaximin gastroresistant granules were designed specifically for CD treatment. They were 
coated with a co-polymer, which was designed to by-pass the stomach and dissolve in the 
duodenum-jejunum, thereby concentrating the active rifaximin in the small intestine. In the 
study, the clinical remission was achieved in 52% of the group who received rifaximin twice 
a day, in 32% of the group who received rifaximin once a day, and in 33% of the group who 
received a placebo dose twice a day. In comparison to the placebo group, the rifaximin 
group was superior in inducing clinical remission of mildly to moderately active CD, 
although the difference was not statistically significant. Nevertheless, the results were 
encouraging and a larger randomized placebo-controlled study is justified.  
In 2008, Shafran and Burgunder reported the treatment of five patients with newly 
diagnosed mild CD with 400 mg rifaximin dose twice daily for 3 months. This was the 
patients’ first therapy without prior biologic or immunomodulatory treatment. The therapy 
was successful in 3 patients and substantial endoscopic and clinical improvements were 
observed. The authors suggested that rifaximin therapy could be an effective first-line 
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against the single pathogen hypothesis with M. avium subsp. paratubercolosis. Nevertheless, 
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study, the clinical remission was achieved in 52% of the group who received rifaximin twice 
a day, in 32% of the group who received rifaximin once a day, and in 33% of the group who 
received a placebo dose twice a day. In comparison to the placebo group, the rifaximin 
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In 2008, Shafran and Burgunder reported the treatment of five patients with newly 
diagnosed mild CD with 400 mg rifaximin dose twice daily for 3 months. This was the 
patients’ first therapy without prior biologic or immunomodulatory treatment. The therapy 
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The same authors performed a retrospective analysis of 68 patients with CD, who were 
treated with rifaximin between 2001 and 2005. Patients had CD localized to the small or 
large intestine, and 56% of patients had previously undergone surgery. Most of the patients 
were treated with rifaximin dose 600 mg/day. Almost half of them were also receiving 
steroids, and some of them were also treated with anti-inflammatory agents, biologics (e.g. 
infliximab), antidiarrheal agents, and immunomodulators. The retrospective analysis 
showed that clinical remission was achieved in 65% of the patients with CD. Interestingly, 
this percentage was a little higher in patients who were not treated with steroids. Among 
the patients who received only rifaximin therapy, 67% achieved remission. These findings 
again substantiate the use of rifaximin alone for the induction of remission in CD (Shafran & 
Burgunder, 2010). 
Several studies on the efficacy of rifaximin in CD have shown that it has a good potential in 
CD therapy, either as a first or second line treatment. Nevertheless, further research of 
rifaximin efficacy in patients with CD is required. Among other things, its precise 
mechanism of action in CD should be clarified. 
4.4 Antibiotics in the prevention of post-operative CD 
Antibiotics are most frequently applied for the prevention of post-operative recurrence of 
CD (Doherty et al., 2009; Doherty et al., 2010; Lal & Steinhart, 2006). Rutgeerts and co-
workers published two double-blind randomized studies of the efficacy of nitroimidazole 
antibiotics in the prevention of postoperative CD (Rutgeerts et al., 2005; Rutgeerts et al., 
1995). In the first study, one week after resection surgery, 30 patients started to receive 
antibiotic metronidazole at a dose of 20 mg/kg body weight once a day for a period of three 
months (Rutgeerts et al., 1995). Another 30 patients received placebo. Nine patients did not 
finish the study, two in the placebo group and seven in metronidazole group. The reasons 
for the latter patients were gastrointestinal intolerance, acute paranoia, polyneuropathy, 
suture leak, and the lack of compliance. After the end of the therapy, patients were observed 
every 6 month for the period of three years. After a 3 month therapy, 21 of 28 (75%) patients 
in the placebo group had recurrent lesion in neoterminal ileum, while this only happened to 
12 of 23 (52%) patients in the metronidazole group. Metronidazole significantly reduced 
endoscopic recurrence, which was observed in 3 of 23 (13%) patients in metronidazole 
group and in 12 of 28 (43%) patients in the placebo group. Statistically significant reduction 
of clinical recurrence was observed only after one year. The reduction was no longer 
significant two and three years after surgery, but the benefit of metronidazole treatment was 
still present. This study showed that metronidazole was effective in preventing early severe 
recurrence of CD. However, several side effects occurred in the metronidazole group, 
including gastrointestinal intolerance, metallic taste, leucopenia, paraesthesias of the limbs, 
abnormal liver function, polyneuropathy, and psychosis. Because of high rates of adverse 
effects with metronidazole, a second study for the prevention of postoperative CD was 
performed with antibiotic ornidazole (Rutgeerts et al., 2005). Ornidazole is also a 
nitroimidazole antibiotic, but supposedly causes fewer side effects than metronidazole. 80 
patients after ileocolonic resection were included. Half of the patients received 500 mg of 
ornidazole twice daily and half received a placebo for 12 months. After the end of the 
treatment, clinical recurrence manifested in 3 of 38 (7.8%) patients in the ornidazol group 
and in 15 of 40 (37.5%) patients in the placebo group. Additionally, the results of clinical 
recurrence were measured two and three years after surgery. After two years, 11 of 37 
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(29.7%) patients had clinical recurrence in the ornidazol group, and 18 of 40 (45%) patients 
in placebo group. After 3 years, 17 of 37 (45.9%) patients had clinical recurrence in the 
ornidazol group and 19 of 40 (45.5%) patients in the placebo group. Similar to metronidazol, 
ornidazol has shown efficacy in preventing postoperative clinical recurrence of CD, but has 
also caused numerous side effects. To alleviate these, the authors suggested the use of a 
smaller dose (500 mg/day) of ornidazol in postoperative therapy of CD. 
When antibiotics are used for preventing postoperative recurrence of CD, they are often 
combined with other therapies for CD, including immunomodulators, probiotics, steroids, 
and others. The studies of combinations of antibiotics with probiotics were presented in the 
Chapter 2.2. The combination of antibiotic metronidazole and immunomodulator 
azathioprine was studied in a placebo-controlled randomized trial to prevent postoperative 
recurrence of CD (D'Haens et al., 2008). It was performed on 81 CD patients after curative 
ileal or ileocolonic resection. The first group of 40 patients received 500 mg metronidazole 
three times per day and 100-150 mg azathioprine once per day for a period of three months. 
The second group of 41 patients received metronidazole without azathioprine. After three 
months, the metronidazole treatment was discontinued, but the study continued for another 
nine months with azathioprine treatment only (the first group received azathioprine and the 
second group placebo). 32 patients from the first group and 29 patients from the placebo 
group reached the end of the study. Endoscopic recurrence was measured three and twelve 
months after the beginning of the study. After 3 months, significant endoscopic recurrence 
occurred in 12 of 35 (34.3%) patients in the first group, and in 20 of 38 (52.6%) patients in the 
placebo group. After twelve months, significant endoscopic recurrence occurred in 14 of 32 
(43.7%) patients in the first group and in 20 of 29 (69%) patients in the placebo group. Also 
after twelve months, inflammatory lesions were not observed in seven patients in the first 
group and only in one patient in the placebo group. There was no clinical recurrence in 
patients after three months of surgery. Twelve months after surgery, 10 clinical recurrences 
were observed, three in the first group and seven in the placebo group. Some adverse effects 
occurred in both groups, but overall the treatment was well tolerated. It can be concluded 
that the combination of antibiotic with immunomodulator is superior to antibiotic alone in 
preventing postoperative recurrence of CD. Because of the shorter period of antibiotic 
treatment, the number of side effects in patients was lower than in previous studies. 
Nevertheless, further studies on larger number of patients are needed to support this 
approach.  
5. Conclusion 
Human intestinal bacteria are an important factor in human health, as well as in the 
pathogenesis of intestinal disorders, including CD. However, none of the proposed 
mechanisms of action can alone sufficiently explain the disease occurrence. Bacterial 
components are undoubtedly involved in the activation of abnormal autoimmune responses 
which further trigger the disease symptoms. The whole picture is however more complex 
with more active bacterial involvement.  
Probiotics are an obvious choice for influencing the intestinal microbiome. Probiotics have 
shown some promising initial results in the treatment of CD. However, in general, they 
were not found to be superior to placebo in increasing the time of remission of CD or 
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preserve hope for probiotics in the treatment of CD. Yeast S. boulardii was shown to be more 
effective than melsalazine in maintaining remission of CD (Guslandi et al., 2000) and 
improving intestinal permeability in CD patients (Van Gossum et al., 2007). Probiotic 
mixture VSL#3 was successful in the treatment of CD-induced arthralgia (Karimi et al., 
2005) and in the prevention of postoperative recurrence of CD (Madsen et al., 2008). These 
studies offer support for the commonly asserted claim that further trials are justified. 
There are several reasons that could explain the failure of other clinical trials and speak in 
favor of probiotics. The overall number of clinical trials is low, as well as the number of 
participants. Trials were designed in different ways, had different goals and measured 
different outcomes. Despite the abundance of bacteria with attributed probiotic properties, 
just a few were used in clinical trials. Additionally, there were differences in doses and 
regimens. Future trials should broaden the spectrum of probiotic bacteria in the treatment. 
Probiotics are not alike and exert effects by different mechanisms. The growing number of 
probiotic bacteria, however, clearly prevents systematic testing of all of them. To overcome 
this difficulty two strategies can be foreseen.  
The first includes testing of larger combinations of bacterial strains. Individual bacteria in 
the mixture would have different effects and could well act synergistically. This view can be 
supported by the success of probiotic mixture VSL#3 relative to individual bacteria Lb. 
rhamnosus GG and Lb. johnsonii LA1. The ultimate example of that approach would be a fecal 
transplant from healthy donors to patients. This has been successfully applied in the 
treatment of C. difficile infection. It was also shown that the changes in the composition of a 
recipient’s intestinal flora were long-lasting. Recipients’ intestinal flora resembled the 
composition of the donor’s flora even after 24 weeks (Grehan et al., 2010). This approach is 
not without risks, as transfer of potential pathogens is difficult to exclude.  
The second approach would necessitate better understanding of the disease etiology and 
modes of action of various bacteria. This would require the use of better animal models of 
CD. The majority of the studies in mice were performed on models of intestinal 
inflammation which resemble that of ulcerative colitis, with inflammatory changes limited 
to the colon. Inflammation was achieved with chemicals or genetic knock-out, which only 
weakly reflect the origin and course of CD in humans. Two mouse models of CD have been 
described, TNF ΔARE and SAMP1/YitFc (Pizarro et al., 2003). They should be applied in the 
search of a single probiotic strain with the desired properties. 
Recombinant probiotics have reasonable potential for the treatment of CD in the future. 
They combine the safety of probiotics with a defined mechanism of action. However, 
solution of the remaining safety concerns and further human clinical trials will be needed 
before they can be recommended. 
Antibiotics constitute the most straightforward approach for interfering with the intestinal 
microbiome by lowering the bacterial content in a mostly unspecific fashion. The approach 
has shown clinical efficacy, but at a price of quite severe adverse effects. Rifaximin could 
assume greater importance in the future since it is a poorly absorbed, broad-spectrum 
antibiotic with fewer side effects. 
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1. Introduction 
Crohn’s disease (CD) is a chronic disorder of the gastrointestinal tract, which was 
characterized by a relapsing–remitting course with trans-mural inflammation of potentially 
any section of the digestive tract, leading to various intestinal and extra-intestinal 
manifestations. Although the etiology is currently unknown, inflammation, immunity, 
genetic and environmental factors have been suggested to predispose to CD.  
The precise etiology of CD is not yet elucidated but the mucosal system is the central 
effector of intestinal inflammation and injury (Fig 1). The dysregulated mucosal immunity 
of the bowel is contributed by varied factors among which cytokines play a central role in 
modulating inflammation. Others are gut associated lymphoid tissues (GALT), pathogen 
recognition receptors (PRRS), professional antigen presenting cells (APCs), epithelial cells of 
gut and resident microflora, etc.  
1.1 Cytokines 
There are two types of cytokines: anti-inflammatory cytokines (IL-10, IL-11, etc) and 
proinflammatory cytokines (IL-1, IL-2, IFNγ, TNFα, IL-12, IL-18, etc). The anti-inflammatory 
cytokines have some beneficial effects in CD. IL-10 is produced by Th2 cells and suppresses 
the production of IL-2 and IFNγ by Th1 cells. Evidences showed that IL-10 and IL-11 might 
be therapeutic agents in CD. IL-10 knockout mice develop severe transmural and 
granulomatous inflammation of the small and large bowel, reminiscent of CD, and the 
inflammation can be prevented by the administration of IL-10. IL-11 is derived from 
mesenchymal cells. Studies showed that IL-11 could attenuate the inflammatory response 
and enhance the integrity of the intestinal mucosa. Among the proinflammatory cytokines, 
TNFα is the most important and widely investigated factor. TNFα is secreted into intestinal 
mucosa by macrophages and monocytes and is bound to T lymphocytes and monocytes. Its 
biological activity is mediated by cell surface TNFα receptors binding to either membrane-
bound or soluble TNFα. TNFα may increase adhesion molecules, allowing for increased cell 
infiltration and enhanced metalloproteinase and collagenase production, which help form 
ulcers and fistulas. It can also mediate recruitment of leukocytes from blood vessels into 
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intraepithelial lymphocyte proliferation and migration. Multiple antibodies to TNFα have 
proven effective in both induction and maintenance of remission for CD. TNFα appears to 
be a determinant in granuloma formation, and, together with IL-6, IL-1 may contribute to 
the constitutional symptoms of IBD and lead to the generation of acute-phase proteins. 
 
 
Fig. 1. Intestinal mucosal (immune) homeostasis in healthy state (Dharmani P, 2008) 
Mucosal homeostasis is maintained by professional APCs (DC) that differentiate pathogens 
from commensals through TLRs and leads to balanced differentiation of naive T cells into 
effector T cells (Th1, Th2 and Th17) against pathogens and Treg and Th3 cells to control the 
inflammation in absence of pathogens. Epithelial cells lining, tight junction proteins and 
mucus layer remains intact separating luminal antigen from immune cells. 
1.2 PPRs 
The recognition, processing and presentation of the luminal antigen is carried out by both 
dedicated APCs such as dendritic cells (DCs) and macrophages, and non-professional APCs 
such as epithelial cells. Two PRRs namely Toll-like receptor (TLR) and Nucleotide binding 
Oligomerization Domans (NOD) proteins are involved in luminal antigen recognition. TLRs 
are membrane bound receptors while NOD proteins are expressed in the cytosols of APCs. 
PPRs recognize molecules shared by pathogens but distinguishable from commensal 
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microbes. Such unique microbial components are collectively referred to as pathogen-
associated molecular patterns (PAMP), which include CpG regions of methylated DNA, 
viral specific ssRNA and dsRNA, peptidoglycans, muramyl dipeptide (MDP) and lipo-
polysaccharides. Both animal and in vitro studies have shown and exaggerated TLR 
expression (especially TLR4), that leads to an incorrect immune response (Th1 or Th17 
mediated) against resident microflora. NOD2/CARD15 gene is famous as it is the first 
predisposing gene of CD. Mutations of the NOD2/CARD15 gene have conclusively 
associated with CD. Both gain and loss of expression of NOD2 gene contributes in 
disturbing mucosal homeostasis. Loss of NOD2 expression cause change in TLR signaling 
pathway and thus leads to an increase in Th1 cytokine and defensins. In contrast, gain of 
expression eventually leads to more Th1 response against the MDP component of microbes. 
1.3 T cell polarisation 
T helper cells have been classified as either Th1 or Th2 on the basis of function and 
according to their ability to elaborate specific cytokines. Th1 cells orchestrate cell-mediated 
immune responses and are characterized by their ability to secrete IL-2, IFNγ and TNFβ. 
IFNγ activates APCs and macrophages to produce IL-12, thereby driving Th1 cells to 
produce even larger amounts of Th1 cytokines. In contrast, Th2 cells mediate humoral 
responses and secrete IL-4, IL-5, IL-6, IL-10 and IL-13. These subsets regulate each other 
reciprocally through key cytokines. IFNγ, produced by Th1 cells, suppresses the 
development of Th2, whereas IL-4, IL-10 and IL-13, secreted by Th2 cells, inhibit Th1 
responses (Fig 2).CD is thought to be associated with Th1 cell cytokines and inhibition of 
Th1 responses could represent a significant goal in the treatment of CD. Intestinal Th1 
activation and cytokine release are associated with the generation of activated matrix 
metalloproteinases (MMPs), which are essential mediators of tissue destruction.  
 
 
Fig. 2. T-helper (Th)-1 and Th2-mediated cytokine profiles and immune response. IL = 
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2. Common categories of biological therapy 
Traditionally, the therapeutic goals in CD include ⅰinduction of a rapid response, ⅱ 
maintenance of glucocorticoid-free remission, ⅲ minimization of complications and 
surgery, ⅳ prevention of disease-related mortality, ⅴ improvement in patients’ quality of 
life, ⅵ minimization of the adverse effects of treatment, and ⅶ the so-called ‘deep 
remission’ (i.e. simultaneous clinical, biological and endoscopic remission). Both mucosal 
healing and deep remission need to be evaluated for their prediction of long-term outcome 
and benefit/risk ratio if treatment escalation becomes necessary. 
Existing CD therapies are an amalgamation of pharmacological agents including 5-
aminosalicylate compounds, corticosteroids, and immunosuppressors (azathioprines, 6-
mercaptopurine, methotrexate, tacrolimus and cyclosporine). Novel biological therapies 
have been developed in recent years based on better understanding of specific 
immunopathological processes in intestinal inflammation. There are several categories of 
biologic therapies that are relevant to CD: 1) antibody-based therapy (monoclonal 
antibodies, receptor fusion proteins, and soluble receptor antagonists), 2) recombinant 
cytokines, 3) nucleic acid-based therapies, 4) hormones and growth factors, 5) cell and gene 
therapy. At present, the biotechnology therapies that are being used in clinical practice or 
investigated for the treatment of CD are predominantly proteins, usually delivered 
intravenously or subcutaneously. The types of therapeutic proteins in used include 
recombinant human proteins with immunoregulatory effects, monoclonal antibodies 
(chimeric, humanized and fully human) and fusions proteins. Here we chose to focus on 
therapies that have been used in clinical trials in CD, some of which have been already or 
may be in the near future approved for commercial daily use (table 1). 
 
Therapy Target Origin Efficacy Side effects 





Safe, being used in 
treatment 
Risk of malignancy and infection, 
infusion site reactions 
Adalimumab Human IgG1 mab 
Safe, being used in 
treatment 
Risk of malignancy and infection, 
infusion site reactions 





Still in clinical trial Local reaction 




Itching, pain, swelling and redness 
at the site of injection 
CDP-870 PEGylated anti-TNFα ab Under clinical trial No reported major side effects 




Not fully established 
Anti-IL-6 R 
ab IL-6 R Human mab Under clinical trial Not fully established 
Anti-IL-12 
p40 ab IL-12 Human mab Safe and effective Possible reactivation of asthma 
Fontolizumab IFNγ Human mab Under phase IIclinical trial Not fully established 
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Supplementation of regulatory cytokines 
Tenovil IL-10 Recombinant cytokine 
Failed to show 
efficacy in phase II 
clinical trial 





Effective in clinical 
study Not fully established 
IL-11 IL-11 Recombinant cytokine 
No efficacy in 
phase II clinical 
trials 
Not fully established 
Inhibition of proliferation of T cells 
Visilizumab CD3 Human ab Under clinical trial Not fully established 
Daclizumab αchain of IL-2R Human mab 
Failed to show 
efficacy in phase II 
clinical trial 
Hypersensitivity 
Basiliximab α chain of IL-2R Human mab Under clinical trail
Mild dizziness, nausea, rashes on 
skin 
Blocking molecule involved in leukocyte adhesion 
Natalizumab Integrin-α4 Human mab Approved by FDA
Sometimes causes fatal brain 
infection (progressive multifocal 
leukoencephalopathy) 
MLN-02 α4β7integrin Human mab Under clinical trial Infusion reaction 





Under clinical trial Not intense severe adverse reactions 





Under phase III 
clinical trials Not fully established 















Helminthes Under clinical trials Not fully established 













Toxic effects of high dose 
chemotherapy and post HCT 
infections 
R: receptor; ab: antibody; mab: monoclonal antibody; ICAM-1: intracellular adhesion molecule-1 
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3. Evaluations of biological treatment 
3.1 Anti-TNFα therapies 
Anti-TNFα mAb is the first agent that was approved for patients with persisting signs and 
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anti-TNFα reagents have been developed and used to inhibit TNFα in patients with CD, 
including the mouse/human chimeric monoclonal antibody (infliximab), the humanized 
monoclonal antibody CDP571 and D2E7 (adalimumab), the human soluble TNFα p55 
receptor (onercept), the p75 soluble TNFα receptor fusion protein (etanercept), and the 
polyethylene glycol (PEG)ylated anti-TNFα antibody fragment CDP-870 (certolizumab 
pegol). Peyrin B L and his colleagues performed a meta-analysis including 21 trials to 
evaluate safety and efficacy of tumor necrosis factor (TNF) antagonists for Crohn's disease 
(Peyrin-Biroulet L, 2008). They concluded that infliximab, adalimumab, and certolizumab 
are effective in luminal Crohn's disease. Efficacy of anti-TNF agents other than infliximab in 
treating fistulizing Crohn's disease requires additional investigations. Longer duration of 
following-up and larger number of patients are required to better assess the safety profile of 
TNF antagonists in CD. We also conducted a meta-analysis about anti-TNFα reagents 
treating CD. As a result, Fifteen RCTs articles with high quality were selected. Compared 
with placebo, anti-TNF-α agents achieved significantly higher rates of clinical response 
(44.9% vs. 30.0%, RR=1.39, 95% CI: 1.16~1.67, P=0.0004) and clinical remission (29.3% vs. 
18.7%, RR=1.63, 95% CI: 1.26~2.09, P=0.0001). We concluded that Anti-TNF-α agents are 
superior to placebo in the treatment of CD and have similar risks of adverse events and 
serious adverse events. Long-term trials with large samples are needed for the assessment of 
its safety and tolerance. Table 2 lists the administrations of some of these agents. 
3.1.1 Infliximab 
Infliximab is the only biologic agent approved in the China, US and Europe for the 
treatment of patients with moderate to severe CD unresponsive to conventional therapy or a 
full and adequate course of corticosteroids and immunosuppressive therapy, and for 
patients with actively draining fistulas. 
The first randomized placebo-controlled trial of infliximab focused on response rates 4 
weeks after a single-blind infusion (Targan SR, 1997). All patients presented moderate to 
severely active disease despite other treatments or had previously been unresponsive to 
treatment with immunomodulators. A single infusion yielded a decrease in the CDAI of ≥70 
points 4 weeks after infusion in 65% of the patients treated with infliximab, compared with a 
17% response in the placebo group. The highest response rate was observed in patients 
receiving infliximab 5mg/kg (81%), with lower response rates in those treated with 10 or 20 
mg/kg (50% and 64%, respectively). 
Rutgeerts et al conducted a study to find out whether repeated infusions of infliximab could 
maintain the response (Rutgeerts P, 1999). Seventy-three patients were randomized to 
receive infliximab or placebo 10 mg/kg every 8 weeks for 36 weeks and were followed up 
until week 48. At week 44, 52.9% patients received infliximab achieved maintenance of 
remission, compared with 20% of placebo-treated patients. Quality of life was consistently 
better (using a inflammatory bowel disease questionnaire) and serum concentrations were 
maintained at remission levels. 
The results were confirmed in the recent multicenter, randomized, placebo-controled, 
double-blind phase III clinical trial: the ACCENT I (A Crohn’s disease Clinical trial 
Evaluating infliximab in a New long-term Treatment regimen) study (Hanaeur SB, 2002). 
Five hundred and seventy three patients with active CD received infliximab 5mg/kg at 
week 0 and were assessed of response at week 2. The responders were then randomized into 
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3 groups. Group I received placebo at week 2 and 6 and then every 8 weeks until week 46. 
Group II received 5mg/kg infliximab at the same time points. Group III received 5mg/kg 
infliximab at week 2 and 6, but followed by 10mg/kg every 8 weeks until week 46. The 
endpoints were the proportion of patients who responded at week 2 and were in remission 
(CDAI<150) at week 30, and the time to loss of response up to week 54 in patients who 
responded. At week 2, 335 patients (58%) responded to infliximab. At week 30, 23 of 110 
(21%) patients in group I were in remission, compared with 44 of 113 (39%) in group II 
(P=0.003) and 50 of 112 (45%) in group III (P=0.0002). The study suggested that patients that 
were repeatedly administrated with infliximab every 8 weeks are more likely acquiring 
sustained clinical remission than those with single infusion. The safety was consistent with 
those in other clinical trials and serious infections were similar across the three groups. 
 
 Infliximab Adalimumab Certolizumab pegol 
Dosage 5 mg kg-1 40 mg 400 mg 
Route of 
administration i.v. s.c. s.c. 
Dosing intervals 8 weeks 2 weeks (e.o.w) 4 weeks 
Induction 5 mg kg
-1 weeks 0, 
2, 6 
168/80 mg (FDA) 
or 80/40 mg 
(EMA) 
400 mg weeks 0, 2, 4 
Dose escalation 10 mg kg
-1 or every 
4-6 weeks 40 mg e.w. 400 mg e. o. w. 
i.v., intra venous; s.c., subcutaneous; e.w., every week; e.o.w., every other week; EMA, European 
Medicines Agency; FDA, Food and Drug Administration 
Table 2. Administrationof biologicalagents in inflammatory bowel disease (Nielsen, 2011) 
A study was conducted early in 1999 by Present DH, et al to investigate whether infliximab 
had the efficacy in healing enterocutaneous fistulas. In their study, 94 adult CD patients 
with fistulas were randomly assigned to receive placebo, 5mg/kg inflximab or 10mg/kg 
inflximab at weeks 0, 2 and 6. As a result, 55% patients assigned to receive 5mg/kg 
infliximab and 38% patients assigned to receive 10mg/kg infliximab had closure of all 
fistulas, as compared with 13% of the patients assigned to placebo. Adverse events were 
similar for the 5mg/kg infliximab group and the placebo group, but there was a trend 
toward more adverse events in the 10mg/kg group. 
The multicenter, randomized, placebo-controlled ACCENT II trial further confirmed the 
efficacy of infliximab as maintenance therapy for fistulas in CD (Sands BE, 2002). After 14-
week lead-in period, 195 of 282 (69%) patients responded. The responders were then 
randomized to receive either 5mg/kg infliximab or placebo every 8 weeks. Forty-eight 
percent of the infliximab group maintained fistula response at week 30 compared with 27% 
of the placebo group. At week 54, 36% of the infliximab group had a complete absence of 
draining fistulas compared with 19% of the placebo group.  
Infliximab is also efficacy for patients who are intolerant of, resistant to or dependent on 
steroids. On study showed that of the first 100 patients administered infliximab, 29 of 40 (73%) 
were able to completely withdraw from steroids (Ricart E, 2001). At study entry in the 
ACCENT I, more than half of the patients were taking corticosteroids; one third of the patients 
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percent of the infliximab group maintained fistula response at week 30 compared with 27% 
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draining fistulas compared with 19% of the placebo group.  
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were able to completely withdraw from steroids (Ricart E, 2001). At study entry in the 
ACCENT I, more than half of the patients were taking corticosteroids; one third of the patients 





There is also evidences that infliximab likely has a role in treating some extraintestinal 
manifestations, such as ankylosing spondylitism peripheral arthritis, pyoderma 
gangrenosum and erythema nodosum. CD patients are at increased risk of low bone mineral 
density (BMD), with reports of prevalence of osteopenia and osteoporosis as high as 50% 
and 10%, respectively. Infliximab may improve BMD in CD patients. A prospective study 
was conducted by Abreu et al to evaluate the effect of infliximab on surrogate markers of 
bone turnover in 38 CD patients. The data obtained demonstrated that bone synthesis 
markers were increased in the infliximab-treated patients (Abreu MT, 2006). Longer-term 
studies are needed to clarify the effect of infliximab on BMD. 
Although efficacy of infliximab for the treatment of CD has clearly been demonstrated, 
serious side effects have been reported. In particular, these include acute infusion reactions, 
delayed hypersensitivity reactions, infections including reactivation of tuberculosis (TB), 
autoantibody formation, and a Lupus-like syndrome. Acute infusion reactions are adverse 
events that occur during infusion or within 2 hours after completion of the infusion. 
According to the manufacturer’s drug insert, 22% of patients administered infliximab 
occurred compared with 9% of patients administered placebo (Lichtenstein GR, 2011). 
Delayed-hypersensitivity reactions can occur several days after infusion. Symptoms include 
severe pruritus, headaches, hand, facial or lip swelling, myalgias, rash, sore throat, and 
dysphagia. In the ACCENT Ⅰ study, the frequency of delayed hypersensitivity reaction was 
2%. Infections have been observed with pathogens, including viral, bacterial, fungal, and 
protozoal organisms. The majority of infections involved the respiratory and urinary tracts. 
Reactivation of latent TB after infusion with infliximab has occurred, mandating screening 
of patients for TB prior to infusion. A purified protein derivative (PPD) should be 
administered to all patients being considered for treatment with infliximab, with the results 
interpreted according to the risk atrata adapted from the American Thoracic Society (ATS), 
patients with a positive PPD should undergo a chest radiograph. Lymphoma has been 
reported in association with all 3 approved TNFα antagonists. A meta-analysis performed 
by Siegel et al suggested that the risk of lymphoma was increased in patients receiving 
infliximab for CD.  
Since infliximab contains exogenous proteins, it can prompt the formation of antibodies-to-
infliximab (ATIs) and thus may lead to the infusion reaction or loss of response. In ACCENT 
I trial, 64/442 (14.5%) developed antibodies. Patients administered a single dose of 
infliximab had higher incidence of ATI formation than those administered scheduled 
maintenance regiments of 5 or 10 mg/kg (28% vs 9% and 6%, respectively). The clinical 
response rates were similar in the patients regardless of their ATI status. The infusion 
reactions were more common in the ATI-positive patients compared with the ATI-negative 
group (16% vs 8%). The majority of the infusion reactions were mild to moderate.  
3.1.2 Adalimumab 
Adalimumab (first named D2E7) is a subcutaneously administered, recombinant, fully 
human, IgG1 monoclonal antibody that binds with high affinity and specificity to human 
TNFα, thus modulating its biologic functions by blocking the interaction with p55 and p75 
cell surface TNF receptors. It is available in a number of countries, including the US and EU 
countries.  
In CD, adalimumab has received both FDA and EMEA approval with the following 
indications: 1) for reducing the signs and symptoms and inducing and maintaining clinical 
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remission in adults with moderately to severely active CD who have had an inadequate 
response to conventional therapy, and 2) for reducing the signs and symptoms and inducing 
clinical remission in these patients if they have also lost response or are intolerant to IFX. 
Therefore, adalimumab is the second biologic therapy approved for the treatment of 
patients with moderately to severely active CD. Adalimumab is administered by 
subcutaneous injection, as commercially available prefilled pen (HUMIRA Pen) containing 
0.8 mL (40 mg) of drug. 
The recommended adalimumab induction dose regimen for adult patients with moderate-
severe CD is usually 80 mg at week 0 followed by 40 mg at week 2. In case there is a need 
for a more rapid response to therapy, the regimen with 160 mg at week 0 (dose can be 
administered as 4 injections in one day or as 2 injections per day for 2 consecutive days) and 
80 mg at week 2 can be used with the awareness that the risk for adverse events is higher 
during induction. After induction treatment, the recommended dose is 40 mg every other 
week via subcutaneous injection as maintenance treatment. For induction treatment, 
adalimumab should be given in combination with corticosteroids. Adalimumab can be 
given as monotherapy in case of intolerance to corticosteroids or when continued treatment 
with corticosteroids is inappropriate (Cassinotti A, 2008). 
In a phase III, placebo-controlled, dose-ranging induction trial named CLASSIC I (CLinical 
Assessment of adalimumab Safety and efficacy Studied as Induction therapy in Crohn’s 
disease), 299 patients with moderate to severe CD, naive to anti-TNF therapy were 
randomized to 4 groups. Patients in group I received adalimumab 40mg at week 0 and 20mg 
at week 2; patients in group II received adalimumab 80mg at week 0 and 40mg at week 2; 
patients in group III received adalimumab 160mg at week 0 and 80mg at week 2; patients in 
group IV received placebo at the same points. All the patients were followed through week 
4. A response was defined as a CDAI score reduction of ≥70 points (70-point response) or of 
≥100 points (100-point response) from week 0, while remission was defined as a CDAI score 
<150. At week 4, patients in group II and group III showed a significantly greater remission 
rate (24% and 36%) than patients in group IV (12%) (P=0.004 among the 3 groups). There 
was a linear dose response across the 3 adalimumab treatment groups at week 4 for the 
endpoints of remission and 100-point response, with only the highest dose group 
demonstrating statistical significance in the pairwise comparisons with placebo: 36% vs 12% 
for remission (p = 0.001) and 50% vs 25% (p = 0.002) for the 100-point response; the 70-point 
response was also significantly higher in the adalimumab recipients than placebo, both for 
the 160/80 mg dosage (59% vs 37%; p = 0.007) and for the 80/40 mg group (59% vs 37%; p = 
0.01). The reduction of CDAI from baseline was evident as early as week 1. Only 11% 
(32/299) of the randomized patients had draining enterocutaneous or perianal fistulas at 
baseline and were unevenly distributed across the treatment groups. The rates of fistula 
improvement and remission for the ADA-treated patients and those receiving placebo were 
not significantly different, but the number of these patients precluded a powered analysis 
(Hanauer SB, 2006).  
A total of 276 patients who completed the 4-week CLASSIC-I trial entered a long-term 
extension study named CLASSIC-II (Sandborn WJ, 2007). This was a randomized, placebo-
controlled, maintenance follow-up trial, demonstrating that adalimumab 40 mg every other 
week or weekly was superior to placebo in maintaining remission for 1 year in patients with 
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Eligible patients (belonging to the pool of CLASSIC-I enrolled patients) were treated with 
adalimumab 40 mg at week 0 (corresponding to week 4 of CLASSIC-I) and week 2. Those in 
remission at both week 0 and week 4 (n = 55) were randomized to receive adalimumab 40 
mg every other week (n = 19), adalimumab 40 mg weekly (n = 18), or placebo (n = 18), 
through 56 weeks. 
At week 56, remission was maintained in 79%, 83%, and 44% of patients in the respective 
groups (primary endpoint), with a statistically significant difference between each 
adalimumab group and placebo (p< 0.05). The 100-point response at week 56 was also better 
in adalimumab recipients (79% vs 89% vs 56%, respectively), as was the 70-point response 
rates (79% vs 89% vs 72%), although differences between groups were not statistically 
significant. 
3.1.3 CDP571 
CDP571 was a humanised monoclonal antibody to human TNF-α. It was constructed by 
linking the complementarity determining regions (CDR) of a murine antihuman TNF 
monoclonal antibody to a human IgG4 antibody. A total number of 396 patients with 
moderate to severe CD were included in a randomized, double blind and placebo controlled 
trial in 2004. The patients were received intravenous 10mg/kg CDP571 or placebo every 8 
weeks to week 24 and were followed up to week 28. Clinical response was defined as a 
decrease in the CDAI to ≥ 100 points or remission (CDAI score ≤ 150 points) at week 28. 
Initial clinical response occurred in 90/263 (34.2%) CDP571 patients and 28/32 (21.2%) 
placebo patients (P=0.011). At week 28, 80/263 (30.4%) CDP571 patients and 31/132 (23.5%) 
placebo patients achieved clinical response (P=0.102). Adverse events were similar in both 
groups. A post hoc analysis of a subgroup of patients with CRP concentrations ≥ 10mg/L 
demonstrated significantly increased response rates for CDP571 10mg/kg at both week 2 
and 28 (Sandborn WJ, 2004). Two controlled trials failed to demonstrate a steroid-sparing 
benefit of CDP571 in patients with steroid-dependent CD. Further clinical development of 
CDP571 for the treatment of CD has been discontinued. 
3.1.4 Certolizumab pegol 
Certolizumab pegol (CDP870) is a humanized TNFα Fab monoclonal antibody fragment 
linked to polyethylene glycol that is administered subcutaneously. A phase Ⅲ, randomized, 
double-blind, multicenter study that assessed the efficacy and tolerability of certolizumab in 
patients with moderate to severe CD showed a modest improvement in response rates, as 
compared with placebo but no significant improvement in remission rates (Sandborn WJ, 
2007). In addition, patients who had a response to induction therapy with certolizumab 
were more likely to have maintained response and remission at 26 weeks with continued 
treatment compared with a switch to placebo. 
3.2 Other novel biological therapies 
3.2.1 Natalizumab 
Natalizumab is a recombinant humanized monoclonal antibody IgG4, with a molecular 
weight of 149 kDa. It contains 95% human peptide sequences and only 5% mouse sequences 
in the complementary determining regions. It inhibits both α4β7-integrin/MAdCAM-1 
interaction and α4β1/VCAM-1 binding. 
ENACT-1 (Efficacy of Natalizumab as Active Crohn’s Therapy) is a randomized double-
blind, placebo-controlled Phase III trial (Sandborn WJ, 2005), in which 905 patients were 
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randomly assigned in a 4:1 ratio to receive an intravenous infusion of 300mg natalizumab or 
placebo at week 0, 4 and 8. The patients were then followed until week 12. The primary end 
point was the proportion of patients who had a clinical response (ΔCDAI score ≥70 points). 
No difference in the response remission (CDAI < 150) rates was seen between the 
natalizumab group and the placebo group (P=0.051 and P=0.12, respectively). A significant 
difference of CRP was present in the subgroup of 660 patients who had a baseline CRP level 
more than 2.87 mg/l compared with the placebo group. 
The patients who responded in the ENACT-1 trial were randomly reassigned in a 1:1 ration 
to receive either natalizumab 300mg intravenously every 4 weeks or placebo and were 
followed up to 36 weeks (ENACT-2) (Sandborn WJ, 2004). At week 36, 61% of natalizumab 
patients had a sustained response compared with 28% in the placebo group (P<0.001). The 
remission rates was also significantly higher in the natalizumab group (44%) than in the 
placebo group (26%) at week 36 (P=0.003). Forty five percent of patients in the natalizumab 
group were no longer taking corticosteroids and remained in remission at week 36 
compared with 22% of patients in the placebo group (P=0.003).  
Natalizumab should not be given with immunomodulators (e.g.6-mercaptopurine, 
azathioprine, cyclosporine or methotrexate) or inhibitors of TNF-a. Corticosteroids should 
be tapered.  
Natalizumab is not approved in Europe for the treatment of CD. It is available in the USA 
under a special restricted distribution program called CD-TOUCH (Tysabri® outreach 
unified commitment for health). Under this program, prescribers, pharmacies, infusion 
centers and patients are made aware of risks of opportunistic infections, including PML. 
Patients are evaluated 3 months after the first infusion, 6 months after the first infusion and 
every 6 months thereafter. Any serious opportunistic or atypical infections are reported 
(Bickston SJ, 2010). 
3.2.2 Fontolizumab 
Fontolizumab is a humanized IgG1 antibody with high binding affinity and specificity for 
IFNγ By inhibiting the binding of IFNγ to its cellular receptor, fontolizumab prevents 
downstream physiologic effects, such as expression of major histocompatibility complex 
class II molecules. 
In a Phase Ⅱ, randomized, double-blind, placebo-controlled study, 201 patients with CDAI 
scores between 250 and 450 were randomized to receive an initial intravenous dose of 1.0 or 
4.0 mg/kg fotolizumab or placebo, and then were received 0.1 or 1.0 mg/kg fontolizumab 
or placebo every 4 weeks. The primary endpoint of efficacy evaluations was the proportion 
of patients who achieved a clinical response (defined as a decrease in the CDAI of ≥100 
points from baseline levels without an accompanying increase in dose of concomitant 
medications for CD) by day 29. Secondary endpoints were clinical response rates on days 43, 
57, 85, 113, and at the 3-month follow-up visit. The response rates were similar in all 
treatment groups (31%–38%) at day 29. At subsequent timepoints a significantly greater 
proportion of patients in the 1.0 mg/kg intravenous / 1.0 mg/kg subcutaneous 
fontolizumab group had clinical response and significantly greater improvement in the 
CDAI score compared with patients who received placebo. The CRP levels were 
significantly improved in the fontolizumab groups. The overall frequency of adverse events 
was similar in all groups (58%–75%) (Reinisch W, 2010). Further clinical studies with 
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3.2.3 Anti-IL-12 P40 antibody  
IL-12 is a heterodimeric molecule composed of IL-12 p40 and IL-12 p35 subunits. The p40 
subunit is also a component of IL-23, in which p40 forms a heterodimer with a p19 subunit. 
IL12/23 is a key cytokine in the Th1/Th17 development and is abundantly produced in the 
gut of CD patients. IL-12 p40 is, therefore, a pivotal target for the treatment of CD.  
A double-blind, placebo controlled randomized study of a humanized IgG1 monoclonal 
antibody against IL-12 p40 (ABT-874) was performed in 79 patients with active CD (Mannon 
PJ, 2004). The patients were randomized to receive seven weekly injections of 1 or 3 mg/kg 
anti-IL-12 or placebo subcutaneously either with or without 4 wk intervals between the first 
two injections. The patients who received 3 mg/kg anti-IL-12 for 7 wk showed a 
significantly greater clinical response rate than the patients treated with a placebo (75% vs 
25%). The production Th1 proinflammatory cytokines from patient’s colonic lamina propria 
mononuclear cells dramatically decreased after the anti IL-12 therapy. The most frequent 
adverse event was a local reaction at the injection site, which was observed with a greater 
rate in the anti IL-12 treated group than in the placebo-treated group. No serious side effects 
were observed during the anti-12 therapy. Anti IL-12 therapy is therefore considered to be a 
safe and effective treatment for active CD. 
4. Conclusion 
There are multiple biological therapies based on different targets in addition to those we 
introduced above. More clinical studies for the efficacy and safety should be conducted. 
Overall, the biological treatments differ from conventional CD therapy in several aspects: 
They are usually peptides or proteins; are administered parenterally; target specific 
molecules, cells, or processes; and their manufacture is more sophisticated and more 
expensive than the conventional drugs. The development of biological therapies is based on 
better understanding of mucosal intestinal processes in homeostasis and uncontrolled 
inflammation and is possible due to great biotechnological progress such as genetic 
engineering and development of novel vehicles. 
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1. Introduction 
Crohn’s disease is a chronic and idiopathic inflammation that can affect any part of the 
gastrointestinal tract and the terminal ileum is the most frequently involved site; moreover, 
the first peak of the disease is between 20 and 30 years of age. Surgery plays a very 
important role in its management: the lifetime risk of surgery is about 70% – 90% [1], for its 
complications or failure of medical treatment and the reoperation rate is approximately 40% 
- 50% within 10-15 years after the first operation [2]. 
Laparoscopic colorectal surgery began in the early 90’s; nowadays the equipment 
development, the surgeons experience and the results of clinical trials lead to affirm the 
feasibility and safety of laparoscopic surgery, which should be considered as the first line 
surgical approach in selected patients. In fact, a less surgical trauma should lead to a better 
preservation of immune response, better cosmetic result, less post-operative pain and faster 
return of bowel functionality with faster hospital discharge [3].  
2. Primary small bowel Crohn’s disease 
Several studies, including four randomized trials [4-7] and three meta-analyses [8-10], 
demonstrated the benefits of laparoscopic approach in the surgical path of small bowel 
Crohn’s disease, regarding short-term outcomes like post-operative pain and analgesics use, 
complication rates, return to normal bowel habitus, hospital stay and cosmesis. For these 
reasons, laparoscopic procedure in primary Crohn’s disease is nowadays worldwide 
considered the first choice surgical treatment. 
Many studies showed laparoscopy is less painful than open surgery and requires less 
analgesics consumption [11-15].  
The reduction of post-operative pain leads to a faster mobilization of patients and to an 
improvement of pulmonary function [17]: these are very important factors to obtain lower 
rates of general complications [18] and a smoother recovery. 
Benefits of laparoscopic surgery could include lower morbidity, a significantly faster 
resumption of bowel function and a shorter hospital stay  [4,6,19-23]. It is well known that the 
use of opiate analgesics negatively affects recovery of gastrointestinal function [24]: 
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1. Introduction 
Crohn’s disease is a chronic and idiopathic inflammation that can affect any part of the 
gastrointestinal tract and the terminal ileum is the most frequently involved site; moreover, 
the first peak of the disease is between 20 and 30 years of age. Surgery plays a very 
important role in its management: the lifetime risk of surgery is about 70% – 90% [1], for its 
complications or failure of medical treatment and the reoperation rate is approximately 40% 
- 50% within 10-15 years after the first operation [2]. 
Laparoscopic colorectal surgery began in the early 90’s; nowadays the equipment 
development, the surgeons experience and the results of clinical trials lead to affirm the 
feasibility and safety of laparoscopic surgery, which should be considered as the first line 
surgical approach in selected patients. In fact, a less surgical trauma should lead to a better 
preservation of immune response, better cosmetic result, less post-operative pain and faster 
return of bowel functionality with faster hospital discharge [3].  
2. Primary small bowel Crohn’s disease 
Several studies, including four randomized trials [4-7] and three meta-analyses [8-10], 
demonstrated the benefits of laparoscopic approach in the surgical path of small bowel 
Crohn’s disease, regarding short-term outcomes like post-operative pain and analgesics use, 
complication rates, return to normal bowel habitus, hospital stay and cosmesis. For these 
reasons, laparoscopic procedure in primary Crohn’s disease is nowadays worldwide 
considered the first choice surgical treatment. 
Many studies showed laparoscopy is less painful than open surgery and requires less 
analgesics consumption [11-15].  
The reduction of post-operative pain leads to a faster mobilization of patients and to an 
improvement of pulmonary function [17]: these are very important factors to obtain lower 
rates of general complications [18] and a smoother recovery. 
Benefits of laparoscopic surgery could include lower morbidity, a significantly faster 
resumption of bowel function and a shorter hospital stay  [4,6,19-23]. It is well known that the 
use of opiate analgesics negatively affects recovery of gastrointestinal function [24]: 





a reduction of post-operative pain, morphine supply and to a quick resolution of paralytic 
ileus and discharge from hospital, respectively. 
Furthermore, laparoscopic surgery improves cosmesis and might induce less adhesions [25]: 
this is very important, because patients are generally young and the reoperations are 
common. 
It has been demonstrated that the introduction of a fast-track perioperative care program, 
also referred to as enhanced recovery after surgery (ERAS) [26, 27], may reduce hospital stay 
to 2-3 days after open colorectal surgery [28, 29], even if high readmission rates are reported [28, 
30]. Only few studies have evaluated the role of laparoscopic approach combined to fast-
track protocols in enhancing recovery after colorectal surgery, obtaining conflicting results: 
Basse et al. [31] found no difference between fast-track patients undergone to laparoscopic or 
open resection, while King et al. [32] found a significant reduction of the hospital stay in fast-
track patients after laparoscopic surgery. The only randomized, multicentric clinical trial 
(LAFA-study) [33] investigating both surgical techniques (laparoscopic and open) combined 
with fast-track and standard care demonstrated that the best option is laparoscopic resection 
embedded in a fast-track care; nevertheless, this study focused on colon cancer, so these 
results have not yet been validated in patients with inflammatory bowel disease.  
The mean conversion rate reported in the current literature is 11,2% and it ranges from 4,8% 
to 29,2% [8] . 
As already reported in some studies [6, 34,35] , the duration of laparoscopic ileocolic resection’s 
laparoscopic surgery can be very similar to open surgery after completion of the learning 
curve by the surgical team. 
It has been demonstrated the safety of laparoscopic ileocolectomy also in the long-term 
outcomes; Eshuis and colleagues [36] showed no differences with open surgery regarding 
reoperations for disease recurrence and non-disease related complications. 
3. Recurrent small bowel Crohn’s disease 
While for primary laparoscopic ileocolectomy there are many clinical trials demonstrating 
short and long-term benefits, in the current literature there are only a few studies 
investigating the feasibility and safety of laparoscopic resection for recurrent disease [37-41]  , 
often considering small sample size.  Recently Chaudhray and colleagues [42] reported one of 
the largest series of patients who underwent laparoscopic ileocolonic resection for recurrent 
Crohn’s disease, demonstrating the same benefits observed after primary resection without 
increased complication rates or delayed discharge. Although longer operating time, 
conversion rate was similar to that reported after primary resection.  
In conclusion, more contributions with larger sample size are needed to go deeper into this 
topic, but laparoscopic approach in recurrent Crohn’s disease should not be avoided in 
principle, because despite high technical difficulty in expert hands can be feasible, safe and 
lead to significant advantages in the postoperative time.  
4. Crohn’s colitis 
Terminal ileitis is the most frequent presentation of Crohn’s disease and more rarely, in 
about 30% of cases, patients have a disease affecting the colon with or without rectal 
involvement. 
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While for small bowel Crohn’s disease laparoscopic technique has been worldwide adopted 
and its benefits well established, in the present literature only a few studies investigated the 
role of laparoscopy in the surgical treatment of Crohn’s colitis.  
The largest series of laparoscopic colectomies for Crohn’s disease has been recently reported 
by Holubar and colleagues [43] from the Mayo Clinic: 92 patients underwent mini-invasive 
colectomies with short postoperative length of stay and low morbidity, confirming previous 
results obtained by other Authors [44,45] . Umanskiy and coworkers [45] also demonstrated 
reduced operative times: this result can be attributed to the high experience reached by the 
surgeons, but also to a selection bias of the patients due to non-randomized inclusion 
criteria of the laparoscopic group. 
Ultimately, laparoscopic approach is feasible and safe in patients with Crohn’s colitis and 
can improve surgical outcome when performed by experienced hands in selected cases; 
however, these findings must be supported by more contributions and are not yet validated 
by randomized-controlled trials. 
5. Gastroduodenal Crohn’s disease 
It is a rare conditions that affect up to 4% of patients with Crohn’disease; it can be an 
asyntomatic endoscopic finding or a clinical-radiological disease where obstruction is the 
most frequent presentation. Medical therapy with PPI and steroids or immunosuppressive 
agents is the current management but sometimes surgery is necessary because of its failure; 
gastrojejunal bypass and stricturoplasty are the validated surgical options. Because this type 
of disease and surgical procedures are very uncommon there is lack of experience in the 
current literature regarding laparoscopic approach in the surgical treatment of 
gastroduodenal Crohn’s disease; in 2008, Shapiro and coworkers from The Mount Sinai 
Medical Center [46] published the first experience of 13 laparoscopic gastrojejunal bypass, 
reporting less morbidity rates and shorter length of stay than after open surgery. 
To date, probably due to the rarity of the disease and limited number of operations, no more 
clinical trials supported these findings and no certain conclusions about benefits of 
laparoscopic procedures in gastroduodenal Crohn’s disease can be drawn.  
6. New technical aspects 
Single-incision laparoscopic surgery 
Single-incision laparoscopic surgery was born in the beginning of the Nineties when the first 
appendectomy and cholecystectomy were performed with the aim of minimizing the 
surgical incisions and morbidity rates, improving cosmesis and short term outcomes respect 
to standard laparoscopic procedures. However, this technique developed slowly and only in 
the last years it has been kept in attention by the surgeons and started to be applied to the 
main operations of general, urologic and gynaecologic surgery. Recently has been published 
the initial experience of single-incision laparoscopic segmental colectomy and ileocolic 
resection for Crohn’s disease [47,48], with longer operative time but similar morbidity rates 
and length of stay compared to laparoscopic assisted procedures. Single-incision 
laparoscopic colectomy seems to be feasible and safe when performed by experts 
laparoscopic surgeons after completion of an additional learning curve, and must be 





a reduction of post-operative pain, morphine supply and to a quick resolution of paralytic 
ileus and discharge from hospital, respectively. 
Furthermore, laparoscopic surgery improves cosmesis and might induce less adhesions [25]: 
this is very important, because patients are generally young and the reoperations are 
common. 
It has been demonstrated that the introduction of a fast-track perioperative care program, 
also referred to as enhanced recovery after surgery (ERAS) [26, 27], may reduce hospital stay 
to 2-3 days after open colorectal surgery [28, 29], even if high readmission rates are reported [28, 
30]. Only few studies have evaluated the role of laparoscopic approach combined to fast-
track protocols in enhancing recovery after colorectal surgery, obtaining conflicting results: 
Basse et al. [31] found no difference between fast-track patients undergone to laparoscopic or 
open resection, while King et al. [32] found a significant reduction of the hospital stay in fast-
track patients after laparoscopic surgery. The only randomized, multicentric clinical trial 
(LAFA-study) [33] investigating both surgical techniques (laparoscopic and open) combined 
with fast-track and standard care demonstrated that the best option is laparoscopic resection 
embedded in a fast-track care; nevertheless, this study focused on colon cancer, so these 
results have not yet been validated in patients with inflammatory bowel disease.  
The mean conversion rate reported in the current literature is 11,2% and it ranges from 4,8% 
to 29,2% [8] . 
As already reported in some studies [6, 34,35] , the duration of laparoscopic ileocolic resection’s 
laparoscopic surgery can be very similar to open surgery after completion of the learning 
curve by the surgical team. 
It has been demonstrated the safety of laparoscopic ileocolectomy also in the long-term 
outcomes; Eshuis and colleagues [36] showed no differences with open surgery regarding 
reoperations for disease recurrence and non-disease related complications. 
3. Recurrent small bowel Crohn’s disease 
While for primary laparoscopic ileocolectomy there are many clinical trials demonstrating 
short and long-term benefits, in the current literature there are only a few studies 
investigating the feasibility and safety of laparoscopic resection for recurrent disease [37-41]  , 
often considering small sample size.  Recently Chaudhray and colleagues [42] reported one of 
the largest series of patients who underwent laparoscopic ileocolonic resection for recurrent 
Crohn’s disease, demonstrating the same benefits observed after primary resection without 
increased complication rates or delayed discharge. Although longer operating time, 
conversion rate was similar to that reported after primary resection.  
In conclusion, more contributions with larger sample size are needed to go deeper into this 
topic, but laparoscopic approach in recurrent Crohn’s disease should not be avoided in 
principle, because despite high technical difficulty in expert hands can be feasible, safe and 
lead to significant advantages in the postoperative time.  
4. Crohn’s colitis 
Terminal ileitis is the most frequent presentation of Crohn’s disease and more rarely, in 
about 30% of cases, patients have a disease affecting the colon with or without rectal 
involvement. 
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While for small bowel Crohn’s disease laparoscopic technique has been worldwide adopted 
and its benefits well established, in the present literature only a few studies investigated the 
role of laparoscopy in the surgical treatment of Crohn’s colitis.  
The largest series of laparoscopic colectomies for Crohn’s disease has been recently reported 
by Holubar and colleagues [43] from the Mayo Clinic: 92 patients underwent mini-invasive 
colectomies with short postoperative length of stay and low morbidity, confirming previous 
results obtained by other Authors [44,45] . Umanskiy and coworkers [45] also demonstrated 
reduced operative times: this result can be attributed to the high experience reached by the 
surgeons, but also to a selection bias of the patients due to non-randomized inclusion 
criteria of the laparoscopic group. 
Ultimately, laparoscopic approach is feasible and safe in patients with Crohn’s colitis and 
can improve surgical outcome when performed by experienced hands in selected cases; 
however, these findings must be supported by more contributions and are not yet validated 
by randomized-controlled trials. 
5. Gastroduodenal Crohn’s disease 
It is a rare conditions that affect up to 4% of patients with Crohn’disease; it can be an 
asyntomatic endoscopic finding or a clinical-radiological disease where obstruction is the 
most frequent presentation. Medical therapy with PPI and steroids or immunosuppressive 
agents is the current management but sometimes surgery is necessary because of its failure; 
gastrojejunal bypass and stricturoplasty are the validated surgical options. Because this type 
of disease and surgical procedures are very uncommon there is lack of experience in the 
current literature regarding laparoscopic approach in the surgical treatment of 
gastroduodenal Crohn’s disease; in 2008, Shapiro and coworkers from The Mount Sinai 
Medical Center [46] published the first experience of 13 laparoscopic gastrojejunal bypass, 
reporting less morbidity rates and shorter length of stay than after open surgery. 
To date, probably due to the rarity of the disease and limited number of operations, no more 
clinical trials supported these findings and no certain conclusions about benefits of 
laparoscopic procedures in gastroduodenal Crohn’s disease can be drawn.  
6. New technical aspects 
Single-incision laparoscopic surgery 
Single-incision laparoscopic surgery was born in the beginning of the Nineties when the first 
appendectomy and cholecystectomy were performed with the aim of minimizing the 
surgical incisions and morbidity rates, improving cosmesis and short term outcomes respect 
to standard laparoscopic procedures. However, this technique developed slowly and only in 
the last years it has been kept in attention by the surgeons and started to be applied to the 
main operations of general, urologic and gynaecologic surgery. Recently has been published 
the initial experience of single-incision laparoscopic segmental colectomy and ileocolic 
resection for Crohn’s disease [47,48], with longer operative time but similar morbidity rates 
and length of stay compared to laparoscopic assisted procedures. Single-incision 
laparoscopic colectomy seems to be feasible and safe when performed by experts 
laparoscopic surgeons after completion of an additional learning curve, and must be 





Laparoscopic resection with transcolonic specimen extraction 
Eshuis and colleagues [49] reported a series of ten patients affected by Crohn’s disease who 
underwent to entirely laparoscopic ileocolic resection with endoscopic transcolonic 
specimen removal. The procedure was possible only for small inflammatory mass (<7-8 cm) 
and needed longer operative time; infectious complications were high with 2 
intraabdominal abscesses and patients did not perceived benefits in terms of body image 
respect to conventional laparoscopic surgery. Thus, based on these findings, benefits of 
laparoscopic resection followed by endoscopic transcolonic specimen extraction are unclear 
and the technique doesn’t seem as safe as conventional laparoscopic surgery. 
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1. Introduction 
Crohn’s disease (CD) is one of two forms of inflammatory bowel diseases (IBD), the other 
being ulcerative colitis (UC).  CD is in fact itself a heterogeneous condition describing a 
group of closely related disease processes that result from an uncontrolled immune 
mediated inflammatory response primarily affecting the alimentary tract. CD may affect any 
part of the gastrointestinal tract and causes transmural intestinal inflammation. It is 
characterized by flares and remission. CD usually presents with diarrhea, abdominal pain 
and/or weight loss. Fever, blood in stool, oral ulcers, and/or perianal lesions may also 
occur. Most patients with CD end up requiring surgery. 
In some cases of colitis, the distinction between CD and UC cannot be clearly made despite a 
detailed evaluation based on a thorough clinical exam, endoscopy, imaging and a biopsy. 
The term “Indeterminate colitis” is used for these cases. Based on the increasing recognition 
of the so-called “indeterminate colitis” and the considerable heterogeneity even within the 
two discrete IBD subtypes, efforts calling for a revisit of IBD classification are under way.  In 
2000, the Working Party for the World Congresses of Gastroenterology, which had met in 
Vienna in1998, published their report in the journal Inflammatory Bowel Diseases and 
proposed the Vienna classification. The Vienna classification attempted to  classify CD based 
on objective variables that included age of onset, disease location, and disease behavior. The 
Vienna classification classifies CD into 24 disease clusters. Since then however, the Vienna 
classification has come under criticism due to its lack of clinical applicability, however it is 
still being used for research purposes. In 2005 Silverberg and colleagues presented the 
report of the Working Party of the Montreal World Congress of Gastroenterology in which 
they put forth the Montreal classification of IBD. Montreal classification classified CD 
largely based on variables chosen by the experts at Vienna except for adding a perianal 
disease modifier variable. Neither Vienna nor Montreal classification commented on the 
extra intestinal manifestations of  CD though.  Extra-intestinal manifestations of CD may 
include rheumatologic, dermatologic, ocular or hepatobiliary conditions. These have been 
identified in the Crohn’s Disease Activity Index (CDAI) initially introduced as far back as 
1979. 
It is estimated that approximately 750, 000 people in the United States have CD. There is a 
lot of variation in data with regard to the incidence and prevalence of CD in the US. For 
example, incidence in the US of CD is estimated at 1 to 6 per 100, 000 . The prevalence of CD 
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1. Introduction 
Crohn’s disease (CD) is one of two forms of inflammatory bowel diseases (IBD), the other 
being ulcerative colitis (UC).  CD is in fact itself a heterogeneous condition describing a 
group of closely related disease processes that result from an uncontrolled immune 
mediated inflammatory response primarily affecting the alimentary tract. CD may affect any 
part of the gastrointestinal tract and causes transmural intestinal inflammation. It is 
characterized by flares and remission. CD usually presents with diarrhea, abdominal pain 
and/or weight loss. Fever, blood in stool, oral ulcers, and/or perianal lesions may also 
occur. Most patients with CD end up requiring surgery. 
In some cases of colitis, the distinction between CD and UC cannot be clearly made despite a 
detailed evaluation based on a thorough clinical exam, endoscopy, imaging and a biopsy. 
The term “Indeterminate colitis” is used for these cases. Based on the increasing recognition 
of the so-called “indeterminate colitis” and the considerable heterogeneity even within the 
two discrete IBD subtypes, efforts calling for a revisit of IBD classification are under way.  In 
2000, the Working Party for the World Congresses of Gastroenterology, which had met in 
Vienna in1998, published their report in the journal Inflammatory Bowel Diseases and 
proposed the Vienna classification. The Vienna classification attempted to  classify CD based 
on objective variables that included age of onset, disease location, and disease behavior. The 
Vienna classification classifies CD into 24 disease clusters. Since then however, the Vienna 
classification has come under criticism due to its lack of clinical applicability, however it is 
still being used for research purposes. In 2005 Silverberg and colleagues presented the 
report of the Working Party of the Montreal World Congress of Gastroenterology in which 
they put forth the Montreal classification of IBD. Montreal classification classified CD 
largely based on variables chosen by the experts at Vienna except for adding a perianal 
disease modifier variable. Neither Vienna nor Montreal classification commented on the 
extra intestinal manifestations of  CD though.  Extra-intestinal manifestations of CD may 
include rheumatologic, dermatologic, ocular or hepatobiliary conditions. These have been 
identified in the Crohn’s Disease Activity Index (CDAI) initially introduced as far back as 
1979. 
It is estimated that approximately 750, 000 people in the United States have CD. There is a 
lot of variation in data with regard to the incidence and prevalence of CD in the US. For 
example, incidence in the US of CD is estimated at 1 to 6 per 100, 000 . The prevalence of CD 
in the US is estimated to be 10-100 per 100,000. There doesn’t seem to be a significant 
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difference in the incidence and prevalence of CD between males and females. The peak age 
of onset for CD is 15-25 years of age. There seems to be another peak between the ages of 45 
and 55. Smoking seems to predispose to CD. 
2. Etiology and pathogenesis 
The most popular theory regarding pathogenesis of CD considers it to be a result of an 
uncontrolled immune mediated inflammatory response to a still unknown trigger that 
occurs in genetically predisposed individuals, primarily affecting the alimentary tract and 
also involving the intestinal flora. 
2.1 Intraluminal factors 
Different triggers have been implicated, both external and auto-antigens. External antigens 
include viruses, bacteria and dietary agents. The most common virus implicated in the 
pathogenesis of CD is the measles virus. The most common external bacterial agent that has 
been implicated in the pathogenesis of CD is Mycobacterium paratuberculosis. An antigen 
on a dietary agent may also trigger an uncontrolled immune mediated inflammatory 
response leading to the development of CD, but no such agent has yet been identified. Auto-
antigens that have been implicated in the pathogenesis of CD may be located on non-
pathogenic bacteria which constitute the intestinal flora. Similarly it is postulated that a 
certain antigenic trigger on a yet unknown luminal agent present in the gastrointestinal tract 
may also trigger an abnormal inflammatory response within the gastrointestinal tract 
leading to intestinal inflammation. 
2.2 Epithelial barrier, innate and acquired immune actors 
Despite the lack of definitive knowledge about the potential triggering agents, it is well 
established that the main mechanism of inflammatory injury is immune mediated and 
that it occurs in genetically predisposed individuals. There are various mechanisms by 
which immune mediated injury takes place. It is a combination of the interaction between 
breakdown in the intestinal epithelial barrier, innate immune system and activation of 
acquired immune mechanisms. An important factor is abnormal or exaggerated immune 
response. HLA Class II molecules that are predominantly found on macrophages are 
considered to be the major mediators of the process of autoimmune injury. They occur in 
high numbers within the intestinal epithelial cells of patients with active CD. The HLA-
Class II molecules are responsible for antigen processing and presentation. HLA-DR 
molecules seem to play the most active role in this regard. Activated macrophages also 
secrete pro-inflammatory cytokines including IL-1, IL-6, IL-8 and TNF-alpha within the 
lamina propria of the intestinal wall. IFN- gamma is also produced and it increases 
intestinal permeability. There is decreased production of IL-2, IL-10, TNF- beta and TGF-
beta, which are down-regulatory cytokines. In patients with IBD,  this may explain 
chronic inflammation. Moreover, direct cell mediated immune mechanisms may also be 
involved in the immune pathogenesis of IBD. It is postulated that B-cell mediated 
mechanisms are also important, as there is increased secretion of IgM and IgG classes of 
antibodies by the intestinal mononuclear cells. Other immune mediators that seem to be 
involved in the pathogenesis of CD include oxygen radicals, most importantly superoxide 
molecules. Oxygen radicals are produced by activated neutrophils and they cause further 
inflammatory injury. Leukotriene Neutrophil Chemotactic Compounds (LNCC) and nitric 
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oxide also enhance the inflammatory process of IBD by causing vasodilatation and 
vascular leakage. It has been demonstrated in animal models that the inflammatory 
process of IBD is enhanced by CD-4+ T helpers. This provides evidence for a dominant 
role of T-cells in the pathogenesis of IBD. Moreover, the effectiveness of TNF-alpha and 
IFN-gamma antibodies in counteracting T-cell mediated inflammatory damage lends 
credence to the belief that both TNF-alpha and IFN-gamma are important mediators of 
the T-cell induced damage in inflammatory bowel diseases. 
2.3 Genetic predisposition 
Up to fifteen percent of patients with CD may have a first degree relative who also suffers 
from IBD. Haplotypes associated with CD are HLA-DR1/DQw5 and HLA-DRB3*0301. IBD1 
susceptibility locus on chromosome 16 is associated with CD. The NOD2 gene located on 
this locus undergoes a mutation leading to abnormality in NOD2 protein, which is an 
intracellular bacterial lipopolysaccharide receptor in monocytes. This mutation is seen in up 
to fifteen percent of patients with CD. The IBD2 susceptibility locus on chromosome 12 is 
also associated with CD. 
3. Management 
3.1 Goals 
The historic goal of treatment of CD was to induce and maintain clinical remission. 
However, it has now become evident that the natural course of disease progression of CD is 
not positively impacted if focus is laid only on clinical remission. Therefore the goal of 
treatment of CD has evolved into a broad stratagem. Current goals of medical management 
of CD include rapid induction and then maintenance of clinical as well as endoscopic 
remission. This seeks to minimize bowel damage. Other goals of management that are now 
actively pursued include decreasing rate of complications, hospitalizations, surgical 
interventions, infections, steroid use, cancer and overall mortality. Moreover, improving 
compliance and health related quality of life (HRQL) also figure prominently among current 
management goals. The goals of CD therapy continue to evolve and eventually will include 
not just minimizing the impact of the disease but perhaps obliterate it altogether. For this 
purpose, research is ongoing in search of additional biological modifiers.  Genetic studies 
are also being undertaken. 
3.2 Approach 
Traditionally, a step up approach was applied that involved starting with corticosteroids 
and evolving to more invasive and newer modalities. Then there was evidence to suggest 
that top-down therapy might be the best way to achieve the evolving goals of therapy. 
However, recently there is more support for the accelerated step-up approach. 
3.3 Supportive therapy 
In regard to diet, there is not a lot of data that suggests a strong link between diet and CD. 
However some diets that have been suggested to possibly be related to onset as well as 
increased disease activity and more severe course include diets consisting of red meats. 
Moreover, diets high in fats and refined carbohydrates also seem to be risk factors for CD 
whereas fruits and vegetables are perhaps protective. Patients are also advised to make a list 
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this locus undergoes a mutation leading to abnormality in NOD2 protein, which is an 
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remission. This seeks to minimize bowel damage. Other goals of management that are now 
actively pursued include decreasing rate of complications, hospitalizations, surgical 
interventions, infections, steroid use, cancer and overall mortality. Moreover, improving 
compliance and health related quality of life (HRQL) also figure prominently among current 
management goals. The goals of CD therapy continue to evolve and eventually will include 
not just minimizing the impact of the disease but perhaps obliterate it altogether. For this 
purpose, research is ongoing in search of additional biological modifiers.  Genetic studies 
are also being undertaken. 
3.2 Approach 
Traditionally, a step up approach was applied that involved starting with corticosteroids 
and evolving to more invasive and newer modalities. Then there was evidence to suggest 
that top-down therapy might be the best way to achieve the evolving goals of therapy. 
However, recently there is more support for the accelerated step-up approach. 
3.3 Supportive therapy 
In regard to diet, there is not a lot of data that suggests a strong link between diet and CD. 
However some diets that have been suggested to possibly be related to onset as well as 
increased disease activity and more severe course include diets consisting of red meats. 
Moreover, diets high in fats and refined carbohydrates also seem to be risk factors for CD 
whereas fruits and vegetables are perhaps protective. Patients are also advised to make a list 
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of others foods that seem to worsen their symptoms and to avoid consuming them. Despite 
a few studies demonstrating benefits of an elemental diet, the risk of malnutrition in 
patients on it has caused decrease in enthusiasm.  
In regard to behavioral management, regular exercise enhances functional capacity of IBD 
patients. Smoking is strongly associated with CD exacerbations. There is observational data 
to suggest that NSAID use may increase CD activity. In patients with CD, behavioral 
counseling and ways to facilitate daily living needs to be ensured.  
3.4 Advances in medical therapy 
Traditional Therapies have included systemic corticosteroids. They were and are still used 
for induction of remission in CD.  While 5-Aminosalicylates like mesalamine have 
traditionally been the primary treatment modality in mild to moderate UC but their 
effectiveness in CD has largely been marginal if any at all. Antibiotics are considered among 
the most effective and safe therapies used to treat patients with mild to moderately active 
CD.  The antibiotics most frequently used are metronidazole and ciprofloxacin. The most 
common traditional immune modulators used to maintain remission in CD  as well as UC 
are azathioprine (AZA) and 6-mercaptopurine (6-MP).The role of methotrexate (MTX) 
appears to be limited to CD.  
Newer Therapies are represented by biological immune modulators. Advances made in 
understanding the pathogenesis of CD have pushed us into the era of biological agents and 
beyond. The most important biological agents being used today are the TNF-alpha blockers. 
However, there is a long list of biologics that work by targeting other areas of the entire 
spectrum of the pathogenesis of CD. 
3.5 TNF blockers 
The first biologic agent that was approved for CD treatment was infliximab (Remicade). 
Infliximab is a half murine half human, chimeric monoclonal antibody consisting of an Fc 
portion as well as a Fab fragment which is active against TNF-alpha.  It is administered 
intravenously, usually every 8 weeks. Infliximab has been found to be effective in inducing 
and maintaining remission in moderate to severe inflammatory as well as fistulizing CD 
disease in several multicenter double-blind, placebo controlled trials. The typical induction 
regimen of infliximab is 5mg/kg intravenously at 0, 2 and 6 weeks followed by 5mg/kg 
intravenous infusion every 8 weeks.Infliximab also reduces the requirements for 
corticosteroids, leads to mucosal healing, and reduces complications such as surgical 
intervention and hospitalization. It has also demonstrated improved quality of life. Initial 
response rates to infliximab may be as high as 75% but is generally maintained in 
approximately one third of patients. 
Adalimumab (Humira) is a monoclonal IgG1 antibody against TNF-alpha which is fully 
humanized and has shown promise in the treatment of CD. Adalimumab is administered 
subcutaneously. Similar to infliximab, adalimumab works as an induction as well as a 
maintenance medication. The Classic I trial revealed that induction with 160 mg of 
adalimumab followed in two weeks by 80 mg of adalimumab  resulted in over 35 percent of 
CD patients achieving remission at 4 weeks follow up.The GAIN (Gauging Response in 
Infliximab Nonresponders) trial was conducted to evaluate response to induction by 
adalimumab of patients which also included those who had either failed to respond to 
infliximab or had developed recurrence of disease after an initial response to infliximab. It 
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was a placebo controlled double-blind trial which revealed that remission rate with 
adalimumab induction was about 21 percent, and not as good as what the Classic I trial had 
revealed. An interesting finding was that those patients who had previously either failed to 
respond to infliximab or had developed disease recurrence actually had decreased remission 
rate in response to adalimumab than the initial response to infliximab induction. The Classic 
II and CHARM trials evaluated the efficacy of maintenance with adalimumab. The CLASSIC 
II trial was a double-blind, placebo-controlled trial and went on for a year. In this trial the 
investigators maintained initial responders on 40mg of adalimumab every week or every 
other week or to placebo. After a year of this trial, 79% of the patients on 40mg every other 
week and 83% of the patients on 40mg of adalimumab every week had achieved remission 
compared to 44% of the placebo group.The CHARM trial studied 854 patients with 
moderate to severe Crohn’s disease. In CHARM, the 80/40 mg induction with adalimumab 
had already taken place. The responders to this induction regimen were then randomized to 
the two maintenance regimens of adalimumab or placebo. These patients were then 
followed for a year. Forty one percent of the patients who received adalimumab every week 
were in remission after about a year, whereas 36 percent of those who were on every other 
week of adalimumab maintenance were in remission. The CLASSIC II and CHARM trials 
also showed that adalimumab could be used as a steroid sparing agent in order to maintain 
remission in patients with CD, as most patients on adalimumab in the CLASSIC II trial were 
off steroids compared to those on placebo. In the CHARM trial, it was seen that the steroid-
free clinical remission rates were significantly higher in those patients who received 
adalimumab versus those who were on placebo. The CHARM trial also revealed a 
statistically significant decrease in hospitalization in patients who were on adalimumab 
versus placebo. Adalimumab also helped heal fistulas in patients with CD. At the end of one 
year, one third of patients who received adalimumab had achieved closure of fistula 
compared to 13 percent of those were treated with placebo. The CHARM trial was extended 
for another one year and the end of the additional year, almost 71 percent of the fistulas had 
healed in patients who received adalimumab.14 
Certolizumab pegol (Cimzia) is a humanized monoclonal agent against TNF-alpha that  is 
comprised of just the Fab fragment and does not contain the Fc moiety.  Certolizumab is 
pegylated by the addition of two polyethylene glycol molecules which increases the half-life 
as well as well its binding affinity to TNF-alpha. Certolizumab pegol is administered once a 
month subcutaneously at 400 mg dose each time. The induction regimen of Cimzia is 400mg 
subcutaneously at week 0, 2 and then 4. So far, two placebo controlled, double blind trials 
have been performed to evaluate certolizumab pegol in CD. PRECISE I (add reference) 
looked at the effectiveness of induction therapy. Even though a benefit was found in 
inducing a response with it compared to patients on placebo, the response was not 
statistically significant. The response to induction was assessed at 2 weeks, 6 weeks and then 
at 26 weeks. It was noted though that the maximum response occurred in patients who had 
CRP level higher than 10mg/dl. Patients with high CRP levels were therefore evaluated 
separately based on a previous post-hoc analysis revealing a greater rate of response in this 
patient population anyway (add reference). The primary endpoints of this study were the 
induction of clinical response at weeks 6 and a response at both weeks 6 and 26.  In this 
study, it was demonstrated that 37% of patients with CRP level higher than 10 mg/l 
experienced response at the end of 6 weeks vs. only 26% in the placebo group. The 
difference in response at weeks 2 and 26 were not statistically significant   
 
Crohn's Disease 192 
of others foods that seem to worsen their symptoms and to avoid consuming them. Despite 
a few studies demonstrating benefits of an elemental diet, the risk of malnutrition in 
patients on it has caused decrease in enthusiasm.  
In regard to behavioral management, regular exercise enhances functional capacity of IBD 
patients. Smoking is strongly associated with CD exacerbations. There is observational data 
to suggest that NSAID use may increase CD activity. In patients with CD, behavioral 
counseling and ways to facilitate daily living needs to be ensured.  
3.4 Advances in medical therapy 
Traditional Therapies have included systemic corticosteroids. They were and are still used 
for induction of remission in CD.  While 5-Aminosalicylates like mesalamine have 
traditionally been the primary treatment modality in mild to moderate UC but their 
effectiveness in CD has largely been marginal if any at all. Antibiotics are considered among 
the most effective and safe therapies used to treat patients with mild to moderately active 
CD.  The antibiotics most frequently used are metronidazole and ciprofloxacin. The most 
common traditional immune modulators used to maintain remission in CD  as well as UC 
are azathioprine (AZA) and 6-mercaptopurine (6-MP).The role of methotrexate (MTX) 
appears to be limited to CD.  
Newer Therapies are represented by biological immune modulators. Advances made in 
understanding the pathogenesis of CD have pushed us into the era of biological agents and 
beyond. The most important biological agents being used today are the TNF-alpha blockers. 
However, there is a long list of biologics that work by targeting other areas of the entire 
spectrum of the pathogenesis of CD. 
3.5 TNF blockers 
The first biologic agent that was approved for CD treatment was infliximab (Remicade). 
Infliximab is a half murine half human, chimeric monoclonal antibody consisting of an Fc 
portion as well as a Fab fragment which is active against TNF-alpha.  It is administered 
intravenously, usually every 8 weeks. Infliximab has been found to be effective in inducing 
and maintaining remission in moderate to severe inflammatory as well as fistulizing CD 
disease in several multicenter double-blind, placebo controlled trials. The typical induction 
regimen of infliximab is 5mg/kg intravenously at 0, 2 and 6 weeks followed by 5mg/kg 
intravenous infusion every 8 weeks.Infliximab also reduces the requirements for 
corticosteroids, leads to mucosal healing, and reduces complications such as surgical 
intervention and hospitalization. It has also demonstrated improved quality of life. Initial 
response rates to infliximab may be as high as 75% but is generally maintained in 
approximately one third of patients. 
Adalimumab (Humira) is a monoclonal IgG1 antibody against TNF-alpha which is fully 
humanized and has shown promise in the treatment of CD. Adalimumab is administered 
subcutaneously. Similar to infliximab, adalimumab works as an induction as well as a 
maintenance medication. The Classic I trial revealed that induction with 160 mg of 
adalimumab followed in two weeks by 80 mg of adalimumab  resulted in over 35 percent of 
CD patients achieving remission at 4 weeks follow up.The GAIN (Gauging Response in 
Infliximab Nonresponders) trial was conducted to evaluate response to induction by 
adalimumab of patients which also included those who had either failed to respond to 
infliximab or had developed recurrence of disease after an initial response to infliximab. It 
 
Advances in Management of Crohn’s Disease 193 
was a placebo controlled double-blind trial which revealed that remission rate with 
adalimumab induction was about 21 percent, and not as good as what the Classic I trial had 
revealed. An interesting finding was that those patients who had previously either failed to 
respond to infliximab or had developed disease recurrence actually had decreased remission 
rate in response to adalimumab than the initial response to infliximab induction. The Classic 
II and CHARM trials evaluated the efficacy of maintenance with adalimumab. The CLASSIC 
II trial was a double-blind, placebo-controlled trial and went on for a year. In this trial the 
investigators maintained initial responders on 40mg of adalimumab every week or every 
other week or to placebo. After a year of this trial, 79% of the patients on 40mg every other 
week and 83% of the patients on 40mg of adalimumab every week had achieved remission 
compared to 44% of the placebo group.The CHARM trial studied 854 patients with 
moderate to severe Crohn’s disease. In CHARM, the 80/40 mg induction with adalimumab 
had already taken place. The responders to this induction regimen were then randomized to 
the two maintenance regimens of adalimumab or placebo. These patients were then 
followed for a year. Forty one percent of the patients who received adalimumab every week 
were in remission after about a year, whereas 36 percent of those who were on every other 
week of adalimumab maintenance were in remission. The CLASSIC II and CHARM trials 
also showed that adalimumab could be used as a steroid sparing agent in order to maintain 
remission in patients with CD, as most patients on adalimumab in the CLASSIC II trial were 
off steroids compared to those on placebo. In the CHARM trial, it was seen that the steroid-
free clinical remission rates were significantly higher in those patients who received 
adalimumab versus those who were on placebo. The CHARM trial also revealed a 
statistically significant decrease in hospitalization in patients who were on adalimumab 
versus placebo. Adalimumab also helped heal fistulas in patients with CD. At the end of one 
year, one third of patients who received adalimumab had achieved closure of fistula 
compared to 13 percent of those were treated with placebo. The CHARM trial was extended 
for another one year and the end of the additional year, almost 71 percent of the fistulas had 
healed in patients who received adalimumab.14 
Certolizumab pegol (Cimzia) is a humanized monoclonal agent against TNF-alpha that  is 
comprised of just the Fab fragment and does not contain the Fc moiety.  Certolizumab is 
pegylated by the addition of two polyethylene glycol molecules which increases the half-life 
as well as well its binding affinity to TNF-alpha. Certolizumab pegol is administered once a 
month subcutaneously at 400 mg dose each time. The induction regimen of Cimzia is 400mg 
subcutaneously at week 0, 2 and then 4. So far, two placebo controlled, double blind trials 
have been performed to evaluate certolizumab pegol in CD. PRECISE I (add reference) 
looked at the effectiveness of induction therapy. Even though a benefit was found in 
inducing a response with it compared to patients on placebo, the response was not 
statistically significant. The response to induction was assessed at 2 weeks, 6 weeks and then 
at 26 weeks. It was noted though that the maximum response occurred in patients who had 
CRP level higher than 10mg/dl. Patients with high CRP levels were therefore evaluated 
separately based on a previous post-hoc analysis revealing a greater rate of response in this 
patient population anyway (add reference). The primary endpoints of this study were the 
induction of clinical response at weeks 6 and a response at both weeks 6 and 26.  In this 
study, it was demonstrated that 37% of patients with CRP level higher than 10 mg/l 
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In the PRECISE 2 trial, researchers randomized week 4 responders to certolizumab pegol 
400mg every 4 weeks to week 26 or placebo. Randomization was again stratified based on 
CRP level. It was demonstrated that 64% of the patients responded to induction therapy. 
This response was maintained in 63% of the intention to treat population up until week 26 
vs. 36% who were receiving placebo).  In terms of clinical remission at week 26, 48% of the 
patients on certolizumab pegol achieved it vs. 29% among the placebo group.   In the end, 
stratification by CRP levels did not appear to yield a significant benefit in any of these 
studies. Moreover, it was noted that the efficacy of certolizumab pegol was not impacted by 
steroid use or the use of infliximab in the past. But once again, those who had received a 
TNF blocker in the past had a lower response rate than those who had never received a 
biologic. The open-label stage of the WELCOME trial was based on CD patients who had 
been unable to tolerate infliximab or who had developed secondary loss of response to it. 
The patients received induction with  certolizumab 400 mg at weeks 0 and 2. The primary 
response defined as a decrease in CDAI of 100 was measured at week 6. It was seen that 55% 
of these patients had responded based on this criterion.  
3.6 Adhesion molecule inhibitors 
Natalizumab (Tysabri) is a monoclonal antibody against the alpha-4 subunit of integrin 
molecules which are important mediators of vascular inflammation. Integrin molecules are 
located on surface of vessels and they play an important role in adhesion and migration of 
inflammatory cells from the vasculature into inflamed tissue. Natalizumab essentially blocks 
integrin association with vascular receptors, limiting adhesion and transmigration of 
leukocytes. Specifically, in CD, natalizumab decreases inflammation by binding to alpha-4 
integrin and thus blocking adhesion and migration of inflammatory leukocytes in the gut. 
Natalizumab has not been studied in patients with UC.  Because of the incidence of PML in 
some cases and in two cases PML leading to death in MS patients who were treated with 
natalizumab, natalizumab was briefly taken off the market. In order to use natalizumab now 
in patients with CD, they must be enrolled in the Crohn’s disease Tysabri® Outreach 
Unified Commitment to Health ( CD-TOUCH™ ).Healthcare providers must also register 
with the program in order to prescribe, dispense or administer natalizumab. Treatment 
must be reauthorized every 6 months. Natalizumab is available only through infusion 
centers registered with the TOUCH™ program. Natalizumab is given in a 300 mg dose 
infused over 1 hour every 4 weeks. It is discontinued if no therapeutic benefit is observed in 
the first 12 weeks. 
Vedolizumab, previously called MLN-0002, MLN-02 or LDP-02, is similar to natalizumab 
but with some important differences. It is a recombinant humanized anti alpha-2 beta-7 
integrin monoclonal antibody, which is undergoing Phase 3 trials to test its efficacy in 
treatment of UC as well as CD. The alpha-2 beta-7 integrin subunit is relatively specific to 
the gastrointestinal tract. The Gemini I, II and III (also called the Millennium Trials) are all 
phase III clinical trials which are being conducted to test efficacy of Vedolizumab in 
inducing and maintaining remission in patient with UC and CD.  
3.7 IL-6 inhibitors 
Toclizumab is a humanized monoclonal antibody directed against the receptor of IL-6. An 
early randomized safety and efficacy trial assessing toclizumab in CD was published in 
2004. The trial had 2 treatment arms and one placebo arm with a total accrual of 36 patients. 
Even though there was a significant difference in serologic and clinical response parameters 
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between those who received toclizumab vs. placebo at assessment of the induction endpoint 
assessment, the highest response rate was two out of 10(20%) patients who received 
toclizumab. No difference was seen in terms of mucosal healing between treatment and 
placebo groups at 12 weeks.. Due to these less than encouraging results in CD, further 
clinical trials evaluating the efficacy of toclizumab in patients with IBD have not conducted 
so far. However, recently, there has been more activity in research assessing efficacy of 
toclizumab in other autoimmune diseases, most importantly rheumatoid arthritis with 
several phase II and phase III clinical trials underway. 
3.8 IFN-γ blockers 
Fontolizumab is a humanized monoclonal antibody fragment that possesses potent 
binding and neutralizing activity against human interferon-γ (IFN-γ). IFN-γ is a 
prominent pro-inflammatory effector cytokines. Two safety and clinical efficacy trials 
assessing the ability of fontolizumab in inducing remission in active CD were published 
in 2006. They did demonstrate a serologic and mucosal response in the patients who 
received fontolizumab but there was no significant difference seen in clinical remission 
between patients on fontolizumab vs. place.. In February 2010, results of a placebo 
controlled Phase 3 trial assessing efficacy of fontolizumab in patients with CD were 
published. In this trial, a total of 201 patients with Crohn's Disease Activity Index (CDAI) 
scores between 250 and 450 were randomized to receive an initial intravenous dose of 1.0 
or 4.0 mg/kg fontolizumab or placebo, followed by up to 3 subcutaneous doses of 0.1 or 
1.0 mg/kg placebo every 4 weeks. At the end of induction phase assessed at 4 weeks, 
there was no significant improvement in patients who had received fontolizumab. 
However, during the maintenance period the patient arm that received 1.0 mg/kg 
intravenous followed by 1.0 mg/kg subcutaneous of fontolizumab group had clinical 
response and significantly greater improvement in the CDAI score compared with 
patients who received placebo. But a similar improved response was not seen in the other 
fontolizumab group. However, all fontolizumab groups had significant improvement in 
C-reactive protein levels. Adverse event rates were similar in all groups. The significantly 
low levels of CRP in patients who received fontolizumab suggested a biological effect of 
fontolizumab on inflammation associated with Crohn’s. Further trials are therefore being 
planned but no trial is currently underway.  
3.9 IL-12/23p40 inhibitor 
Interleukin-12 (IL-12) and Interleukin-23 (IL-23) are functionally closely associated 
effector cytokines that seem to play an active role in promoting intestinal inflammation in 
inflammatory bowel disease. IL-12 and IL-23 are structurally separate but both exist 
linked to a common subunit p40. IL-12 attaches to the p40 subunit through its unique 
subunit p35 whereas IL-23 is attached to p40 through its unique subunit p19. Both IL-12 
and IL-23 attach to cell surface receptors on T-helper cells to trigger Th1 and Th17 
mediated inflammatory cascades respectively. Briakinumab is also a human monoclonal 
antibody directed against IL-12/23p40 subunit.. Results of a phase II dose ranging and 
efficacy study published in 2004 demonstrated a significantly higher response in patients 
on briakinumab (75%) compared to placebo (25%) at the end of 7 weeks (P=0.03). (84)A 
subsequent phase IIb randomized double blind placebo controlled clinical efficacy trial 
was started in 2007. The trial sought to test safe dose and efficacy of briakinumab in 
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was started in 2007. The trial sought to test safe dose and efficacy of briakinumab in 
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moderate to severely active CD however it was terminated in April, 2010 without 
publication of findings. There are no other clinical trials underway testing briakinumab in 
CD or UC (Abbott ;.Dose Ranging Study Comparing the Efficacy, Safety and 
Pharmacokinetics of Intravenous Infusions of ABT-874 vs Placebo in Subjects With Active 
Crohn's Disease  . In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of 
Medicine (US). 2000- [cited 2010 Oct 12]. Available from: http://clinicaltrials.gov/show/ 
NCT00562887). 
STA-5326 mesylate (also called apilimod mesylate) is a small molecule that blocks the 
release of IL-12 from peripheral blood mononuclear cells. In 2006, results of a safety and 
dose-ranging study with an accrual of 73 that evaluated oral STA-5326 mesylate (apilimod 
mesylate) in CD were published. They revealed a remission rate of between 15 and 36% at 
the end of 4 weeks. Approximately half of the patients demonstrated a decrease in mucosal 
disease activity. A subsequent phase II dose-ranging randomized placebo control clinical 
trial assessing the efficacy of oral STA-5326 mesylate (apilimod mesylate) in CD was 
undertaken between 2005 and 2008, but the results have not been published yet (B.Sands; 
Synta Pharmaceutical Corp. Study of STA-5326 Mesylate in Patients With Moderate to 
Severe Crohn's Disease In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of 
Medicine (US). 2000- [cited 2010 Oct 12]. Available from: http://clinicaltrials.gov/show/  
NCT00138840). Another similar randomized double blind placebo control  phase II study 
that sought to assess peripheral mononuclear and cytokine responses to oral STA-5326 
mesylate (apilimod mesylate) was completed in December 2008. The results of this study 
have not been published yet. There have been no additional studies evaluating STA-5326 
mesylate (apilimod mesylate) in CD since then. There are also no studies that have assessed 
STA-5326 mesylate in UC yet (P.Mannon; Synta Pharmaceutical Corp. Study of STA-5326 
Mesylate in Patients With Moderate to Severe Crohn's Disease In: ClinicalTrials.gov 
[Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2010 Oct 12]. 
Available from: http://clinicaltrials.gov/show/NCT00234741). 
Ustekinumab, a human monoclonal antibody has specific affinity to the p40 subunit. By 
doing this, ustekinumab prevents IL-12 and Il-23 from attaching to their cell surface T-
helper cell receptors and therefore helps prevent the subsequent inflammatory process. 
Results of a double blind crossover clinical study assessing efficacy of ustekinumab in 
moderate to severe CD were published in 2008. They demonstrated a statistically significant 
difference in clinical response (53%) in patients who received ustekinumab vs. those who 
were in the placebo arm (30%) (P=0.02) by the end of week 6 but this difference was not 
maintained at the end of week 8 (49% with ustekinumab vs. 40% with placebo; P=0.34). It 
was noted however that when the subgroup of previous non-responders to infliximab were 
evaluated separately, the difference in clinical response to ustekinumab vs. placebo became 
statistically significant.  Consequently, a multicenter double-blind placebo controlled 
randomized trial testing efficacy and safety of ustekinumab in subjects with moderately to 
severely active CD previously treated with TNF blockers was started. This trial is still 
ongoing with no results published so far. (Centocor Inc;. A Study of Safety and Effectiveness 
of Ustekinumab in Patients With Moderate to Severe Active Crohns Disease Who Have Been 
Previously Treated With Anti-TNF Therapy. In: ClinicalTrials.gov [Internet]. Bethesda 
(MD): National Library of Medicine (US). 2000- [cited 2010 Oct 12]. Available from: 
http://clinicaltrials.gov/show/ NCT 00771667). There are no ongoing trials testing efficacy 
of ustekinumab involving UC patients. 
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3.10 Other promising agents affecting cytokines 
Thalidomide is a glutamic acid derivative that has historically been notorious for its 
devastating teratogenic potential, a property most probably linked to it toxic effect on 
endothelial tissue structures. There is growing evidence that thalidomide in fact also 
effectively inhibits transcription of TNF among other of its functions that may also be of 
value in combating intestinal inflammation in IBD.  In a retrospective study published in 
2007, thalidomide was shown to potentially be an effective in some patients with refractory 
luminal and fistulizing Crohn’s disease. Randomized Controlled Trials testing efficacy of 
thalidomide in adults with active CD have not begun yet. It is important to note that an RCT 
conducted in children with CD, testing efficacy OF lenalidomide, an analogue of 
thalidomide  in treatment of active CD did not demonstrate any significant benefit over 
placebo (94). Similarly, despite pre-clinical evidence to support efficacy of thalidomide and 
lenalidomide in decreasing intestinal inflammation associated with IBD, no maintenance 
trials have yet been published to justify its safety for use in humans.  However, clinical trials 
are being planned. 
RDP58 is an oral d-amino acid decapeptide that has powerful immunosuppressive activity 
which includes inhibition of TNF synthesis as well inhibition of IFN-γ, IL-2 and IL-12.  It has 
been demonstrated in murine models that RDP58 is extremely effective in reducing 
intestinal inflammation including histological scores in colitis. RDP58 has also demonstrated 
variable efficacy in treatment of several inflammatory and presumably autoimmune 
conditions that include IBD,  interstitial cystitis and autoimmune encephalomyelitis. RDP58 
has demonstrated ex vivo anti-inflammatory activity in tissue from patients with CD. It has 
also demonstrated efficacy in vivo murine models. 
3.11 Mucosal barrier enhancement/restoration 
The intestinal epithelium is a part of the innate immune system of the intestinal tract. It 
functions as a protective wall that seeks to maintain a balance between the contents of the 
lumen and the immune cells and matrix that lie on the other side.  
Intestinal epithelial cells are the individual units that give rise to this normally impenetrable 
intestinal barrier by forming tight junctions. Any insult that results in the failure of the tight 
junctions to keep the contents of the two environments separate is what heralds intestinal 
inflammation by activating a hyper-reactive acquired immune system made up primarily of 
effector cells. 
Emerging therapies include therapeutic agents that seeks to enhance or restore this 
important protective immune play. Teduglitide is a dipeptidyl peptidase IV resistant 
glucagon-like peptide-2 (GLP-2) analogue. The manner in which GLP-2 repairs the intestinal 
epithelium is still unclear. However, it is being tested for its ability to restore the intestinal 
epithelial barrier. Results of a randomized, placebo-controlled, double-blind trial evaluating 
efficacy of teduglutide in inducing clinical and mucosal remission in moderate to-severe CD 
were published in 2010. They demonstrated a significant difference in clinical response and 
therefore more studies have been planned. 
Growth hormone has also demonstrated positive effects on enhancing function of 
neutrophils. Somatropin,  growth hormone, has demonstrated efficacy in repairing the 
intestinal epithelium in pre-clinical studies. Some early studies have demonstrated that 
somatropin enhances the innate immune system and repairs the intestinal epithelium 
through its positive impact on protein synthesis. A phase III study evaluating the efficacy of 
somatropin in induction of histological healing in children with Crohn's Disease (CD) was 
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moderate to severely active CD however it was terminated in April, 2010 without 
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completed. Publication of the results of this trial is still pending CD (L.Denson; Children's 
Hospital Medical Center, Cincinnati. Trial of Growth Hormone Therapy in Pediatric Crohn's 
DiseaseIn: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 
2000- [cited 2010 Oct 12]. Available from: http://clinicaltrials.gov/show/NCT00109473).  
Another agent that has demonstrated the ability to enhance the innate immune system is the 
synthetic growth factor Sargramostim. Sargramostim is a granulocyte-macrophage colony 
stimulating factor (GM-CSF) which specifically stimulates production of  neutrophils, 
monocytes, and epithelial cells.  A phase 1 study published in 2009 assessed efficacy of 
sargramostim in treatment of patients with moderately to severely active CD. The study 
demonstrated modest benefit with only a few patients experiencing clinical remission. There 
were no serious reported adverse drug events. 
Recently published results of a placebo-control randomized trial that assessed the efficacy of 
sargramostim in corticosteroid-dependent patients with Crohn's disease demonstrated that 
it was more effective than placebo in inducing corticosteroid-free remission. It was also 
demonstrated that treatment with sargramostim was associated with significant 
improvements in health-related quality of life. Two phase III clinical trials testing efficacy of 
sargramostim in treatment of moderate to severe CD have recently been completed but 
results have not been published yet 
(Medical Montor; Genzyme. Efficacy (Induction of Response/Remission) and Safety Study 
in Patients With Moderate to Severe Crohn's Disease  In: ClinicalTrials.gov [Internet]. 
Bethesda (MD): National Library of Medicine (US). 2000- [cited 2010 Oct 12]. Available from: 
http://clinicaltrials.gov/show/NCT00206674) (Medical Monitor; Genzyme.Study in 
Patients With Crohn's Disease Who Are Steroid Dependent, Despite Previous Unsuccessful 
Attempts to Reduce Steroids Due to Worsening of Crohn's Disease In: ClinicalTrials.gov 
[Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2010 Oct 12]. 
Available from: http://clinicaltrials.gov/show/NCT00206596). 
There is evidence for granulocyte colony-stimulating factor’s (G-CSF) ability to inhibit 
effects of T helper 1 cells and of its ability to induce IL-10-secreting regulatory T cells. 
Filgrastim, a synthetic granulocyte colony-stimulating factor (G-CSF) that specifically 
stimulates production of neutrophils has also shown promise in early safety and efficacy 
trials.  In a recently published early phase study, the clinical benefit of G-CSF therapy in 
active CD was tested.  The results of the study were important as it was demonstrated that 
clinical benefit from G-CSF treatment was associated with induction of IL-10 secreting T 
cells as well as a rise in plasmacytoid dendritic cells in the lamina propria of the inflamed 
intestinal mucosa. Another phase I study assessing the efficacy of G-CSF in inducing an 
immune and clinical response in CD patients was recently completed but the results of this 
trial have not been published yet National Institute of Allergy and Infectious Diseases;  
National Institutes of Health Clinical Center. G-CSF to Treat Crohn's Disease In: 
ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 
2010 Oct 12]. Available from: http://clinicaltrials.gov/show/NCT00025805). 
3.12 Intra-luminal targets 
While there is no paucity of hypotheses regarding implication of intra-luminal agents as 
triggers of inflammation, the real advance in devising therapeutic strategies by modulating 
intra-luminal agents has been the realization that intestinal inflammation seen in CD is 
actually a result of an imbalance between the intestinal milieu comprising of micobiota, 
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most likely gut commensals on one side and various components of the immune system on 
the other. This theory receives more credence with the observation of increased 
inflammation seen in murine models with defects in any of these components. 
Based on the sometimes contradictory observations made, it is very plausible that there are 
indeed competing and opposing effects of microorganisms in the gut. This dilemma is 
explained well when one notes that intestinal inflammation is not just the net result of the 
imbalance between intra-luminal antigens and intestinal immune actors but in fact is also 
related to the imbalance between the so considered commensal and pathogenic strain of 
bacteria residing within the intestinal lumens. 
Another group of intraluminal actors that has recently garnered the interest of researchers 
comprises the parasitic helminths.  It has been postulated that as development and 
industrialization became harbingers of improved hygiene, intestinal colonization of people 
with helminths, a fact of life across the entire globe just a hundred years ago, began to 
subside.  Additionally, it was noted that almost precisely around the same period,  there 
began to occur a substantial increase in the  incidence of autoimmune conditions such as 
inflammatory bowel disease among populations residing in these rapidly industrializing 
nations. The association between the two phenomena became clearer when evidence of the 
role of helminths in depressing the intestinal immune reaction also began to emerge. It is 
now being seen that there seems to be a rapidly rising rate of inflammatory bowel disease 
among the urbanized populations of several rapidly developing countries whereas their 
rural counterparts continue to largely enjoy protection from this process. Another theory 
brought to the fore is popularly termed as the "IBD hygiene hypothesis".  It theorizes that 
immune deregulation occurs early in childhood among populations that are brought up in 
extremely hygienic environments largely devoid of helminthic colonization. It has been 
postulated that intestinal helminthic colonizers may actually enhance one’s immune 
regulation processes. Through this mechanism, they may prove to be effective weapons 
against the various effector cells that are the greatest drivers of  the inflammatory cascade 
representative of CD.  
There is also evidence based on murine models suggesting that helminths have a protective 
effect against the development of colitis.  There is evidence based on an open-label clinical 
trial done on patients with CD that supports the therapeutic role of helminths in these 
patients.  These studies used live ova from porcine whipworm as an oral therapeutic 
intervention.  
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completed. Publication of the results of this trial is still pending CD (L.Denson; Children's 
Hospital Medical Center, Cincinnati. Trial of Growth Hormone Therapy in Pediatric Crohn's 
DiseaseIn: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 
2000- [cited 2010 Oct 12]. Available from: http://clinicaltrials.gov/show/NCT00109473).  
Another agent that has demonstrated the ability to enhance the innate immune system is the 
synthetic growth factor Sargramostim. Sargramostim is a granulocyte-macrophage colony 
stimulating factor (GM-CSF) which specifically stimulates production of  neutrophils, 
monocytes, and epithelial cells.  A phase 1 study published in 2009 assessed efficacy of 
sargramostim in treatment of patients with moderately to severely active CD. The study 
demonstrated modest benefit with only a few patients experiencing clinical remission. There 
were no serious reported adverse drug events. 
Recently published results of a placebo-control randomized trial that assessed the efficacy of 
sargramostim in corticosteroid-dependent patients with Crohn's disease demonstrated that 
it was more effective than placebo in inducing corticosteroid-free remission. It was also 
demonstrated that treatment with sargramostim was associated with significant 
improvements in health-related quality of life. Two phase III clinical trials testing efficacy of 
sargramostim in treatment of moderate to severe CD have recently been completed but 
results have not been published yet 
(Medical Montor; Genzyme. Efficacy (Induction of Response/Remission) and Safety Study 
in Patients With Moderate to Severe Crohn's Disease  In: ClinicalTrials.gov [Internet]. 
Bethesda (MD): National Library of Medicine (US). 2000- [cited 2010 Oct 12]. Available from: 
http://clinicaltrials.gov/show/NCT00206674) (Medical Monitor; Genzyme.Study in 
Patients With Crohn's Disease Who Are Steroid Dependent, Despite Previous Unsuccessful 
Attempts to Reduce Steroids Due to Worsening of Crohn's Disease In: ClinicalTrials.gov 
[Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2010 Oct 12]. 
Available from: http://clinicaltrials.gov/show/NCT00206596). 
There is evidence for granulocyte colony-stimulating factor’s (G-CSF) ability to inhibit 
effects of T helper 1 cells and of its ability to induce IL-10-secreting regulatory T cells. 
Filgrastim, a synthetic granulocyte colony-stimulating factor (G-CSF) that specifically 
stimulates production of neutrophils has also shown promise in early safety and efficacy 
trials.  In a recently published early phase study, the clinical benefit of G-CSF therapy in 
active CD was tested.  The results of the study were important as it was demonstrated that 
clinical benefit from G-CSF treatment was associated with induction of IL-10 secreting T 
cells as well as a rise in plasmacytoid dendritic cells in the lamina propria of the inflamed 
intestinal mucosa. Another phase I study assessing the efficacy of G-CSF in inducing an 
immune and clinical response in CD patients was recently completed but the results of this 
trial have not been published yet National Institute of Allergy and Infectious Diseases;  
National Institutes of Health Clinical Center. G-CSF to Treat Crohn's Disease In: 
ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 
2010 Oct 12]. Available from: http://clinicaltrials.gov/show/NCT00025805). 
3.12 Intra-luminal targets 
While there is no paucity of hypotheses regarding implication of intra-luminal agents as 
triggers of inflammation, the real advance in devising therapeutic strategies by modulating 
intra-luminal agents has been the realization that intestinal inflammation seen in CD is 
actually a result of an imbalance between the intestinal milieu comprising of micobiota, 
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most likely gut commensals on one side and various components of the immune system on 
the other. This theory receives more credence with the observation of increased 
inflammation seen in murine models with defects in any of these components. 
Based on the sometimes contradictory observations made, it is very plausible that there are 
indeed competing and opposing effects of microorganisms in the gut. This dilemma is 
explained well when one notes that intestinal inflammation is not just the net result of the 
imbalance between intra-luminal antigens and intestinal immune actors but in fact is also 
related to the imbalance between the so considered commensal and pathogenic strain of 
bacteria residing within the intestinal lumens. 
Another group of intraluminal actors that has recently garnered the interest of researchers 
comprises the parasitic helminths.  It has been postulated that as development and 
industrialization became harbingers of improved hygiene, intestinal colonization of people 
with helminths, a fact of life across the entire globe just a hundred years ago, began to 
subside.  Additionally, it was noted that almost precisely around the same period,  there 
began to occur a substantial increase in the  incidence of autoimmune conditions such as 
inflammatory bowel disease among populations residing in these rapidly industrializing 
nations. The association between the two phenomena became clearer when evidence of the 
role of helminths in depressing the intestinal immune reaction also began to emerge. It is 
now being seen that there seems to be a rapidly rising rate of inflammatory bowel disease 
among the urbanized populations of several rapidly developing countries whereas their 
rural counterparts continue to largely enjoy protection from this process. Another theory 
brought to the fore is popularly termed as the "IBD hygiene hypothesis".  It theorizes that 
immune deregulation occurs early in childhood among populations that are brought up in 
extremely hygienic environments largely devoid of helminthic colonization. It has been 
postulated that intestinal helminthic colonizers may actually enhance one’s immune 
regulation processes. Through this mechanism, they may prove to be effective weapons 
against the various effector cells that are the greatest drivers of  the inflammatory cascade 
representative of CD.  
There is also evidence based on murine models suggesting that helminths have a protective 
effect against the development of colitis.  There is evidence based on an open-label clinical 
trial done on patients with CD that supports the therapeutic role of helminths in these 
patients.  These studies used live ova from porcine whipworm as an oral therapeutic 
intervention.  
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